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Summary	 	
There	is	an	increasing	demand	on	health	and	social	care	to	provide	high	quality	
care	to	older	adults	in	the	UK	as	the	population	of	this	vulnerable	group	grows.	
These	services	should	meet	the	needs	of	 individuals	who	can	have	a	range	of	
acute	 and	 chronic	 conditions.	 	 The	 capacity	 for	 NHS	 services	 to	 meet	 these	
demands	 is	 limited	 and	 therefore	 care	 homes	 provide	 accommodation	 and	
health	 services	 to	 meet	 this	 unmet	 need.	 In	 the	 lay	 press,	 there	 have	 been	
concerns	 regarding	 medication	 management	 in	 care	 homes	 and	 there	 is	
evidence	in	the	literature	that	this	process	is	sub-optimal.	The	aim	of	this	thesis	
therefore	was	to	explore	medicines	management	in	care	homes	focusing	on	the	
areas	 of	 prescribing,	 administration	 and	 medicines	 waste.	 A	 retrospective	
analysis	of	anonymised	medication	administration	records	(MAR	charts)	and	an	
audit	 of	 medicines	 waste	 was	 employed	 to	 achieve	 this	 aim.	 The	 analysis	
revealed	 that	 a	 significant	 number	 of	 residents	 (84%)	 were	 exposed	 to	
polypharmacy,	 potentially	 inappropriate	 medications	 (87%),	 anticholinergic	
burden	(5%	with	an	AEC	score	³	5),	and	a	significant	number	of	administration	
errors	 (6	 administration	 errors	 per	 resident	 per	 week).	 The	 study	 also	
demonstrated	 a	 significant	 volume	 of	wasted	medicines	 in	 care	 homes.	 As	 a	
consequence	of	these	issues	residents	in	care	homes	are	potentially	exposed	to	
practices	that	may	lead	to	harm	and	will	likely	increase	the	demand	on	health	
and	 social	 care	 resources.	 Careful	 consideration	 of	 prescribing	 practices	 is	
needed	 to	 reduce	medicines	burden	and	efforts	 should	be	made	 to	embed	a	
multidisciplinary	approach	to	the	care	residents.	In	conclusion,	further	study	of	
the	clinical	 consequences	of	prescribing	and	medication	errors	 in	care	homes	
should	 be	 explored	 as	 a	 matter	 of	 urgency	 and	 efforts	 should	 be	 made	 to	
maximise	the	therapeutic	benefits	of	medications	and	reduce	the	cost	of	wasted	
medicines.			
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1.1 Care	Homes	
In	the	United	Kingdom,	 institutional	 long-term	care	for	older	adults	 is	principally	
provided	 by	 independently	 owned	 care	 homes,	 which	 provide	 accommodation,	
together	with	nursing	and/or	personal	care.	Older	adults	enter	care	homes	because	
it	is	no	longer	possible	to	provide	the	level	of	care	required	at	home	either	due	to	
insufficient	capacity	within	domiciliary	care	or	the	services	provided	by	domiciliary	
care	providers	do	not	meet	the	individual’s	needs.	According	to	the	Care	Standards	
Act	 2000	Part	 1	 Section	3,	 the	Department	of	Health	 states	 “a	 care	home	 is	 an	
establishment	 that	 provides	 accommodation,	 together	 with	 nursing	 or	 personal	
care,	for	persons	who	are	or	have	been	ill,	who	have	or	have	had	a	mental	disorder,	
who	are	disabled	or	infirm	and	who	are	or	have	been	dependent	on	alcohol	or	drugs,	
it	does	not	include	hospitals,	independent	clinics	or	children’s	homes”	(Department	
of	Health	2003).	
	
Care	homes	can	largely	be	divided	into	two	categories,	residential	and	nursing	
homes	that	are	distinguished	by	the	extent	of	care	provided	to	residents.	Prior	
to	the	introduction	of	the	Care	Standards	Act	2000,	which	was	implemented	in	
April	2002,	there	was	a	definitive	difference	between	these	two	main	types	of	
care	homes.	Residential	care	homes	were	defined	as	"An	establishment	which	
provides	 residential	 care,	 not	 including	 nursing,	 for	 disabled	 or	 elderly	 infirm	
people	 including	 the	 elderly	mentally	 ill"	 (Heath	 2006),	 whilst	 nursing	 homes	
were	defined	as	"An	establishment	which	provides	residential	and	nursing	care	
for	sick,	disabled	or	elderly	infirm	people,	including	the	elderly	mentally	ill	...	run	
usually	 by	 the	 private	 or	 voluntary	 sector.	 Some	 nursing	 homes	 are	 dually	
registered	as	nursing	and	residential	homes"	(Age	UK	2018a).	Now,	all	homes	are	
termed	‘care’	homes,	with	the	distinction	that	nursing	care	homes	are	registered	
to	provide	nursing	care	on	a	24-hour	basis.	The	terms	‘residential’	and	‘nursing’	
home	have	also	ceased	to	apply	formally	following	the	 implementation	of	the	
Care	 Standards	Act	 although	 the	 terms	 are	 still	 used	 in	 common	parlance.	 In	
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essence	 nursing	 homes,	 have	 24-hour	 on-site	 nursing	 care	 available	 from	
registered	nurses	to	support	residents	who	require	a	continuous	nursing	care.	In	
residential	care	homes	healthcare	assistants	or	 ‘carers’	support	residents	with	
their	daily	activities	such	as	eating,	taking	medicines,	washing	and	dressing	but	
do	not	provide	continuous	nursing	care.		
Increasingly	 care	 homes	 are	 adopting	 a	 mixed	 approach	 and	 provide	 both	
residential	and	nursing	places.	If	a	care	home	has	different	‘wings’	or	‘wards’	for	
nursing	and	personal	care	that	together	form	one	registered	premise,	the	entire	
site	 is	 regarded	as	 a	 care	home	with	nursing	provision	 (National	 Institute	 for	
Health	Research	2016b).	
Whilst	the	majority	of	care	homes	provide	services	for	older	adults,	some	care	
homes	principally	support	those	with	mental	or	sensory	impairments	(including	
dementia)	 and	 a	 number	 of	 care	 homes	provide	 specialist	 care	 for	 particular	
patient	 cohorts	 such	 as	 those	 requiring	 palliative	 care	 	 (Centre	 for	 Policy	 on	
Ageing	 2011).	 As	 such,	 care	 homes	 are	 categorised	 according	 to	 the	 services	
provided	and	the	types	of	residents’	that	a	care	home	caters	for	(Lievesley	et	al.	
2011)(Centre	for	Policy	on	Ageing,	2011).		
1.1.1 The	Care	Home	Population	in	the	UK	
At	the	time	of	this	study,	within	the	UK	there	are	reported	to	be	4,699	nursing	
homes	and	6,023	residential	homes	supporting	an	estimated	421,100	residents	
that	are	aged	65	and	over	(Age	UK	2018b).	For	comparison,	there	are	142,000	
hospital	beds	in	the	UK	which	indicates	that	the	care	home	population	is	nearly	
3	times	greater	than	the	secondary	care	population	(Ewbank	et	al.	2017).	The	
average	size	of	a	care	home	in	the	UK	is	20	beds	and	only	10%	of	care	homes	
have	more	than	50	beds	with	almost	3,000	homes	operating	with	five	or	fewer	
beds.		
In	Wales,	there	are	a	total	of	22,706	beds	across	673	care	homes	with	an	average	
of	34	beds	per	home	(Moultrie	and	Rattle	2015).	This	is	approximately	twice	the	
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number	 of	 beds	 available	 in	 secondary	 care	 (10,934	 beds)	 (Smith	 2017).		
Ownership	is	distributed	between	local	authorities,	 larger	group	providers	(15	
groups	with	4	or	more	care	homes),	smaller	group	providers	(51	groups	with	2	
or	 3	 care	 homes)	 and	 single	 home	 providers	 (363	 providers).	 Larger	 group	
providers	 tend	 to	 operate	 homes	 with	 higher	 numbers	 of	 beds	 than	 other	
operators	(see	Table	1.1).			
Table	 1.1	 Average	 number	 of	 beds	 by	 type	 of	 care	 home	 provider	 in	 Wales.	 Adapted	 from	
(Moultrie	and	Rattle	2015)	
Type	of	provider	 Number	of	homes	(n	
=	673)	
Average	number	of	
beds	(range)	
Large	groups	(³	4	care	homes)	 113	 46	(25	–	78)	
Small	groups	(2	-	3	care	homes)	 113	 32	
Single	provider	 363	 31	
Local	authority	 84	 30	
	
1.1.2 Regulation	of	Care	Homes	
In	England	and	Wales,	care	homes	are	governed	by	the	Care	Standards	Act	2000,	
in	Scotland	by	the	Regulation	of	Care	Act	(Scotland)	2001	and	in	Northern	Ireland	
by	the	Health	and	Personal	Social	Services	Act	(Northern	Ireland)	2002.	These	
legislative	acts	have	resulted	in	the	introduction	of	a	series	of	national	minimum	
standards	by	the	Department	of	Health,	the	Scottish	Executive	and	the	Welsh	
Assembly	 (see	CQC	2014).	 These	 represent	 the	minimum	standards	 that	 care	
homes	must	meet	to	retain	their	registration.	The	Care	Standards	Act	gives	the	
secretary	of	state,	the	power	to	introduce	new	standards	at	any	time	without	
any	further	legislation	(CQC	2014).		
Each	standard	is	prefaced	by	a	statement	of	good	practice	and	also	an	outcome	
is	detailed	for	each	standard	(see	Table	1.2).	Underneath	each	standard	is	a	set	
of	 requirements	all	 of	which	need	 to	be	met	 to	achieve	 compliance	with	 the	
standard.		
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Table	1.2	Minimum	standards	for	care	homes	set	out	in	Care	Homes	for	Older	People:	National	Minimum	Standards	(CQC	2014)	
Standard	 					Outcome	
Choice	of	home	 	
1. Information	 Prospective	service	users	have	the	information	they	need	to	make	an	informed	choice	about	where	to	live.		
2. Contract	
3. Needs	Assessment	
Each	service	user	has	a	written	contract/statement	of	terms	and	conditions	with	the	home		
No	service	user	moves	into	the	home	without	having	had	his/her	needs	assessed	and	been	assured	that	these	will	be	met.	
4. Meeting	Needs	 Service	users	and	their	representatives	know	that	the	home	they	enter	will	meet	their	needs.	
5. Trial	Visits	 Prospective	service	users	and	their	relatives	and	friends	have	an	opportunity	to	visit	and	assess	the	quality,	facilities	and	suitability	
of	the	home.	
6. Intermediate	Care	 Service	users	assessed	and	referred	solely	for	intermediate	care	are	helped	to	maximise	their	independence	and	return	home.	
Health	and	Personal	Care	 	
7. Service	User	Plan	 The	service	user’s	health,	personal	and	social	care	needs	are	set	out	in	an	individual	plan	of	care.	
8. Health	Care	 Service	users	make	decisions	about	their	lives	with	assistance	as	needed.	
9. Medication	 Service	 users,	 where	 appropriate,	 are	 responsible	 for	 their	 own	 medication,	 and	 are	 protected	 by	 the	 home’s	 policies	 and	
procedures	for	dealing	with	medicines.	
10. Privacy	and	Dignity	 Service	users	feel	they	are	treated	with	respect	and	their	right	to	privacy	is	upheld.		
11. Dying	and	Death	 Service	users	are	assured	that	at	the	time	of	their	death,	staff	will	treat	them	and	their	family	with	care,	sensitivity	and	respect.	
Daily	Life	and	Social	Activities	 	
12. Social	Contact	and	Activities	 Service	users	 find	the	 lifestyle	experienced	 in	the	home	matches	their	expectations	and	preferences,	and	satisfies	their	social,	
cultural,	religious	and	recreational	interests	and	needs.	
13. Community	Contact	 Service	users	maintain	contact	with	family/friends	/representatives	and	the	local	community	as	they	wish.	
14. Autonomy	and	Choice	 Service	users	are	helped	to	exercise	choice	and	control	over	their	lives.	
15. Meals	and	Mealtimes	 Service	users	receive	a	wholesome	appealing	balanced	diet	in	pleasing	surroundings	at	times	convenient	to	them.	
Complaints	and	Protection	 	
16. Complaints	 Service	users	and	their	relatives	and	friends	are	confident	that	their	complaints	will	be	listened	to,	taken	seriously	and	acted	upon.	
17. Rights	 Service	users’	legal	rights	are	protected.	
18. Protection	 Service	users	are	protected	from	abuse.	
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Environment	 	
19. Premises	 Service	users	live	in	a	safe,	well-maintained	environment.		
20. Shared	Facilities	 Service	users	have	access	to	safe	and	comfortable	indoor	and	outdoor	communal	facilities.	
21. Lavatories	 and	 Washing					
Facilities	
Service	users	have	sufficient	and	suitable	lavatories	and	washing	facilities.		
	
22. Adaptations	and	Equipment	 Service	users	have	the	specialist	equipment	they	require	to	maximise	their	independence.	
23. Individual	 Accommodation:	
Space	Requirements	
Service	users’	own	rooms	suit	their	needs.	
	
24. Furniture	and	Fittings	 Service	users	live	in	safe,	comfortable	bedrooms	with	their	own	possessions	around	them.	
25. Heating	and	Lighting	 Service	users	live	in	safe,	comfortable	surroundings.		
26. Hygiene	 and	 Control	 of	
Infection	
The	home	is	clean,	pleasant	and	hygienic.		
	
Staffing	 	 	
27. Staff	Complement	 								Service	users’	needs	are	met	by	the	numbers	and	skill	mix	of	staff.	
28. Qualifications	 								Service	users	are	in	safe	hands	at	all	times.	
29. Recruitment	 								Service	users	are	supported	and	protected	by	the	home’s	recruitment	policy	and	practices.	
30. Staff	Training	 								Staff	are	trained	and	competent	to	do	their	jobs.	
Management	and	Administration	 	
31. Day	to	Day	Operations	 								Service	users	 live	 in	a	home	which	 is	run	and	managed	by	a	person	who	is	fit	to	be	 in	charge,	of	good	character	and	able	to	
discharge	his	or	her	responsibilities	fully.	
32. Ethos	 								Service	users	benefit	from	the	ethos,	leadership	and	management	approach	of	the	home.	
33. Quality	Assurance	 								The	home	is	run	in	the	best	interests	of	service	users.				
34. Financial	Procedures	 								Service	users	are	safeguarded	by	the	accounting	and	financial	procedures	of	the	home.	
35. Service	User’s	Money	 								Service	users’	financial	interests	are	safeguarded.	
36. Staff	Supervision	 								Staff	are	appropriately	supervised.	
37. Record	Keeping	 								Service	users’	rights	and	best	interests	are	safeguarded	by	the	home’s	record	keeping	policies	and	procedures.	
38. Safe	Working	Practices	 								The	health,	safety	and	welfare	of	service	users	and	staff	are	promoted	and	protected.	
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Standard	9	specifically	relates	to	medicines	and	is	concerned	with	the	safe	and	
effective	 use	 of	 medicines	 by	 care	 home	 residents.	 The	 outcome	 essentially	
states	 that	 residents	 should	 retain	 responsibility	 for	 their	 own	 medication	
wherever	practicable	but	should	be	protected	by	the	specific	medicines	related	
policies	and	practices	developed	by	 the	care	home.	The	standard	describes	a	
number	of	requirements	for	the	use	and	management	of	medicines	in	the	home	
(see	Table	1.3)		
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Table	1.3	Standard	9	requirements	for	medicines	in	care	homes	(adapted	from	(Department	of	
Health	2003)	
Standard	9	requirements	
9.1	
	
The	registered	person	ensures	that	there	is	a	policy	and	staff	adhere	to	procedures,	
for	the	receipt,	recording,	storage,	handling,	administration	and	disposal	of	medicines,	
and	service	users	are	able	to	take	responsibility	for	their	own	medication	if	they	wish,	
within	a	risk	management	framework.		
9.2	 The	 service	user,	 following	assessment	as	able	 to	 self-administer	medication,	has	a	
lockable	space	in	which	to	store	medication,	to	which	suitably	trained,	designated	care	
staff	may	have	access	with	the	service	user’s	permission.	
9.3	 Records	 are	 kept	 of	 all	medicines	 received,	 administered	 and	 leaving	 the	 home	 or	
disposed	of	to	ensure	that	there	is	no	mishandling.	A	record	is	maintained	of	current	
medication	for	each	service	user	(including	those	self-administering).	
9.4	 Medicines	in	the	custody	of	the	home	are	handled	according	to	the	requirements	of	
the	 Medicines	 Act	 1968,	 guidelines	 from	 the	 Royal	 Pharmaceutical	 Society,	 the	
requirements	of	 the	Misuse	of	Drugs	Act	1971	and	nursing	staff	abide	by	the	UKCC	
Standards	for	the	administration	of	medicines.	
9.5	 Controlled	Drugs	administered	by	staff	are	stored	in	a	metal	cupboard,	which	complies	
with	the	Misuse	of	Drugs	(Safe	Custody)	Regulations	1973.	
9.6	 Medicines,	 including	 Controlled	Drugs,	 for	 service	 users	 receiving	 nursing	 care,	 are	
administered	by	a	medical	practitioner	or	registered	nurse.	
9.7	 In	residential	care	homes,	all	medicines,	including	Controlled	Drugs,	(except	those	for	
self-administration)	are	administered	by	designated	and	appropriately	 trained	staff.	
The	 administration	 of	 Controlled	 Drugs	 is	 witnessed	 by	 another	 designated,	
appropriately	trained	member	of	staff.	
The	training	for	care	staff	must	be	accredited	and	must	include:		
(i) basic	knowledge	of	how	medicines	are	used	and	how	to	recognise	and	
deal	with	problems	in	use;		
(ii) the	 principles	 behind	 all	 aspects	 of	 the	 home’s	 policy	 on	 medicines	
handling	and	records.	
9.8	 Receipt,	administration	and	disposal	of	Controlled	Drugs	are	recorded	in	a	Controlled	
Drugs	register.	
9.9	 The	 registered	manager	 seeks	 information	and	advice	 from	a	pharmacist	 regarding	
medicines	 policies	within	 the	 home	 and	medicines	 dispensed	 for	 individuals	 in	 the	
home.	
9.10	 Staff	monitor	the	condition	of	the	service	user	on	medication	and	call	in	the	GP	if	staff	
are	concerned	about	any	change	in	condition	that	may	be	a	result	of	medication,	and	
prompt	the	review	of	medication	on	a	regular	basis.	
9.11	 When	a	service	user	dies,	medicines	should	be	retained	for	a	period	of	seven	days	in	
case	there	is	a	coroner’s	inquest.	
Care	homes	are	regulated	to	ensure	these	standards	are	maintained.	In	England,	
this	is	by	the	Care	Quality	Commission	(CQC),	Care	Inspectorate	Wales	(CIW)	in	
Wales,	 the	 Care	 Inspectorate	 (CI)	 in	 Scotland	 and	 Regulation	 and	 Quality	
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Improvement	Authority	(RQIA)	in	Northern	Ireland.	In	Wales,	the	responsibility	
of	CIW	is	to	regulate	care	providers	to	ensure	that	they	provide	effective,	safe	
and	 high-quality	 care	 to	 their	 service	 users	 according	 to	 legislative	 and	
regulatory	 requirements.	 CIW	 regulate	 and	 inspect	 a	 variety	 of	 care	 settings.	
These	include	(i)	care	homes	which	provide	services	for	both	children	and	adults;	
(ii)	 domiciliary	 support	 service	 that	 provide	 home	 care;	 (iii)	 adult	 placement	
schemes;	(iv)	child	minders;	(v)	children’s	day	care;	(vi)	 independent	fostering	
agencies;	 (vii)	 voluntary	 adoption	 agencies;	 (viii)	 residential	 family	 centre	
services,	and	(ix)	adoption	support	services	(Care	Inspectorate	Wales	2018a).		
With	respect	to	care	homes,	CIW	inspect	homes	against	the	minimum	standards	
for	care	homes	(see	Table	1.2)	which	are	specified	by	the	Care	and	Social	Act	
2008.	Where	concerns	or	issues	are	identified,	CIW	has	the	power	to	enforce	a	
range	 of	 actions	 including	 issuing	 non-compliance	 notices,	 cancelling	 the	
registration	 of	 the	 care	 home,	 and	 in	 extreme	 cases	 initiating	 criminal	
prosecution	proceedings	where	an	individual(s)	in	the	care	home	is	subject	to	or	
at	risk	of	significant	harm	(Care	Inspectorate	Wales	2018b).	
In	addition	to	the	Care	Act	2008,	care	homes	and	their	staff	will	also	be	subject	
to	a	range	of	ancillary	standards	set	out	by	a	variety	of	agencies	and	professional	
bodies.	 For	 example,	 healthcare	 professionals	working	 in	 care	 homes	will	 be	
subject	to	professional	standards	set	by	their	regulatory	body	(e.g.		the	Nursing	
and	Midwifery	Council	 for	nurses)	and	care	homes	will	be	subject	 to	national	
and/or	EU	quality	standards	for	example	related	to	relevant	health	and	safety	
acts	and	safeguarding	the	confidentiality	of	residents’	information	as	set	out	in	
the	Data	Protection	Act	1998.		
1.1.3 Staff	in	care	homes	
Care	homes	(both	residential	and	nursing)	employ	a	variety	of	staff	to	support	
the	personal	and	health	care	needs	of	their	residents.		Standards	27	–	30	of	the	
National	Minimum	Standards	were	developed	to	ensure	that	(i)	the	health	and	
personal	care	needs	of	residents	are	met	both	in	terms	of	the	number	and	skills	
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mix	of	staff	(Std	27);	(ii)		the	staff	complement	have	appropriate	qualifications	
(50%	with	NVQ	level	2	or	equivalent	(Std	28);	(iii)	the	care	home	has	a	formal	
recruitment	process	to	ensure	the	protection	of	service	users	(Std	29)	and	(iv)	
ongoing	staff	training	and	development	to	ensure	staff	are	competent	(Std	30).		
All	nursing	homes	must	employ	registered	nurses	(RN)	i.e.	they	are	currently	on	
the	NMC	register	and	both	nursing	homes	and	residential	homes	will	employ	
care	assistants	CA	who	are	defined	as	“a	person	offering	personal	care	to	older	
people	who	may	or	may	not	have	NVQs”	(Heath	2006);	care	assistants	with	NVQ	
level	2	or	greater	are	commonly	described	as	‘qualifieds'.		
In	homes	with	nursing	care,	registered	nurses	are	employed	to	provide	specialist	
nursing	care	and	to	supervise	the	care	provided	by	care	assistants.	There	will	be	
registered	nursing	cover	continuously	over	a	full	24-hour	period	(Department	of	
Health	Social	 Services	and	Public	 Safety	2015).	 	 In	 residential	 care	homes	 i.e.	
those	 without	 nursing,	 registered	 nurses	 from	 community	 and	 primary	 care	
services	visit	the	home	to	provide	nursing	care	when	required	and	to	provide	
guidance	and	support	to	care	assistants	(Spilsbury	et	al.	2015).		
The	registered	nursing	workforce	in	care	homes	has	primarily	been	trained	to	
care	for	patients	in	primary	or	secondary	care,	rather	than	specifically	for	those	
in	the	care	home	setting.	As	a	consequence,		nurses	are	often	poorly	prepared	
to	meet	the	complex	needs	of	older	people	in	care	homes	and	there	is	limited	
formal	nursing	education	to	address	this	knowledge	and	skills	gap	(Royal	College	
of	Nursing	2012;	Spilsbury	et	al.	2016;	Stevens	2011).	Concerns	have	been	raised	
about	the	quality	of	nursing	care	provided	to	people	living	in	care	homes	(CQC	
2014).	 In	recent	years,	the	status	of	the	nursing	workforce	 in	care	homes	has	
emerged	as	a	matter	of	public	policy	concern	due	to	the	significant	problems	
with	recruitment	and	retention	of	nurses.	In	addition,	workforce	data	indicates	
that	the	number	of	nurses	working	in	community	health	services	has	declined	
over	recent	years,	and	the	number	working	in	senior	‘district	nurse’	posts	has	
fallen	 dramatically,	 creating	 a	 growing	 demand–capacity	 gap	 which	 will	
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consequently	 reduce	 their	 recruitment	 into	 care	 homes	 (NHS	 Improvement	
2016).	Compounding	this	issue,	has	been	the	high	rate	of	staff	turnover	in	care	
homes	and	then	the	difficulty	in	recruiting	staff	with	the	appropriate	skills	mix	
as	often	new	starters	lack	the	necessary	skills	which	they	must	then	learn	‘on	the	
job’	 (Royal	 College	 of	 Nursing	 2012).	 Recent	 NICE	 Guidance	 (2015)	 has	
highlighted	the	importance	of	care	homes	employing	nursing	staff	with	the	right	
knowledge,	attitudes	and	approach	to	ensure	nurses	are	competent,	appreciate	
the	challenges	of	working	in	the	sector	and	understand	how	to	promote	quality	
of	 care.	 This	 	 includes	working	with	 primary	 and	 community	 care	 services	 to	
ensure	 appropriate	 management	 of	 the	 health	 needs	 of	 residents	 and	 to	
minimise	the	risk	of	unnecessary	hospital	admissions(	NICE	2014;	NICE	2015).	
Ensuring	 older	 people	 can	 access	 high	 quality	 nursing	 care	 in	 care	 homes	 is	
crucial	particularly	as	 there	 is	now	a	 considerable	overlap	 in	 the	dependency	
levels	and	care	needs	amongst	residents	in	care	homes	with	and	without	nursing	
(Lievesley	et	al.	2011).	
Backhaus	and	colleagues,	identified	through	the	literature	and	their	professional	
network,	the	importance	of	developing	competencies	for	care	home	staff.	They	
highlighted	the	increasing	number	of	bachelor-educated	registered	nurses	(i.e.	
those	 with	 University	 degrees)	 working	 in	 care	 homes	 which	 they	 indicated	
might	lead	to	an	improvement	in	quality	of	life	and	quality	of	care	for	nursing	
home	residents;	similar	improvements	have	been	identified	in	secondary	care.	
The	study	highlighted	that	such	individuals	have	an	improved	ability	to	manage	
increasingly	complex	patients	in	an	increasingly	constrained	healthcare	setting	
(Backhaus	et	al.	2015),	although	there	 is	no	clear	evidence	that	nurses	with	a	
university	degree	provide	better	care.	Another	study	by	Heath	and	one	by	Nolan,	
sought	to	identify	the	distinct	contribution	of	nurses	in	the	care	home	setting	by	
comparing	 the	outcomes	of	care	 interventions	delivered	by	 registered	nurses	
(RNs)	with	those	of	care	assistants	in	nursing	homes	for	older	people	in	the	UK.	
The	study	concluded	that	the	RNs	role	is	broad	and	multifunctional	in	the	care	
homes	 and	 their	 knowledge,	 experience,	 skills	 and	 caring	 approach	 strongly	
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influences	resident	outcomes	(	Nolan	et	al.	2008;	Heath	2010)	.		
1.2 Residents	of	care	homes	
In	England	and	Wales	there	are	estimated	to	be	9.2	million	people	aged	65	years	
and	over	and	this	number	is	expected	to	increase	to	around	19	million	by	2050.	
More	than	80%	of	this	population	will	likely	require	some	form	of	institutional	
care	which	could	include	admission	to	a	care	home	(Moore	and	Hanratty	2013).		
As	of	2017,	there	are	over	420K	people	in	the	UK	aged	65	and	over	residing	in	
care	homes	(Age	UK	2018b)	and	nearly	half	of	these	are	aged	85	and	over	(Smith	
et	al.	2015).	
People	 who	 live	 in	 care	 homes	 are	 commonly	 described	 as	 service	 users,	
residents	or	clients;	the	term	‘resident’	will	be	used	throughout	this	thesis.	Such	
residents	have	always	varied	in	terms	of	their	health	needs	however,	in	the	past	
decade,	 the	 resident	 population	 has	 changed	 dramatically	 to	 include	 people	
living	with	‘severe’	frailty	and	illness	(Dudman	et	al.	2018).	Historically,	residents	
of	nursing	homes	have	required	more	 intensive	care	than	those	 in	residential	
homes.	However,	the	pressures	on	health	and	social	care	services	in	the	UK	have	
blurred	the	boundaries	between	nursing	and	residential	care.	As	a	consequence,		
carers	are	now	providing	 increasingly	complex	 types	of	care	 to	 residents	 that	
have	traditionally	been	delivered	by	registered	nurses.	This	shift	towards	care	
homes	housing	residents	with	more	complex	health	and	social	care	needs	has	
been	partly	driven	by	government	policy	to	keep	people	in	their	own	homes	for	
as	long	as	possible	by	improving	domiciliary	care.	As	a	result,	individuals	become	
residents	of	care	homes	when	their	health	and	social	needs	are	more	advanced	
and	when	it	is	impractical	to	manage	their	conditions	at	home	(National	Institute	
for	health	Research	2016a).	
The	average	care	home	resident	is	likely	to	be	female	aged	85	or	over	with	six	or	
more	 clinical	 diagnoses,	 taking	 seven	 or	 more	 medications,	 and	 living	 with	
significant	 physical	 disabilities,	 mental	 health	 problems	 and	 cognitive	
impairment	(Gladman	et	al.	2015).	Such	patients	are	commonly	said	to	suffer	
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from	 ‘Geriatric	 Syndrome’	 (Won	 et	 al.	 2013)	 a	 broad	 definition	 of	 clinical	
conditions	 such	 as	 delirium,	 falls,	 frailty,	 dizziness,	 syncope	 and	 urinary	
incontinence.	 Combined,	 these	 syndromes	 have	 a	 significant	 impact	 on	 a	
resident	quality	of	 life	and	result	 in	high	levels	of	disability	(see	Chapter	2	 for	
further	 details).	 Indeed,	 75%	 of	 all	 residents	 in	 care	 homes	 are	 classed	 as	
severely	disabled	and	estimates	suggest	that	as	many	as	76%	of	residents	either	
require	assistance	with	their	mobility	or	are	immobile.	As	a	consequence,	falls	
are	common	in	care	homes	where	rates	vary	from	3	to	13	falls	per	1,000	bed	
days	(Burns	and	Nair	2014).	UK	care	home	residents	fall	on	average	two	to	six	
times	per	year	and	up	to	a	third	of	falls	in	care	homes	result	in	injury	and	1	in	20	
results	in	a	fracture	(Rubenstein	et	al.	1996).		It	is	worth	noting	that	falls	in	older	
people	is	a	major	precipitant	of	people	moving	from	their	own	home	to	long-
term	nursing	or	residential	care	(Oliver	et	al.	2007).	
In	addition,	some	78%	of	care	home	residents	have	at	least	one	form	of	cognitive	
impairment	 (NHS	 England	 2016a).	 	 Dementia	 is	 one	 of	 the	 major	 causes	 of	
cognitive	 impairment	 and	 although	 there	 is	 a	 spectrum	 of	 dementias,	
Alzheimer's	 disease	 has	 been	 reported	 to	 be	 the	 most	 common	 cause	 of	
progressive	 dementia	 in	 care	 homes	 (comprising	 62%	 of	 all	 residents	 with	
dementia)	 followed	by	dementia	 related	to	vascular	causes	 (27%	of	 residents	
with	 dementia)	 (The	 Alzheimer's	 Society	 demographics	 and	 statistics,	 2013).	
Dementia	 is	 associated	with	 behavioral	 and	 psychological	 symptoms	 such	 as	
changes	 in	 mood,	 memory	 loss,	 apathy,	 confusion,	 anxiety,	 and	 difficulty	 in	
finding	the	right	words	and	progressive	difficulty	with	task	that	need	planning.	
These	 symptoms	 generally	 result	 in	 a	 reduced	quality	 of	 life	 and	 impede	 the	
ability	 of	 individuals	 to	 communicate	 medicine-related	 problems	 (Matthews	
2002;	Alldred	2007).		
Meeting	the	health	and	care	needs	of	this	vulnerable	population	is	made	more	
challenging	by	their	average	life	expectancy	on	arrival	at	the	home	which	is	as	
little	as	12-30	months	(Baylis	and	Perks-Baker	2017).			
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1.3 Reasons	for	admission	to	care	homes	
The	reason	for	admission	to	care	homes	is	multifactorial.	In	their	seminal	work	
Andersen	&	Aday	indicated	that	entry	into	a	nursing	home	could	be	attributed	
to	 three	 variables:	 (i)	 personal	 attributes	 that	 predispose	 individuals	 to	 seek	
care;	(ii)	enabling	factors	that	influence	access	to	care	and	(iii)	need	factors	as	
reflected	by	health	status,	disease	and	functional	disability	(Andersen	and	Ann	
Aday	1978).	Subsequently,	a	range	of	studies	have	examined	the	predictors	for	
care	home	admission	and	have	found	that	 	 the	most	common	risk	factors	for	
admission	were	older	age,	biological	sex	 (women),	 reduced	 levels	of	Personal	
and	Instrumental	Activities	of	Daily	Living,	cognitive	impairment,	living	alone	and	
the	 presence	 of	 key	 medical	 conditions	 (Sinclair	 et	 al.	 1988).	 These	 medical	
conditions	include	stroke	and	dementia	where	for	example	in	Belgium	they	have	
been	associated	with	36%	and	43%	of	admissions	to	nursing	home	respectively	
(Van	Rensbergen	and	Nawrot	2010).	In	another	study	Banaszak	et	al.	identified	
heart	 disease,	 urinary	 incontinence	 and	 dementia	 as	 significant	 predictors	 of	
nursing	home	admission	(Banaszak-Holl	et	al.	2004).	Similarly	McNabney	et	al.	
demonstrated	that	more	than	40%	of	residents	admitted	to	nursing	homes	had	
at	least	one	of	four	chronic	medical	diagnoses:	congestive	heart	failure,	chronic	
obstructive	 pulmonary	 disease,	 diabetes	 mellitus	 or	 Parkinson's	 disease	
(McNabney	et	al.	2007).		
1.4 Medicines	use	in	care	homes	and	polypharmacy	
One	of	the	factors	that	places	residents	at	high	risk	of	adverse	health	outcomes	
is	polypharmacy.	There	are	a	number	of	definitions	of	polypharmacy	including	
quantitative	(normally	individuals	prescribed	5	or	more	medicines)	or	qualitative	
(medicines	prescribed	without	an	appropriate	clinical	diagnosis)	(Masnoon	et	al.	
2017).	 Care	 home	 residents	 commonly	 meet	 the	 range	 of	 definitions	 for	
polypharmacy.	Indeed,	the	mean	number	of	medicines	prescribed	per	resident	
in	care	homes	has	increased	substantially	from	4.9	in	1998	to	8.0	in	2007	(Furniss	
et	al.	2000).	Whilst	the	mean	number	of	medicines	has	now	somewhat	stabilised	
at	8	per	 resident,	 it	 is	not	uncommon	 to	 find	 residents	 taking	as	many	as	20	
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medicines	(Alldred	et	al.	2009).	In	addition	to	prescribed	medications	and	dietary	
supplements,	there	is	evidence	that	residents	take	over-the-counter	drugs	and	
complementary	 and	 alternative	 medicines;	 these	 are	 often	 provided	 by	 the	
resident’s	relatives	(Duerden	M	2013).		
The	 consequences	 of	 polypharmacy	 and	 inappropriate	 prescribing	 in	 older	
adults	in	primary	and	secondary	care	settings	is	well	established	(Maher	et	al.	
2014).	 For	 example,	polypharmacy	has	been	 shown	 to	be	associated	with	an	
increased	risk	of	adverse	drug	events	(ADEs)	in	older	adults	and	is	responsible	
for	up	 to	12%	of	all	hospitalisations	 in	 the	elderly	population	 (Parameswaran	
Nair	et	al.	2016).	 It	also	has	an	 impact	on	medicines	adherence	rates	 in	older	
adults	which	 has	 been	 shown	 to	 be	 directly	 proportionate	 to	 the	 number	 of	
drugs	 prescribed	 (Colley	 and	 Lucas	 1993)	 with	 more	 frequent	 doses	 missed	
resulting	in	increased	financial	burden	to	health	service	providers	(Kojima	et	al.	
2012;	Maher	et	al.	2014).	In	contrast,	there	is	a	paucity	of	literature	examining	
the	consequences	of	polypharmacy	in	care	homes.		
1.4.1 The	management	of	medicines	in	care	homes	
Unlike	in	an	individual’s	home	where	they	manage	their	own	medicines,	in	care	
homes	medicines	are	generally	managed	by	staff,	although	residents	retain	the	
right	 to	 administer	 their	 own	 medicines	 wherever	 possible.	 Medicines	
management	 is	a	complex	multifactorial	process	and	represents	an	important	
and	understudied	element	of	a	resident’s	care.	It	is	a	resource	intensive	process	
and	has	been	shown	to	account	for	as	much	as	40-50%	of	care	home	staff	time	
(Alldred	et	al.	2009).		
Medication	management	broadly	includes	six	key	components:	(i)	the	care	home	
orders	the	residents’	medicines;	(ii)	a	prescriber	prescribes	the	medicines;	(iii)	
the	medicines	are	dispensing	from	a	community	pharmacy	and	supplied	to	the	
care	homes;	(iv)	the	medicines	are	stored	at	the	care	home;	(v)	the	medicines	
are	administered	to	residents	in	the	care	home	–	this	is	associated	with	recording	
and	monitoring	processes	and	(vi)	any	unused	medicines	are	returned	at	the	end	
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of	the	month.		It	is	clear	that	a	range	of	healthcare	professionals	play	a	role	in	
medicines	 related	 activities	 prior	 to	 the	 medicine	 reaching	 the	 resident	 and	
various	 legislative	 and	 regulatory	 mechanisms	 must	 be	 in	 place	 to	 ensure	
effective	medicines	management	procedures.		
1.4.1.1 The	prescribing	process	
In	the	United	Kingdom	(UK),	good	practice	guidance	on	prescribing	is	provided	
by	 relevant	 professional	 bodies	 such	 as	 the	 General	 Medical	 Council	 (GMC)	
(2013)	and	the	General	Pharmaceutical	Council	(GPhC)	(2015).	Prescribing	is	a	
complex	 process	 that	 requires	 a	 comprehensive	 approach	 by	 clinicians,	
considering	key	aspects	such	as:	
• Patient	understanding,	choice	and	consent	for	treatment	
• Appropriate	knowledge	of	the	health	condition(s)	to	be	addressed	
• Appropriate	medicines	prescribed	to	treat	or	prevent	diseases	
• Prescribing	 decision	 making	 supported	 by	 evidence	 based	 clinical	
guidance	(local	and/or	national)	
• Potential	adverse	reactions	to	drugs	are	recognised	and	mitigated	
• Potential	 drug-drug	 interactions	 are	 recognised	 and	 addressed	 (Royal	
Pharmaceutical	Society	2014)		
	 	
Any	 failure	 to	 address	 these	 key	 aspects	 may	 ultimately	 lead	 to	 potentially	
inappropriate	 prescribing	 (PIP).	 	 The	 term	 ‘inappropriate	 prescribing’	 broadly	
covers	 three	activities:	 (i)	over-prescribing	 (prescribing	a	drug	without	a	valid	
indication);	 (ii)	 miss-prescribing	 (incorrectly	 prescribing	 a	 drug	 for	 a	 valid	
indication)	 and	 (iii)	 under-prescribing	 ‘failure	 to	 prescribe	 an	 indicated	 drug’	
(Anrys	et	al.	2015).	
	
The	majority	 of	 care	 homes	 are	 serviced	by	more	 than	one	 general	 practice.	
Traditionally,	the	General	Practitioner	(GP)	that	an	individual	is	registered	with	
remains	 responsible	 for	 their	medical	 care	 (including	 prescribing)	 when	 they	
enter	 the	care	home.	However,	prescribing	 interventions	may	also	arise	 from	
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other	 practitioners	 including	 secondary	 care	 doctors	 (as	 a	 consequence	 of	 a	
hospital	 admission	 or	 for	 specialist	 care),	 allied	 healthcare	 practitioners	
(dentists,	non-medical	prescribers	etc.)	and	out-of-hours	doctors.	Ultimately	this	
results	in	multiple	sources	of	prescribing	interventions	by	individuals	who	may	
not	have	full	access	to	the	resident’s	health	and	medication	records.		
Critically,	 quality	 of	 prescribing	 is	 an	 important	 determinant	 of	wellbeing	 for	
older	adults	with	inappropriate	or	excessive	use	of	medicines	shown	to	increase	
mortality,	 hospital	 admission,	 falls,	 functional	 impairment,	 and	 cognitive	
decline.	For	example,	Ruggiero	and	colleagues	found	that	care	home	residents	
receiving	two	or	more	potentially	inappropriate	medications	(PIMs)	had	a	75%	
higher	 risk	 of	 being	 hospitalised,	 (hazard	 ratio	 [HR]	 1.73;	 95%	 CI	 1.14,	 2.60),	
during	a	12-month	follow	up	period	(Ruggiero	et	al.	2010).	Similarly,	Klarin	and	
colleagues	 studied	an	older	 adult	 (>75	years	old)	population	 in	 Sweden	 for	 a	
three-year	period.	They	reported	that	almost	~20%	of	the	population	received	
an	inappropriate	drug	and	this	resulted	in	an	increased	risk	of	at	least	one	acute	
hospitalisation	(odds	ratio	2.72	(95%	CI	1.64,	4.51)		(Klarin	et	al.	2005).		
The	prevalence	of	potentially	 inappropriate	prescribing	 (PIP)	 in	care	homes	 is	
reasonably	well	documented	but	varies	depending	on	the	study.	In	their	seminal	
systematic	review,	Morin	and	colleagues	found	the	prevalence	of	inappropriate	
prescribing	 ranged	 from	 27%	 in	 the	 USA	 to	 nearly	 50%	 in	 some	 European	
countries	(Morin	et	al.	2016).	In	England	and	Wales	nearly	30%	of	all	residents	
in	care	homes	have	been	prescribed	at	least	one	PIM;	most	commonly	this	was	
an	 antipsychotic	 or	 anticholinergic	 (Shah	 et	 al.	 2012).	 Of	 note,	 Cox	 and	
colleagues	 identified	 a	 3-fold	 increase	 in	 the	 rate	 of	 falls	 in	 nursing	 home	
residents	 who	 were	 prescribed	 an	 antipsychotic	 and	 antidepressant	 drugs.	
(Hartikainen	et	al.	2007;	Cox	et	al.	2016).		
In	addition,	inappropriate	prescribing	has	been	shown	to	lead	to	an	increase	in	
healthcare	 expenditure,	 for	 example	 as	 a	 consequence	 of	 the	 cost	 of	
hospitalisation	due	to	preventable	adverse	drug	reactions	(Chiatti	et	al.	2012)	
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(Maher	 et	 al.	 2014)	 which	 has	 been	 estimated	 to	 be	 nearly	 US$2	 billion	
(Rocchiccioli et	al.	2007)	in	the	US.		
1.4.1.2 Ordering	and	dispensing		
Dispensing	is	another	important	element	of	the	medicines	management	process	
in	care	homes.	The	general	mechanism	is	that	each	care	home	will	be	registered	
to	 a	 single	 community	 pharmacy.	 Towards	 the	 end	 of	 a	medicines	 cycle	 (28	
days),	staff	 in	the	care	home	will	order	medicines	for	the	next	cycle	from	the	
community	 pharmacy.	 The	 community	 pharmacy	 then	 requests	 the	
prescriptions	 from	the	relevant	GP	practice(s).	On	receipt	of	 the	prescription,	
the	 pharmacist	 will	 clinically	 check	 the	 prescription	 before	 members	 of	 the	
pharmacy	team	(normally	technicians)	assemble	and	dispense	the	medications	
on	the	prescription;	standard	operating	procedures	support	these	activities	 in	
the	community	pharmacy.	Prior	to	sending	the	medicines	to	the	care	home,	the	
pharmacist	or	an	accredited	checking	technician	will	undertake	a	final	accuracy	
check	of	the	medicines.	There	are	two	ways	in	which	medicines	are	supplied	to	
care	homes:	 (i)	 in	 individual	packs,	 labelled	with	 resident’s	name	and	dosage	
details	or	(ii)	using	monitored	dosage	systems	(MDS).		This	depends	on	both	the	
request	 of	 the	 care	 home	 manager	 or	 owner,	 and	 whether	 the	 community	
pharmacy	 to	which	 they	 are	 registered	 offers	 an	MDS	 service	 (Alldred	 et	 al.	
2009).		
1.4.1.3 Monitored	Dosage	Systems		
MDS	 is	 a	 storage	 device	 for	 solid	 medications	 aimed	 at	 simplifying	 the	
administration	of	medication	by	or	to	patients	/	residents.	It	is	a	type	of	Multi-
Compartment	 Compliance	 Aid	 (MCA).	 They	 are	 usually	 filled	 at	 the	 point	 of	
dispensing	 in	a	pharmacy	and	can	be	particularly	useful	 in	care	homes	where	
medication	 is	 administered	 to	 a	 large	 number	 of	 residents.	 MDS	 has	 been	
reported	 to	have	a	number	of	benefits	 including	enhancing	 the	adherence	of	
residents	to	a	medication	regimen	and		minimising	errors	related	to	the	dose	of	
the	 medication	 (Bhattacharya	 2005).	 MDS	 is	 not	 without	 disadvantages	
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however.	 In	 general,	 the	 system	 is	 only	 suitable	 for	 oral	 solid	 medications	
although	there	are	specialist	systems	(e.g.	Biodose)	that	allows	for	liquid	dosage	
forms.	 However	 none	 of	 the	 systems	 are	 suitable	 for	 ‘when	 required’	
medications.	Estimates	suggest	that	approximately	40%	of	all	medicines	in	a	care	
home	 are	 packaged	 in	 MDS	 systems	 (Alldred	 et	 al.	 2009).	 The	 Royal	
Pharmaceutical	 Society	 state	 that	 MDS	 is	 not	 recommended	 for	 some	
medications	including	on	demand	medication,	drugs	with	potential	cytotoxicity,	
drugs	with	variable	dosing	and	hygroscopic	or	photosensitive	drugs	(Pountney	
2010).	 Nevertheless,	 MDS	 remains	 the	 most	 common	 system	 used	 in	 Care	
Homes	for	medicines	management.		
1.4.1.4 The	medication	administration	process	in	care	homes	
Medication	administration	 is	one	of	 the	most	 important	 functions	 for	 staff	 in	
care	homes.	In	nursing	homes,	nurses	fulfil	this	task	whilst	 in	care	homes	it	 is	
trained	carers.	Usually,	there	are	four	drug	administration	rounds	per	day	which,	
in	most	cases,	coincide	with	residents’	meal	times	(8:00,	12:00,	16:00	and	20:00).	
Generally,	 one	 member	 of	 staff	 will	 conduct	 the	 drug	 administration	 round	
which	can	take	anywhere	between	30	minutes	to	two	hours	depending	on	the	
number	 of	 residents	 and	 number	 of	 medications	 administered	 in	 each	 care	
home	(Alldred	et	al.	2009).	
Medicines	administration	in	the	care	home	setting	has	become	more	complex	in	
the	 past	 40	 years	 as	 a	 result	 of	 the	 increasing	 number	 of	 drugs	 and	 routes	
available	to	treat	residents	who	have	 increasingly	complex	conditions	and	co-
morbidities.	Medications	are	supplied	by	different	drug	companies	and	can	have	
different	 brand	 names	 and	 packaging	 and	 this	 compounds	 the	 complexity	 of	
medicines	administration	particularly	where	MDS	is	not	implemented	(Joshi	et	
al	2007)(Edwards	and	Axe	2015).	Ultimately,	there	must	be	clear	and	up	to	date	
written	procedures	for	administering	medicines	in	the	care	home	and	care	home	
managers	 should	 ensure	 that	 these	procedures	 are	 followed	 (Wilson	D	 et	 al.	
2011).	
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The	 administration	 of	medicines	 in	 care	 homes	 is	 highly	 regulated	 through	 a	
series	of	standards	and	legislative	mechanisms	in	the	Health	and	Social	Care	Act	
2008:	
1. Regulation	13	which	states	“The	registered	Person	must	protect	service	
users	against	the	risks	associated	with	the	unsafe	use	and	management	
of	 medicines,	 by	 means	 of	 making	 appropriate	 arrangements	 for	 the	
obtaining,	 recording,	 handling,	 using,	 safe	 keeping,	 dispensing,	 safe	
administration	and	disposed	of	medicines	used	for	the	purposes	of	the	
regulated	activity.”	
	
2. Outcome	 9	 (Management	 of	Medicines)	 of	 the	 Essential	 Standards	 of	
Quality	and	Safety	states	“People	who	use	services:		
I. Will	have	their	medicines	at	the	times	they	need	them,	and	in	a	
safe	way.	ii.	Wherever	possible	will	have	information	about	the	
medicine	 being	 prescribed	 made	 available	 to	 them	 or	 others	
acting	on	their	behalf.		
	
In	 turn	 this	 means	 providers	 “must	 handle	 medicines	 safely,	 securely	 and	
appropriately,	ensure	that	medicines	are	prescribed	and	given	by	people	safely	
and	 follow	 published	 guidance	 about	 how	 to	 use	 medicines	 safely.”					
(Oxfordshire	Clinical	Commissioning	Group	2015).	
A	 number	 of	 professional	 organisations	 have	 recognised	 the	 issues	 that	 can	
occur	in	care	homes	during	medicines	administration	rounds	and	have	produced	
corresponding	guidelines	 (Centre	 for	Policy	on	Aging	2011).	 For	example,	 the	
Royal	 Pharmaceutical	 Society	 has	 published	 a	 variety	 of	 guidelines	 including	
‘Improving	Pharmaceutical	Care	in	Care	Homes’	(Royal	Pharmaceutical	Society	
in	Scotland	2012),	 ‘Improving	Medicines	Use	for	Care	Home	Residents’	 (Royal	
Pharmaceutical	 Society	Wales	2016)	 and	 ‘The	handling	of	medicines	 in	 social	
care’	(Royal	Pharceutical	Soceity	of	Great	Britain	2007)	aimed	at	improving	the	
quality	of	care	 for	care	home	residents	with	an	emphasis	on	safe	handling	of	
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medicines.	 The	 key	 points	 in	 these	 documents	 were:	 (i)	 the	 need	 to	 deliver	
personalised		pharmaceutical	care	to	care	home	residents	based	on	individual	
need;	 (ii)	ensuring	equity	of	care	by	delivering	 the	same	standards	of	care	 to	
residents	in	care	home	as	would	be	received	by	their	peers	living	in	their	own	
home;	(iii)	quality	of	care	should	be	enhanced	by	developing	the	knowledge	and	
skills	of	all	healthcare	professionals	involved	in	providing	care	to	residents;	(iv)	
the	 need	 for	 integrated	 partnership	 working	 and	 communication	 with	 other	
healthcare	professionals	 to	ensure	pharmacists	will	be	able	to	maximise	their	
expertise	in	the	pharmaceutical	care	of	residents;	(v)	the	importance	of	sharing	
best	practice	between	pharmacists	working	in	the	care	homes	setting	to	reduce	
any	unwarranted	variation	in	care;	and	(vi)	empowering	frontline	practitioners	
to	deliver	change	by	working	with	residents	and	staff	in	care	home	to	overcome	
any	issue	that	may	impact	the	delivery	of	care	and	the		medicines	management	
process	(Royal	Pharmaceutical	Society	in	Scotland	2012).	
In	addition,	the	Nursing	and	Midwifery	Council	has	produced	a	set	of	guidelines	
called	the	‘Standards	for	medicines	management’	that	outlines	the	principles	of	
safe	and	effective	management	and	administration	of	medicines.	The	guideline	
provides	26	standards	that	aim	to	ensure	all	medicines	related	activities	adhere	
to	best	practice	for	safe	and	effective	administration	of	medicines		(Standards	
for	medicine	management	2010).	
Essentially,	 these	regulations	and	guidelines	focus	on	ensuring	commissioners	
and	 service	providers	 regularly	 review	and	audit	 their	policies,	processes	and	
local	governance	arrangements	to	guarantee	quality	system	are	in	place	in	care	
homes.	Further,	they	ensure	clear	lines	of	accountability	and	responsibility	in	the	
effective	management	 and	 administration	 of	medicines	 in	 care	 homes	 (NICE	
2014).	
1.5 Medicines	administration	errors	
Despite	 policies	 and	 procedures	 that	 seek	 to	 regulate,	 and	 quality	 assure	
medicines	 management	 (including	 administration)	 in	 care	 homes,	 there	 is	
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evidence	within	the	literature	of	failures	in	systems	and	processes	that	lead	to	
errors	in	medicines	administration.			
The	seminal	UK	study	in	this	area	is	the	‘Care	Homes	Use	of	Medicines	Study’	or	
CHUMS	 study.	 In	 this	 study,	 the	 investigators	 reviewed	 the	 medicines	
administration	 process	 in	 55	 care	 homes	 in	 England.	 Two	 drug	 rounds	 were	
observed	 for	 each	 of	 the	 256	 residents	 included	 in	 the	 study.	 	 The	 authors	
determined	 that	 care	 home	 staff	 spend	 as	much	 as	 40-50%	of	 their	 time	 on	
activities	that	are	related	to	medicines	administration	and	that	errors	occur	in	
8.4%	of	 all	 administrations	per	medication	 round.	 The	 authors	 also	observed	
that	~70%	of	residents	were	exposed	to	at	least	one	medication	error	per	day.		
Of	 the	 errors	 observed,	 approximately	 50%	were	 dose	 ‘omissions’	 and	more	
than	20%	were	incorrect	doses.	The	areas	identified	for	“priority	attention”	in	
the	 report	 included	 the	 Medication	 Administration	 Record	 (MAR)	 chart,	 the	
medication	 round	 itself	 and	 in	 particular	 dealing	 with	 interruptions	 and	
distractions,	as	well	as	improving	lines	of	communication	between	the	medicine	
provider	(generally	a	pharmacy)	and	care	home	staff	(Alldred	et	al.	2009).		
The	 CHUMS	 study	 is	 by	 no	 means	 the	 only	 example	 of	 poor	 medicines	
management	 in	care	homes.	Szczepura	et	al,	 (2011),	undertook	a	prospective	
analysis	 of	 13	 care	 homes	 (9	 residential	 and	 4	 nursing)	 over	 3-month	 period	
observing	~	190,000	medicines	administrations.	The	authors	examined	both	the	
incidence	and	types	of	medicines	administration	errors	(MAEs).	A	total	of	2,289	
potential	MAEs	were	identified	over	the	3-month	study	period	from	a	total	of	
188,249	administrations.	More	than	90%	of	the	residents	were	exposed	to	at	
least	one	error	with	51%	of	the	residents	exposed	to	a	serious	error;	a	serious	
error	was	defined	as	‘any	attempt	to	give	medication	to	the	wrong	resident	or	
to	give	medication	which	had	been	discontinued’.	Of	note,	less	than	a	third	of	
the	 staff	 involved	 in	 administering	 medicines	 (12/41)	 were	 aware	 of	 the	
potential	for	error	in	their	care	homes.	In	those	who	recognized	the	potential	for	
error,	 interruptions	 and	 distractions	were	 cited	 in	 around	 50%	 of	 cases	 as	 a	
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contributory	factor	that	may	lead	to	administration	errors.		Similarly,	50%	of	staff	
indicated	 they	 were	 “'stressed'	 or	 'under	 pressure	 to	 complete	 the	 round'”;	
issues	of	stress	and	time	pressures	were	said	to	be	more	prevalent	in	residential	
homes	compared	to	nursing	homes	(Szczepura	et	al.	2011).		
A	 number	 of	 studies	 have	 also	 reported	 on	 the	 impact	 of	 interruptions	 and	
distractions	 on	medicines	 administrations,	 Scott-Cawiezell	 and	 colleagues	 for	
example	have	reported	a	positive	relationship	between	interruptions	and	rate	
of	 administration	 errors	 with	 (p	 <	 0.099)	 through	 observing	 44	 medication	
administration	for	907	residents	in	5	nursing	homes	(Scott-Cawiezell	et	al.	2007).	
Similarly,	Biron	and	colleagues	reported	on	the	rate	of	interruptions	experienced	
by	 nursing	 staff	 during	medicines	 administration	 rounds.	 In	 an	 observational	
study	the	authors	reported	an	overall	interruption	rate	of	6.3	interruptions	per	
hour.	In	the	main	these	distractions	were	from	other	nurse	colleagues	(29.3%)	
or	 as	 a	 result	 of	 ‘system	 failures’	 that	 included	 missing	 medication	 or	
equipment	(22.8%)	during	the	preparation	phase	and	from	self-initiation	e.g.	to	
undertake	 secondary	 tasks	 (16.9%)	 and	 patients	 (16.0%)	 during	 the	
administration	 phase.	 Whilst	 the	 authors	 did	 not	 investigate	 the	 clinical	
consequences	 of	 these	 interruptions,	 they	 indicated	 that	 medicines	
administration	 rounds	were	 not	 protected	 from	 interruptions	 and	 this	 posed	
significant	risks	to	residents.		(Biron	et	al.	2009).	
Issues	associated	with	medicines	administrations	in	care	homes	are	not	confined	
to	the	UK.	A	study	of	Dutch	care	homes	found	examples	of	administration	errors	
including	 staff	 failing	 to	 supervise	 residents	 taking	 their	medication	 (this	was	
particularly	 concerning	 for	 those	 with	 dementia),	 and	 irregular	 timing	 of	
medicines	administration	with	medications	frequently	administered	more	than	
an	hour	early	or	late	(van	den	Bemt	et	al.	2009).	A	study	in	the	US	by	Pierson	et	
al.	 reported	 on	 the	 implementation	 of	 a	 web-based	 error	 reporting	 system	
introduced	 in	 nursing	 homes	 in	 North	 Carolina.	 Of	 the	 25	 homes	 that	
volunteered	to	take	part	in	the	study,	23	entered	error	reports	into	the	system	
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during	the	one-year	study	period.	Six	hundred	and	thirty-one	error	reports	were	
made	 related	 to	 2,731	 discrete	 error	 instances.	 The	 most	 common	 errors	
reported	 were	 dose	 omission	 (32%),	 overdose	 (14%),	 under	 dose	 (7%),	
administration	 to	 the	wrong	 patient	 (6%),	 and	wrong	medicine	 administered	
(6%),	and	wrong	strength	of	medicine	administered	(6%).	Most	errors	occurred	
during	 the	administration	round	 itself	 (47%)	and	67%	of	 the	errors	 that	were	
deemed	to	have	the	most	impact	on	patient	health	were	at	the	point	of	patient	
administration.	 Around	 50%	 of	 the	 errors	 were	 determined	 to	 be	 as	 a	
consequence	of	basic	human	error	(Pierson	et	al.	2007).		
Van	den	Bemt	and	co-workers	quantified	errors	in	medicines	administrations	in	
a	trio	of	nursing	homes	in	the	Netherlands	serving	127	residents.		The	study	was	
a	 disguised	 observational	 study	 over	 a	 two-week	 period	 but	 limited	 to	
observations	 on	 Monday,	 Wednesday,	 Thursday	 and	 Friday.	 Of	 the	 2,025	
administrations	observed,	errors	were	observed	in	428,	an	error	rate	of	~	21%.	
Staff	 frequently	 failed	 to	 supervise	 residents	 taking	 their	 medications	 and	
medicines	were	often	inappropriately	handled	for	example	enteric	coated	and	
modified	release	formulations	were	frequently	crushed	prior	to	administration	
(van	 den	 Bemt	 et	 al.	 2009).	 Particular	 classes	 of	 drugs	 were	 noted	 to	 be	
problematic,	for	example	patients	prescribed	antibiotics	had	a	higher	risk	of	a	
medicine	administration	error.	A	study	in	care	homes	in	the	county	of	Gwent	in	
South	Wales	 by	 Hussain	 and	Walker	 revealed	 similar	 findings.	 In	 a	 two-year	
period,	 18%	 of	 antibiotic	 regimens	 prescribed	 were	 administered	
inappropriately	(500	of	2,859	courses)	(Hussain	and	Walker	1999).	
Of	 note	 the	 timing	of	 the	 administration	 round	appears	 to	play	 a	 role	 in	 the	
prevalence	of	errors.	Van	den	Bemt	and	colleagues	reported	the	morning	(7am	
–	10am)	and	lunch	(10am	–	2pm)	rounds	lead	to	greater	incidence	of	errors	with	
odds	ratios	of	2.28	and	1.96	respectively	compared	to	afternoon	and	evening	
rounds	 where	 no	 change	 in	 the	 incidence	 of	 error	 was	 observed.	 It	 was	
hypothesised	that	this	was	largely	due	to	the	higher	workload	placed	on	staff	in	
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the	morning	where	medicines	administration	 rounds	are	 just	one	part	of	 the	
normal	morning	routine	which	includes	amongst	other	things	helping	residents	
out	of	bed,	personal	hygiene	routines,	getting	residents	dressed	and	having	their	
breakfast.	One	suggested	solution	to	the	pressures	on	staff	at	the	morning	round	
was	for	pharmacists	to	determine	whether	a	medicine	needs	to	be	administered	
in	 the	morning	 round(s)	 or	 whether	 they	 could	 be	moved	 to	 the	 afternoon.	
Where	 a	 prescription	 indicates	 for	 example	 the	 medicine	 should	 be	
administered	once	daily	 the	default	 is	 to	administer	 the	medicine	at	 the	 first	
medicines	round.	This	means	that	the	volume	of	medicines	administered	in	the	
morning	is	often	significantly	higher	than	in	 later	rounds	(van	den	Bemt	et	al.	
2009).		
Deshmukh	and	Sommerville	compared	drug	administration	records	before	and	
after	a	series	of	interventions	by	pharmacists	at	two	private	nursing	homes	in	
Norfolk.	A	total	of	173	interventions	were	made	classified	into	three	categories:	
(i)	interventions	related	to	residents’	therapy;	(ii)	interventions	related	to	nurse	
administration;	 and	 (iii)	 interventions	 related	 to	 blood	 tests.	 The	 baseline	
analysis	 indicated	 that	 although	 the	 two	 homes	 had	 written	 procedures	 for	
medicines	 administration,	 only	 58%	 of	 all	 administrations	 were	 being	
administered	in	accordance	with	these	guidelines.	The	most	frequent	deviation	
from	the	written	procedures	was	a	failure	to	formally	identify	the	resident	prior	
to	 administration	 and	 recording	 the	 administration	 without	 witnessing	
consumption.	 In	 addition,	 there	 was	 a	 failure	 to	 administer	 medicines	 in	
accordance	with	 the	prescriber’s	 intentions	 in	21.2%	of	 all	 administration	 for	
regular	medications	and	79.2%	of	all	administrations	for	‘when	required’	drugs.	
Of	 note	 2.7%	 and	 18.9%	 of	 administrations	 of	 regular	 and	 ‘when	 required	
medicines’	were	not	recorded	at	all	(Deshmukh	and	Sommerville	1996).	
There	is	 limited	anecdotal	evidence	that	the	landscape	is	similar	 in	Wales,	for	
example	 in	 2006	 the	 national	 service	 framework	 for	 older	 people	 in	 Wales	
indicated	 that	 medication	 administration	 errors	 occur	 frequently	 both	 in	
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hospitals	 and	 care	 homes.	 The	 report	 stated	 that	 “administration	 errors	
especially	 non-administration	 occur	 relatively	 frequently	 both	 in	 hospital	 and	
care	settings”	 (Welsh	Assembly	Government	2006).	However,	no	quantitative	
data	was	provided.	To	date	then,	there	has	been	little	work	examining	the	scale	
of	 the	 issues	 in	 Care	 Homes	 in	 Wales.	 To	 guard	 against	 medication	 errors,	
regulations	 and	 national	 minimum	 standards	 	 have	 been	 established	 in	
Wales(Welsh	Assembly	Government	2004)	and	in	England(CQC	2016)	to	help	to	
improve	 the	 quality	 of	medicines	management	 in	 care	 homes.	 Nevertheless,	
care	homes	continue	to	have	difficulties	in	achieving	a	satisfactory	performance	
in	medicines	management.	The	CQC	in	England	for	example	reported	that	nearly	
30%	 of	 care	 homes	 in	 England	 failed	 to	 meet	 the	 standards	 on	 medicines	
management	in	2015-16	(CQC	2016).		
Identifying	the	root	causes	of	medication	errors	in	Care	Homes	is	an	important	
and	 necessary	 step	 in	 establishing	 solutions	 to	 the	 problem.	 However,	 the	
evidence	is	equivocal,	and	it	has	been	difficult	to	determine	the	primary	cause(s)	
of	medication	errors	in	care	homes.	This	has	been	as	a	consequence	of	a	number	
of	 factors	 not	 least	 a	 general	 lack	 of	 research	 in	 the	 care	 home	 setting	 and	
varying	methodological	approaches	to	identify	medication	errors.	Nevertheless,	
a	number	of	causative	factors	have	been	identified.	For	instance,	in	the	CHUMs	
study,	 staff	 workload,	 lack	 of	 medicines	 training,	 interruptions	 during	
administration	rounds	together	with	a	lack	of	team	work	between	health	care	
professionals	were	factors	cited	as	contributors	to	medicine	errors	(Alldred	et	al.	
2009).	 Other	 studies	 have	 highlighted	 that	 the	 appropriate	 education	 and	
training	 of	 staff	 is	 key	 in	 ensuring	 appropriate	 care	 for	 residents	 with	 staff	
discussion	and	problem-solving	activities	leading	to	positive	outcomes	without	
necessarily	the	need	for	a	formal	educational	programme.	(Nolan	et	al.	2008)	
Human	 factors	 also	 plays	 a	 role	 with	 for	 example	 Ulanimo	 and	 colleagues	
reporting	that	tiredness	and	exhaustion	of	staff	were	responsible	for	nearly	33%	
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of	medication	errors	in	nursing	homes	with	45%	of	these	errors	attributed	to	not	
checking	the	patient’s	name	(Ulanimo	et	al.	2007).	
Interruptions	during	 the	administration	process	 is	 also	acknowledged	 to	be	a	
cause	of	administration	errors	impacting	on	the	efficiency,	quality,	and	safety	of	
administration	 processes	 (Thomson	 et	 al.	 2009).	 The	 literature	 broadly	
distinguishes	 between	 three	 types	 of	 interruption:	 interruptions	 mid	 task,	
interruptions	between	tasks,	and	system	failures	(e.g.	poor	access	to	equipment	
and	supplies)	(	King's	College	London	2010).	
Ultimately,	 irrespective	 of	 the	 cause	 of	 medicines	 related	 errors	 in	 the	 care	
home,	they	have	the	capacity	to	result	in	significant	harm	to	the	resident.	Such	
harm	 may	 increase	 the	 risk	 of	 an	 unintended	 health	 intervention,	 hospital	
admission,	 A&E	 visit	 or	 in	 the	 most	 extreme	 cases	 death.	 Moreover,	 these	
outcomes	are	associated	with	significant	human	resource	and	financial	burden.	
The	financial	burden	is	not	only	associated	with	the	cost	of	any	intervention	but	
also	from	the	generation	of	medicines	waste	which	is	estimated	to	be	£300M	
per	annum	(Hazell	and	Robson	2015).		Given	the	predicted	£30bn	funding	gap	in	
the	NHS	 (NHS	England	2016b),	 reducing	 the	 financial	 burden	associated	with	
ineffective	medicines	management	is	a	priority.		
1.6 Scope	of	thesis	
The	 increasing	 population	 of	 older	 adults	 in	 the	 UK	 is	 associated	 with	 an	
increasing	demand	for	health	and	social	care	services	to	provide	high	quality	care	
to	meet	the	needs	of	individuals	with	a	range	of	acute	and	chronic	conditions.	
The	drive	to	keep	individuals	in	primary	care	and	prevent	their	admission	to	the	
secondary	care	setting	along	with	the	bed	constraints	within	the	hospital	setting	
has	placed	significant	strain	on	domiciliary	care	services.	As	a	consequence,	the	
number	of	older	adults	living	in	care	homes	has	increased.	One	of	the	primary	
functions	 of	 care	 homes	 is	 to	 support	 residents	 to	 take	 their	 medicines	
appropriately.	 There	 is	 evidence	 in	 the	 literature	 however	 that	 medicines	
management	is	not	optimal	and	that	this	may	result	in	resident	harm.	Therefore,	
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the	 research	 in	 this	 thesis	 is	 driven	 by	 an	 objective	 to	 explore	 medicines	
management	in	care	homes	focussing	primarily	on	prescribing,	administration	
and	waste.		
The	objective	in	Chapter	2	was	to	evaluate	the	prescribing	landscape	in	ten	care	
homes	in	the	South	Wales	region.	Using	a	retrospective	analysis	of	Medicines	
Administration	Records	(MAR	charts),	the	extent	of	polypharmacy	(>5	medicines	
prescribed)	 (Jiron	 et	 al.	 2015)	 and	 excessive	 polypharmacy	 (>10	 medicines	
prescribed)	 was	 evaluated	 for	 each	 resident	 and	 the	 number	 of	 residents	
receiving	 potentially	 inappropriate	 medicines	 was	 calculated.	 Similarly,	 the	
anticholinergic	burden	was	calculated	for	all	residents.	Anticholinergic	burden	is	
associated	with	cognitive	impairment	and	increased	risk	of	falls	(amongst	other	
adverse	drug	reactions)	in	older	adults.	More	generally,	the	extent	of	prescribing	
by	 therapeutic	 class	was	 evaluated	 to	 provide	 an	 overview	 of	 the	medicines	
prescribed	to	care	home	residents.		
Chapter	 3	 builds	 on	 the	 findings	 in	 Chapter	 2	 by	 exploring	 the	 quality	 of	
medicines	management	in	home	residents	using	the	same	MAR	charts	that	were	
used	 in	 Chapter	 2.	 Errors	 were	 classified	 into	 five	 primary	 categories:	
administration,	 MAR	 chart	 errors,	 stock	 errors,	 regulatory	 errors	 and	
miscellaneous	errors	that	could	not	be	fully	categorised	based	on	MAR	charts	
alone.	A	particular	 focus	of	 the	 study	was	on	administration	errors	 i.e.	doses	
omitted,	 extra	 doses	 given,	 a	 deviation	 from	 the	 prescribed	 dose,	 an	
administration	 at	 the	 wrong	 time	 etc.	 This	 was	 used	 to	 calculate	 an	
administration	error	rate	as	a	function	of	the	total	number	of	opportunities	for	
error	and	the	error	rate	by	resident.	The	administration	errors	associated	with	
PIMs	were	also	described.		
In	Chapter	4,	the	medicines	waste	generated	in	care	homes	was	explored.	Data	
was	extracted	from	the	monthly	return	books	and	physical	counts	of	medicines	
in	the	home	were	also	made.	Using	medicines	prices	listed	in	the	British	National	
Formulary,	the	total	value	of	medicines	wasted	in	the	homes	investigated	was	
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calculated.	 	 The	 waste	 was	 categorised	 according	 to	 therapeutic	 class	 and	
whether	it	was	a	medicine	prescribed	on	a	regular	or	when	required	basis.		
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2.1 Introduction	
2.1.1 An	Aging	population	
Across	the	globe,	the	population	of	adults	over	65	years	of	age	(older	adults)	is	
increasing.	A	major	study	in	2010	predicted	that	as	a	consequence	of	increased	
life	 expectancy,	 in	 both	 developed	 and	 developing	 countries,	 the	 older	 adult	
population	would	 continue	 to	 rise	 for	 the	 next	 4	 decades	 (Stegemann	 et	 al.	
2010);	this	increase	is	mostly	seen	for	people	aged	80	years	and	over.	Table	2.1	
illustrates	the	predicted	changes	in	the	older	adult	population	over	the	next	40	
years.	Unfortunately,	overall	life	expectancy	is	increasing	faster	than	healthy	life	
expectancy	i.e.	the	average	number	of	years	lived	in	good	health.		In	the	UK,	the	
trend	in	the	older	adult	population	is	similar	with	an	expected	rise	in	the	number	
of	people	aged	65	and	over	from	11.8M	in	2018	to	more	than	16M	by	2040	(Age	
UK	2018);	at	this	point	the	older	adult	population	will	represent	almost	a	quarter	
of	the	UK	population.		
Table	2.1	predicted	changes	in	the	population	of	people	aged	>65	over	the	next	40	years	in	both	
developed	and	developing	countries.	(adapted	from	(Stegemann	et	al.	2010)	
	 2010	 2020	 2030	 2040	 2050	
Developed	countries	[people	in	millions]	
Total	population	 1,365,899	 1,397,353	 1,411,479	 1,412,224	 1,402,753	
Population	³	65	years	 204,140	 248,215	 298,215	 327,122	 343,396	
%	of	total	population	 14.9	 17.8	 21.1	 23.2	 24.5	
Developing	countries	[people	in	millions]	
Total	population	 5,539,491	 6,267,938	 6,903,864	 7,408,412	 7,785,103	
Population	³	65	years	 323,716	 467,255	 671,557	 919,185	 1,122,963	
%	of	total	population	 5.8	 7.5	 9.7	 12.4	 14.4	
This	 dramatic	 shift	 in	 the	 population	 is	 predicted	 to	 place	 extra	 pressure	 on	
healthcare	 services	 in	 both	 primary	 and	 secondary	 care.	 The	 older	 adult	
population	is,	at	least	in	part,	susceptible	to	multiple	chronic	co-morbidities	and	
vulnerable	to	polypharmacy	and	as	a	result	adverse	drug	reactions.		At	around	
75	years	of	age	there	is	an	inflexion	point	where	the	number	of	adults	reporting	
that	they	are	‘disabled’	is	greater	than	the	number	reporting	‘good	health’	(see	
Figure	 2.1)	 These	 factors	 are	 likely	 to	 place	 significant	 burden	 on	 an	 already	
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constrained	health	service	and	increase	costs	associated	with	the	provision	of	
healthcare	 to	 such	 individuals	 	 (Bonaga	 et	 al.	 2018).	 In	 addition,	 there	 is	 an	
ongoing	trend	to	develop	more	complex	therapeutic	modalities	and	advanced	
formulations	 to	 treat	 a	 range	 of	 emerging	 and	 complex	 conditions	 including	
Alzheimer’s,	 cancer	 and	 resistant	 infections	 as	 the	 older	 adult	 population	
continue	to	live	longer	(Brown	2015).		
	
	
Figure	2.1	Percentage	of	people	in	England	&	Wales	2011	reporting	’Good	health’,	or	‘Disability’	
in	different	age	ranges.	Taken	from	(Brown	2015)	
2.1.2 The	normal	aging	process	
Aging	 is	 a	gradual	progressive	process	 characterised	by	physiological	 changes	
and	an	observable	decline	 in	body	 functions	 together	with	an	 increase	 in	 the	
susceptibility	 to	 the	adverse	effects	of	drugs	 (Mangoni	 and	 Jackson	2003).	 In	
addition	to	physiological	decline,	there	are	age-related	neurological	deficits	that	
can	result	in	visual,	motor	and	cognitive	impairment	which	can	reduce	quality	of	
life	and	indeed	impede	an	individual’s	ability	to	manage	their	medications	safely	
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and	effectively.	The	major	physiological	and	functional	changes	that	occur	with	
aging	 along	with	 the	 consequence	 of	 such	 changes	 on	 pharmacokinetics	 are	
shown	 in	 Table	 2.2	 (adapted	 from	 (Stegemann	 et	 al.	 2010)).	 These	 changes	
impact	the	absorption,	metabolism,	distribution	and	elimination	of	drugs	which	
can	 be	 unpredictable	 and	 subject	 to	 significant	 inter-	 and	 intra-	 patient	
variability	but	ultimately	may	lead	to	adverse	drug	reactions	(Stegemann	et	al.	
2010).	 As	 a	 consequence,	 careful	 consideration	 should	 be	 made	 when	
prescribing	for	this	population.	
Table	2.2	Age-related	physiological	changes	and	their	pharmacokinetic	consequences.	
Physiological	changes	in	older	adults	 Pharmacokinetic	consequences	
• Increased	gastric	pH	
• Delayed	gastric	emptying	
• Reduced	splanchnic	blood	flow	
• Decreased	gastrointestinal	mobility	
Slightly	decreased	absorption	
(rarely	clinical	significant)	
• Increased	body	fat	
• Decreased	lean	body	mass	
Increased	 volume	 of	 distribution	 and	 half-life	 of	
lipophilic	drugs	
• Decreased	total	water	 Increased	 plasma	 concentration	 of	 hydrophilic	
drugs	
• Decreased	serum	albumin	 Increased	 free	 fraction	 in	 plasma	 of	 a	 few	 highly	
protein-bound	acidic	drugs	
• Increased	a	1-acid	glycoprotein	 Decreased	free	fraction	of	basic	drugs	
• Decreased	hepatic	blood	flow	 First-pass	metabolism	can	be	less	effective	
• Decreased	hepatic	mass	 Phase	 I	metabolism	of	some	drugs	may	be	slightly	
impaired		
• Decreased	renal	blood	flow	and	
glomerular	filtration	rate	
Renal	elimination	of	drugs	can	be	impaired	
There	are	also	potential	age-related	changes	in	the	pharmacological	response	to	
drug	therapy	however,	these	changes	are	generally	related	to	specific	drugs.	For	
instance,	the	use	of	the	same	dose	of	b-adrenoceptor	blockers	in	older	adults	
can	 be	 less	 effective	 compared	 to	 younger	 adults	 due	 to	 a	 decrease	 in	 the	
sensitivity	 of	 b-adrenoceptors	 in	 the	 heart	 with	 aging.	 Conversely,	
benzodiazepines,	which	are	frequently	used	to	treat	sleep	disturbance	in	older	
adults,	are	subject	to	increased	sensitivity	and	the	dose	should	be	decreased	by	
2-3	fold	in	older	adults	(Woodward	1999).	
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2.1.3 Geriatric	Syndromes	
Some	older	adults	are	susceptible	to	a	spectrum	of	clinical	conditions	that	are	
categorised	 as	 geriatric	 syndromes.	 Although	 there	 is	 no	 global	 consensus	
defining	the	range	of	geriatric	syndromes	(Won	et	al.	2013),	the	most	commonly	
cited	 syndromes	 are	 frailty,	 falls,	 urinary	 incontinence,	 osteoporosis,	
unintentional	weight	loss,	sleep	disturbances,	delirium,	dementia	and	cognitive	
impairment	 (see	 below	 for	 description).	 The	 reasons	 for	 the	 development	 of	
each	syndrome	is	multifactorial	but	there	are	likely	to	be	shared	risk	factors	and	
ultimately,	accumulation	of	such	syndromes	is	likely	to	have	a	significant	impact	
on	an	individuals’	quality	of	life.	
2.1.3.1 Commonly	cited	geriatric	syndromes		
(i) Delirium	is	characterised	by	a	sudden	decline	in	attention	and	cognitive	
function	and	can	follow	two	primary	forms	(i)	hyperactive	with	agitation	
or	(ii)	hypoactive	with	lethargy.	Delirium	has	an	incidence	of	14-56%	in	
older	 adults	 and	 is	 associated	 with	 a	 significant	 mortality	 rate	 in	
hospitalised	patients	(Fong	et	al.	2009).	Nearly	half	the	cases	of	delirium	
in	secondary	care	are	thought	to	be	preventable	by	interventions	such	as	
‘The	Hospital	Elder	Life	Programme’	(HELP)(Inouye	et	al.	2000)	which	is	
considered	one	of	 the	most	 effective	 intervention	 to	 reduce	both	 the	
incidence	of	delirium	rate	and	the	resultant	hospital	costs.		
(ii) Falls	 represent	 a	 life-threatening	 issue	 that	 affects	more	 than	 30%	 of	
older	adults	(Inouye	et	al.	2007).	It	can	result	in	an	unintended	hospital	
admission,	 long	 term	 institutionalisation,	 functional	 decline	 and	
increased	health	care	expenditure	(Tinetti	et	al.	1994).	A	variety	of	risk	
factors	are	associated	with	falls	including	adverse	drug	reactions,	visual	
acuity	problems,	physical	weakness,	arthritis	and	the	individual’s	physical	
environment.	 	 A	 number	 of	 educational	 interventions	 have	 been	
conducted	 to	 reduce	 the	 risk	 of	 falls	 including	 raising	 falls	 awareness	
among	older	adults	using	media,	brochures,	 lectures	etc.	 and	 through	
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educational	programmes	to	health	care	providers	(AGS	PANEL	ON	FALLS	
PREVENTION	2001).	
(iii) Frailty	 is	 a	 syndrome	 that	 affects	 nearly	 10%	 of	 older	 adults	 and	 is	
primarily	associated	with	the	female	sex.		Frailty	is	a	consequence	of	a	
variety	of	factors	including	weight	loss,	muscle	weakness,	slow	walking	
speed,	exhaustion	and	low	physical	activity	(Collard	et	al.	2012)(Bonaga	
et	al.	2018).	
(iv) Dementia	is	a	common	problem	that	affects	nearly	25%	of	adults	aged	
80	and	over	(Health	in	Aging.org	2017b)	of	which	Alzheimer’s	disease	is	
the	main	 type.	 Dementia	 is	 associated	with	 a	 decline	 in	memory	 and	
cognition	and	can	affect	an	individual’s	ability	to	perform	normal	tasks.	
There	are	broadly	 two	 types	of	 interventions	 to	ameliorate	dementia,	
and	 these	 are	 (i)	 non-pharmacological	 interventions	 such	 as	 Cognitive	
Stimulation	 Therapy	 (CST),	 or	 (ii)	 pharmacological	 interventions	which	
aim	to	slow	the	progress	of	cognitive	impairment	(Conn	and	Seitz	2010).	
(v) Urinary	incontinence	is	a	highly	prevalent	condition	which	affects	about	
30-65%	of	older	adults	and	is	particularly	prevalent	in	females	(Cook	and	
Sobeski	2013).	 It	may	occur	due	 to	age-related	changes	 in	 the	urinary	
tract,	 urinary	 infections	 or	 other	 unrelated	 causes	 such	 as	 cancer,	
diabetes,	 cognitive	 impairment	 and	 stroke.	 	 The	 most	 effective	
intervention	remains	pelvic	floor	muscle	strengthening	training	to	reduce	
urgency	of	urinary	incontinence.	(Roe	et	al.	2011)	
(vi) Sleep	disturbances	are	a	common	problem	that	affects	the	quality	of	an	
individual’s	 life	and	may	 lead	to	 falls,	depression	and	a	range	of	other	
health	issues	(Health	in	Aging.org	2017a).	Some	57%	of	older	adults	 in	
the	US	are	reported	to	have	chronic	insomnia	(Abad	and	Guilleminault	
2018).	A	number	of	contributory	factors	lead	to	sleep	problems	including	
socioeconomic	 status,	 certain	medications,	 acute	 and	 chronic	medical	
conditions	 (e.g.	 heart	 disease,	 persistent	 cough	 and	 depression).	
Interventions	such	as	improving	sleep	hygiene	and	avoiding	stimuli	are	
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preferred	 to	 pharmacological	 interventions	 (Sagayadevan	 et	 al.	 2017;	
Suzuki	et	al.	2017).	
(vii) Osteoporosis	 is	 a	 progressive	disease	 that	 affects	 nearly	 42%	of	 older	
adults	 in	 the	 UK,	 causing	 bone	 fragility	 that	 can	 result	 in	 debilitating	
fractures	 (National	 Osteoporosis	 Society	 2015).	 It	 is	 characterised	 by	
decreased	bone	mass	and	therefore	 it	should	be	mandatory	for	adults	
over	70	years	of	age	to	have	a	bone	mass	density	test.	Increased	calcium	
and	 vitamin	 D	 supplements	 are	 effective	 intervention	 to	 prevent	
osteoporotic	 fractures	 in	 addition	 to	 weight-bearing	 and	 strength	
training	exercises	(Daware	2014).	
(viii) Unintentional	weight	 loss	 (>	 5%	of	 body	mass	 loss	 in	 the	 last	 year)	 is	
another	 common	 problem	 that	 affects	 older	 adults	 and	 may	 lead	 to	
weakness,	falls,	and	other	health	issues.	It	 is	reported	to	affect	13%	of	
the	older	adult	population	(Ruscin	et	al.	2005).	Diminished	sense	of	taste	
is	 one	 of	 the	 main	 causes	 however,	 medications	 and	 other	 medical	
conditions	also	contribute.	Limited	evidence	is	available	on	the	beneficial	
effect	 of	 either	 nutritional	 or	 pharmacological	 interventions	 on	
improving	weight	in	the	frail	older	adult	population	(Stajkovic	et	al	2011).	
Many	of	these	syndromes	overlap	or	are	a	causative	factor	of	each	other	and	as	
a	 consequence	of	geriatric	 syndromes,	older	adults	are	 likely	be	prescribed	a	
greater	 number	 and	 range	 of	 medicines	 and	 are	 likely	 to	 require	 additional	
support	to	take	such	medications	effectively	and	to	reduce	the	risk	of	adverse	
drug	reactions	(Duerden	2013).		
2.1.4 Polypharmacy	
The	complex	medical	conditions,	long	term	illnesses,	multiple	co-morbidities	and	
geriatric	syndromes	that	affect	some	older	adults	often	require	multiple	drug	
therapies	as	the	primary	intervention	to	either	cure,	prevent,	treat,	control	or	
improve	 the	 quality	 of	 life	 of	 individuals.	 Given	 the	 age-related	 changes	 in	
pharmacokinetics	 and	 pharmacodynamics	 in	 this	 population,	 this	 makes	 the	
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appropriate	 use	 of	 medicines	 more	 challenging.	 Ultimately,	 the	 incidence	 of	
polypharmacy	in	older	adults	is	significant	and	the	negative	consequences	of	this	
can	be	more	pronounced.	There	are	more	than	24	definitions	of	polypharmacy	
(see	Bushardt	et	al.	2008),	although	the	majority	focus	on	the	absolute	number	
of	medications	prescribed	(see	Table	2.3).		In	a	recent	systematic	review	of	the	
definitions	of	polypharmacy,	over	80%	of	the	identified	definitions	were	purely	
numerical	and	half	of	 these	defined	polypharmacy	as	 the	use	of	 five	or	more	
medications	on	a	daily	basis	(Masnoon	et	al.	2017).		
Table	2.3	Numerical	definition	of	polypharmacy	and	associated	terms	by	duration	of	therapy/	
healthcare	setting	(adapted	from	Masnoon	et	al.	2017)	
Term	 Number	of	medications	 References	
Polypharmacy	
		
³	2	for	240	days	(long	term)	 (Veehof	et	al.	2000)	
³	5	medications	in	the	same	month	 (Jiron	et	al.	2015)	
>	5	medications	for	³	90	days	 (Narayan	and	
Nishtala	2015)	
³	5	medications	in	the	same	quarter	of	a	year	 (Kann	et	al.	2015)	
³	5	medicines	at	hospital	discharge	 (Nobili	et	al.	2011)	
5	to	9	medicines	on	the	same	day	of	
maximum	number	of	prescriptions	of	the	
study	year	
(Chan	et	al.	2009b)	
5	to	9	medications	for	³	90	days	 (Nishtala	and	
Salahudeen	2015)	
5	to	9	medicines	during	hospital	stay	 	
³	10	medicines	during	hospital	stay	 (Sganga	et	al.	2014)	
Major	polypharmacy	 ³	10	on	the	day	of	maximum	number	of	
prescriptions	of	the	study	year	
(Chan	et	al.	2009b)	
Hyper-polypharmacy	 ³	10	medications	for	³	90	days	 Nishtala	and	
Salahudeen	2015)	
Excessive	polypharmacy	 ³	10	medications	in	the	same	quarter	of	a	
year	
(Kann	et	al.	2015)	
	 ³	10	medications	during	hospital	stay	 (Vetrano	et	al.	
2014)	
Persistent	
polypharmacy	
³	5	medications	for	181	days	 (Chan	et	al.	2009a)	
Chronic	polypharmacy	 ³	5	medications	in	1	month	for	6	months	
(consecutive	or	not)	in	a	year	
(Franchi	et	al.	2013)	
Other	studies	have	defined	polypharmacy	according	to	the	appropriateness	of	
medicines	being	prescribed	 rather	 than	 the	absolute	number	 (see	Table	2.4).	
Here,	 polypharmacy	 is	 either	 described	 as	 appropriate	 polypharmacy	
“medication	used	to	treat	complex	or	multiple	conditions	where	medicines	have	
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to	 be	 optimised	 or	 prescribed	 according	 to	 best	 evidence”	 and	 problematic	
polypharmacy	where	 “multiple	medications	 are	prescribed	 inappropriately	or	
the	intended	benefit	of	the	medication	is	not	realised”	(Duerden	2013).		
Table	2.4	Descriptive	definitions	of	polypharmacy	and	associated	terms	(adapted	from	(Masnoon	
et	al.	2017)	
Term	 Definition	 References	
Polypharmacy	 • Patients	 visiting	 multiple	 pharmacies	 to	 obtain	
medications		
• Co-prescribing	multiple	medications	
	
• Simultaneous	and	long-term	use	of	different	drugs	by	the	
same	individual	
• Polypharmacy	definition	 ranges	 from	the	use	of	a	 large	
number	 of	 medications,	 to	 the	 use	 of	 potentially	
inappropriate	 medications,	 medication	 underuse	 and	
medication	duplication	
• Potentially	inappropriate	medications	
	
• Use	of	multiple	medications	concurrently	and	the	use	of	
additional	medications	to	correct	adverse	effects	
• Use	of	medications	which	are	not	clinically	indicated	
	
• More	drugs	being	prescribed	or	taken	than	are	clinically	
appropriate	in	the	context	of	a	patient’s	comorbidities	
(Gillette	 et	 al.	
2015)	
(Filkova	et	al.	
2014)	
(Joaquim	and	
Campos	2011)	
(Maggiore	et	
al.	2010)	
	
	
(Bushardt	et	
al.	2008)	
(Medeiros-
Souza	et	al.	
2007)	
(Fulton	and	
Allen	2005)	
(Zarowitz	et	
al.	2005)	
Appropriate	
polypharmacy	
Optimisation	 of	 medications	 for	 patients	 with	 complex	
and/or	 multiple	 conditions	 where	 medicine	 usage	 agrees	
with	best	evidence	
Rational	
(Cadogan	et	
al.	2015)	
Rational	
polypharmacy	
and	
indiscriminate	
prescribing	
Rational	 polypharmacy	 recognizes	 legitimate	 prescribing	
and	 indiscriminate	 prescribing	 suggests	 inappropriate	
prescribing	 (the	 terms	 “legitimate	 prescribing”	 and	
“inappropriate	prescribing”	were	not	explained)	
(Ballentine	
2008)	
Pseudo-
polypharmacy	
Patients	being	recorded	as	taking	more	medications	than	
they	are	actually	taking	
(Rollason	and	
Vogt	2003)	
This	diverse	range	of	definitions	creates	confusion	for	researchers	and	therefore	
Gillette	et	al.	introduced	a	new	term	-	‘extraordinary	prescribing’	(Gillette	et	al.	
2015).	The	term	is	an	attempt	to	dilute	the	contribution	of	the	absolute	number	
of	medications	prescribed	(which	may	be	appropriate	in	patients	with	multiple	
disease	states)	and	rather	focus	on	the	consequences	of	prescribing.	The	authors	
indicate	 that	 ‘extraordinary	 prescribing’	 defines	 “patients	 who	 are	 taking	
medications	that	are	either	grossly	excessive	or	not	beneficial	for	that	patient”	
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(Gillette	et	al.	2015).	To	date,	the	term	is	yet	to	gain	traction	and	polypharmacy	
remains	the	choice	term.	Although	polypharmacy	and	inappropriate	prescribing	
are	sometimes	used	interchangeably,	there	are	key	differences.	A	patient	might	
be	described	as	subject	 to	polypharmacy	 for	example	 if	 they	are	 taking	more	
than	 five	medications.	 However,	 the	 prescribing	may	 be	 entirely	 appropriate	
given	the	patient’s	condition(s).	Inappropriate	prescribing	therefore	should	be	
defined	as	“the	use	of	medicines	whose	potential	harms	outweigh	their	benefits	
or	 frequent	 omission	 of	 potentially	 beneficial	 medications	 or	 prescription	 of	
medications	without	clear	indications”	(OʼConnor	et	al.	2012).	
2.1.5 Potentially	inappropriate	medications	
Potentially	inappropriate	medications	(PIM)	are	those	medications	in	which	the	
risk	 of	 adverse	 drug	 reactions	 outweighs	 any	 potential	 clinical	 benefits	
particularly	 when	 safer	 and	more	 effective	medicines	 are	 available.	 The	 risk	
associated	 with	 the	 prescribing	 of	 PIMs	 is	 the	 emergence	 of	 adverse	 drug	
reactions	in	patients.	This	has	the	potential	to	result	in	an	unintended	hospital	
admission,	 an	 A&E	 visit	 and	 increased	mortality	 and	morbidity	 (Bjerre	 et	 al.	
2015).	 A	 variety	 of	 screening	 tools	 have	 been	 developed	 to	 assess	 the	
appropriateness	 of	 medications	 in	 older	 adults	 (see	 Table	 2.5)	 and	 to	 make	
changes	to	medicines	regimens	as	a	consequence.		The	tools	largely	fall	into	two	
categories:	(i)	an	implicit	approach	which	is	based	entirely	on	the	judgment	of	a	
clinician(s)	after	a	review	of	a	patient	or	(ii)	an	explicit	approach	where	there	is	
a	categorical	 list	of	drugs	 that	are	considered	as	potentially	 inappropriate	 for	
individuals	(Kashyap	and	Iqbal	2014).				
Although	the	implicit	approach	is	perhaps	the	preferred	model	as	it	is	based	on	
assessing	 the	 patient,	 their	 conditions	 and	 their	 medicines,	 it	 is	 a	 time-
consuming	 approach	 and	 is	 dependent	 on	 the	 knowledge	 and	 skills	 of	 the	
clinician	 and	 their	 subsequent	 judgment	 according	 to	 each	 individual.	While	
explicit	 criteria	 lack	 the	 person-centered	 approach,	 they	 provide	 a	 set	 of	
consistent	 standards	 (drug	 or	 disease	 oriented)	 that	 are	 approved	 by	 a	
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consensus	panel,	and	enable	the	clinician	reviewing	an	individual’s	medicines	to	
make	 judgments	on	 the	 current	best	 evidence.	 They	also	provide	 for	 a	desk-
based	 review	 of	 a	 patient’s	 medicines	 which	 is	 less	 resource	 intensive	 than	
implicit	methods.		
Beers	criteria	was	chosen	for	this	study	because	it	is	one	of	the	most	commonly	
used	explicit	criteria	to	identify	the	prevalence	of	PIMs.	The	criteria	categorises	
medications	into:	(i)	those	that	should	be	avoided	in	older	adults	aged	65	and	
over;	(ii)medicines	to	be	used	with	caution	(independent	of	disease	or	condition)	
and	 (iii)	 medicines	 that	 should	 be	 avoided	 in	 particular	 disease	 states	 or	
conditions.	Of	note,	as	the	researcher	did	not	have	access	to	the	medical	records	
of	residents	in	care	homes,	Beers	criteria	provided	a	framework	to	identify	PIMs	
independent	of	clinical	diagnosis.	Other	tools	e.g.	STOPP/START	are	less	valuable	
when	clinical	diagnosis	is	not	available.		
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Table	2.5	Screening	tools	for	the	identification	of	potentially	inappropriate	medications	in	older	adults	(adapted	from	(Kashyap	and	Iqbal	2014).	
Screening	tools	 Method	used	 Positive	characteristics		 Limitations	
Explicit	Methods	
Beer’s	criteria	
(Beers	et	al.	1991)	
Derived	 from	 published	 reviews,	
expert	 opinions	 and	 consensus	
techniques	 without	 clinical	
judgement	 about	 the	 presenting	
patient.		
Identifies	 and	 groups	 medications	 that	 may	 be	
inappropriate	for	older	adults	into	three	categories:	
(i)	drugs	that	should	be	avoided	in	older	adults;	(ii)	
drugs	 that	 exceed	 the	 maximum	 recommended	
daily	 dose;	 (iii)	 drugs	 that	 should	 be	 avoided	 in	
combination	with	specific	co-morbidity.	
The	 criteria	 do	 not	 contain	 all	 causes	 of	 potentially	
inappropriate	 prescribing	 (e.g.	 drug	 interactions	 are	 not	
included).	Controversy	exists	over	some	of	the	medications	
that	are	considered	to	be	potentially	inappropriate.	
IPET	Criteria	
(Naugler	et	al.	2000)	
This	 is	a	 revised	version	of	Canadian	
McLeod	criteria.		
It	includes	14	instances	of	inappropriate	prescribing	
and	identifies	38	agents	as	contraindicated	or	likely	
to	 cause	 drug-drug	 or	 drug-disease	 interactions	
based	on	risk-benefit	ratio.	
The	criteria	not	based	on	physiological	systems.	The	criteria	
is	not	comprehensive;	there	are	only	14	cited	situations	to	
be	avoided.		
Zhan	criteria	
(Zhan	et	al.	2001)	
A	variation	of	the	1997	version	of	the	
Beer’s	criteria	
It	has	utility	for	identifying	prescribing	problems	in	
retrospective	 review	 of	 older	 adult’s	 medication	
lists.		
It	has	limited	applicability	to	geriatric	clinical	practice	as	it	
has	low	levels	of	inter-rater	reliability	and	is	focused	only	on	
those	 drugs	 which	 should	 be	 avoided	 in	 older	 adults	
without	 any	 consideration	 of	 drug	 dosage	 form,	 drug-	
disease	interactions,	or	drug-drug	combinations	
Rancourt	criteria	
(Rancourt	et	al.	2004)	
Primarily	 based	 on	 Beer’s	 and	
McLeod	 criteria.	 Updated	 and	
validated	 using	 modified	 Delphi	
method	by	local	experts	in	long-term	
care	setting	of	Quebec	city,	Canada.		
Includes	a	wide	range	of	potentially	 inappropriate	
medicines	and	is	arranged	according	to	drug	classes	
along	 with	 their	 ATC	 code	 for	 ease	 of	 use	 and	
matches	data	on	an	international	level.	
The	 criteria	 is	 based	 on	 observations	 from	 one	 clinical	
setting	in	one	region	i.e.	long	term	care	settings	in	Quebec	
City.	 It	 is	 also	 more	 oriented	 towards	 assessment	 of	
psycholeptic	 drugs	 and	 there	 is	 a	 lack	 of	 evidence	 with	
respect	to	inter-rater	reliability.		
Health	 Plan	 Employer	
Data	 and	 Information	
Set	(HEDIS)	Criteria	2006	
(National	 Committee	 on	
Quality	Assurance	2018)	
Provides	a	 list	of	drugs	which	should	
always	 be	 avoided	 in	 elderly.	 It	
identifies	 rates	 of	 inappropriate	
prescribing	 in	 the	 elderly	 based	 on	
Beer’s	criteria.		
It	 is	 currently	 being	 used	 in	 the	 2006	Health	 Plan	
Employer	Data	and	Information	Set	(HEDIS)	in	2006	
to	assess	quality	of	care	for	older	Americans		
The	 criteria	 does	 not	 include	 all	 the	drugs	 listed	 in	 Beers	
criteria	 and	 the	 drugs	 are	 not	 classified	 according	 to	
severity.	There	is	 lack	of	convincing	evidence	showing	the	
benefits	of	using	HEDIS	Criteria.	
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Screening	tools	 Method	used	 Positive	characteristics		 Limitations	
STOPP	criteria	
(Gallagher	et	al.	2008)	
Part	1	of	the	STOPP/START	criteria,	this	is	
a	validated	screening	tool	of	older	adult’s	
medicines	 called	STOPP	 (Screening	Tool	
of	 Older	 People’s	 potentially	
inappropriate	 Prescriptions).	 It	
incorporates	 commonly	 encountered	
instances	 of	 potentially	 inappropriate	
prescribing	 in	 older	 people	 including	
drug-drug	and	drug-disease	interactions,	
drugs	which	adversely	affect	older	adults	
at	 risk	 of	 falls	 and	 duplicate	 drug	 class	
prescriptions.	
The	 criteria	 are	 easy	 to	 use	 as	 they	 are	 based	 on	
physiological	systems	similar	to	the	pattern	of	most	
drug	formularies.	Each	criterion	is	accompanied	by	a	
concise	 explanation	 as	 to	 why	 the	 prescription	 is	
potentially	inappropriate.	
The	evaluation	of	this	tool	requires	additional	studies	
in	different	settings	and	different	countries.	
START	criteria	
(Gallagher	et	al.	2008)	
Part	2	of	the	STOPP/START	criteria,	this	is	
a	 screening	 tool	 to	 alert	 prescribers	 to	
the	right	treatment.	It	was	prepared	and	
validated	 for	 identifying	 prescribing	
omissions	in	older	adults.		
It	 is	 a	 valid,	 reliable	 and	 comprehensive	 screening	
tools	 that	 enables	 the	 prescriber	 to	 appraise	 an	
older	patient's	prescription	drugs	 in	 the	context	of	
his/her	concurrent	diagnoses	
The	international	applicability	of	STOPP	and	START	has	
not	been	established.	Requires	access	 to	 the	patient	
and	their	records.	
Winit-Watjana	citeria	
(Winit-Watjana	 et	 al.	
2008)	
These	 explicit	 criteria	 list	 high-risk	
medications	 with	 potential	 adverse	
reactions,	drug-disease	 interactions	and	
drug-drug	interactions.	According	to	this	
list	 drugs	 acting	 on	 central	 nervous	
system,	 musculoskeletal	 system	 and	
cardiovascular	 system	 were	 high-risk	
medications	in	elderly.	
This	 list	 has	 addressed	 different	 issue	 of	
inappropriate	 prescribing	 and	 most	 of	 identified	
inappropriate	medications	were	 similar	 among	 the	
different	explicit	criteria	
This	tool	is	not	experienced	in	different	clinical	settings	
and	also	lack	of	inter-rater	reliability	
Implicit	Methods	
Medication	
Appropriateness	 Index	
(MAI)		
(Hanlon	et	al.	1992)	
An	 implicit	 criterion	 developed	 by	
Hanlon	 et	 al	 in	 1992	 and	 modified	 in	
1997.	 It	 is	 intended	 to	 be	 a	 reliable,	
standardized	 method	 of	 addressing	
multiple	 elements	 of	 prescribing,	
applicable	 to	 a	 variety	 of	 medications,	
clinical	conditions	and	settings.	
Excellent	 intra-rater	 and	 inter-rater	 reliability	
associated	with	 this	 tool	which	was	 tested	 in	both	
the	 inpatient	 and	 ambulatory	 settings.	 It	 has	
numerous	 components	 to	 check	 the	
appropriateness	of	a	medicine	and	can	be	applied	to	
all	 type	 of	 medication	 in	 the	 context	 of	 patient-
specific	characteristics	
A	more	time-consuming	criteria	as	it	takes	10	minutes	
to	assess	each	drug.		
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2.1.5.1 National	Prescribing	Indicators	(NPIs)	
In	addition	to	determining	the	appropriateness	of	medicines	at	the	patient	level,	
a	variety	of	organisations	have	sought	 to	establish	national	 standards	 for	 the	
prescribing	of	a	range	of	medicines	called	National	Prescribing	Indicators.	These	
NPIs	 are	 used	 to	 promote	 therapeutic	 priorities	 and	 enable	 stakeholders	 to	
compare	and	contrast	the	prescribing	of	a	medicine(s)	by	different	prescribers	
or	organisations.	Ultimately,	the	NPIs	serve	to	benchmark	prescribers	against	a	
set	of	agreed	and	evidence-based	standards.		In	Wales,	the	NPIs	are	‘owned’	by	
the	All	Wales	Medicines	Strategy	Group	(AWMSG)	(All	Wales	Medicines	Strategy	
Group	 2017)	 and	 feature	 three	 distinct	 categories:	 (i)	 safety	 indicators;	 (ii)	
antimicrobial	stewardship	indicators	and	(iii)	efficiency	indicators.	Whilst	not	all	
the	 indicators	 are	 directly	 relevant	 to	 the	 care	 home	 setting,	 anticholinergic	
burden	is	a	key	indicator	in	this	setting.			
2.1.5.1.1 Anticholinergic	Burden	
Residents	 in	 care	 homes	 are	 widely	 prescribed	 drugs	 with	 anticholinergic	
properties	 (DAP)	 to	 treat	 a	 variety	 of	 disorders	 including	 gastrointestinal	
disturbances,	motion	 sickness,	 sleep	 disorders	 and	 Parkinson’	 disease.	 These	
drugs	exert	their	action	through	blockade	of	muscarinic	receptors.	However,	the	
non-selective	 blockade	 of	 this	 receptor	 results	 in	 unwanted	 central	 and	
peripheral	side	effects	leading	to	dry	mouth,	constipation,	blurred	vision,	urinary	
retention,	sedation,	cognitive	impairment	and	delirium	(Tune	2001).	In	addition,	
older	adults	are	more	susceptible	to	the	adverse	effects	of	DAPs	due	to	the	age-
related	 changes	 in	 pharmacokinetic	 and	 pharmacodynamics	 which	 may	
exacerbate	 their	 impact	 on	 this	 vulnerable	 population.	 Even	when	 individual	
medicines	 have	 a	 low	 level	 of	 anticholinergic	 activity,	 	 where	 they	 are	 used	
cumulatively	 they	 have	 been	 associated	with	 increased	 cognitive	 impairment	
and	mortality	(Fox	et	al.	2014).	As	a	consequence,	there	is	a	drive	to	reduce	the	
anticholinergic	burden	in	individuals	over	65	years	of	age.		
	
       
	
Chapter	2	
	 53	
2.2 Aims	and	objectives:	
The	 aim	 of	 the	 present	 study	 is	 to	 explore	 the	 prescribing	 of	 medicines	 to	
resident	in	care	homes.			
The	objectives	are:	
1. To	identify	the	medicines	prescribed	to	care	home	residents.	
2. To	assess	the	prevalence	of	polypharmacy	and	excessive	polypharmacy	
in	care	homes	residents.	
3. To	assess	the	prevalence	of	PIMs	prescribed	to	care	homes	residents.	
2.3 Methods	
2.3.1 Ethical	Approval	
Prior	to	commencing	this	study	ethical	approval	was	obtained	from	the	Cardiff	
School	 of	 Pharmacy	 and	 Pharmaceutical	 Sciences	 (SPPS)	 Research	 Ethics	
Committee	 (see	 Appendix	 1).	 	 This	 study	 involved	 secondary	 analysis	 of	
anonymised	 patient	 data	 therefore	 consent	 from	 individual	 resident	was	 not	
required.	
2.3.2 Recruitment	of	care	homes	
This	 project	 formed	 part	 of	 a	 wider	 study	 funded	 by	Welsh	 Government	 to	
explore	 the	 implementation	of	 an	 electronic	MAR	 system.	 The	project	was	 a	
collaboration	 between	 Cardiff	 University	 and	 a	 commercial	 partner,	 Invatech	
Health.	Recruitment	was	led	by	Invatech	Health	although	the	inclusion/exclusion	
criteria	and	the	recruitment	methodology	were	developed	in	partnership.	Ten	
care	 homes	 were	 recruited	 by	 purposive	 sampling	 from	 the	 Abertawe	 Bro	
Morgannwg	University	Health	 Board	 (ABMU)	 in	Wales.	 To	 be	 eligible	 for	 the	
study,	 the	nursing	or	residential	home	had	to	be	 located	 in	the	ABMU	health	
board,	 primarily	 cater	 for	 older	 adults,	 be	 fully	 registered	with	 the	 Care	 and	
Social	Services	 Inspectorate	Wales	(CSSIW,	now	Care	Inspectorate	Wales)	and	
currently	use	a	paper-based	MAR	chart	system.	 Identifying	care	homes	 in	the	
health	board	was	achieved	in	two	parts.	In	Part	1,	care	homes	in	the	three	local	
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borough	councils	comprising	the	ABMU	health	board	were	identified	from	the	
Care	 and	 Social	 Service	 Inspectorate	Wales	 (CSSIW)	 directory	 of	 care	 homes	
(http:/cssiw.org.uk/find-a-care-service/service-directory/?	 lang=en).	 The	
directory	was	filtered	for	adult	residential	services	in	the	Swansea,	Neath	Port	
Talbot	and	Bridgend	borough	councils.	In	Part	2,	the	Lang	Buisson	commercial	
database	of	care	homes	was	used	to	obtain	telephone	numbers,	addresses	and	
contact	names	for	the	care	homes	identified	in	Part	1.	
An	 introductory	 letter	was	 sent	out	 from	 the	ABMU	Health	Board	 to	 all	 care	
homes	to	invite	them	to	a	launch	event	to	find	out	more	about	the	project.	All	
care	homes	were	 invited	 to	express	 interest	and	volunteer	 to	sign	up	 for	 the	
project.	The	manager	of	each	participating	care	home	was	approached	to	obtain	
written	informed	consent.		
2.3.3 Data	collection	and	extraction	
Anonymised	MAR	charts	were	received	from	the	ten	participating	care	homes	in	
October	2014	covering	a	28-day	medicines	 cycle	 that	 ran	 from	September	 to	
October.	An	anonymisation	process	was	carried	out	in	the	care	homes	such	that	
any	section	of	the	MAR	chart	that	could	identify	the	resident	was	anonymised.	
This	included	the	resident’s	name	and	room	number,	any	information	in	relation	
to	 the	 pharmacy	 that	 supplied	 medication	 to	 the	 home	 and	 any	 further	
information	that	could	link	the	MAR	charts	to	any	single	person,	organisation	or	
service	 user	 other	 than	 the	 service	 provider	 themselves.	 A	 patient	 ID	 was	
assigned	to	each	resident	based	on	their	date	of	birth.	
The	medicines	prescribed	for	each	resident	was	extracted	directly	from	the	MAR	
chart	and	classified	according	to	therapeutic	categories	in	the	British	National	
Formulary	(BNF	2017).	Information	extracted	from	the	MAR	charts	included:	(i)	
date	of	birth;	(ii)	name	of	drug;	(ii)	strength	of	drug;	(iii)	type	of	formulation;	(iv)	
dose	of	prescribed	drug;	(v)	frequency	of	administration;	(vi)	quantity	received;	
(vii)	 type	 of	medication	 i.e.	whether	 regular	 or	 ‘when	 required’	medications.	
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Dressings,	nutritional	supplements	and	related	appliances	were	not	included	in	
the	study.		
2.3.4 Data	analysis	
Medication	data	for	a	28-day	period	was	collected	and	entered	into	Microsoft	
Excel	for	Mac	version	15.33	(Microsoft	Corporation;	Seattle,	USA).	Descriptive	
statistics	were	generated	to	(i)	categorise	the	prescribed	medicines	against	BNF	
therapeutic	class	and	(ii)	 to	calculate	the	prevalence	of	polypharmacy	(five	or	
more	medications	prescribed)	 (Jiron	et	al.	 2015)	and	excessive	polypharmacy	
(ten	or	more	medications	prescribed)	(Kann	et	al.	2015).			
2.3.4.1 Calculating	the	prevalence	of	potentially	inappropriate	medicines	
The	fourth	update	of	Beers	criteria	(Samuel	2015)	was	used	to	determine	the	
prevalence	 of	 potentially	 inappropriate	medicines	 use	 across	 the	medication	
profiles	of	260	residents	in	the	ten	care	homes	included	in	this	study.	The	2015	
Beers	criteria	classifies	53	medication	or	medication	classes	into	three	classes:	
(i)	 34	 medications	 or	 medications	 classes	 that	 should	 be	 avoided	 (or	
deprescribed)	for	patients	aged	65	years	and	older	irrespective	of	their	disease	
or	condition;	(ii)	medications	or	medication	classes	that	should	be	avoided	in	19	
specific	disease	or	syndromes;	and	(iii)	14	medications	that	should	be	used	with	
caution.		
	In	the	current	study,	the	focus	was	on	classes	(i)	and	(iii)	 in	Beers	criteria	 i.e.		
those	medications	or	classes	of	medication	that	should	be	avoided	and	those	
that	should	be	used	with	caution;	class	(ii)	was	not	applicable	as	the	researcher	
did	 not	 have	 access	 to	 patient	 records	 that	 would	 have	 provided	 diagnostic	
criteria	for	prescribed	medications.		Only	one	modification	to	Beers	criteria	was	
made:	 Zopiclone	was	 included	 in	 the	 list	 of	 (non-benzodiazepines	 hypnotics)	
replacing	 Eszopiclone	 because	 Zopiclone	 is	 commercially	 available	 in	 the	 UK	
(rather	than	eszopiclone).	A	description	of	the	included	medicines	classes,	the	
rationale	for	inclusion	and	the	strength	of	evidence	can	be	found	in	Tables	2.6	
and	2.7.			The	final	list	of	medications	used	in	the	analysis	featuring	32	individual	
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medications	that	should	be	avoided	in	older	adults	and	12	individual	medications	
that	should	be	used	with	caution	can	be	seen	more	conveniently	in	Table	2.8.		
Beers	 criteria	 was	 applied	 to	 care	 home	 10	 (nursing	 home	 with	 specialised	
population	having	early	onset	dementia).	In	this	home,	some	residents	were	<	
65	 which	 is	 outside	 of	 the	 scope	 of	 Beers	 criteria.	 However,	 analysis	 of	 the	
prescribing	 patterns	 in	 these	 residents	 showed	 similar	 levels	 for	 example	 of	
polypharmacy	as	those	in	other	homes	(residents	>	65).	As	such,	the	researcher	
concluded	that	whilst	the	resident	age	profile	may	not	have	matched	Beers,			it	
remained	valid	given	their	prescribing	to	apply	Beers	criteria	in	this	small	number	
of	residents.		This	is	not	without	precedent.	A	study	in	Belfast	applied	STOPP	/	
START	criteria	to	a	population	of	patients	aged	40-65	(Moriarty	et	al.	2017)	i.e.	
outside	the	normal	framework.			
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Therapeutic	class,	Drugs	 Rationale	 Recommendation	 Quality	of	
Evidence	
Strength	of	
Recommendation	
BNF	category	
Anticholinergics	
Promethazine	
Hyroxyzine	
Highly	 anticholinergic;	 clearance	 reduced	 with	
advanced	age,	and	tolerance	develops	when	used	as	
hypnotic;	 risk	of	confusion,	dry	mouth,	constipation,	
and	 other	 anticholinergic	 effects	 or	 toxicity	 Use	 of	
diphenhydramine	 in	 situations	 such	 as	 acute	
treatment	 of	 severe	 allergic	 reaction	 may	 be	
appropriate	
Avoid	 Moderate	 Strong	 Antihistamine	
Antispasmodics	
Scopolamine	
Highly	anticholinergic,	uncertain	effectiveness	 Avoid	 Moderate	 Strong	 Antispasmodics	
Hyoscine	butyl	
bromide	
Antithrombotic	
Dipyridamole,	 oral	 short-
acting	 (does	 not	 apply	 to	
the	 extended-	 release	
combination	with	aspirin)	
May	 cause	 orthostatic	 hypotension;	 more	 effective	
alternatives	 available;	 intravenous	 form	 acceptable	
for	use	in	cardiac	stress	testing	Safer,	
Avoid	 Moderate	 Strong	 Antiplatelet	
Anti-infective	
*Nitrofurantoin	
Potential	 for	 pulmonary	 toxicity,	 hepatoxicity,	 and	
peripheral	neuropathy,	especially	with	long-	term	use;	
safer	alternative	available	
Avoid	 in	 individuals	 with	
creatinine	 clearance	 <30	
mL/min	 or	 for	 long-term	
suppression	to	bacteria	
low	 Strong	 Urinary	tract	
infections	
Cardiovascular	
*Digoxin	
Use	in	atrial	fibrillation:	should	not	be	used	as	a	first-
line	agent	in	atrial	fibrillation,	because	more-effective	
alternatives	 exist	 and	 it	 may	 be	 associated	 with	
increased	mortality	
Use	
Avoid	as	first-line	therapy	for	
atrial	fibrillation	
atrial	
fibrillation:	
moderate	
atrial	fibrillation:	
strong	
Cardiac	glycosides	
Central	nervous	system	
Antidepressants,	alone	or	
in	combination	
*	Amitriptyline	
*	Paroxetine	
	
	
	
	
	
Recommendation	
Highly	anticholinergic,	sedating,	and	cause	orthostatic	
hypotension;	safety	profile	of	 low-	dose	doxepin	(≤6	
mg/d)	comparable	with	that	of	placebo	
Avoid	 High	 Strong	 *	Paroxetine-
Selective	serotonin	
reuptake	inhibitors	
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Therapeutic	class,	Drugs	 Rationale	 Recommendation	 Quality	of	
Evidence	
Strength	of	
Recommendation	
BNF	category	
Antipsychotics,	first-	
(conventional)	and	
second-	(atypical)	
generation	
Increased	 risk	 of	 cerebrovascular	 accident	 (stroke)	
and	greater	rate	of	cognitive	decline	and	mortality	in	
persons	 with	 dementia	 Avoid	 antipsychotics	 for	
behavioural	problems	of	dementia	or	delirium	unless	
nonpharmacological	 options	 (e.g.,	 behavioural	
interventions)	have	failed	or	are	not	possible	and	the	
older	adult	is	threatening	substantial	harm		
Avoid,	 except	 for	
schizophrenia,	 bipolar	
disorder,	or	short-term	use	as	
antiemetic	 during	
chemotherapy	
Moderate	 Strong	 Antipsychotics,	first-	
and	second-	
generation	
Benzodiazepines	Short-	
and	intermediate-	acting	
*Lorazepam	
*Oxazepam	
*Temazepam	
Older	 adults	 have	 increased	 sensitivity	 to	
benzodiazepines	and	decreased	metabolism	of	 long-
acting	agents;	in	general,	all	benzodiazepines	increase	
risk	of	cognitive	impairment,	delirium,	falls,	fractures,	
and	motor	vehicle	crashes	in	older	adults	
Avoid	 Moderate	 Strong	 Anxiolytics	
Temazepam-Hpnotics	
Benzodiazepines	Long-
acting	
*Diazepam	
*Clonazepam	
May	 be	 appropriate	 for	 seizure	 disorders,	 rapid	 eye	
movement	 sleep	 disorders,	 benzodiazepine	
withdrawal,	 ethanol	 withdrawal,	 severe	 generalized	
anxiety	disorder,	and	periprocedural	anesthesia	
Avoid	 Moderate	 Strong	 Diazepam-Anxiolytics	
Clonazepam	-Control	
of	epilepsies	
Nonbenzodiazepine,	
benzodiazepine	receptor	
agonist	hypnotics	
Zolpidem	
*Zopiclone	
	
Benzodiazepine-receptor	 agonists	 have	 adverse	
events	 similar	 to	 those	 of	 benzodiazepines	 in	 older	
adults	 (e.g.,	 delirium,	 falls,	 fractures);	 increased	
emergency	 department	 visits	 and	 hospitalizations;	
motor	vehicle	crashes;	minimal	improvement	in	sleep	
latency	and	duration	
Avoid	 Moderate	 Strong	 Hypnotics	
*Zopiclone	instead	of	
Eszopiclone	
Insulin,	sliding	scale	 Higher	risk	of	hypoglycemia	without	improvement	in	
hyperglycemia	 management	 regardless	 of	 care	
setting;	 refers	 to	 sole	 use	 of	 short-	 or	 rapid-acting	
insulins	to	manage	or	avoid	hyperglycemia	in	absence	
of	 basal	 or	 long-acting	 insulin;	 does	 not	 apply	 to	
titration	of	basal	insulin	or	use	of	additional	short-	or	
rapid-	 acting	 insulin	 in	 conjunction	 with	 scheduled	
insulin	(i.e.	correction	insulin)	
	
	
	
Avoid	 Moderate	 Strong	 Short	and	rapid-
acting	insulin	in	the	
absence	of	basal	or	
long	acting	insulin	
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Therapeutic	class,	Drugs	 Rationale	 Recommendation	 Quality	of	
Evidence	
Strength	of	
Recommendation	
BNF	category	
Proton-pump	inhibitors	 Risk	of	Clostridium	difficile	infection	and	bone	loss	and	
fractures	
Avoid	 scheduled	 use	 for	 >8	
weeks	 unless	 for	 high-risk	
patients	 (e.g.,	 oral	
corticosteroids	 or	 chronic	
NSAID	 use),	 erosive	
esophagitis,	 Barrett’s	
esophagitis,	 pathological	
hypersecretory	 condition,	 or	
demonstrated	 need	 for	
maintenance	treatment	(e.g.,	
due	 to	 failure	 of	 drug	
discontinuation	 trial	 or	 H2	
blockers	
High	 strong	 Proton-pump	
inhibitors	
Non-cyclooxygenase-
selective	NSAIDs,	oral:	
*Ibuprofen	
Increased	 risk	 of	 gastrointestinal	 bleeding	 or	 peptic	
ulcer	disease	in	high-risk	groups,	including	those	aged	
>75	 or	 taking	 oral	 or	 parenteral	 corticosteroids,	
anticoagulants,	or	antiplatelet	agents;	use	of	proton-
pump	 inhibitor	or	misoprostol	 reduces	but	does	not	
eliminate	 risk.	 Upper	 gastrointestinal	 ulcers,	 gross	
bleeding,	 or	 perforation	 caused	 by	 NSAIDs	 occur	 in	
approximately	1%	of	patients	treated	for	3–6	months	
and	 in	 ~2–4%	 of	 patients	 treated	 for	 1	 year;	 these	
trends	continue	with	longer	duration	of	use	
Avoid	 chronic	 use,	 unless	
other	 alternatives	 are	 not	
effective,	 and	 patient	 can	
take	gastro-	protective	agent	
(proton-	 pump	 inhibitor	 or	
misoprostol)	
Moderate	 Strong	 Non-Steroidal	Anti-
inflammatory	Drugs	
NSAIDs	
Table	2.6	Drugs	to	be	avoided	in	older	adults	(adapted	from	Samuel,	2015)	
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Therapeutic	class,	Drugs	 Rationale	 Recommendation	 Quality	of	
Evidence	
Strength	of	
Recommendation	
BNF	category	
Aspirin	for	primary	prevention	
of	cardiac	events	
Lack	of	evidence	of	benefit	versus	risk	in	adults	aged	
≥80	
	
Use	with	caution	in	adults	
aged	≥80	
Low	 Strong	 Antiplatelet	
Diuretics	 May	exacerbate	or	cause	syndrome	of	inappropriate	
antidiuretic	 hormone	 secretion	 or	 hyponatremia;	
monitor	 sodium	 level	 closely	 when	 starting	 or	
changing	dosages	in	older	adults	
Use	with	caution	 Moderate	 Strong	 Diuretics	
Carbamazepine	
Mirtazapine	
SNRIs	
SSRIs	
TCAs	
Control	epilepsy	
Other	antidepressants	
SNRIs	
SSRIs	
TCAs	
Table	2.7	Drugs	to	be	used	with	caution	in	older	adults	(adapted	from	Samuel,	2015)
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Table	2.8	Potentially	inappropriate	medicines	used	to	characterise	prescribing	in	this	study	
High	risk	medications	 Therapeutic	category	according	to	
Beers	criteria		
Therapeutic	category	
according	to	BNF	
Drugs	that	should	be	avoided	
1.	Promethazine	 Anticholinergics	 Antihistamine	
2.	Hydroxyzine	 Anticholinergics	 Antihistamine	
3.	Dipyridamole	 Antithrombotic	 Antiplatelet	
4.	Aripiprazole	 Antipsychotic	 Antipsychotic	
5.	Pericyazine	 Antipsychotic	 Antipsychotic	
6.	Amisulpuride	 Antipsychotic	 Antipsychotic	
7.	Promazine	 Antipsychotic	 Antipsychotic	
8.	Prochlorperazine	 Antipsychotic	 Antipsychotic	
9.	Olanzapine	 Antipsychotic	 Antipsychotic	
10.	Haloperidol	 Antipsychotic	 Antipsychotic	
11.	Risperidone	 Antipsychotic	 Antipsychotic	
12.	Sulpiride	 Antipsychotic	 Antipsychotic	
13.	Quetiapine	 Antipsychotic	 Antipsychotic	
14.	Fluphenazine	 Antipsychotic	 Antipsychotic	
15.	Chlorpromazine	 Antipsychotic	 Antipsychotic	
16.	Trifluoperazine	 Antipsychotic	 Antipsychotic	
17.	Oxazepam	 Benzodiazepines	Short-	and	intermediate	 Anxiolytic	
18.	Lorazepam	 Benzodiazepines	Short-	and	intermediate	 Anxiolytic	
19.	Diazepam	 Benzodiazepines	Short-	and	intermediate	 Anxiolytic	
20.	Digoxin	>125mcg	 Cardiovascular	 Cardiac	glycoside	
21.	Clonazepam	 Benzodiazepines	Long-acting	 Control	of	epilepsies	
22.	Hyoscine	Butyl	
bromide	
Antispasmodics	 Antispasmodics	
23.	Zolpidem	 Hypnotic	 Hypnotic	
24.	Zopiclone	 Non-benzodiazepine,	benzodiazepine	
receptor	agonist	hypnotics	
Hypnotic	
25.	Temazepam	 Benzodiazepines	Short-	and	intermediate	 Hypnotic	
26.	Nitrazepam	 Hypnotic	 Hypnotic	
27.	Ibuprofen	 Non-cyclooxygenase-selective	NSAIDs,	
oral	
NSAIDs	
28.	Lansoprazole	 PPIs	 PPIs	
29.	Omeprazole	 PPIs	 PPIs	
30.	Amitriptyline	 TCA	 TCA	
31.	Paroxetine	 Antidepressants,	alone	or	in	combination	 SSRIs	
32.	Short	and	rapid-
acting	insulin		
Insulin;	in	the	absence	of	basal	or	long	
acting	insulin	
Insulin	
Drugs	that	should	be	use	with	caution	
1.	Aspirin	 Aspirin	for	primary	prevention	of	
cardiac	events	
Antiplatelet	
2.	Furosemide	
3.	Bumetanide	
4.Bendroflumethiazide	
5.	Spironolactone		
6.	Co-amilofruse	
Diuretic	
Diuretic	
Diuretic	
Diuretic	
Diuretic	
Diuretic	
Diuretic	
Diuretic	
Diuretic	
Diuretic	
7.	Citalopram	 SSRIs	 SSRIs	
8.	Sertraline	 SSRIs	 SSRIs	
9.	Venlafaxine	 SNRIs	 SNRIs	
10.	Duloxetine	 SNRIs	 SNRIs	
11.	Carbamazepine	 Carbamazepine	 Control	of	epilepsy	
12.	Mirtazapine	 Mirtazapine	 Other	antidepressants	
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2.3.4.1.1 Anticholinergic	burden	
A	retrospective	review	of	the	medicines	data	on	the	collected	MAR	charts	was	
made	 to	 identify	 drugs	 with	 anticholinergic	 properties	 (DAPs).	 Those	 with	
anticholinergic	 properties	 were	 scored	 (scale	 1	 –	 3)	 according	 to	 the	
Anticholinergic	 Effect	 on	 Cognition	 (AEC)	 criteria	 set	 out	 in	 the	 National	
Prescribing	 Indicators	 in	Wales	 2017-18	 (All	Wales	Medicines	 Strategy	Group	
2017).	A	total	AEC	score	was	then	calculated	for	each	resident.	
2.3.5 Statistical	analysis	
Univariate	 analysis	 (Pearson	 correlation)	 was	 performed	 to	 examine	 factors	
associated	with	PIMs	including;	(i)	average	age,	(ii)	prevalence	of	polypharmacy,	
(iii)	average	number	of	medications	prescribed	and	(iv)	number	of	residents	per	
care	 home.	 The	 analysis	 was	 conducted	 using	 Graph	 Pad	 Prism	 version	 7	
(Graphpad	 Software;	 California,	 USA).	 p	 <	 0.05	 was	 considered	 statistically	
significant.		
2.4 Results	
2.4.1 Care	Home	Characteristics	
Overall,	 some	260	 residents	 residing	 in	 ten	 care	homes	were	 included	 in	 this	
study;	the	characteristics	of	the	ten	care	homes	are	detailed	in	Table	2.9.		The	
majority	of	residents	(154;	59%)	were	85	years	of	age	or	over	whilst	the	average	
age	of	a	resident	was	83±	8.06	years	(range	40-108	years).	With	the	exception	of	
care	home	10,	which	 specialized	 in	 care	of	patients	with	dementia	 (including	
early	onset	dementia),	the	care	homes	were	broadly	similar	in	characteristics	i.e.	
the	average	age	of	the	residents	was	broadly	similar	as	was	the	average	number	
of	medicines	prescribed	per	resident	(8.3	[95%	CI	8.3	to	7.8]).		For	the	majority	
of	residents,	their	medicines	were	primarily	regular	medicines	(average	number	
of	 regular	medicines	 per	 resident	 ranged	 between	 5	 and	 10	 across	 the	 care	
homes)	with	“when	required’	medications	a	smaller	proportion	of	a	resident’s	
prescribed	regimen	(average	number	of	when	required	medicines	per	resident	
ranged	between	<1	and	2).	The	range	in	the	number	of	medicines	prescribed	per	
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patient	 was	 quite	 dramatic.	 In	 care	 home	 4	 there	 were	 examples	 where	
residents	 were	 not	 prescribed	 any	 medications	 whilst	 in	 care	 home	 10,	 a	
resident	was	prescribed	25	unique	medicines.		
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	Table	2.9	Care	Home	characteristics	(n=10)	with	descriptive	analysis	of	medications	used	by	residents	in	each	care	home.		
Care	Home	number	 CH	1	
Residential	
CH	2	
Nursing	
CH	3	
Nursing	
CH	4	
Nursing	
CH	5	
Nursing	
CH	6	
Nursing	
CH	7	
Nursing	
CH	8	
Residential	
CH	9	
Nursing	
CH	10	
Nursing*		
Number	of	
residents	
19	 21	 25	 26	 53	 20	 17	 24	 14	 41	
Average	age	in	
years	±SD	(range)	
89±5(81-95)	 75±4(79-102)	 88±9(66-99)	 86±6(72-95)	 88±6(76-108)	 88±4(79-95)	 86±5(67-96)	 87±8(62-99)	 79±12(64-97)	 64±12(40-98)	
Number	of	meds	
prescribed	
113	 148	 176	 247	 383	 164	 124	 144	 147	 513	
Mean	number	of	
meds	per	resident	
(95%	CI)	
6		
(5.9%;	4.5-
7.4)	
7.0		
(7%;	5.6-8.5)	
7.0		
(7%;	5.9-8.1)	
9.5	
(9.4%;	7.8-
11.1)	
7.2	
(7.2%;	6.2-
8.2)	
8.2	
(8.1%;	6.4-
9.9)	
7.2	
(7.2%;	5.7-
8.8)	
6.0	
(6%;	4.7-7.3)	
10.6	
(10.6%;	8.6-
12.6)	
12.5	
(12.4%;	10.8-
14.1)	
Median	number	of	
meds	per	resident	
(range)	
6(2-13)	 7(2-15)	 7(2-14)	 9(0-19)	 7(1-18)	 7(2-16)	 7(3-13)	 6(1-14)	 10.5(3-16)	 12(3-25)	
Mean	No	of	regular	
meds	per	resident	
5	 6	 6	 9	 6	 7	 7	 4	 8	 10	
Mean	No	of	PRN	
meds	per	resident	
1	 <1	 <1	 1	 <1	 1.1	 <1	 2	 2	 2	
*care	home	10	specialised	in	the	care	of	individuals	with	dementia	
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2.4.2 General	medicines	patterns	in	care	home	residents	
In	total,	2,164	medicines	were	prescribed	for	the	260	residents	studied.	These	
medicines	were	categorised	using	the	BNF	according	to	the	body	system	where	
they	have	their	effect	(see	Figure	2.2).		The	system	for	which	drugs	were	most	
commonly	 prescribed	 was	 the	 central	 nervous	 system	 which	 accounted	 for	
nearly	 32%	of	 the	medicines	 prescribed.	 This	was	 followed	by	 cardiovascular	
system	 at	 20%	 and	 gastro-intestinal	 system	 medications	 at	 15%.	 Combined,	
these	body	systems	accounted	for	more	than	65%	of	all	the	drugs	prescribed.	
Thereafter,	the	prescribing	for	other	body	systems	did	not	represent	more	than	
10%	 of	 the	 medicines	 prescribed.	 Of	 note,	 drugs	 to	 treat	 disorders	 of	 the	
immune	system,	malignant	disease	and	drugs	used	as	anesthetics	represented	
less	than	1%	of	all	the	drugs	prescribed	combined.		
Table	2.10	provides	an	analysis	of	the	prescribing	patters	at	the	individual	care	
home	 level.	 The	 prescribing	 was	 found	 to	 be	 reasonably	 similar	 across	 the	
homes.	Drugs	 that	 act	 on	 the	 gastro-intestinal	 system,	 cardiovascular	 system	
and	nervous	system	were	the	top	three	therapeutic	areas	in	all	care	homes	(with	
the	 exception	 of	 care	 home	 10)	 and	 accounted	 for	 greater	 than	 59%	 of	
prescribed	medicines	in	all	homes.	Care	home	10,	which	specialises	in	the	care	
of	 individuals	 with	 dementia,	 had	 a	 much	 higher	 prevalence	 of	 prescribing	
related	to	drugs	that	act	on	the	nervous	system	(50.68%)	and	a	lower	prevalence	
of	drugs	that	act	on	the	cardiovascular	system	(6.82%).	As	shown	in	Table	2.9,	
the	average	age	of	residents	in	care	home	10	(64	years)	is	much	lower	than	other	
homes.	Given	that	the	incidence	of	cardiovascular	disease	increases	with	age,	
this	finding	is	perhaps	not	surprising.		
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Figure	2.2	The	percentage	of	medicines	prescribed	in	the	ten	care	homes	examined	in	this	study	
categorised	by	the	body	system	in	which	they	exert	their	therapeutic	effect.	Drugs	acting	on	the	
nervous	 system	 (~32%),	 cardiovascular	 system	 (~20%)	 and	 gastro-intestinal	 system	 (~15%)	
accounted	for	over	65%	of	all	the	drugs	prescribed.			
Total=2164 medicines prescribed
14.97%  Gastro-intestinal system
20.10%  Cardiovascular system
3.70%  Respiratory system
31.79%  Nervous system
4.57%  Infections
7.62%  Endocrine system
1.16%  Genito-urinary system
0.18%  Immune system and malignancy disease
9.43%  Blood and nutrition
1.94%  Musculoskeletal system
1.76%  Eye 
2.68%  Skin
0.09%  Anaesthetic
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Table	2.10	Breakdown	of	medicines	prescribed	to	residents	in	each	care	home	by	body	system.	The	prescribing	patterns	across	the	ten	care	homes	was	reasonably	
consistent	with	therapeutics	acting	on	the	gastro-intestinal	system,	cardiovascular	system	and	nervous	system	accounting	for	~60%	or	more	of	the	medicines	prescribed	
to	residents.		
	 Medicines	prescribed	to	residents	categorised	by	body	system	(%)	
	 CH1	 CH2	 CH3	 CH4	 CH5	 CH6	 CH7	 CH8	 CH9	 CH10	 Mean	 S.D	
Gastro-intestinal	system	 15.04	 18.24	 17.61	 10.12	 13.58	 18.90	 14.52	 13.89	 16.33	 15.40	 15.36	 2.59	
Cardiovascular	system	 26.55	 25.00	 21.59	 21.05	 29.77	 17.07	 33.06	 28.47	 12.93	 6.82	 20.10	 8.11	
Respiratory	system	 4.42	 8.11	 1.14	 5.67	 2.35	 2.44	 3.23	 4.17	 6.80	 2.73	 3.70	 2.19	
Nervous	system	 19.47	 20.95	 29.55	 27.94	 21.67	 31.71	 16.94	 26.39	 40.82	 50.68	 31.79	 10.43	
Infections	 1.77	 9.46	 2.84	 9.72	 5.22	 3.66	 2.42	 2.78	 2.04	 3.51	 4.57	 2.93	
Endocrine	system	 12.39	 6.08	 8.52	 7.69	 9.40	 6.10	 8.06	 7.64	 4.08	 5.85	 7.62	 2.29	
Genito-urinary	system	 0.00	 1.35	 1.14	 2.83	 0.78	 1.22	 0.00	 2.08	 2.04	 0.58	 1.16	 0.92	
Immune	system	and	malignant	
disease	
0.88	 0.00	 0.00	 0.00	 0.26	 0.00	 0.81	 0.69	 0.00	 0.00	 0.18	 0.38	
Blood	and	nutrition	 11.50	 8.78	 7.95	 10.53	 10.70	 12.80	 7.26	 8.33	 7.48	 8.58	 9.43	 1.87	
Musculoskeletal	system	 0.00	 0.68	 2.84	 2.43	 1.57	 2.44	 4.84	 0.69	 2.04	 1.95	 1.94	 1.36	
Eye	 3.54	 1.35	 4.55	 1.21	 3.13	 2.44	 2.42	 0.00	 1.36	 0.00	 1.76	 1.49	
Skin	 4.42	 0.00	 2.27	 0.81	 1.31	 1.22	 6.45	 4.86	 4.08	 3.70	 2.68	 2.09	
Anaesthetic	 0.00	 0.00	 0.00	 0.00	 0.26	 0.00	 0.00	 0.00	 0.00	 0.19	 0.09	 0.10	
Total	number	of	medicines	
prescribed	 113	 148	 176	 247	 383	 164	 124	 144	 147	 513	 	
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A	 sub-analysis	 of	 the	 medicines	 prescribed	 within	 the	 categories	 of	 (i)	
gastrointestinal	 system;	 (ii)	 endocrine	 system;	 (iii)	 nervous	 system;	 (iv)	
respiratory	system	and	(v)	cardiovascular	system	is	shown	in	Figure	2.3.		For	the	
medicines	 acting	 on	 the	 central	 nervous	 system,	 non-opioid	 analgesics,	
hypnotics	and	sedatives,	antidepressant	and	antipsychotic	drugs	were	the	most	
commonly	prescribed	drugs	in	this	category	at	22%,	17%	and	16%	respectively.			
While	for	cardiovascular	medications,	antiplatelets,	lipid	modifying	agents	and	
diuretics	 were	 the	 most	 widely	 prescribed	 drugs	 at	 23%,	 17%	 and	 15%	
respectively.	 In	 terms	 of	 medicines	 acting	 on	 the	 gastro-intestinal	 system,	
laxatives	 (57%)	 and	 PPIs	 (32%)	 accounted	 for	 almost	 90%	 of	 medicines	
prescribed.	 Similarly,	 B2-agonist	 and	 antihistamines	 were	 the	 most	 widely	
prescribed	medicines	within	the	respiratory	area	at	40%	and	30%	respectively.	
Whilst	 in	 the	 endocrine	 system,	 both	 oral	 anti-diabetic	 drugs	 and	 drugs	 for	
treating	disorders	of	bone	metabolism	were	similarly	prescribed	at	23%	each.	
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Figure	2.3	Breakdown	of	prescribing	to	care	home	residents	by	body	system.		
Gastrointestinal system drugs
0.62%  Chronic inflammatory 
bowel disorders
4.63%  Antispasmodics
57.41%  laxatives
2.16%  Antidiarrheal
1.54%  Dyspepsia
1.23%  H2-receptor antagonist
32.41%  PPIs
Nervous system drugs
2.47%  Dementia 
12.79%  Epilepsy
17.01%  Hypnotic/Sedative
15.70%  Depression
9.30%  Antipsychotic/1st generation
6.40%  Antipsychotic/2nd generation
3.05%  Parkinson
0.73%  Antiemetic
22.38%  Analgesic/Non-opioid
10.03%  Analgesic/Opioid
0.15%  Alcohol dependence
Endocrine system drugs
8.97%  Oral corticosteroids
5.13%  Insulin
23.08%  Oral diabetic drugs
23.08%  Disorders of bone metabolism
1.28%  Female sex hormone 
responsive therapy 
38.46%  Antithyroid drugs 
Respiratory system drugs
6.25%  
Antimuscarin
ic30.00%  Antihistamine
40.00%  Beta2 agonist
20.00%  Inhaled corticosteroids
2.50%  Mast cell stabiliser
1.25%  Mucolytic
Cardiovascular system drugs
4.83%  Cardiac glycoside 
23.45%  Antiplatelet
3.68%  Antithrombotic
0.23%  adrenaline
9.66%  Beta-blockers
8.74%  Calcium- blockers
16.78%  Diuretics
9.89%  ACI
2.30%  A II antagonist
15.40%  Lipid modifying agents
5.06%  Nitrates
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2.4.3 Prevalence	of	polypharmacy	
The	prevalence	of	polypharmacy	(residents	receiving	≥	5	meds)	and	excessive	
polypharmacy	(residents	receiving	≥	10	meds)	in	the	ten	care	homes	examined	
as	 part	 of	 this	 study	 is	 shown	 in	 Table	 2.11.	 The	 average	 incidence	 of	
polypharmacy	was	84%	(range	68%	to	96%)	and	excessive	polypharmacy	was	
33%	(range	11%	to	76%).	As	can	be	seen,	 the	variability	between	homes	was	
much	greater	for	excessive	polypharmacy	than	for	polypharmacy.	Care	homes	9	
and	10	had	 the	highest	prevalence	of	excessive	polypharmacy	 (71%	and	76%	
respectively)	and	more	than	90%	of	their	residents	experienced	polypharmacy.	
Whilst	 the	 sample	 size	 is	 too	 small	 to	 draw	 any	 firm	 conclusions,	 it	 is	worth	
noting	that	the	two	residential	care	homes	featured	residents	with	some	of	the	
lowest	levels	of	polypharmacy.		
Table	2.11	Percentage	of	care	home	residents	exposed	to	polypharmacy	and	excessive	
polypharmacy.	
Care	Home	 Percentage	of	residents	with	
polypharmacy	(≥	5	meds)	
Percentage	of	residents	with	
excessive	polypharmacy	(≥	10	meds)	
1. Residential	 68%	 11%	
2. Nursing	 81%	 14%	
3. Nursing	 88%	 12%	
4. Nursing	 96%	 46%	
5. Nursing	 77%	 19%	
6. Nursing	 90%	 30%	
7. Nursing	 76%	 24%	
8. Residential	 75%	 17%	
9. Nursing	 93%	 71%	
10. Nursing	 95%	 76%	
Whole	cohort	 84	%	 33%	
	
2.4.4 Prevalence	of	potentially	inappropriate	prescribing		
Beers	criteria	was	applied	to	all	the	medications	prescribed	to	the	260	residents	
included	in	this	study.	In	total,	44	PIMs	were	seen	to	be	prescribed	across	the	10	
care	homes.	A	 total	 of	 226	 residents	 (87%)	 received	at	 least	 one	PIM	and	of	
these,	 nearly	 half	 were	 prescribed	 three	 or	 more	 PIMs	 (43%),	 26%	 were	
prescribed	 two	 PIMs	 and	 31%	were	 prescribed	 one	 PIM	 (see	Table	 2.12).	Of	
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note,	the	two	residential	homes	in	the	study	(care	homes	1	&	8)	had	the	lowest	
prevalence	of	residents	receiving	one	or	more	PIM	(63%	and	71%	respectively).			
Table	2.12	The	percentage	of	residents	receiving	potentially	inappropriate	medications.	On	
average,	87%	of	residents	were	prescribed	a	potentially	inappropriate	medicine	(range	63%	to	
100%).			
Care	Home	 Number	of	
residents	
(total	=	261)	
%	of	all	
residents	
receiving	at	
least	one	PIM	
%	receiving	
1	PIMs	
%	receiving	
2	PIMs	
%	receiving	
³3	PIMs	
1	 19	 63%	 58%	 -----	 5%	
2	 21	 86%	 33%	 33%	 19%	
3	 25	 76%	 16%	 28%	 32%	
4	 26	 92%	 15%	 27%	 50%	
5	 53	 87%	 34%	 26%	 26%	
6	 20	 95%	 15%	 35%	 45%	
7	 17	 94%	 53%	 24%	 18%	
8	 24	 71%	 33%	 29%	 8%	
9	 14	 100%	 14%	 14%	 71%	
10	 41	 100%	 7	%	 10%	 83%	
	 Total	 87%	 31%	 26%	 43%	
	
Out	of	 all	 the	medications	prescribed	 (2,164	medications	 in	 total),	 28%	 (615)	
were	PIMs	(range	12%	to	37%)	and	this	was	divided	into	PIMs	that	should	be	
avoided	(17%)	and	PIMs	that	should	be	used	with	caution	(11%)	(see	Table	2.13).		
Table	2.13	Percentage	of	medicines	prescribed	in	care	homes	that	are	PIMs	sub-categorised	as	
to	whether	they	should	be	avoided	or	used	with	caution.		
Care	Home	 No	of	medications	
prescribed	
%	of	medicines	
that	are	PIMs		
%	of	medicines	
that	should	be	
avoided	
%	of	medicines	
to	be	used	with	
caution	
1	 113	 																12%	 3%	 9%	
2	 148	 25%	 11%	 14%	
3	 176																													 28%	 17%	 11%	
4	 247	 28%	 15%	 13%	
5	 383																													 27%	 14%	 13%	
6	 164	 30%	 15%	 15%	
7	 124																													 22%	 12%	 10%	
8	 144	 21%	 8%	 13%	
9	 147																												 37%	 26%	 11%	
10	 513	 34%	 27	%	 7%	
	 Total																											 28%	 17%	 11%	
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As	can	be	seen	in	Table	2.13,	it	is	apparent	that	the	prevalence	of	medicines	to	
be	avoided	was	 lower	 in	 the	 residential	homes	 than	 the	nursing	homes	 (care	
home	 1	 at	 3%	 to	 be	 avoided	 and	 care	 home	 8	 at	 8%	 to	 be	 avoided).	 The	
prevalence	of	PIMs	was	particularly	high	in	homes	9	and	10	where	PIMs	to	be	
avoided	accounted	for	more	than	25%	of	all	medicines	prescribed	(26%	and	27%	
respectively);	 in	 total	 PIMs	 accounted	 for	more	 than	 a	 third	 of	 all	medicines	
prescribed	in	care	homes	9	and	10	(37%	and	34%	respectively).		
A	breakdown	of	the	residents	receiving	either	PIMs	to	be	avoided	or	to	be	used	
with	 caution	 in	 each	 care	 home	 is	 provided	 in	 Table	 2.14.	 	 There	 was	 no	
discernible	pattern	in	the	data,	in	five	of	the	care	homes	patients	receiving	one	
or	more	PIMs	 to	be	avoided	was	more	prevalent	 than	 those	 to	be	used	with	
caution	(care	homes	4,	5,	7,	9	and	10),	in	three	care	homes	the	reverse	was	true	
(care	homes	1,	2	and	8;	of	note	1	and	8	are	residential	homes)	whilst	in	two	care	
homes	the	prevalence	was	identical	(care	homes	3	and	6).	Across	the	population	
studied,	the	prevalence	of	residents	receiving	at	least	one	PIMs	that	should	be	
avoided	or	used	with	caution	was	identical	at	60%.		
Table	 2.14	 percent	 of	 potential	 inappropriate	medication	 based	 on	 two	 lists	 of	 Beers	 criteria	
received	by	resident	in	each	care	home	
	 %	of	residents	
receiving	at	least	
one	PIMs	
%	of	residents	
receiving	one	
PIMs	
%	of	residents	
receiving	2	PIMs	
%	of	residents	
receiving	
³3	PIMs	
Care	Home	 Avoid	 Caution	 Avoid	 Caution	 Avoid	 Caution	 Avoid	 Caution	
1	 16%										47%	 11%		 47%	 5%											 ----	 ----	 ----	
2	 43%										71%	 19%												52%	 19%												19%	 5%	 ----	
3	 56%										56%	 20%												40%	 16%												16%	 20%												----	
4	 81%										73%	 38%												42%	 23%												19%	 19%											12%	
5	 68%										58%	 38%												38%	 28%												17%	 2%														4%	
6	 75%										75%	 35%												45%	 25%												20%	 15%											10%	
7	 59%										53%	 42%												41%	 12%													6%	 6%														6%	
8	 42%										50%	 42%												33%	 ----															13%	 ----														4%	
9	 93%										71%	 21%												36%	 21%													29%	 50%												7%	
10	 95%										56%	 10	%											39%	 17%													12%	 68%												5%	
Total	 60%										60%	 28%											41%	 18%	 	15%	 20%	 5%	
N.B.	some	residents	may	receive	PIM(s)	to	be	avoided	and	used	with	caution.	
Table	 2.15	 provides	 a	 breakdown	 of	 the	 categories	 of	 PIMs	 prescribed	 to	
residents.		The	highest	level	of	prescribing	was	for	proton	pump	inhibitors	(PPIs)	
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with	 40%	 of	 all	 residents	 receiving	 a	 PPI	 followed	 by	 antipsychotics	 (32%),	
antiplatelets	 (26%),	 hypnotics	 (24%)	 and	 anxiolytics	 (22%);	 for	 all	 other	
therapeutic	classes,	the	prevalence	was	less	than	20%.			
Table	2.15	Prevalence	of	residents	receiving	PIMs	according	to	BNF	therapeutic	category.	PPIs,	
antipsychotics,	antiplatelets,	hypnotics	and	anxiolytics	were	the	most	commonly	observed	PIMs	
each	of	which	had	a	prescribing	prevalence	of	more	than	20%	of	the	residents.			
Therapeutic	class		 Number	of	residents	receiving	
a	medication	(n	=	260	
residents)	
Percentage	of	residents	
receiving	a	medication	
(rounded)	
Antihistamine	 2	 <	1	
Antiplatelet	 68	 26	
Antipsychotic	 83	 32	
Antispasmodic	 6	 2	
Anxiolytic	 58	 22	
Cardiac	glycoside	 2	 <	1	
Control	of	epilepsies	 13	 5	
Hypnotic	 62	 24	
Insulin	 3	 1	
K	sparing	diuretic	 5	 2	
Loop	diuretic	 43	 17	
NSAIDs	 7	 3	
Other	antidepressants	 22	 8	
PPIs	 105	 40	
SNRIs	 9	 3	
SSRIs	 38	 15	
TCA	 6	 2	
Thiazide	diuretic	 6	 2	
Urinary	tract	infection	 5	 2	
	
A	statistical	analysis	using	Pearson	correlation	was	undertaken	to	identify	if	the	
prescribing	of	 at	 least	 one	PIM	 to	 a	 resident	was	 associated	with	 either	 age,	
number	of	residents	in	a	care	home,	mean	number	of	medicines	prescribed	per	
resident	 or	 the	 extent	 of	 polypharmacy.	 The	 analysis	 revealed	 a	 positive	
correlation	 between	 the	 prescribing	 of	 a	 PIM	 and	 the	 average	 number	 of	
medications	 taken	 by	 a	 resident	 (p	 <	 0.0051)	 as	 well	 as	 the	 extent	 of	
polypharmacy	(p	<	0.0184).	Conversely,	no	significant	association	was	observed	
between	the	prescribing	of	PIMs	and	average	age	(p	<	0.2393)	or	the	number	of	
residents	in	a	home	(p<	0.7414)	(see	Table	2.16)	
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Table	 2.16	 Pearson	 correlation	 between	 prevalence	 of	 PIMs	 and	 a	 range	 of	 parameters.	
Polypharmacy	and	 the	number	of	medicines	prescribed	 showed	a	 strong	 correlation	with	 the	
potentially	inappropriate	prescribing.			
%	of	residents	receiving	at	least	one	
PIM	vs	
Pearson	r		 95%	CI																 P	value	
Extent	of	polypharmacy	 0.7218	 (0.16-0.92)	 0.0184*	
Average	age	 -0.410	 (-0.82-0.29)	 0.2393	
Mean	number	of	meds	 0.8038	 (0.29-0.94)	 0.0051**	
Number	of	residents	 0.1199	 (-0.55-0.69)	 0.7414	
	
2.4.5 Anticholinergic	burden	in	care	home	residents	
Of	the	260	residents	included	in	this	study,	52%	(n=135)	were	prescribed	at	least	
one	 drug	 with	 anticholinergic	 properties	 (DAP).	 An	 ‘anticholinergic	 effect	 on	
cognition’	(AEC)	score	was	applied	to	each	drug	and	the	total	score	calculated	
for	each	resident.	Of	all	the	DAPs	prescribed	41%	(n=107)	attracted	an	AEC	Score	
of	1,	12%	(n=31)	an	AEC	score	of	2,	and	10%	(n=26)	an	AEC	score	3	(data	not	
shown).	Table	2.17	provides	a	breakdown	of	the	number	of	residents	with	a	total	
AEC	score	of	1,	2	or	3	or	more	by	care	home.	In	total,	45	residents	(17%)	were	
receiving	DAPs	that	attracted	a	cumulative	AEC	score	of	three	or	more,	24	(9%)	
an	 AEC	 score	 of	 two	 and	 66	 (25%)	 an	 AEC	 score	 of	 one.	 	 There	 was	 quite	
considerable	variability	 in	 the	prevalence	by	care	home.	For	example,	 in	care	
home	1,	just	2	residents	of	19	(~1%)	received	a	DAP	whilst	in	care	home	10	that	
rose	to	34	residents	of	41	(84%)	receiving	a	DAP.	Of	note	both	care	homes	9	and	
10	 had	 a	 significant	 percentage	 of	 residents	 (36%	 and	 54%	 respectively)	
attracting	 an	 AEC	 score	 of	 three	 or	more.	 	 As	 can	 be	 seen	 in	 Figure	 2.4,	 14	
residents	 (5.4%)	 accumulated	 AEC	 scores	 that	 place	 them	 at	 risk	 of	 severe	
cognitive	impairment	whilst	31	residents	(11.9%)	accumulated	scores	that	are	
likely	 to	be	 clinically	 relevant	 	 (Pfistermeister	 et	 al.	 2017).	Although	different	
scales	 have	 been	 developed	 to	 identify	 anticholinergic	 burden,	 the	 clinical	
consequences	of	the	calculated	burden	has	been	shown	to	be	broadly	similar	
(Salahudeen	et	al.	2015)	therefore,	AEC	score	was	applied	in	this	current	study	
given	it	was	carried	out	in	Wales	where	AEC	is	the	preferred	scale.	
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Table	2.17	number	of	residents	prescribed	medicines	with	a	cumulative	AEC	Score	of	1,2	or	³	3	
per	care	home	
Care	home	 No.	of	
residents	
Residents	with	an	
AEC	score	of	1	(%)	
Residents	with	an	
AEC	score	of	2	(%)	
Residents	with	an	AEC	
score	of	3	or	more	(%)	
1	 19	 1	(5%)	 ----	 1	(5%)	
2	 24	 7	(29%)	 2	(8%)	 -----	
3	 25	 7	(28%)	 1	(4%)	 2	(8%)	
4	 26	 14	(54%)	 2	(8%)	 3	(12%)	
5	 53	 11	(21)	 4	(8%)	 5	(9%)	
6	 20	 7	(35%)	 4	(20%)	 3	(15%)	
7	 17	 2	(12%)	 ----	 2	(12%)	
8	 24	 6	(25%)	 4	(17%)	 2	(8%)	
9	 14	 3	(21%)	 3	(21%)	 5	(36%)	
10	 41	 8	(20%)	 4	(10%)	 22	(54%)	
Total	 260	 66	(25%)	 24	(9%)	 45	(17%)	
	
	
Figure	2.4	Anticholinergic	effect	on	cognition	scores	in	care	home	residents.	Some	14	residents	
(5.4%)	are	likely	to	be	at	risk	of	significant	cognitive	impairment	(AEC	score	of	five	or	more)	and	
11	residents	(4.2%)	accumulated	scores	that	are	likely	to	be	clinically	relevant	(AEC	score	of	3	or	
4). 
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2.5 Discussion	
There	is	evidence	in	the	literature	that	residents	of	care	homes	are	more	likely	
to	 be	 exposed	 to	 inappropriate	 prescribing	 compared	 to	 patients	 in	 other	
settings	 (Loganathan	 et	 al.	 2011;	 Shah	 et	 al.	 2012).	 The	 incidence	 of	
polypharmacy	 in	 the	 older	 adult	 care	 home	population	 is	 also	 thought	 to	 be	
more	pronounced	than	other	age	matched	populations	(Bronskill	et	al.	2012).	
Combined	with	a	continual	decline	in	health	status,	this	can	have	a	number	of	
consequences	including	the	emergence	of	geriatric	syndromes	that	include	falls,	
functional	and	cognitive	impairment	and	a	reduced	resistance	to	adverse	drug	
events	that	can	ultimately	lead	to	unintended	A&E	visits,	hospital	admissions	or	
in	the	worst	case,	death	(Lau	et	al.	2005;	Klarin	et	al.	2005;	Hilmer	et	al.	2007).	
In	 this	 current	 study,	 the	medications	 prescribed	 to	 260	 residents	 in	 10	 care	
homes	in	the	Abertawe	Bro	Morgannwg	University	Health	Board	were	examined	
through	a	retrospective	analysis	of	paper-based	MAR	charts	that	covered	a	28-
day	medicines	 cycle	 (September	 to	October	 2014);	 this	 provided	 a	 surrogate	
prescribing	data	set	as	currently	 there	 is	no	national	data	set	 that	specifically	
details	prescribing	 in	 care	homes.	A	number	of	parameters	were	explored	 to	
assess	the	landscape	of	prescribing	including	(i)	the	prevalence	of	polypharmacy	
(³	 	 5	 medicines	 prescribed)	 and	 excessive	 polypharmacy	 (³	 10	 medicines	
prescribed);	(ii)	the	prevalence	of	potentially	inappropriate	medicines	as	defined	
by	Beers	criteria	 for	Potentially	 Inappropriate	Medication	Use	 in	Older	Adults	
and	(iii)	the	anticholinergic	burden	placed	on	residents	due	to	their	medicines.		
All	medicines	were	 included	 in	 the	 analysis	with	 the	 exception	 of	 borderline	
substances	and	appliances.		
As	has	been	demonstrated	in	the	literature,	the	care	home	residents	explored	in	
this	 study	 were	 prescribed	 significantly	 higher	 number	 of	 medications	 than	
those	in	other	health-care	settings	(Chen	et	al.	2001).	For	example,	the	average	
number	of	medicines	taken	by	residents	in	this	study	was	eight	which	compares	
to	2.03	for	people	aged	65-74	and	2.02	for	those	aged	75	and	over	in	the	later	
study.	There	is	some	evidence	that	entry	into	the	care	home	has	an	impact	on	
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the	number	of	medicines	a	resident	is	prescribed.	For	example,	Koopmans	and	
colleagues	 explored	 the	 number	 of	 medicines	 an	 individual	 was	 prescribed	
immediately	prior	to	entering	a	care	home	and	then	six	weeks	later.		The	authors	
found	 a	 small	 but	 significant	 increase	 in	 the	 mean	 number	 of	 medications	
prescribed	to	residents	and	the	 increase	was	most	pronounced	for	medicines	
that	act	on	the	central	nervous	(Koopmans	et	al.	2003).		
The	 residents	 in	 this	 current	 study	were	 representative	of	 the	UK	care	home	
population	in	terms	of	age	(Smith	et	al.	2015)	with	an	average	age	of	83	years	
(range	40	–	108).	The	average	number	of	medicines	prescribed	per	resident	was	
found	to	be	eight	(range	from	0	to	25	medications).	The	findings	in	the	literature	
in	terms	of	the	average	number	of	medicines	prescribed	for	care	homes	is	fairly	
consistent.	 For	 example	 in	 the	 seminal	 CHUMS	 study,	 investigators	 reviewed	
MAR	charts	for	256	resident	across	55	UK	care	homes	(residential,	nursing	and	
mixed)	and	found	that	residents	received	an	average	of	8	medications	(Alldred	
et	 al.	 2009).	 Similarly,	 	 Gordon	 and	 colleagues	 	 reported	 an	 average	 of	 8	
medicines	per	resident	in	a	cohort	study	conducted	in	11	care	homes	in	the	UK	
(Gordon	et	al.	2014).	
Similar	 findings	 have	 been	 demonstrated	 internationally.	 For	 example,	 Beers	
and	 colleagues	 investigated	 patterns	 of	 medication	 use	 in	 12	 care	 homes	
housing	 850	 residents	 in	 the	 US	 (Beers	 et	 al.	 1988).	 They	 determined	 that	
residents	 were	 prescribed	 an	 average	 of	 eight	 medicines.	 Similarly,	 a	 cross-
sectional	study	undertaken	in	all	nursing	homes	in	Helsinki,	Finland	with	1987	
residents	reported	an	average	of	eight	medicines	per	residents	(Hosia-Randell	et	
al.	2008).	Some	studies	however,	have	reported	lower	averages.	For	example,	
Furniss	 and	 colleagues	 investigated	 the	 impact	 of	 pharmacists	 undertaking	
medication	reviews	in	14	nursing	homes	in	the	UK.	In	their	baseline	data	(330	
patients)	they	reported	that	the	average	number	of	medications	prescribed	to	
each	residents	was	five	(Furniss	2002).		
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Despite	 some	variability	 in	 the	 average	number	of	medications	prescribed	 to	
residents	 across	 these	 studies,	 all	 studies	 conclude	 that	 there	 is	 a	 high	
prevalence	 of	 polypharmacy	 in	 the	 older	 adult	 care	 home	 population.	
Polypharmacy	 has	 been	 described	 in	 a	 number	 of	 ways	 (see	 section	 2.1.4)	
including	 absolute	 quantitative	 measures	 (normally	 five	 or	 more	 prescribed	
medicines)	or	using	outcome-based	measures	(essentially	the	appropriateness	
of	the	prescribed	medicines).	In	this	current	study,	a	quantitative	definition	was	
used	because	the	researcher	did	not	have	access	to	residents’	medical	records	
and	therefore	a	qualitative	judgement	on	the	appropriateness	of	the	prescribed	
medicine(s)	 based	 on	 individual	 patient	 factors	 could	 not	 be	made	 given	 the	
absence	of	a	clinical	diagnosis.		
In	this	current	study,	the	incidence	of	polypharmacy	was	determined	to	be	84%	
i.e.	84%	of	residents	were	prescribed	five	or	more	medicines.	The	literature	is	
variable	 in	 this	 regard.	 For	 example	 in	 a	 European	 study	 	 (Czech	 Republic,	
England,	 Finland,	 France,	Germany,	 Italy,	 and	The	Netherlands)	 in	 57	nursing	
homes	with	 4,023	 residents,	 50%	 of	 the	 participants	were	 prescribed	 five	 or	
more	medicines	(Onder	et	al.	2012).	This	was	comparable	with	a	study	in	the	US	
that	utilised	a	National	Nursing	Home	Survey	to	survey	13,403	nursing	homes	
residents	and	identified	a	prevalence	of	polypharmacy	in	40%	of	the	population	
studied	(Dwyer	et	al.	2010).	In	contrast,	a	prevalence	of	93%	was	reported	for	
302	residents	in	8	nursing	homes	in	Sweden	(Inger	et	al.	2010).	More	recently,	
there	has	been	a	focus	on	excessive	polypharmacy	i.e.	patients	receiving	ten	or	
more	 medicines.	 In	 this	 study	 33%	 of	 all	 residents	 received	 10	 or	 more	
medications.	Again,	there	is	variability	in	the	literature.	Elseviers	and	colleagues	
explored	a	stratified	random	sample	of	Belgian	nursing	homes	and	found	that	
nearly	30%	of	residents	received	10	medications	or	more	(Elseviers	et	al.	2010).	
Similar	 findings	were	observed	 in	 the	US	 through	 the	National	Nursing	Home	
survey	which	 reported	a	40%	prevalence	 rate	 (Dwyer	et	 al.	 2004)	 and	a	37%	
prevalence	rate	was	reported	in	11	Veterans	Affairs	Medical	Centers	(Hajjar	et	
al.	2005).	However,	in	a	cross-sectional	study	conducted	with	68,939	Canadian	
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nursing	home	residents,	the	prevalence	of	excessive	polypharmacy	was	roughly	
half	that	found	in	other	studies	at	15.5%	(Bronskill	et	al.	2012).	It	is	difficult	to	
conclusively	 determine	 the	 reasons	 for	 this	 variability,	 however	 a	 number	 of	
hypotheses	 have	 been	 put	 forward	 in	 the	 literature	 (O’Sullivan	 et	 al.	 2013;	
Garfield	et	al.	2009;	Pierson	et	al.	2007)	.	These	include	a	higher	prevalence	in	
nursing	homes	compared	to	residential	(reflecting	the	complexity	of	patients	in	
these	settings)	(Schuler	et	al.	2008)	and	the	type	of	specialist	care	provided	by	
some	homes.	 Indeed,	 in	 this	 current	 study,	 residents	of	 care	home	10	which	
specialized	in	the	care	of	individuals	with	dementia	were	found	to	have	a	higher	
prevalence	 of	 polypharmacy	 (95%)	 and	 excessive	 polypharmacy	 (66%)	 in	
comparison	to	other	homes.		Of	the	ten	care	homes	included	in	this	study,	eight	
homes	 were	 nursing	 and	 two	 were	 residential.	 	 Whilst	 the	 sample	 size	 was	
relatively	small	and	any	conclusions	should	be	made	with	caution,	there	were	
trends	in	the	data.	For	example,	residents	in	the	two	residential	homes	had	the	
lowest	prevalence	of	polypharmacy	and	were	in	the	bottom	half	for	excessive	
polypharmacy.		
The	clinical	consequences	of	polypharmacy	are	well	documented	and	are	as	a	
consequence	 of	 drug	 related	 problems	 related	 to	 drug-drug	 interactions,	
adverse	 drug	 reactions	 and	 in	 the	 older	 adult	 population	 the	 added	 risk	 of	
developing	geriatric	syndromes	(Hughes	et	al.	2016).	A	variety	of	studies	have	
highlighted	these	consequences.		For	example	a	study	by	Nguyen	and	colleagues	
in	a	1200	bed	nursing	home	in	the	USA	found	that	there	was	a	two-fold	increase	
in	the	prevalence	of	adverse	drug	events	in	residents	receiving	nine	medications	
or	more	(Nguyen	et	al.	2006).	Similarly,	Resnick	and	colleagues	demonstrated	
that	nearly	25%	of	the	242	residents	residing	in	26	assisted	living	facilities	in	the	
US	were	admitted	to	hospital	or	had	an	unintended	accident	and	emergency	visit	
due	to	polypharmacy	(Resnick	et	al.	2018);	of	note,	the	authors	found	that	rates	
of	 polypharmacy	 were	 higher	 than	 in	 other	 settings.	 	 Also,	 Delcher	 and	
colleagues	found	a	direct	relationship	between	the	number	of	medications	used	
and	 the	 prevalence	 of	 drug-drug	 interactions	 in	 newly	 admitted	 older	 adults	
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(65+)	to	a	community-based	hospital	in	Canada.	In	their	study,	the	probability	of	
drug-drug	 interactions	 was	 increased	 from	 50%	 in	 patients	 taking	 5-9	
medications	 to	 100%	 when	 the	 patients	 received	 20	 medications	 or	 more	
(Delcher	et	al.	2015).	Of	note	 in	this	current	study	three	residents	(from	260)	
were	receiving	20	or	more	medications	(data	not	shown).	Jyrkka	̈	and	colleagues	
investigated	the	impact	of	polypharmacy	on	cognitive	impairment	in	294	older	
adults	(75+)	in	Finland.	In	patients	receiving	5	medicines	or	less,	20%	were	found	
to	have	some	level	of	cognitive	impairment.	This	increased	to	more	than	50%	in	
those	patients	receiving	10	or	more	medications	(Jyrkkä	et	al.	2011).	Kojima	and	
colleagues	focused	on	the	impact	of	polypharmacy	on	the	incidence	of	falls.	The	
authors	followed	172	older	adults	(average	age	76	years)	in	an	outpatient	setting	
in	Japan	and	found	that	32	of	these	patients	experienced	a	fall	during	the	study	
period.	 	Using	 a	multiple	 logistic	 regression	 analysis,	 the	 absolute	number	of	
drugs	prescribed	was	significantly	associated	with	the	incidence	of	falls	and	was	
independent	of	age,	sex	and	extent	of	comorbidity	(Kojima	et	al.	2012).		
One	 of	 the	 factors	 partly	 responsible	 for	 polypharmacy	 is	 thought	 to	 be	
‘prescribing	cascades’.	A	prescribing	cascade	is	defined	as	a	process	where	the	
adverse	effects	of	one	drug	are	misdiagnosed	as	a	new	symptom	that	results	in	
a	 prescription	 to	 treat	 the	 new	 symptom	 rather	 than	 addressing	 the	 original	
adverse	drug	effect.	This	creates	additional	risk	from	the	new	drug	and	in	some	
instances,	increases	the	incidence	of	geriatric	syndromes.	For	example,	the	use	
of	anticholinergic	drugs	to	treat	the	extrapyramidal	effects	of	antipsychotics,	has	
the	potential	to	expose	the	resident	to	anticholinergic	adverse	effects	such	as	
orthostatic	hypotension,	urinary	retention	and	blurred	vision	which	in	turn	may	
adversely	 increase	 the	 risk	 of	 falls	 and	 cognitive	 impairment	 (Lavan	 and	
Gallagher	2016;	Cahir	et	al.	2010).	
Patient	related	factors	such	as	female	sex	(Chen	et	al.	2001;	Hosia-Randell	et	al	
2008;	Jyrkkä	2011),	older	adults	residing	in	care	homes	(Chen	et	al.	2001;	Haider	
et	 al.	 2008)	 and	 socioeconomic	 characteristics	 such	 as	 low	 educational	
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attainment	(Haider	et	al.	2008)	have	also	been	shown	to	be	positively	associated	
with	the	risk	of	polypharmacy.	One	factor	where	there	is	conflicting	evidence	is	
age.	Some	studies	have	shown	that	older	adults	aged	75	and	over	are	more	likely	
to	be	exposed	to	polypharmacy	when	compared	to	those	aged	65-74	(Chen	et	
al.	 2001).	While	 other	 studies	 have	 found	 that	 being	 85	 and	 over	 is	 strongly	
associated	 with	 polypharmacy	 (Linjakumpu	 et	 al.	 2002)	 and	 excessive	
polypharmacy	(Jyrkkä	2011).	In	contrast,	other	studies	have	reported	that	there	
is	no	significant	correlation	between	age	and	polypharmacy	(Chin	et	al.	1999;	
Junius-Walker	et	al.	2007;	Vieira	De	Lima	et	al.	2013).	
In	addition,	health	related	factors	such	as:	(i)	poor	health	status	(Junius-Walker	
et	 al.	 2007);	 (ii)	 multiple	 co-morbidity	 with	 at	 least	 three	 or	more	 diagnosis	
(Vieira	De	Lima	et	al.	2013;	Dwyer	et	al.	2010;	Schuler	et	al.	2008),	(iii)	nutritional	
deficiencies	(Hosia-Randell	et	al.	2008;	Jyrkkä	2011);	(iv)	impairment	in	physical	
activity,	and	(v)	progressive	loss	in	cognitive	capacity	(Jyrkkä	2011)	are	positively	
associated	with	polypharmacy	in	older	adults.		
Beyond	 the	 clinical	 consequences	 to	 the	 resident,	 polypharmacy	 has	 been	
associated	with	 increasing	health	care	expenditure.	For	example,	a	study	was	
undertaken	 in	 Sweden	 between	 2005	 and	 2009	 to	 determine	 the	 impact	 of	
increasing	polypharmacy	on	prescribed	drug	expenditure	(PDE).		The	prevalence	
of	polypharmacy	(³5	prescribed	drugs)	increased	by	8.3%	over	this	period	(from	
11.1%	to	12.0%)	and	the	prevalence	of	excessive	polypharmacy	(³10	prescribed	
drugs)	 increased	by	9.9%	over	(from	2.4%	to	2.6%).	Overall,	PDE	increased	by	
4.8%	 and	 for	 patients	 with	 polypharmacy	 or	 excessive	 polypharmacy	 PDE	
increased	by	6.2%	and	7.3%	respectively.	Of	note	in	a	simulation	that	sought	to	
neutralise	 increases	 in	polypharmacy,	no	 increase	 in	 total	PDE	was	measured	
(Hovstadius	and	Petersson	2013).	Similarly,	the	increased	incidence	of	adverse	
drug	 events	 with	 polypharmacy	 has	 been	 shown	 to	 increase	 the	 risk	 of	
hospitalisation	which	increases	health	expenditure	(Onder	et	al.	2002).	In	a	study	
conducted	with	6628	Japanese	older	adults	(65+)	using	a	health	insurance	claims	
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data,	 polypharmacy	 was	 a	 major	 predictor	 of	 potentially	 inappropriate	
prescribing,	 increased	 outpatient	 visits	 and	 risk	 for	 hospital	 admission	 that	
resulted	 in	 an	 increase	 of	 more	 than	 30%	 in	 the	 healthcare	 expenditure	
(Akazawa	et	al.	2010).	A	small	number	of	studies	in	the	US	have	attempted	to	
estimate	the	costs	of	medicines	use	and	polypharmacy	in	the	care	home	setting.	
A	study	by	Kamboj	and	colleagues	in	Louisiana	(US)	nursing	homes	determined	
the	average	cost	of	medicines	per	resident	per	day	to	be	$182	with	an	annual	
estimated	 cost	 of	 $2184	 per	 resident.	 	 The	 authors	 found	 that	 older	 adults	
receiving	multiple	medications	 in	 nursing	 home	were	 associated	with	 higher	
expenditure	 (Kamboj	 et	 al.	 1999).	 These	 costs	 appear	 to	 be	 rising	 with	 for	
example,		Trygstad	and	colleagues	reporting	the	cost	of	medicines	had	reached	
nearly	 $6000	per	 resident	 per	 year	 in	 253	US	 nursing	 homes	 (Trygstad	 et	 al.	
2005).		
There	have	been	a	number	of	studies	which	have	sought	to	examine	a	range	of	
interventions,	 primarily	 pharmacist	 lead,	 to	 reduce	 the	 prevalence	 of	
polypharmacy	 in	 care	 home	 residents.	 A	 study	 by	 Zermansky	 and	 colleagues	
investigated	the	impact	of	pharmacists	conducting	clinical	medication	reviews	
on	661	elderly	care	home	residents.	The	authors	reported	a	substantial	change	
in	residents’	medication	regimens	with	a	mean	number	of	changes	of	3.1	per	
resident,	 although	 no	 change	 in	 drug	 costs	 was	 observed	 (Zermansky	 et	 al.	
2006).	 	 Furniss	 and	 colleagues	 reported	 a	 decrease	 in	 the	 mean	 number	 of	
prescribed	medication	 from	5.4	 to	4.2	during	a	pharmacist	 intervention	 in	14	
nursing	homes	in	the	UK	(Furniss	et	al.	2000).	The	clinical	consequences	of	such	
interventions	 remains	 equivocal	 however	 with	 some	 studies	 reporting	 that	
medication	 reviews	 do	 not	 improve	 mortality	 rates	 or	 functional	 capacity	
(Zermansky	and	Silcock	2009)	or	reduce	hospital	admissions	(Wallerstedt	et	al.	
2014).		
In	 this	 current	 study,	 there	 was	 an	 exploration	 of	 the	 general	 prescribing	
landscape	 in	 care	 homes.	 Medicines	 that	 act	 in	 the	 central	 nervous	 system	
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(31%),	cardiovascular	system	(20%)	and	gastro-intestinal	system	(14%)	were	the	
most	commonly	prescribed	medicines.	This	correlates	with	findings	from	studies	
in	care	homes	in	the	UK	(Furniss	et	al.	2000;	Ryan	et	al.	2013)	and	internationally	
(Dwyer	et	al.	2010;	Beloosesky	et	al.	2013;	Pinto	et	al.	2013).	
In	the	central	nervous	system,	analgesics	(22.4%),	hypnotics	&	sedatives	(17%)	
and	antipsychotics	(16.4%)	were	the	most	frequently	prescribed	medicines.	This	
finding	was	similar	to	that	reported	in	several	studies	within	the	same	setting.	
For	example,	an	earlier	study	by	Avorn	and	colleagues	in	12	care	homes	in		the	
US	reported	that	29%	of	residents	received	an	hynotic	and	28%	an	antipsychotic	
(Avorn	and	Gurwitz	1995).	For	analgesics,	Sandvik	and	colleagues	investigated	
the	 trends	 in	 analgesic	prescribing	 to	 care	home	 residents	 in	Norway	 for	 the	
period	 2000	 to	 2011.	 Over	 those	 11	 years,	 the	 prescribing	 of	 paracetamol	
increased	by	113%	from	22.7%	of	residents	to	48.4%	of	residents.	Similarly,	the	
prevalence	of	opioid	prescribing	 increased	from	1.9%	to	17.9%	(Sandvik	et	al.	
2016).		
In	terms	of	analgesics,	non-opioid	analgesics	were	more	commonly	prescribed	
in	comparison	to	other	types.	The	 incidence	of	mild	to	moderate	pain	 in	care	
home	residents	is	known	to	be	with	up	to	75%	of	residents	suffering	from	pain	
(Mahoney	and	Peters	2008).	As	a	consequence,	 the	prescribing	of	non-opioid	
analgesics	is	high		(Dwyer	et	al.	2010).		Although	serious	adverse	drug	events	are	
rarely	associated	with	non-opioid	analgesics,	they	are	commonly	prescribed	in	
volume	as	‘when	required’	medications.		The	result	is	that	they	are	responsible	
for	 increased	 medicines	 costs,	 and	 constitute	 a	 significant	 source	 of	 wasted	
medicines	in	care	homes	(see	Chapter	4).	
Consistent	with	other	studies	 (Ruggiero	et	al.	2010;	Sunil	M	Shah	et	al.	2012;	
Beers	et	al.	1988;	B.	Hagen	et	al.	2005;	Vieira	De	Lima	et	al.	2013;	Snowdon	et	
al.	 2005;	 Stevenson	 et	 al	 2010),	 the	 prescribing	 of	 psychotropic	 medicines	
(hypnotics/anxiolytics	and	antipsychotics)	was	observed	in	more	than	half	the	
residents	in	this	current	study.	A	population-based	data-linkage	study	in	the	UK	
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by	Maguire	and	co-workers	on	250,617	individuals	aged	65	and	over	found	that	
the	 prescribing	 of	 psychotropic	 drug	 was	 significantly	 higher	 in	 care	 home	
residents	 (20.3%)	 compared	with	 community	 dwelling	 older	 adults	with	 only	
(1.1%).	In	addition,	the	prescribing	of	antipsychotics	and	hypnotics	increased	by	
more	than	10%	after	admission	to	a	care	home	(Maguire	et	al.	2013).	Of	note,	
more	than	quarter	of	antipsychotics	prescribed	in	care	homes	are	prescribed	in	
the	absence	of	a	definitive	diagnosis	of	severe	mental	health	problems	(Shah	et	
al.	2011)	and	they	are	used	for	extended	periods	of	time	without	review	(Simoni-
Wastila	 et	 al.	 2014).	 	Given	 that	 their	 efficacy	 in	older	 adults	 is	 questionable	
(Wilfling	 et	 al.	 2015),	 there	 has	 been	 much	 discussion	 in	 the	 popular	 press	
surrounding	 the	 use	 of	 antipsychotics	 in	 older	 adults	 in	 care	 homes	 and	
particularly	 in	 those	 with	 dementia	 where	 antipsychotics	 are	 used	 off-label	
(Briesacher	et	al.	2013).	There	is	evidence	in	the	literature	that	has	highlighted	
serious	safety	issues	around	the	use	of	antipsychotics	with	increased	risk	of	falls	
(French	et	al.	2007),	stroke,	cognitive	impairment	and	even	death	(Huybrechts	
et	al.	2012;	Schneider	et	al.	2006;	Alldred	et	al.	2007;	Schneider	et	al.	2005).		
The	same	is	true	of	hypnotics	and	anxiolytics,	which	have	been	associated	with	
an	increased	risk	of	falls	(Ray	et	al.	2000;	Mcmahon	et	al.	2014;	Berry	et	al.	2016),	
hip	fractures	(Wang	et	al.	2001;	van	der	Hooft	et	al.	2008)	and	functional	and	
cognitive	 impairments	 (Foy	 et	 al.	 1995;	Nazareth,	 Burkhardt	 2008)	 especially	
when	 such	medications	 are	used	 for	 extended	periods.	Ultimately,	 the	wide-
spread	use	of	psychotropic	agents	 in	older	adults	 is	 a	 concern	because	of	 an	
acute	susceptibility	to	the	adverse	effects	of	central	nervous	system	medicines	
and	their	propensity	to	lead	to	the	development	or	progression	of	a	variety	of	
geriatric	syndromes.		
Another	 area	 of	 prescribing	 in	 older	 adults	 that	 has	 seen	 intense	 scrutiny	 in	
recent	years	 is	 the	use	of	drugs	with	anticholinergic	properties	 (DAPs)	due	to	
their	 propensity	 to	 adversely	 affect	 cognition	 and	 physical	 function.	 In	 this	
current	study,	more	than	50%	of	the	residents	received	at	least	one	DAP.	Using	
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the	 Anticholinergic	 Effect	 on	 Cognition	 scale,	 a	 score	 was	 calculated	 for	 any	
resident	 receiving	 one	 or	 more	 DAPs.	 Scores	 of	 3	 -	 4	 are	 considered	 to	 be	
clinically	relevant	and	scores	above	five	place	residents	at	risk	of	severe	cognitive	
impairment	(Campbell	et	al.		2009;	Fox	et	al.	2014;	Pfistermeister	et	al.	2017).	In	
this	current	study,	11.9%	of	all	residents	had	a	clinically	significant	score	and	5%	
had	a	score	that	would	indicate	a	significant	risk	of	cognitive	impairment.	The	
highest	 incidence	of	anticholinergic	burden	was	 seen	 in	 care	home	10	where	
more	 than	 half	 the	 residents	 had	 an	 AEC	 Sore	 of	 three	 or	 more.	 This	 is	 a	
concerning	finding	as	dementia	patients	will	have	pre-existing	cognitive	decline	
which	is	likely	to	be	exacerbated	by	the	anticholinergic	burden.		
With	 regards	 to	 medicines	 that	 act	 in	 the	 gastro-intestinal	 system,	 the	
prescribing	 of	 laxatives	 was	 particularly	 prevalent	 with	 more	 than	 50%	 of	
residents	receiving	one	or	more	 laxatives.	This	 is	consistent	with	a	number	of	
studies	that	have	identified	laxatives	to	be	commonly	prescribed	in	care	homes	
(Snowdon	et	al.	2006;		Jerry	Avorn,	Jerry	H.	Gurwitz	1995;	Chen	et	al.	2014).	The	
high	prescribing	rate	has	been	attributed	to	a	range	of	patient	related	factors	in	
this	 cohort	 particularly	 related	 to	 age,	 lack	 of	mobility,	 poor	 diet	 or	 the	 side	
effects	 of	 a	 number	 of	 medications	 commonly	 used	 in	 this	 population		
(Suominen	et	al.	2005;	Ehrenberg	and	Ehnfors	1999).		However,	this	may	lead	to	
chronic	use	of	laxatives	in	some	residents	which	may	cause	further	drug	related	
problems	 including	 electrolyte	 and	 mineral	 imbalances,	 severe	 dehydration,	
laxative	dependence,	chronic	constipation,	internal	organ	damage	and	increased	
colon	cancer	risk	(International	Longevity	Centre-UK	2013).		
Whilst	the	prevalence	of	polypharmacy	and	the	general	prescribing	patterns	in	
care	home	provides	some	insight	into	the	risks	of	negative	clinical	consequences	
of	medicines	 use	 in	 care	 home	 residents,	 it	 is	 less	 useful	 in	 determining	 the	
appropriateness	 of	 prescribed	 medicines.	 It	 is	 more	 useful	 to	 assess	 the	
prevalence	 of	 prescribing	 of	 potentially	 inappropriate	 medicines	 using	
standardised	criteria.		
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To	explore	the	prescribing	of	potentially	inappropriate	medicines,	BEERs	criteria	
(Samuel	2015)	was	used	to	assess	the	prevalence	of	PIMs	using	prescribing	data	
captured	from	MAR	charts;	BEERs	criteria	has	been	used	in	a	variety	of	studies	
to	assess	prescribing	in	care	homes	in	the	Europe	and	the	USA	(King	and	Roberts	
2007;	Niwata	et	al.	2006;	Varallo	et	al.	2012;	Storms	et	al.	2017;	Stafford	et	al.	
2011;	Perri	2005;	Mamun	et	al.	2004;	Vieira	De	Lima	et	al.	2013;	Ruggiero	et	al.	
2010;	Pinto	et	al.	2013).	Some	87%	of	the	residents	in	this	current	study	were	
prescribed	at	least	one	PIM	and	43%	were	prescribed	three	or	more	PIMs.	The	
PIMs	were	 sub-categorised	 into	 those	 that	 should	be	avoided	and	 those	 that	
should	be	used	with	caution.	Some	60%	of	residents	received	at	least	one	PIM	
that	should	be	avoided	and	20%	received	three	or	more	PIMs	that	should	be	
avoided.	Similarly,	60%	of	 residents	 received	at	 least	one	PIM	that	 should	be	
used	with	caution	but	only	5%	received	three	or	more	PIMs	that	should	be	used	
with	caution.	Some	residents	received	a	combination	of	PIMs	to	be	avoided	and	
used	 with	 caution	 (data	 not	 shown).	 Irrespective	 of	 this,	 the	 prevalence	 of	
inappropriate	 prescribing	 (at	 least	 against	 BEERs	 criteria)	 was	 significant.	 	 A	
number	of	studies	including	those	in	Brazil	(Vieira	De	Lima	et	al.	2013),	Belgium	
(Anrys	et	al.	2018),	Finland	(Hosia-Randell	et	al.	2008)	and	Japan	(Niwata	et	al.	
2006)	have	sought	to	estimate	the	prevalence	of	PIMs	prescribing	for	care	home	
residents.	 The	 reported	 prevalence	 shows	 a	 high	 degree	 of	 variability	 with	
studies	reporting	a	prevalence	of	at	 least	one	PIM	anywhere	between	20%	to	
80%	 (King	and	Roberts	2007;	Niwata	et	al.	 2006;	Varallo	et	al.	 2012;	 	 (Hosia-
Randell	et	al.	2008;	Barnett	et	al.	2011;	Hwang	et	al.	2015;	O’Sullivan	et	al.	2013;	
Vieira	de	Lima	et	al.	2013;	Verrue	et	al.	2012;	Ryan	et	al.	2013).		In	the	UK	and	
Ireland,	the	landscape	is	similar,	for	example	O’Sullivan	and	colleagues	explored	
prescribing	 to	 732	 residents	 in	 14	 nursing	 homes	 and	 long	 stay	 community	
hospitals.	They	found	that	50%	of	the	residents	were	receiving	at	least	one	PIM	
(O’Sullivan	et	al.	2013),	not	too	dissimilar	to	this	current	study.	However,	 in	a	
cross-sectional	study	of	10,387	care	home	residents,	33%	were	prescribed	a	PIM	
compared	 to	 21%	 in	 the	 community	 setting	 (Shah	 et	 al.	 2012).	 Whilst	 this	
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heterogeneity	 in	 the	 literature	 might	 be	 influenced	 by	 the	 unavailability	 of	
certain	medications	in	different	countries	or	due	to	differences	in	study	design	
and	 duration,	 it	 is	 clear	 that	 there	 is	 a	 substantial	 level	 of	 potentially	
inappropriate	 prescribing	 to	 care	 home	 residents	 both	 nationally	 and	
internationally.	
In	agreement	with	findings	related	to	polypharmacy,	the	prevalence	of	PIMs	was	
lower	 in	 the	two	residential	care	homes	 included	 in	 this	study.	 	Although	the	
numbers	are	small,	this	finding	might	suggest	that	residents	in	residential	homes	
are	 less	 likely	 to	 have	 complex	 clinical	 conditions	 requiring	 prescribing	
interventions	 compared	 to	 those	 in	 nursing	 home.	 Care	 home	 1	 had	 a	
particularly	interesting	pattern	of	PIMs	where	the	prevalence	of	medicines	to	be	
used	with	caution	 (46%)	dramatically	outweighed	 those	 to	be	avoided	 (16%).	
While	 in	nursing	home	10	(nursing	with	specialist	dementia	care),	the	 inverse	
was	true	i.e.		65%	of	residents	received	medicines	that	should	be	avoided	and	
only	5%	received	medicines	that	should	be	used	with	caution.		
It	 should	 be	 noted	 that	 the	 study	 design	 utilised	 here	 did	 not	 allow	 for	 a	
determination	of	the	reasons	why	residents	were	prescribed	PIMs	i.e.	whether	
it	is	related	to	poor	prescribing	habits,	non-evidence-based	indications,	complex	
health	 conditions	 associated	 with	 the	 residents,	 or	 the	 prescribing	 cascade	
phenomenon.	Therefore,	further	studies	should	seek	to	address	this	gap	in	the	
knowledge	 base	 using	 a	 resident’	medical	 records	 to	make	 a	 comprehensive	
judgment	with	regards	to	the	appropriateness	of	medications	used	according	to	
each	clinical	condition.	
In	 this	 study,	 a	 moderate	 negative	 correlation	 was	 identified	 between	 the	
prevalence	of	PIMs	and	advancing	age	which	is	in	agreement	with	other	studies	
(O’Sullivan	et	al.	2013;	Vieira	De	Lima	et	al.	2013).		It	is	unclear	why	this	is	the	
case	 but	 may	 be	 associated	 with	 deprescribing	 protocols	 in	 end	 of	 life	 care	
(Holmes	et	al.	2006;	Liu	2014).		
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In	 contrast,	 a	 higher	 number	 of	 prescribed	medications	 and	 the	 presence	 of	
polypharmacy	was	a	strong	predictor	of	PIMs	prevalence.	This	finding	has	been	
corroborated	in	a	variety	of	studies	both	in	the	UK	(O’Sullivan	et	al.	2013)	and	
internationally	(Fiss	et	al.	2011;	Ryan	et	al.	2013;	Pinto	et	al.	2013;	Vieira	De	Lima	
et	al.	2013;	Niwata	et	al.	2006;	Tommelein	et	al.	2015;	Chen	et	al.	2012)	in	care	
homes	and	in	other	health	care	settings	(Maio	et	al.	2006;	Gallagher	et	al.	2011;	
Fialová	et	al.	2005;	Frazier	2005).	
Other	factors	have	also	been	identified	to	have	a	positive	association	with	the	
prescribing	of	PIMs.	For	example,	a	number	of	studies	have	found	that	females	
are	 more	 likely	 to	 be	 prescribed	 PIMs	 (Pinto	 et	 al.	 2013;	 Rigler	 et	 al.	 2004;	
Bierman	et	al.	2007).	Other	studies	have	found	that	poor	health	status	(Fu	et	al.	
2004)	and	multiple	 co-morbidities	are	 risk	 factors	 for	 the	prescribing	of	PIMs	
(Chin	et	al.	1999;	Klarin	et	al.	2005;	Vieira	de	Lima	et	al.	2013;	Elseviers	et	al.	
2014).	 Of	 note,	 length	 of	 stay	 in	 a	 care	 home	 is	 associated	 with	 significant	
increase	in	the	likelihood	of	being	prescribed	a	PIM	(Chen	et	al.	2012;	Rancourt	
et	al.	2004).	
Although	the	prescribing	of	a	PIM	does	not	necessarily	result	in	patient	harm,	
the	use	of	inappropriate	medicines	has	been	associated	with	increased	negative	
health	outcomes	(Lund	et	al.	2010;	Hedna	et	al.	2015;	Donna	2008;	Heider	et	al.	
2017).	For	example,	the	use	of	anxiolytics,	sedatives	or	hypnotics	may	increase	
the	incidence	of	falls	and	fractures	among	older	adults.	This	finding	was	reported	
in	 a	 case	 control	 study	 in	 the	 USA	 with	 17,198	 patients	 aged	 65	 and	 over	
receiving	 benzodiazepines	 and	 related	 drugs.	 The	 authors	 reported	 that	
benzodiazepine	use	was	associated	with	an	increase	 in	the	relative	risk	of	hip	
fracture	and	this	increased	with	dose,	interacting	drugs	and	the	risk	was	highest	
at	the	point	of	initiation	of	the	benzodiazepine	(Zint	et	al.	2010).	Of	note,	some	
22%	and	24%	of	residents	in	this	current	study	were	prescribed	an	anxiolytic	or	
hypnotic	respectively.			
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More	 broadly,	 a	 link	 has	 been	 established	 between	 Beers	 criteria	 and	 the	
incidence	of	drug	related	problems	in	care	home	residents	leading	to	drug-drug	
interactions	(Hosia-Randell	et	al.	2008)	and	unintended	hospital	admission	(Fick	
et	al.	2001;	Klarin	et	al.	2005;	Lau	et	al.	2005;	Jano	and	Aparasu	2007;	Budnitz	et	
al.	 2007).	 As	Gallagher	 and	O’Mahony	 noted,	 nearly	 half	 of	 715	 older	 adults	
receiving	Beers	criteria	PIMs	were	subjected	to	acute	hospital	admission	due	to	
their	related	adverse	drug	events	in	the	UK	(Gallagher	and	O’Mahony	2008).	This	
was	 confirmed	 by	 a	 prospective	 study	 conducted	 in	 six	 European	 teaching	
hospitals	 (Switzerland,	 Spain,	Belgium,	 Italy,	 and	 the	UK)	on	900	older	 adults	
which	revealed	a	significant	association	between	Beers	criteria	PIMs	and	recent	
hospitalisation	(p	<	0.01)	(Gallagher	et	al.	2011).		
Furthermore,	exposure	to	PIMs	has	been	shown	to	increase	health	care	cost.	In	
an	earlier	study	by	Fick	and	colleagues	in	the	USA	on	2,336	Medicare	managed	
care	 patients	 aged	 65	 and	 over,	 a	 significant	 association	 was	 demonstrated	
between	high	prevalence	of	PIMs	use	and	total	cost	paid	(p	<	0.0001)	(Fick	et	al.	
2001).	 Similarly,	 a	 study	 by	 Donna	 and	 colleagues	 in	 a	 community	 dwelling	
population	with	17,971	individual	aged	65	and	over	in	the	USA,	reported	a	two-
fold	 increase	 in	 the	 utilisation	 of	 health	 care	 services	 with	 a	 significant	
correlation	between	the	number	of	PIMs	used	and	overall	 cost	 (Donna	2008)	
This	was	in	agreement	with	a	study	using	a	retrospective	observational	approach	
in	Germany	with	521,644	out-patients	aged	65	and	over.	This	study	reported	an	
increase	in	mean	total	health	care	cost	by	€2321	due	to	PIMs	related	adverse	
drug	events	(Heider	et	al.	2017).		
Several	studies	have	sought	to	 investigate	the	effect	of	 interventions	that	are	
designed	 to	 reduce	 the	 prescribing	 of	 PIMs	 in	 care	 homes.	 A	 range	 of	
interventions	were	examined	including:	medication	reviews,	case	conferencing,	
clinical	decision	support	systems,	educational	interventions	and	some	of	these	
have	been	tested	in	care	homes	(Alldred	et	al.	2013).	For	example	several	studies	
have	 evaluated	 the	 effect	 of	 training	 on	 the	 rate	 of	 prescribing	 /	 use	 of	
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psychotropic	 drugs	 versus	 behavioral	 management	 techniques	 (Fossey	 et	 al.	
2006;	B.	F.	Hagen	et	al.	2005;	Meador	et	al.	1997).	These	studies	have	found	a	
decrease	 in	 the	number	of	 residents	using	 such	medications	or	 reductions	 in	
their	 dosages	 with	 training.	 Other	 studies	 have	 emphasised	 the	 role	 of	 the	
pharmacist	or	the	multidisciplinary	team	in	reducing	inappropriate	prescribing	
through	medication	reviews	or	the	use	of	screening	tools.	These	interventional	
approaches	 generally	 focus	 on	 deprescribing.	 Deprescribing	 is	 defined	 as	 ‘a	
process	 of	 withdrawing,	 changing	 or	 even	 reducing	 the	 dose	 of	 the	 current	
medications	of	older	adults’	 (Woodward	2003).	Deprescribing	approaches	are	
suggested	to	decrease	both	adverse	drug	events	and	medicines	costs	(Garfinkel	
et	al.	2010).	However,	the	clinical	impacts	of	these	interventions	in	reducing	the	
risk	of	harm	to	the	patients	associated	with	PIMs	is	still	equivocal	(Furniss	et	al.	
2000;	Zermansky	et	al.	2006;	Roberts	et	al.	2001;	Koria	et	al.	2018;	Patterson	et	
al.	2014;		Cooper	et	al.	2015).	
In	conclusion,	this	chapter	has	described	the	prescribing	patters	for	260	older	
adults	 in	 ten	 care	 homes	 in	 the	 South	 Wales	 region.	 The	 prevalence	 of	
polypharmacy	(5+	medicines),	excessive	polypharmacy	(10+	medicines)	and	the	
use	of	potentially	inappropriate	medicines	was	significant	but	in	line	with	studies	
in	 the	 literature.	 A	 significant	 number	 of	 residents	 were	 also	 exposed	 to	 a	
significant	anticholinergic	burden.	Together,	this	is	likely	to	place	some	residents	
at	risk	of	cognitive	impairment,	geriatric	syndromes	and	increased	morbidity	and	
mortality.	 In	 an	 already	 vulnerable	 population,	 careful	 consideration	 of	
prescribing	 practice	 is	 needed	 and	 efforts	 should	 be	 made	 to	 reduce	 the	
medicines	burden	on	such	individuals.		
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3.1 Introduction	
3.1.1 Medication	administration	record	charts	
When	 medicines	 are	 administered	 to	 residents	 in	 care	 homes,	 the	
administration	must	be	documented	on	Medicines	Administration	Record	(MAR)	
charts.	 MAR	 charts	 represent	 the	 core	 documentary	 record	 of	 medicines	
administration	 to	 residents.	 Each	 resident	 should	have	a	 separate	MAR	chart	
that		provides	details	about	the	resident	including	their	name,	date	of	birth	and	
allergy	 status,	 contains	 a	 list	 of	 all	 the	medicines	 to	 be	 administered	 to	 the	
resident	 with	 associated	 dosage	 instructions,	 any	 special	 instructions	 or	
precautions	 associated	 with	 the	 medicines,	 and	 provides	 a	 grid	 in	 which	
administrations	are	recorded;	where	an	administration	is	not	made	the	reason	
for	the	omission	should	be	noted	using	defined	codes	(NICE	2015).		
There	is	no	single	defined	format	for	a	MAR	chart,	however	the	contents	will	be	
broadly	 similar	 allowing	 for	 effective	 administration	 to	 the	 resident	 and	
subsequent	recording	of	such	an	administration.	In	general,	the	majority	of	care	
homes	operate	 a	28-day	medicines	 cycle	 and	 therefore	MAR	charts	normally	
have	a	28-day	duration.	MAR	charts	are	 typically	generated	by	 the	Pharmacy	
that	supplies	the	care	home	with	the	resident’s	medication.	MAR	charts	may	be	
printed	or	may	be	handwritten.	Printed	MAR	charts	are	preferable	to	most	care	
homes	because	they	are	more	legible	and	avoid	clerical	errors	that	may	occur	
during	the	transcribing	of	information	from	one	document	to	another	(Centre	
for	Policy	on	Aging	2011).	For	an	example	of	a	MAR	chart	see	Figure	3.1.		
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Figure	3.1	Exemplar	Medication	Administration	Record	(MAR)	chart.	This	MAR	chart	covers	a	28-
day	medicines	cycle.	Resident	and	prescriber	information	(redacted)	is	in	the	top	left-hand	corner.	
The	 left-hand	 column	 features	 the	medicines	 to	 be	 administered	 to	 this	 resident	 along	 with	
associated	dosing	instructions.	The	grids	to	the	right	of	the	medicines	information	allows	those	
administering	to	record	the	administration	or	provide	a	code	to	indicate	why	an	administration	
has	not	been	made.		
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Sometimes,	medicines	may	be	changed	during	the	monthly	cycle	either	through	
addition	of	‘interim’	medicines	for	example	for	acute	conditions	or	a	resident’s	
existing	medication	may	change	 for	example	due	 to	changes	 in	 the	dose.	For	
interim	medications,	a	separate	MAR	chart	is	provided.	For	changes	to	existing	
medicines,	 a	 responsible	 staff	 member	 will	 hand	 amend	 the	 existing	 MAR	
chart(s)	 to	 reflect	 the	 changes	 in	 a	 clear	 and	 legible	 way;	 the	 prescriber	
instigating	these	changes	should	be	documented	and	all	amendments	should	be	
signed	and	witnessed.		
The	 act	 of	 recording	 medicines	 administrations	 is	 an	 important	 regulatory	
requirement.	 For	 example,	 under	 the	 Care	Homes	 (Wales)	 Regulations	 2002,	
each	 care	 home	 must	 have	 a	 ‘registered	 person’	 who	 retains	 overall	
responsibility	for	ensuring	the	effective	recording,	handling,	safe	keeping,	safe	
administration	 and	 disposal	 of	 medicines.	 In	 England,	 the	 Care	 Quality	
Commission	has	issued	quality	and	safety	guidelines	highlighting	the	provider’s	
responsibility	to	comply	with	the	regulations	of	the	Health	and	Social	Care	Act	
2008.	 The	 guidelines	 emphasise	 the	 importance	 of	 embedding	 effective	
procedures	 with	 regards	 to	 medicines	 management	 and	 documentation	 of	
medicines	administration.		
	
In	Wales,	completed	MAR	charts	are	inspected	by	the	Care	Inspectorate	Wales	
(CIW)	 in	 order	 to	 determine	 the	 quality	 of	 medicines	 management	 and	 to	
measure	 compliance	 against	 the	 National	 Minimum	 Standards	 (Care	
Inspectorate	Wales	2014).	These	National	Minimum	Standards	address	 seven	
main	themes:	(i)	choice	of	home;	(ii)	health	and	personal	care;	(iii)	daily	life	and	
social	activities;	(iv)	complaints	and	protection	(v)	environmental	standards	(vi)	
staffing	(vii)	management	and	administration;	for	a	detailed	explanation	of	the	
standards	see	Chapter	1.		
3.1.1.1 Documentation	process	
Ensuring	that	all	of	the	information	on	the	MAR	chart	is	accurate,	up-to-date	and	
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compliant	with	regulatory	requirements	remains	the	responsibility	of	the	care	
home	(NICE	2014).	In	practice	however,	this	task	is	generally	undertaken	by	the	
pharmacist	 when	 the	 MAR	 chart	 is	 generated	 at	 the	 pharmacy	 as	 the	
medications	are	being	assembled	(Alldred	et	al.	2009).			
Once	 the	medication	has	been	administered	 to	 the	 resident	according	 to	 the	
date	and	time	indicated	on	the	MAR	chart,	the	MAR	charts	should	be	annotated	
to	 indicate	 an	 administration	 has	 been	 made.	 	 This	 annotation	 should	 be	
completed	 as	 soon	 as	 possible	 and	 certainly	 should	 not	 be	 left	 blank.	 If	 a	
prescribed	medicine	 is	 not	 administered	 to	 the	 resident,	 there	 are	 normally	
‘codes’	specified	on	the	MAR	chart	that	should	be	used	to	define	the	reason	that	
the	administration	has	been	omitted	(see	Table	3.1).	On	completion,	MAR	charts	
must	be	retained	for	3	years	after	which	they	can	be	destroyed.	(NICE	2014).	
Table	3.1	Examples	of	codes	used	on	MAR	charts	to	denote	records	of	administration	
Code	 Definition	
A	 Absent	
N	 Nausea	or	vomiting	
H	 Hospitalised	
D	 Destroyed	
R	 Refused	
NT	 Not	Taken	
C	
L	
D/C	
O	
S	
M	
Q	
Carer’s	Notes	(overleaf)	
On	Leave	
Discontinued	
Other*	
Asleep	
Made	Available	
Offered	but	not	required	
*	where	a	reason	of	‘other’	is	used,	this	needs	to	be	defined.		
Of	note,	the	codes	are	not	standardized	across	the	sector	and	as	a	consequence	
there	may	be	some	differences	in	care	homes	with	regards	to	the	number	and	
range	of	codes	used	to	cover	all	the	possible	reasons	for	not	giving	the	medicine.	
Somewhat	 confusingly,	 care	 homes	may	 use	 different	 letters	 with	 the	 same	
definition.		
3.1.2 The	medicines	administration	process	
There	 are	 normally	 four	 administration	 rounds	 per	 day	which	 are	 commonly	
  	
Chapter	3	
	 113	
labelled	 either	 as:	 (i)	 8am,	 12pm,	 4pm	 and	 8pm	 rounds	 or	 (ii)	 morning,	
afternoon,	teatime	and	bed	rounds.	Medicines	are	stored	on	a	trolley	along	with	
the	 MAR	 charts.	 	 In	 the	 majority	 of	 care	 homes	 the	 trolley	 contains	 three	
different	categories	of	medicines.	Regular	medications	in	the	form	of	tablets	and	
capsules	that	are	packed	in	a	Monitored	Dosage	System	(MDS).	This	system	was	
introduced	 in	 1990s	 to	 facilitate	 medicines	 administrations	 through	 pre-
packaged	medications	 in	 compartments	 that	 correspond	 to	 the	day	and	 time	
that	they	are	to	be	given	(Alldred	et	al.	2011).	MDS	‘trays’	are	usually	assembled	
in	the	pharmacy	and	can	be	useful	in	the	administration	process	as	it	does	not	
require	 the	 individual	 administering	 the	medicines	 to	 ‘pot	 up’	 the	 resident’s	
medicines	 from	 original	 packs.	 ‘When	 required’	medicines	 are	 stored	 on	 the	
trolley	 in	 their	 original	 packs	 and	 are	 only	 administered	 should	 the	 patient	
require	them.	Formulations	that	cannot	be	included	in	the	MDS	system	but	are	
regular	items	such	as	liquids,	topical	medicines,	inhalers	etc.	are	also	stored	in	
their	original	containers.	Estimates	suggest	that	40%	of	medicines	administered	
to	residents	are	contained	in	MDS	systems	(Alldred	et	al.	2009).		On	commencing	
an	administration	round,	the	medicines	trolley	is	wheeled	to	the	resident	by	the	
staff	member	undertaking	the	round.		
Before	 administering	 the	medicines,	 the	 ‘five	 rights’	 should	be	 considered	 to	
ensure	safe	administration	of	medicines	i.e.	right	patient,	right	drug,	right	dose,	
right	route	and	right	time	(Federico	2015;	Denham	2007).	To	do	so,	the	member	
of	staff	administering	medicines	will	confirm	the	identity	of	the	resident	matches	
the	MAR	chart	and	will	then	use	the	MAR	chart	to	guide	the	administration.	They	
should	ensure	that	the	doses	in	the	MDS	system	are	consistent	with	the	MAR	
chart	i.e.	the	correct	strength,	dosage	form,	route	of	administration	and	number	
of	dosage	units	to	administer.	Similarly,	the	MAR	chart	should	be	used	to	identify	
any	medicines	to	be	administered	that	are	not	in	the	MDS	tray	and	perform	the	
same	checks.	Finally,	they	should	identify	any	when	required	medicines	on	the	
MAR	 chart,	 ascertain	 whether	 the	 patient	 needs	 the	 medicines	 (against	 a	
defined	protocol)	and	if	so	administer	them.			
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Having	 administered	 the	 medicines,	 it	 is	 important	 to	 document	 the	
administration.	This	should	be	completed	immediately	following	administration	
of	each	individual	dose	to	the	resident	(NICE,	2014)	and	administration	boxes	
should	 not	 be	 left	 blank	 (National	 Institute	 for	Health	 Research	 2016).	 If	 left	
blank,	 this	 could	 result	 for	 example	 in	 extra	 doses	 being	 given	 as	 there	 is	 a	
possibility	that	another	 individual	will	assume	that	the	resident	didn’t	receive	
the	medication.	This	failure	to	document	an	administration	has	been	shown	to	
directly	result	in	medication	errors	(Haw	et	al.	2007;		Dickens	2007).	In	practice,	
there	is	anecdotal	evidence	that	administrations	are	actually	signed	for	once	the	
round	has	been	completed	rather	than	immediately	following	administration	to	
a	resident.			
3.1.3 Impact	of	documentary	errors	on	the	administration	process	
The	 MAR	 chart	 is	 used	 as	 a	 guide	 by	 the	 member	 of	 staff	 administering	
medicines.	Therefore,	any	documentary	errors	on	the	MAR	chart	may	 lead	to	
errors	in	administration.		Whilst	there	are	only	a	limited	number	of	studies	that	
have	highlighted	documentary	problems	with	MAR	charts,	issues	that	have	been	
identified	in	the	literature	include	(i)	discontinued	medications	that	continue	to	
be	administered	because	they	have	not	been	removed	from	the	MAR	chart;	(ii)	
newly	prescribed	medicines	that	are	not	added	to	the	original	MAR	chart	and	
are	 therefore	 not	 administered;	 (iii)	 discrepancies	 between	 the	 MAR	 chart	
administration	instructions	and	the	label	on	the	medication;	(iv)	alterations	to	
dose	and	frequency	of	existing	medicines	by	a	prescriber	that	are	not	updated	
on	the	MAR	chart;	 (v)	new	prescriptions	 issued	during	the	monthly	cycle	that	
may	result	in	a	resident	having	several	MAR	charts	with	different	starting	dates	
(Smith	2004).	A	key	study	in	the	field	is	the	Care	Homes	Use	of	Medicines	Study	
(CHUMS)	 (Alldred	et	 al.	 2009)	which	evaluated	medicines	management	 in	 55	
care	 homes	within	 3	 different	 areas	 of	 England.	 The	 authors	 concluded	 that	
22.3%	of	the	256	residents	studied	were	subject	to	at	least	one	administration	
error.	Whilst	the	study	didn’t	specifically	focus	on	errors	in	the	MAR	charts,	it	
was	reported	that	improper	documentation	was	one	of	the	contributing	factors	
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that	 lead	 to	medication	 errors.	 This	 was	 in	 addition	 to	 poor	 communication	
among	 health	 care	 providers,	 distractions,	 lack	 of	 adequate	 policies	 and	
environmental	factors	(Alldred	et	al.	2009).	The	problem	of	documentary	errors	
is	not	unique	to	the	UK.	In	a	study	in	the	US,	58	handwritten	MAR	charts	were	
reviewed	revealing	24%	had	missing	information	and	19%	had	missing	directions	
for	use	of	the	medicines	(Gray	et	al.	2006).	In	an	earlier	study	conducted	in	a	US	
nursing	 home,	 charts	 were	 reviewed	 by	 a	 clinical	 pharmacist	 consultant	 and	
‘charting	 and	 transcription’	 errors	 were	 among	 the	 leading	 causes	 of	
administration	issues	(Vlasses	et	al.	1977).	 In	a	study	in	Australia	by	Qian	and	
colleagues,	this	time	in	the	residential	care	home	setting,	a	review	of	MAR	charts	
revealed	a	variety	of	errors	including	duplicate	signatures	for	some	medicines	
administrations	and	a	failure	to	report	the	time	of	administration	due	to	lack	of	
space	on	the	documentation	(Qian	et	al.	2015).	Human	factors	that	have	been	
shown	 to	 contribute	 to	 documentary	 errors	 include	 inadequate	 staff	 training	
and	an	absence	of	a	protocol	for	completing	MAR	chart	documentation	(Alldred	
and	Standage	2011).	It	is	worth	highlighting	that	documentary	errors	are	not	a	
unique	feature	of	care	homes,	indeed	in	a	systematic	review	by	Keers	et	al.	in	
the	 secondary	 care	 setting,	documentary	errors	were	 similarly	a	 contributory	
factor	that	lead	to	administration	errors.	(Keers	et	al.	2013b).	
	
In	the	same	way	that	inappropriate	prescribing	can	result	in	harm	to	residents,	
administration	 errors	 such	 as	 dose	 omissions,	 extra	 doses,	 wrong	 drug	
administered,	wrong	strength	administered	etc.	can	lead	to	significant	harm.	In	
this	study	then,	MAR	charts	were	retrospectively	analysed	to	identify	errors	in	
administration.		
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3.2 Aims	and	Objectives	
The	 aim	 of	 this	 current	 study	 was	 to	 identify	 the	 types	 and	 prevalence	 of	
medicines	management	errors	in	care	homes	through	a	retrospective	analysis	of	
MAR	charts.		
The	objectives	were:	
1. To	characterise	the	types	of	errors	that	may	be	identified	through	MAR	
charts	
2. To	develop	a	protocol	to	identify	errors	on	MAR	charts	
3. To	 undertake	 a	 retrospective	 analysis	 of	 MAR	 charts	 to	 quantify	 the	
errors	identified.	
4. To	 identify	 the	 prevalence	 of	 errors	 associated	 with	 potentially	
inappropriate	medications	(PIMs).	
3.3 Methods	
3.3.1 Overview	of	study	design	
This	 study	 featured	a	 retrospective	 study	of	medication	errors	 in	 care	homes	
using	MAR	charts.	Ten	care	homes	were	recruited	for	the	study	and	MAR	charts	
were	collected	over	a	28-day	medicines	cycle	in	September	2014.	All	the	records	
of	medicines	administration	on	the	MAR	charts	were	assumed	to	be	accurate	
representations	 of	 the	 administrations	 that	 took	 place	 in	 the	 care	 home.	 An	
outline	of	the	study	design	is	shown	in	Figure	3.2.		
	
Figure	3.2	Schematic	of	the	study	design	
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3.3.2 Ethical	approval	
Prior	to	commencing	this	study	ethical	approval	was	obtained	from	the	Cardiff	
School	 of	 Pharmacy	 and	 Pharmaceutical	 Sciences	 (SPPS)	 Research	 Ethics	
Committee	(see	Appendix	1).		
3.3.3 Recruitment	of	care	homes	
Ten	care	homes	were	recruited	by	purposive	sampling	from	the	Abertawe	Bro	
Morgannwg	University	Health	Board	(ABMU)	in	Wales.	A	full	description	of	the	
recruitment	process	is	described	in	Chapter	2	section	2.3.2.	Briefly,	the	inclusion	
criteria	was	 that	 the	home	was	 located	 in	 the	ABMU	health	board,	 primarily	
catered	for	older	adults,	was	registered	with	the	Care	Inspectorate	Wales	(CIW)	
and	that	they	used	a	paper-based	MAR	chart.		
3.3.4 MAR	chart	collection	
Anonymised	MAR	charts	were	received	from	the	ten	participating	care	homes	in	
October	2014	covering	a	28-day	medicines	 cycle	 that	 ran	 from	September	 to	
October.	A	full	description	is	provided	in	Chapter	2	section	2.3.3.		
3.3.5 Development	of	MAR	chart	evaluation	protocol	
3.3.5.1 Categorisation	of	medication	errors	
In	 this	 study,	 the	 definition	 of	 a	medication	 error	was	 adopted	 from	 the	 US	
National	Coordinating	Council	 for	Medication	Error	Reporting	and	Prevention:	
‘Any	preventable	event	that	may	cause	or	lead	to	inappropriate	medication	use	
or	 patient	 harm	while	 the	medication	 is	 in	 the	 control	 of	 health	professional,	
patient	 or	 consumer.’	 This	 definition	was	 chosen	 as	 it	 provides	 the	 broadest	
description	of	a	medication	error.		
Errors	were	assessed	and	categorised	based	on	The	National	Institute	for	Health	
and	Care	Excellence	(NICE	2014)	guidance	for	Medicines	Management	in	Care	
Homes.	These	guidelines	outline	a	series	of	best	practices	related	to	the	safe	and	
effective	use	of	medicines	in	care	homes.	The	areas	of	the	guidance	that	were	
used	 to	 inform	 the	development	of	a	protocol	 to	 identify	errors	were:	 (i)	1.4	
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Ensuring	that	records	are	accurate	and	up	to	date;	 (ii)	1.7	Accurately	 listing	a	
resident’s	medicines	(medicines	reconciliation);	(iii)	1.12	Receiving,	storing	and	
disposing	of	medicines;	(iv)	1.14	Care	home	staff	administering	to	residents.	A	
table	of	the	sub-categories	of	the	guidance	used	to	develop	the	protocol	can	be	
found	in	Appendix	2.	This	resulted	in	the	production	of	an	initial	set	of	criteria	
by	which	MAR	charts	could	be	assessed	(see	Table	3.2).	
Table	3.2	Initial	criteria	for	identifying	medicines	related	errors	on	MAR	charts.		
Criteria	 Notes	for	assessing	MAR	chart	
MAR	 charts	 should	 record	 the	 Date	 of	 Birth	
(DoB)	and	allergy	status	of	the	resident	
Check	for	allergy	status,	DoB	
MAR	charts	should	indicate	any	reason	for	not	
giving	medicine(s)	using	a	defined	code	
Check	 for	 empty	 administration	 boxes,	
undefined	codes		
Medication	 administration	 times	 should	 be	
consistent	with	stated	medicines	rounds	
Check	for	timing	of	administration	against	
time	indicated	on	MAR	chart	
All	 hand-written	 changes	 on	 the	MAR	 charts	
should	be	signed	by	a	witness	
Identify	 any	 hand	 amendment	 and	 check	
for	second	signature	
Medicines	 must	 have	 clear	 instructions	 for	
administration	
Identify	 any	 medicines	 listed	 with	 as	
directed	 instructions	 or	 with	 no	
administration	instructions		
Controlled	 Drug	 administrations	 should	 be	
witnessed	and	signed	
Identify	Controlled	Drugs	on	MAR	chart	and	
check	to	see	if	witness	signature	is	present	
MAR	 charts	 should	 record	 the	 maximum	
frequency	of	PRN	medications	
Identify	 PRN	 medicines	 and	 check	 to	 see	
maximum	 frequency	 listed;	 for	
paracetamol	 containing	 products	 ensure	
instructions	 indicate	 minimum	 of	 4-hour	
period	between	administrations			
MAR	 charts	 should	 record	 complete	
information	for	each	medication	
Check	for	name,	strength	and	formulation	
MAR	charts	should	record	the	quantity	of	each	
medicine	 for	 the	 current	 medicines	 cycle	
received	
Check	 for	 quantity	 discrepancy	 between	
the	 received	 medication	 and	 quantity	
carried	over	from	previous	cycles	
	
A	batch	of	MAR	charts	 from	a	single	care	home	(care	home	0;	comprising	19	
residents	for	the	June/July	2010	medicines	cycle)	was	then	analysed	to	identify	
any	discrepancies	against	the	criteria	listed	in	Table	3.2;	this	was	undertaken	by	
members	of	the	research	team	(n	=	10),	lead	by	the	researcher,	reviewing	each	
MAR	chart	independently.		The	research	team	then	met	to	discuss	the	identified	
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errors	and	any	identified	errors	that	were	not	listed	in	the	initial	criteria	in	order	
to	 develop	 a	 refined	 protocol	 and	 error	 categorisation.	 This	 was	 achieved	
through	a	series	of	face-to-face	discussions	until	consensus	was	reached	within	
the	team.	After	each	meeting	the	MAR	chart	analysis	rulebook	was	updated	and	
the	MAR	 charts	 from	 Care	 Home	 0	were	 re-analysed.	N.B.	 results	 from	 Care	
Home	0	were	not	included	in	the	final	analysis.		
Once	 the	 protocol	 was	 finalised	 (see	 Appendix	 3)	 a	 validation	 step	 was	
undertaken.	In	this	step,	members	of	the	research	team	(n	=	10)	analysed	Care	
Home	1	(comprising	19	residents	for	September/October	2014)	independently	
using	the	rulebook.	A	face-to-face	team	meeting	confirmed	that	errors	extracted	
by	 individual	 team	 members	 were	 consistent	 across	 the	 research	 team.	 	 A	
schematic	of	the	methodological	approach	is	shown	in	Figure	3.3.		
	
	
Figure	3.3	Schematic	of	how	the	research	team	validated	the	protocol	(rulebook)	to	ensure	
consistency	of	data	extraction	from	MAR	charts.
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The	final	categories	used	for	assessment	of	medication	errors	are	shown	in	Table	
3.3.		
The	 remaining	 nine	 care	 homes	were	 assigned	 to	 a	 separate	member	 of	 the	
research	team	(n	=	9)	and	analysed	using	the	rule	book.		This	process	was	co-
ordinated	and	overseen	by	the	author	of	this	PhD;	in	total	for	the	ten	care	homes	
examined	 in	 this	 study,	 720	 MAR	 charts	 were	 reviewed.	 	 Two	 pragmatic	
assumptions	were	made	when	analysing	the	MAR	charts	and	these	were:	
• The	documentation	of	administrations	was	an	accurate	reflection	of	the	
administrations	that	took	place	
• Anything	that	was	not	written	on	the	MAR	charts	did	not	occur	unless	
otherwise	stated	by	the	service	provider.	
	
The	study	design	was	discussed	with	a	statistician	who	indicated	that	a	Kappa	
coefficient	 for	 inter-rater	 reliability	 was	 not	 needed	 given	 the	 overall	
management	of	the	research	team	by	the	researcher.	
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Table	3.3	Finalised	categories	of	MAR	chart	errors.	
Category	 Subcategory	 Origin	of	the	error	 Example	
Regulatory	Errors	
	 1) ‘As	directed’	instruction	 Prescriber,	Pharmacy	and	CH	Staff		 As	directed	is	written	on	the	label		
	 2) Undefined	code	used	 CH	Staff	 A	code	used	is	not	defined	on	MAR	chart,	e.g.	(O)	was	written	without	clear	
definition	
	 3) Incorrect	number	of	signature	 CH	Staff	 Hand	amendment	with	insufficient	signatures,	e.g.	changes	in	the	daily	doses	was	
hand	amended	with	one	signature.		
	 4) Drug	name	misspelt	 Pharmacy	and	CH	Staff	 Incorrect	spelling	of	product	name	
	 5) No	maximum	PRN	dose	 Prescriber,	Pharmacy	 A	maximum	dose	PRN	does	not	stated	on	label	
	 6) Missing	chart	information	 Pharmacy,	CH	Staff	
	
Information	not	related	to	medication	is	missing	from	the	chart,	e.g.	date	of	birth,	
start	date	of	chart,	allergies	etc.	
Administration	Errors	
	 1) Missed	medication	cycle	 Care	home	staff	 No	dose	is	administered	for	all	28	days,	e.g.	no	entry	on	chart	for	Furosemide.	
	 2) Omission	 	 An	administration	box	is	empty.	(Each	empty	box	is	a	separate	error)	
	 3) Deviation	from	stated	dose	 	 The	instructions	on	the	administration	label	are	not	followed.	(Each	deviation	is	a	
separate	error),	e.g.	two	doses	was	given	for	Complan	sachets	once	daily	instead	
of	one	dose	twice	a	day.	
	 4) Extra	dose	 	 An	administration	of	an	additional	dose	of	a	prescribed	medication,	e.g.	
Carbamazepine	was	given	twice	daily	instead	of	once	daily.	
	 5) Wrong	time	 	 A	dose	administered	at	different	time	from	the	prescribed	time	(±1	hr)	
e.g.	Mirtazapine	was	administered	at	tea	time	instead	of	night.	
	 6) Deviation	from	PRN	protocol	 	 Administrations	of	when	required	medication	that	does	not	follow	the	PRN	
protocol.	
	 7) Unexplained	crossing	out	of	an	
administration	
	 A	cancelled	/	crossed	out	administration	with	no	explanation.	
MAR	chart	Errors	
	 1) Dose	Absent	
	
Prescriber	and	Pharmacy	and	CH	
Staff	for	all	sub-categories	
The	dose	is	completely	absent	from	the	label,	e.g.	no	dose	was	written	for	
Warfarin	but	instead	(dose	according	to	INR	was	written).	
	 2) Strength	Absent	 	 The	strength	is	completely	absent	from	the	label,	e.g.	no	strength	was	written	for	
Hyoscine	s/c	injections.	
	 3) Formulation	Absent	 	 The	formulation	is	completely	absent	from	label,	e.g.	no	formulation	was	written	
for	Mirtazpine.	
	 4) Duplicate	Entry	 	 There	is	more	than	one	entry	for	the	same	product,	e.g.	a	duplicate	entry	was	
observed	with	Carbamazepine.	
	 5) Missing	Time	 	 The	time	section	of	chart	for	administered	doses	is	not	filled	in,	e.g.	time	was	
missing	for	administration	of	Risperidone.	
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	 6) Incomplete	Dosage	Information	 	 There	are	incomplete	dosage	instructions,	e.g.	no	site	of	application	for	a	cream,	
or	no	frequency	stated.	
Stock	Errors	
	 1) Quantity	Discrepancy	 CH	Staff	 The	amount	administered	exceeds	the	amount	recorded	in	stock.	
	 2) No	Date	Recorded	 	 No	date	is	recorded	for	received	stock	
	 3) No	Quantity	Recorded	 	 No	quantity	is	recorded	for	received	stock	
	 4) No	Signature	 	 No	signature	is	present	for	received	stock.	
Errors	that	cannot	be	categorised		
	 1) Miscellaneous*	 N/A	 Include	any	error	that	could	not	be	categorised	from	the	available	data,	e.g.	
Controlled	drugs	were	administered	without	second	signature.	
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3.3.6 Data	extraction	and	analysis	
MAR	 charts	 were	 received	 from	 ten	 care	 homes	 comprising	 260	 unique	
residents.	 The	 MAR	 charts	 were	 reviewed	 against	 the	 validated	 protocol	
(rulebook)	 and	errors	 extracted	 and	 recorded	using	 a	data	 collection	 form	 in	
Microsoft	Excel	for	Mac	version	15.33	(Microsoft	Corporation;	Seattle,	USA).	The	
data	 collection	 form	 (see	 Appendix	 4)	 had	 fields	 for:	 care	 home	 number,	
resident	 date	 of	 birth,	 age	 in	 years,	 resident	 id	 number,	 total	 number	 of	
medications	 administered	 to	 resident,	 chart	 number	 (if	 more	 than	 1	 per	
resident),	number	of	medications	on	chart,	name	of	medication,	controlled	drug	
classification,	BNF	section,	BNF	category,	presence	of	an	error	(Yes/No),	date	of	
error,	drug	round	during	which	error	took	place	(wherever	possible),	whether	a	
PRN	protocol	is	needed	for	the	drug	and	was	available,	the	main	category	of	the	
error,	the	sub-category,	and	a	brief	description	of	the	error.	
The	type	and	frequency	of	medication	errors	from	the	MAR	charts	of	the	260	
residents	were	recorded	and	data	entered	into	an	Excel	spreadsheet	designed	
for	 this	 purpose.	 Descriptive	 statistics	 were	 produced	 in	 Microsoft	 Excel.		
Administration	errors	and	MAR	chart	errors	were	isolated	for	further	analysis	as	
these	errors	were	deemed	to	be	more	 likely	 to	cause	harm	to	residents	 than	
other	categories.	
3.3.6.1 Quality	Assurance	
Once	data	entry	was	complete,	a	quality	assurance	process	was	carried	out.	The	
researcher	 extracting	 the	 errors	 from	 the	 MAR	 charts	 read	 through	 their	
Microsoft	Excel	Spreadsheet	to	identify	any	obvious	mistakes.	Finally,	a	sample	
of	10%	of	resident’s	data	across	the	ten	care	homes	was	randomly	selected	by	
the	PhD	author	and	checked	for	errors.	If	any	mistakes	were	identified	they	were	
corrected	and	another	sample	of	10%	was	selected	and	checked,	repeating	until	
no	mistakes	were	found.	Residents	were	selected	by	resident	number	using	a	
random	number	generator	(Randomness	and	Integrity	Services	Ltd).	
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3.3.7 Calculating	error	rate	
Error	rate	per	resident	was	calculated	using	total	number	of	opportunities	for	
errors	(TOE)	as	a	denominator	and	number	of	errors	identified	as	the	numerator	
(see	Equation	1).		Total	opportunities	for	errors	comprises	the	total	number	of	
doses	scheduled	to	be	administered	in	accordance	with	the	prescriber's	orders	
plus	any	extra	doses	given	i.e.	it	is	the	total	number	of	doses	administered	to	a	
resident,	whether	appropriate	or	not,	plus	any	omitted	doses	(Tissot	et	al.	1999;	
Flynn	et	al.	2002).	The	numerator	was	total	number	of	errors	(TNE,	 i.e.,	more	
than	1	error	per	dose	could	be	counted)	(Keers	et	al.	2013a).	
	
Equation	1:	!""#"	"%&' = 	 )*+,'"	#-	'""#".	/0'1&/-/'02#&%3	#44#"&*1/&/'.	-#"	'""#". ×100	
	
Although,	there	are	several	different	denominators	used	to	estimate	the	rate	of	
medication	errors	(Lewis	et	al.	2009;	James	et	al.	2009),	the	total	opportunities	
for	 errors	 is	 a	 well-established	 parameter	 (Alldred	 2009;	 Keers	 et	 al.	 2013a;	
Berdot	et	al.	2012).	In	this	current	study	TOE	was	used	based	on	CHUMS	study,	
the	seminal	study	in	this	field.	The	numerator	can	be	either	the	number	of	dose	
administrations	with	one	or	more	errors	(OME;	 i.e.	each	dose	 is	binary	either	
correct	 or	 incorrect),	 or	 the	 total	 number	 of	 errors	 (TNE;	 i.e.	 a	 dose	 can	 be	
associated	with	more	than	one	error)	(Keers	et	al.	2013a).		TNE	has	the	tendency	
to	inflate	error	rate	and	indeed	can	result	 in	error	rates	that	are	greater	than	
100%.	 Conversely	 OME	 may	 not	 capture	 the	 extent	 of	 the	 error	 because	 a	
resident	may	receive	the	wrong	drug,	at	the	wrong	strength	and	at	the	wrong	
time	but	this	would	only	be	counted	as	one	error	in	the	calculation	of	the	error	
rate.	 In	 this	 study,	 the	 TNE	 was	 used	 as	 the	 best	 compromise	 of	 the	 two	
methods.			
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3.3.8 Counting	 the	 total	 number	 of	 opportunities	 for	 error	 in	 each	 care	
homes	
The	total	opportunities	for	errors	was	calculated	directly	from	MAR	charts	by	the	
researcher.	A	protocol	(see	Appendix	5)	was	created	for	this	process	to	include	
all	the	scheduled	medications	on	the	MAR	charts	plus	any	deviations	from	the	
scheduled	medicines	as	described	in	MAR	chart	annotations.	In	most	cases	this	
information	 could	 be	 gathered	 from	 the	 dosing	 instructions	 however,	 there	
were	a	number	of	caveats	where	‘workarounds’	were	needed.	These	included:		
• Commonly,	for	paracetamol	and	paracetamol	related	products,	although	
the	 products	 were	 prescribed	 as	 a	 regular	 medication,	 they	 were	
administered	as	when	required	medications	(PRN).	A	decision	was	taken	
to	only	include	actual	administrations	in	the	count	of	opportunities	for	
error	not	the	scheduled	administrations	in	this	case.	
• Where	dosing	 instructions	were	ambiguous	(e.g.	apply	as	often	as	you	
like!!)	administrations	were	counted.		
• There	 were	 cases	 where	 two	 MAR	 charts	 were	 found	 for	 the	 same	
medication(s).	It	was	clear	that	some	individuals	administered	from	the	
one	 chart	 and	 other	 individuals	 from	 the	 second	 chart.	 None	 of	 the	
administrations	for	these	duplicate	medicines	overlapped	and	therefore	
only	one	scheduled	administration	was	counted.		
• The	letters	used	by	some	staff	as	a	signature	to	denote	an	administration	
in	some	cases	overlapped	with	defined	MAR	chart	codes	for	example	one	
staff	member	used	the	initial	N	to	mark	an	administration	but	that	was	
also	 the	 home’s	 code	 for	 nausea	 and	 vomiting.	 In	 this	 case,	 the	
researcher	used	her	own	judgement	in	counting	medicines.		
• Hand-made	 amendments	 to	 dosing	 schedules	 were	 not	 followed	 by	
some	staff	i.e.	the	original	dosing	schedule	was	followed.	In	this	case	the	
opportunities	for	error	was	based	on	actual	administrations	and	not	the	
new	schedule.	
• PRN	 medications	 were	 excluded	 from	 the	 counting	 process	 because,	
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there	was	no	distinct	protocol	or	policy	for	their	administration	within	
the	 recruited	 care	 homes.	 This	 made	 any	 interpretation	 of	 the	
prescribers’	intention	against	the	administration	practice	flawed.	
3.3.9 Identifying	errors	with	potentially	inappropriate	medications	
Administration	 related	 errors	 associated	 with	 potentially	 inappropriate	
medications	were	extracted	from	MAR	charts.	Beers	criteria	was	used	to	classify	
medicines	as	potentially	 inappropriate.	For	a	description	of	Beers	 criteria	 see	
Chapter	 2;	 a	 list	 of	 Beers	 criteria	medications	 and	medication	 classes	 can	be	
found	in	Table	2.8.		
3.4 Results	
3.4.1 Frequency	of	errors	identified	
MAR	charts	for	all	residents	(260)	from	each	of	ten	care	homes	were	analysed	
over	a	28-day	medicines	cycle	with	the	exception	of	care	home	2,	from	which	
the	analysis	was	for	17	days	only.	The	errors	identified	were	recorded,	analysed	
and	categorised	according	to	five	distinct	categories:	(i)	administration	errors;	
(ii)	 regulatory	 errors;	 (iii)	 stock	 errors,	 (iv)	 MAR	 chart	 errors	 and	 (v)	
miscellaneous	errors.	Table	3.4	details	the	absolute	number	of	errors	identified	
in	each	care	home	across	all	error	categories	and	those	related	to	administration	
errors	alone	i.e.	those	errors	that	are	most	immediately	patient	facing.
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Table	3.4	Total	number	of	errors	identified	for	10	care	homes	
Care	
Home	
No	of	residents	 Total	number	of	errors	
identified	(all	categories)	
Number	of	administration	
errors	identified		
1	 19	 648	 419	
2*	 21	 1369	 460	
3	 25	 1593	 707	
4	 26	 1533	 731	
5	 53	 2947	 1613	
6	 20	 1335	 401	
7	 17	 1086	 584	
8	 24	 360	 96	
9	 14	 1571	 697	
10	 41	 3820	 1062	
*17	days	of	administration	data	was	available;	for	all	other	homes	it	was	28	days.		
3.4.2 Average	number	of	errors	residents	are	exposed	to	each	week	
Given	 the	 variability	 in	 resident	 occupancy	 in	 each	 care	 home,	 the	 absolute	
number	of	errors	is	less	informative	than	the	potential	resident	exposure	to	an	
error.	Therefore,	the	number	of	errors	per	resident	per	week	was	calculated	in	
terms	 of	 the	 total	 number	 of	 errors	 identified	 in	 each	 home	 and	 the	
administration	 errors	 (see	 Table	 3.5).	 As	 can	 be	 seen,	 even	 in	 the	 best	
performing	care	homes,	a	resident	was	likely	to	be	exposed	to	four	errors	per	
week	and	in	the	poorest	performing	homes	that	rate	rises	to	28	errors	per	week.		
Not	 all	 the	 categories	 of	 errors	 pose	 an	 immediate	 risk	 to	 patient-safety,	
however,	administration	errors	are	more	likely	do	so	as	they	are	directly	patient	
facing	 and	 therefore	 an	 ‘error’	 rate	per	 resident	per	week	 for	 administration	
errors	was	also	 calculated.	 The	best	performing	 care	home	was	 care	home	8	
which	had	the	lowest	number	of	administration	errors	per	resident	per	week	at	
one	error	and	the	highest	number	of	errors	was	12	administration-related	errors	
per	resident	per	week	in	care	home	9.		Given	the	small	sample	size,	the	relative	
efficiencies	 of	 nursing	 homes	 versus	 residential	 care	 homes	 could	 not	 be	
elucidated	in	this	study.	
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Table	3.5	Number	of	errors	per	resident	per	week	(total	for	all	error	categories	and	administration	
errors)	
Care	Home	 Number	of	errors	per	resident	per	
week	
Number	of	administration	errors	per	
resident	per	week	
1	 9	 6	
2	 14	 5	
3	 16	 7	
4	 15	 7	
5	 14	 8	
6	 17	 5	
7	 16	 9	
8	 4	 1	
9	 28	 12	
10	 23	 6	
Average	±SD	 17±10	 6±3	
	
3.4.3 The	error	rate	as	a	function	of	the	opportunities	for	errors	
In	addition	to	calculating	the	error	rate	as	a	function	of	the	number	of	errors	a	
resident	 was	 likely	 to	 be	 exposed	 to	 each	 week,	 the	 error	 rate	 was	 also	
calculated	as	a	function	of	the	total	opportunities	for	error	(see	section	3.3.7).	
The	error	rate	for	administration	errors	is	shown	in	Table	3.6.		The	overall	error	
rate	across	the	ten	care	homes	was	19.1%	i.e.	for	all	the	opportunities	for	error,	
19.1%	were	associated	with	an	administration	error.	Across	the	ten	care	homes,	
the	error	rate	ranged	from	2.9%	(care	home	8)	to	12.3%	(care	home	5).	The	mean	
error	rate	was	8.6%	with	a	narrow	standard	deviation	of	0.03%	demonstrating	
limited	variability	across	the	homes.		 	
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Table	 3.6 Medicines	 administration	 error	 rate	 in	 each	 care	 home	 as	 a	 function	 of	 the	 total	
opportunities	for	errors.		In	the	best	performing	care	home	(number	8),	2.9%	of	all	opportunities	
for	an	error	were	associated	with	an	administration	error	whilst	in	the	worst	performing	home	
(number	7)	this	increased	to	12.3%.			
Care	home	 Total	opportunities	for	errors	 Error	rate	for	administration	errors	
1	 4062	 10.3%	
2	 4333	 10.6%	
3	 7100	 9.9%	
4	 8288	 8.8%	
5	 13744	 11.7%	
6	 6053	 6.6%	
7	 4751	 12.3%	
8	 3224	 2.9%	
9	 8948	 7.8%	
10	 22314	 4.8%	
Total	 82,817	 19.1%	
	 Mean		±	S.D.	 8.6	±	0.03	
	
3.4.4 Errors	by	care	home	
The	absolute	number	of	errors	identified	in	each	care	home	for	each	of	the	error	
categories	used	in	this	study	is	shown	in	Table	3.7.	
Table	 3.7	 The	 absolute	 number	 of	 medicines	 related	 errors	 identified	 in	 the	 ten	 care	 homes	
examined	in	this	study.		 
	
In	 order	 to	 better	 compare	 homes,	 the	 percentage	 of	 each	 error	 type	 was	
calculated	 from	the	 total	number	of	errors	 identified	 in	each	care	home	 (see	
Table	3.8	 and	 Figure	 3.4).	Whilst	 there	 is	 evidence	 of	 inter-home	 variability,	
some	patterns	do	emerge.	For	seven	of	the	ten	homes	(1,	3,	4,	5,	7,	8	and	9),	
	 Number	of	errors	
	 Administration	 Regulatory	 MAR	chart	 Stock		 Misc.	 Total	
Care	Home		 	 	 	 	 	 	
1	 419	 79	 20	 126	 4	 648	
2	 460	 149	 56	 593	 111	 1369	
3	 707	 124	 85	 286	 391	 1593	
4	 731	 143	 53	 339	 267	 1533	
5	 1613	 424	 164	 417	 329	 2947	
6	 401	 155	 51	 620	 108	 1335	
7	 584	 129	 37	 313	 23	 1086	
8	 96	 89	 44	 93	 38	 360	
9	 697	 206	 79	 362	 227	 1571	
10	 1062	 246	 141	 588	 1783	 3820	
              
	
	
Chapter	3	
	 130	
administration	errors	were	the	most	frequently	encountered	errors	(range	27%	
-	 65%).	 For	 the	 remaining	 three	 homes,	 stock	 was	 the	 most	 frequently	
encountered	error	in	two	homes	(homes	2	and	6)	and	miscellaneous	errors	was	
the	most	common	error	category	 in	care	home	10.	 	 In	the	majority	of	homes	
(8/10),	 MAR	 chart	 errors	 (errors	 associated	 with	 incomplete	 or	 absent	
information	on	the	MAR	chart)	were	the	least	commonly	encountered	errors.			
Table	3.8	Percentage	breakdown	of	each	error	type	for	each	care	home.	In	seven	of	the	ten	care	
homes,	 administration	 errors	 represented	 the	most	 frequently	 encountered	 error	 type.	 In	 the	
remaining	three	homes,	for	two	homes	stock	errors	were	the	most	commonly	encountered	error	
whilst	for	the	final	home	it	was	miscellaneous	errors.		
	
	
Figure	3.4	Percentage	breakdown	of	each	error	type	for	each	care	home.	In	seven	of	the	ten	care	
homes,	 administration	 errors	 represented	 the	most	 frequently	 encountered	 error	 type.	 In	 the	
remaining	three	homes,	for	two	homes	stock	errors	were	the	most	commonly	encountered	error	
whilst	for	the	final	home	it	was	miscellaneous	errors.		
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	 Care	Home	Number	
Errors	(%	of	total)	 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	
1. Regulatory	 12	 11	 8	 9	 14	 12	 12	 25	 13	 6	
2. Administration		 65	 34	 44	 48	 55	 30	 54	 27	 44	 28	
3. MAR	chart		 3	 4	 5	 3	 6	 4	 3	 12	 5	 4	
4. Stock	 19	 43	 18	 22	 14	 46	 29	 26	 23	 15	
5. Miscellaneous		 1	 8	 25	 17	 11	 8	 2	 11	 14	 47	
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3.4.5 Prevalence	of	errors	in	each	of	the	primary	error	categories	
A	breakdown	of	the	frequency	of	errors	by	sub-category	for	the	primary	error	
categories	of	(i)	administration	errors;	(ii)	MAR	chart	errors;	(iii)	regulatory	errors	
and	(iv)	stock	errors	was	calculated	and	is	presented	here.	
3.4.5.1 Administration	errors	
Administration	 errors	were	 broken	 down	 into	 six	 subcategories:	 (i)	 deviation	
from	the	stated	dose;	(ii)	a	missed	medicines	cycle;	(iii)	an	omitted	dose;	(iv)	an	
extra	dose;	(v)	dose	administered	at	the	wrong	time	and	(vi)	an	administration	
has	been	 crossed	out	without	 explanation.	A	breakdown	of	 the	 frequency	of	
errors	in	each	care	home	under	these	six	categories	is	depicted	in	Table	3.9	and	
Figure	3.5.	Omitted	doses	were	found	to	be	the	most	common	error	type	within	
the	administration	error	category	in	all	care	homes	with	the	exception	of	care	
home	6	where	incorrect	timing	of	an	administration	was	the	most	common.		The	
range	in	the	percentage	of	administration	errors	accounted	for	by	omitted	doses	
was	 5%	 (in	 care	 home	 6)	 up	 to	 99%	 (in	 care	 home	 9).	 A	 number	 of	 the	
subcategories	were	not	associated	with	high	levels	of	error	 in	any	of	the	care	
homes	 studied.	 Deviation	 from	 the	 stated	 dose	 (range	 0	 –	 3%)	 and	 an	
unexplained	 crossing	 out	 of	 an	 administration	 (range	 0.4%	 to	 2%)	 were	
particularly	uncommon	both	in	terms	of	the	absolute	number	of	errors	identified	
(data	not	 shown)	 and	 their	 contribution	 to	 the	 administration	error	 category	
within	each	home	as	a	whole.		An	unexplained	missed	medication	cycle	(i.e.	a	
resident	did	not	receive	one	or	more	medicines	for	the	entirety	of	a	28-day	cycle)	
displayed	some	variability	 (range	0%	up	to	13%).	Whilst	 there	were	 four	care	
homes	(3,	6,	9	and	10)	where	no	resident	missed	a	medicine(s)	for	the	duration	
of	a	medicines	cycle,	in	the	remaining	care	home	at	least	one	resident	did	not	
receive	one	or	more	of	their	medicine(s)	for	the	entirety	of	the	cycle.			
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Table	3.9	Breakdown	of	administration	errors	(percentage)	by	subcategory.	Data	is	presented	as	
percentage	of	the	total	number	of	administration	errors	identified.	In	all	care	homes	(with	the	
exception	of	care	home	6)	omitted	doses	was	the	most	frequent	error	type	identified.			
	
	
Figure	3.5 The	frequency	of	administration	errors	(percentage)	broken	down	into	subcategories.	
In	all	care	homes	with	the	exception	of	care	home	6,	omitted	doses	were	the	most	frequent	error	
type	identified.			
3.4.5.2 MAR	chart	errors	
The	MAR	chart	error	category	was	comprised	of	 six	 sub-categories	 related	 to	
either	missing	information	about	the	drug	or	a	duplicate	entry	for	a	drug	on	the	
MAR	chart.	 Specifically,	 the	 sub-categories	were	 (i)	 the	dose	of	 the	drug	was	
absent;	(ii)	the	formulation	of	the	drug	was	absent;	(iii)	the	strength	of	the	drug	
0 50 10
0
1
2
3
4
5
6
7
8
9
10
Percent
C
ar
e 
ho
m
e 
nu
m
be
r Deviation from stated dose
Missed medication cycle 
Omitted dose 
Extra dose
Wrong time 
Crossing out
	 Care	Home	Number	
Administration	Errors	%	 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	
Deviation	from	stated	
dose	
1	 0	 0	 0	 0.1	 0.5	 0	 0	 0	 3	
Missed	medication	cycle		 6	 2	 0	 2	 2.9	 0	 5	 13	 0	 0	
Omitted	dose		 45	 86	 91	 64	 82	 5	 84	 84	 99	 94	
Extra	dose	 40	 5	 2	 17	 11	 29	 10	 1	 0.1	 2	
Wrong	time		 7	 5	 6	 15	 3	 64	 0.1	 0	 0	 0.6	
Crossing	out	 1	 2	 1	 2	 1	 1.5	 0.9	 2	 0.9	 0.4	
Absolute	No	of	errors	 419	 460	 707	 731	 1613	 401	 584	 96	 697	 1062	
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was	 absent;	 (iv)	 the	 required	 time	 of	 the	 administration	was	 absent;	 (v)	 the	
dosing	 information	 was	 absent	 or	 (vi)	 the	 MAR	 chart(s)	 for	 the	 resident	
contained	a	duplicated	medication.	Whilst	the	absolute	number	of	MAR	chart	
errors	identified	in	the	care	homes	was	relatively	small	(20	–	164	errors;	range	3	
–	 12%	 of	 all	 errors	 identified	 in	 each	 home;	 see	 Table	 3.10	 and	 Figure	 3.6)	
nevertheless	 such	 errors	 are	 associated	 with	 risk	 to	 the	 patient.	 With	 the	
exception	of	 care	home	1,	 there	were	examples	 in	all	 care	homes	where	 the	
dosage	instructions	were	incomplete	on	the	MAR	chart.	Indeed,	in	care	home	6	
some	43	of	 the	 51	MAR	 chart	 errors	 (84%)	were	 associated	with	 incomplete	
information.	Similarly,	with	 the	exception	of	care	homes	4	and	7,	 there	were	
examples	 in	 all	 care	 homes	 of	MAR	 charts	where	 the	 dose	was	 absent.	 This	
would	prevent	the	individual	administering	the	drug	cross-referencing	with	the	
MDS	tray	or	the	medicines	pack	to	ensure	the	dose	is	correct	 if	 it	was	on	the	
label.	In	eight	out	of	the	ten	homes,	the	scheduled	time	for	the	administration	
was	absent	from	the	MAR	chart.	Where	the	medicine	was	packaged	in	an	MDS	
tray,	the	person	administering	the	medicine	would	be	guided	to	administer	the	
medicine	according	to	the	schedule	on	the	tray.	However,	for	medicines	that	are	
not	packaged	in	an	MDS	tray	(liquids,	inhalers	etc)	then	the	person	administering	
would	 have	 to	 use	 their	 judgement	 as	 to	 when	 the	 medicine	 should	 be	
administered.	Of	note,	in	seven	care	homes	there	were	examples	of	medicines	
being	duplicated	like-for-like	on	a	resident’s	MAR	chart(s)	increasing	the	risk	that	
a	resident	will	receive	duplicate	therapy	unnecessarily.		
Table	3.10	Breakdown	of	MAR	chart	errors	(percentage)	by	subcategory.	Data	is	presented	as	
percentage	of	the	total	number	of	MAR	chart	errors	identified.		
	 Care	Home	Number	
MAR	chart	Errors	(%)	 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	
Dose	absent	 75	 11	 2	 0	 18	 8	 0	 36	 2	 50	
Formulation	absent		 0	 9	 2	 40	 26	 0	 19	 36	 0	 0	
Strength	absent	 5	 4	 4	 3	 10	 8	 0	 8	 0	 3	
Missing	time		 15	 18	 29	 21	 2	 0	 30	 0	 54	 23	
Duplicate	medication	 5	 13	 19	 6	 16	 0	 5	 0	 0	 1	
Incomplete	dosage	
information		
0	 45	 44	 30	 28	 84	 46	 20	 44	 23	
Absolute	No	of	errors	 20	 56	 85	 53	 164	 51	 37	 44	 79	 141	
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Figure	3.6 The	frequency	of	MAR	chart	errors	(percentage)	broken	down	into	subcategories.		
3.4.5.3 Regulatory	errors	
Regulatory	errors	are	errors	related	to	contraventions	of	regulatory	standards	
or	guidance.	 In	 this	case,	 the	regulatory	errors	category	was	comprised	of	six	
sub-categories:	(i)	medicines	written	up	with	‘as	directed’	directions;	(ii)	missing	
chart	 information	 (e.g.	DOB,	allergy	 status);	 (iii)	no	maximum	dose	stated	 for	
when	 required	 (prn)	 drugs;	 (iv)	 the	 drug	 name	 was	 spelt	 incorrectly;	 (v)	 a	
signature	is	missing	(for	example	when	a	dose	is	changed	mid-cycle)	and	(vi)	an	
undefined	code	is	used	on	the	MAR	chart	to	detail	some	piece	of	information	
about	an	administration.	The	breakdown	of	regulatory	errors	by	subcategory	are	
shown	in	Table	3.11	and	Figure	3.7.	The	absolute	number	of	 instances	where	
drug	name	was	misspelt	was	very	small	and	 indeed	 in	 the	majority	of	homes	
(6/10)	there	were	no	examples	of	this	error.	In	the	homes	where	this	error	was	
identified,	it	was	primarily	associated	with	hand	written	charts	rather	than	those	
that	were	printed.	In	all	care	homes	there	were	MAR	charts	where	medicines	
were	written	up	with	‘as	directed’	dosing	instructions.	In	the	case	of	medicines	
packed	in	MDS	trays	the	decision	on	the	appropriate	dosing	would	have	been	
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made	by	the	pharmacy	team	when	assembling	the	tray.	However,	for	medicines	
that	are	not	assembled	in	MDS	trays,	this	would	require	somebody	in	the	care	
home	 making	 a	 clinical	 decision	 on	 how	 and	 when	 it	 the	 medicine	 be	
administered.	 Similarly,	 in	 8/10	 homes,	 there	 were	 examples	 where	 ‘when	
required’	medicines	did	not	have	a	maximum	dose	stated.	This	relies	on	those	
administering	 the	 medicines	 to	 have	 the	 requisite	 clinical	 knowledge	 to	
understand	when	the	maximum	number	of	administrations	has	been	achieved	
in	any	24-hour	period.		
Table	3.11	Breakdown	of	MAR	chart	errors	(percentage)	by	subcategory.	Data	is	presented	as	
percentage	of	the	total	number	of	regulatory	errors	identified.		
	
	
Figure	3.7 The	frequency	of	regulatory	errors	(percentage)	broken	down	into	subcategories.		
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	 Care	Home	Number	
Regulatory	errors	 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	
As	directed		 32	 8	 18	 3	 10	 14	 7	 7	 5	 29	
Missing	chart	information		 20	 23	 9	 23	 36	 7	 14	 30	 3	 5	
No	maximum	prn	dose	 0	 11	 11	 8	 1	 3	 0	 1	 4	 6	
Drug	name	misspelt		 0	 0	 0	 2	 1	 2	 0	 2	 0	 0	
Missing	signature	 28	 30	 35	 54	 36	 43	 74	 34	 32	 22	
Undefined	code		 20	 28	 27	 10	 16	 31	 5	 26	 56	 38	
Absolute	number	of	errors	 79	 149	 124	 143	 424	 155	 129	 89	 206	 246	
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It	 is	 a	 regulatory	 guidance	 that	 the	 hand	 amendment	 related	 to	 changes	 in	
dosing	or	any	instruction	of	medications	should	be	signed	by	two	members	of	
staff	 on	 the	MAR	 chart.	 However,	 in	 all	 care	 homes	 there	 was	 a	 significant	
number	 of	medicines	 administrations	where	 a	witness	 signature	was	missing	
(range	22%	-	74%	of	MAR	chart	errors	identified).		
In	all	care	homes,	there	were	MAR	charts	that	did	not	contain	resident	related	
information	such	as	the	DOB	(which	is	used	for	identification	purposes)	or	allergy	
status	(which	is	used	to	ensure	a	resident	does	not	receive	a	medication	which	
they	are	allergic	to).	Table	3.12	shows	the	number	of	residents	 in	each	home	
that	had	MAR	charts	that	did	not	contain	sufficient	information.		
Table	3.12	Number	of	residents	in	each	home	with	a	MAR	chart	that	had	missing	information	
(DOB	or	allergy	status)	
Care	Home	 Number	of	residents	 Number	 of	 residents	 with	 missing	 information	 on	
their	MAR	chart	(%)	
1	 19	 58%	
2	 21	 71%	
3	 25	 32%	
4	 26	 42%	
5	 53	 91%	
6	 20	 45%	
7	 17	 65%	
8	 24	 88%	
9	 14	 36%	
10	 41	 27%	
	
In	many	cases,	 individuals	 that	made	an	administration	used	a	 code	 to	make	
some	comment	about	the	administration.	However,	these	codes	were	ad	hoc	
and	did	not	conform	to	those	defined	on	the	MAR	chart.	There	were	instances	
of	the	use	of	such	undefined	codes	in	all	homes.	Examples	of	such	codes	are	O	
or	 S	which	may	have	 related	 to	out	of	 stock	or	 stock	 issue	but	 there	was	no	
definition	on	the	chart.			
3.4.5.4 Stock	errors	
Whilst	stock	errors	may	not	lead	to	immediate	resident	harm,	where	stock	is	not	
accounted	 for	 appropriately,	 it	 may	 for	 example	 run	 out	 prematurely	 which	
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could	 lead	 to	 delays	 in	 resident	 treatment.	 In	 this	 study,	 stock	 errors	 were	
broken	down	into	four	sub-categories:	(i)	no	date	of	receipt	of	stock	is	recorded;	
(ii)	the	quantity	of	stock	received	was	not	recorded;	(iii)	no	signature	is	made	to	
acknowledge	receipt	of	stock	and	(iv)	there	are	quantity	discrepancies	where	the	
amount	administered	exceeds	the	recorded	stock.	A	breakdown	of	these	errors	
can	be	seen	Table	3.13	and	Figure	3.8.	The	majority	of	errors	in	this	category	
were	 associated	with	 the	date	of	 the	 arrival	 of	 stock	not	 been	 recorded	 and	
nobody	in	the	home	signing	to	indicate	receipt	of	such	stock.	These	categories	
were	fairly	consistent	across	the	homes	in	terms	of	the	frequency	of	the	errors	
identified.	Whilst	in	some	homes,	records	of	the	quantity	of	medicines	received	
was	almost	entirely	complete	(care	homes	1,	7,	9	and	10),	in	other	homes	there	
were	 a	 fairly	 significant	 number	 of	 instances	 where	 the	 quantity	 of	 stock	
received	 was	 not	 recorded.	 For	 example,	 in	 care	 home	 6,	 there	 were	 217	
instances	where	the	stock	received	was	not	recorded.	This	accounted	for	34%	of	
all	the	stock	errors	identified	in	this	care	home.	Discrepancies	in	the	quantity	of	
medicines	received	was	fairly	variable	across	the	homes.		For	example,	in	care	
home	 7	 there	 were	 no	 discrepancies	 between	 the	 stock	 recorded	 and	 the	
medicines	administered	whilst	in	care	home	10	there	were	105	instances	where	
the	amount	administered	exceeded	the	recorded	stock;	this	accounted	for	18%	
of	all	stock	errors	in	care	home	10.		
Table	 3.13	 Breakdown	 of	 stock	 errors	 (percentage)	 by	 subcategory.	 Data	 is	 presented	 as	
percentage	of	the	total	number	of	stock	errors	identified.		
	
	 Care	Home	Number	
Stock	errors	 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	
No	date	recorded		 41	 31	 32	 74	 31	 33	 49	 37	 49	 44	
No	quantity	recorded		 2	 31	 26	 10	 29	 34	 2	 22	 0.3	 2	
No	signature	recorded	 40	 31	 34	 14	 31	 33	 49	 36	 42	 36	
Quantity	discrepancy		 17	 7	 8	 2	 9	 0.3	 0	 5	 9	 18	
Absolute	number	of	errors	 126	 593	 286	 399	 417	 620	 313	 93	 362	 588	
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Figure	3.8 The	frequency	of	stock	errors	(percentage)	broken	down	into	subcategories.		
3.4.6 Relationship	between	the	number	of	medicines	administered	and	the	
frequency	of	errors		
There	is	some	evidence	in	the	literature	that	the	frequency	of	medicines	related	
errors	 in	 care	 homes	 is	 associated	 with	 the	 total	 number	 of	 medicines	
administered	 (Barber	 et	 al.	 2009b).	 A	 Pearson	 correlation	 co-efficient	 was	
therefore	calculated	for	the	total	number	of	medicines	administered	versus	the	
frequency	of	(i)	administration	errors;	(ii)	MAR	chart	errors;	(iii)	regulatory	errors	
and	 (iv)	 stock	errors.	Table	3.14	 shows	 the	output	of	 the	Pearson	correlation	
calculation.		
Table	3.14	Assessment	of	the	correlation	between	the	total	number	of	medicines	administered	
and	the	frequency	of	medicines	related	errors	identified.		
	 Pearson	correlation	
coefficient	
P	value	 Strength	of	
correlation		
Direction	of	
correlation	
Administration	errors	 0.7452	 0.0134	 Strong	 Positive	
MAR	chart	errors	 0.848	 0.0019	 Strong	 Positive	
Regulatory	errors	 0.6962	 0.0253	 Moderate	 Positive	
Stock	errors	 0.4755	 0.1649	 Not	significant	
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The	 analysis	 revealed	 a	 statistically	 significant	 strong	 positive	 relationship	
between	 the	 total	 number	 of	 medicines	 administered	 and	 the	 number	 of	
administration	errors	(r	=	0.7452;	p	=	0.0134)	and	MAR	chart	errors	(r	=	0.848;	
p	 =	 0.0019).	 A	 statistically	 significant	moderate	 positive	 correlation	was	 also	
observed	between	total	number	of	medicines	administered	and	the	number	of	
regulatory	errors	identified	(r	=	0.6962;	p	=	0.0253).	However,	for	stock	errors,	
there	 was	 no	 statistically	 significant	 correlation	 between	 total	 number	 of	
medicines	administered	and	the	number	of	stock	errors	identified.		
3.4.7 Medication	errors	associated	with	potentially	inappropriate	medicines	
Given	 the	high	prevalence	of	prescribing	of	PIMs	 identified	 in	 this	 study	 (see	
Chapter	2)	an	analysis	of	the	administration	and	MAR	chart	errors	associated	
with	such	medicines	was	undertaken.	Table	3.15	shows	the	number	of	residents	
across	 the	 ten	 care	 homes	 that	 were	 exposed	 to	 an	 administration	 error	
associated	with	their	PIM	and	the	number	of	 residents	 that	had	a	MAR	chart	
error	 associated	 with	 their	 PIM;	 some	 residents	 may	 have	 had	 both	 an	
administration	error	and	a	MAR	chart	error	associated	with	their	PIM.		As	can	be	
seen,	with	 the	exception	of	 the	cardiac	glycosides,	 there	were	 residents	with	
administration	errors	in	all	categories	of	PIMs.		In	terms	of	MAR	chart	errors,	the	
number	 of	 residents	 with	 a	 MAR	 chart	 error	 associated	 with	 their	 PIM	 was	
significantly	 lower	 and	 indeed,	 no	 MAR	 chart	 errors	 were	 identified	 for	
hypnotics,	potassium	sparing	diuretics,	NSAIDs,	SNRIs,	SSRIs,	thiazide	diuretics	
or	drugs	used	to	treat	urinary	tract	infections.	A	substantial	number	of	residents	
were	 exposed	 to	 administration	 errors	 associated	 with	 their	 PIM.	 This	 was	
particularly	prevalent	for	antiplatelets	(23	residents,	33.8%),	antipsychotics	(37	
residents,	44.6%)	drugs	for	the	control	of	epilepsy	(7	residents	53.8%),	and	other	
antidepressants	 (11	 residents,	 50%);	 the	 prevalence	 was	 high	 for	 other	
categories	 but	 the	 analysis	 is	 not	 robust	 given	 the	 low	 number	 of	 residents	
receiving	such	medicines.	
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Table	3.15	Prevalence	of	administration	errors	and	MAR	chart	errors	associated	with	PIMs.	Data	is	presented	as	the	total	number of	residents	identified	with	errors.	
PIM	 Number	of	residents	receiving	a	PIM		 Number	of	residents	with	one	or	more	
administration	errors	related	to	a	PIM		
Number	of	residents	where	the	PIM	
had	a	MAR	chart	error		
Antihistamine	 2	 0	(0.00%)	 0	(0.00%)	
Antiplatelet	 68	 23	(33.8%)	 2	(2.9%)	
Antipsychotic	 83	 37	(44.6%)	 4	(4.8%)	
Antispasmodic	 6	 2	(33.3%)	 1	(16.7%)	
Anxiolytic	 58	 16	(27.6%)	 1	(1.7%)	
Cardiac	glycoside	 2	 0	(0.00%)	 2	(100%)	
Control	of	epilepsy	 13	 7	(53.8%)	 2	(15.4%)	
Hypnotic	 62	 12	(19.4%)	 0	(0%)	
Insulin	 3	 1	(33.35)	 2	(66.7%)	
K	sparing	diuretic	 5	 1	(20.0%)	 0	(0%)	
Loop	diuretic	 43	 10	(23.3%)	 5	(11.6%)	
NSAIDs	 7	 2	(28.6%)	 0	(0%)	
Other	antidepressants	 22	 11	(50.0%)	 1	(4.5%)	
PPIs	 105	 23	(21.9%)	 2	(1.9%)	
SNRIs	 9	 4	(44.4%)	 0	(0%)	
SSRIs	 38	 8	(21.1%)	 0	(0%)	
TCA	 6	 2	(33.3%)	 1	(16.7%)	
Thiazide	diuretic	 6	 1	(16.7%)	 0	(0%)	
Urinary	tract	infection	 5	 3	(60.0)	 0	(0%)	
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A	 breakdown	of	 the	 administration	 errors	 associated	with	 PIMs	 categories	 is	
provided	in	Table	3.16.	Dose	omission	was	the	most	frequent	error	identified	in	
almost	all	class	of	PIMs	and	the	prevalence	was	particularly	high	for	antiplatelets	
(47	 omissions),	 antipsychotics	 (147	 omissions),	 anxiolytics	 (119	 omissions),	
hypnotics	(49	omissions)	and	PPIs	(64	omissions).		Of	note,	although	the	absolute	
number	of	extra	doses	administered	was	low,	there	were	nine	instances	of	an	
extra	dose	of	an	antipsychotic	being	administered	and	29	instances	of	an	extra	
dose	of	a	PPI	being	administered.	 	Similarly,	there	were	28	instances	where	a	
hypnotic	was	administered	too	early	 i.e.	not	as	a	night	time	dose.	The	clinical	
impact	of	such	errors	remains	to	be	elucidated.		
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Table	3.16	Breakdown	of	administration	errors	by	subcategory	for	PIMs.	Data	is	presented	as	the	number	of	errors	per	subcategory.	
PIM	 Deviation	from	stated	dose	 Missed	medication	cycle	 Omitted	dose		 Extra	dose	 Wrong	time	 Crossing	out	
Antihistamine	 0	 0	 0	 0	 0	 0	
Antiplatelet	 0	 1	 47	 1	 22	 1	
Antipsychotic	 0	 0	 147	 9	 0	 3	
Antispasmodic	 2	 0	 26	 0	 1	 0	
Anxiolytic	 0	 0	 119	 3	 31	 1	
Cardiac	glycoside	 0	 0	 0	 0	 0	 0	
Control	of	epilepsies	 0	 0	 13	 1	 27	 0	
Hypnotic	 0	 0	 49	 0	 28	 0	
Insulin	 	0	 0	 1	 0	 0	 0	
K	sparing	diuretic	 0	 1	 0	 0	 0	 0	
Loop	diuretic	 0	 1	 21	 2	 28	 1	
NSAIDs	 0	 0	 15	 0	 0	 0	
Other	antidepressants	 0	 0	 15	 0	 28	 1	
PPIs	 0	 1	 64	 29	 2	 0	
SNRIs	 0	 0	 23	 1	 26	 0	
SSRIs	 0	 0	 14	 0	 0	 1	
TCA	 0	 0	 2	 0	 0	 0	
Thiazide	diuretic	 0	 0	 1	 0	 0	 0	
Urinary	tract	infection	 0	 0	 5	 0	 0	 1	
	
              
	
	
Chapter	3	
	
	
143	
3.4 Discussion	
A	 retrospective	 analysis	 of	 paper-based	 medication	 administration	 records	
(MAR	charts)	was	undertaken	in	ten	care	homes	in	the	South	Wales	region	to	
explore	 the	 nature	 and	 extent	 of	 errors	 related	 to	 medicines	 management.	
Medicines	management	was	used	here	in	the	broadest	context	from	the	receipt	
of	stock	through	to	the	administration	of	medicines	to	residents.		A	total	of	25	
distinct	 errors	 types	 were	 identified	 that	 were	 categorised	 into	 five	 main	
categories:	(i)	administration	errors;	(ii)	MAR	charts	errors;	(iii)	regulatory	errors;	
(iv)	stock	errors	and	(v)	miscellaneous	errors	that	could	not	be	assessed	without	
further	 information.	 The	 error	 categories	 that	 were	 used	 in	 this	 study	 were	
informed	by	The	National	Institute	for	health	and	Care	Excellence	(NICE	2014)	
guidance	for	Medicines	Management	in	Care	Homes.	An	initial	set	of	criteria	for	
identifying	medicines	 related	errors	on	MAR	charts	was	devised	and	 this	was	
used	 to	 analyse	 a	 batch	 of	MAR	 charts	 from	 a	 ‘test’	 care	 home.	 Through	 an	
iterative	process,	the	criteria	were	refined	until	consensus	was	achieved	within	
the	research	team.	An	analysis	 ‘rule	book’	was	then	used	to	analyse	the	MAR	
charts	of	260	residents	over	a	28-day	medicines	cycle.			
There	 are	 a	 variety	 of	methodologies	 that	 can	 be	 used	 to	 identify	medicines	
errors	 in	 health	 and	 social	 care	 settings	 including	 patient	 monitoring,	 chart	
review,	analysis	of	computer	records,	observation,	error	reporting,	and	claims	
data	 (Montesi	 and	 Lechi	 2009).	 Each	of	 these	methodologies	 have	 their	 own	
advantages	and	disadvantages.	For	example,	the	direct	observation	of	patient	
care	 is	 accurate	 and	 effective	 in	 capturing	 active	 errors.	 However,	 it	 is	 time	
consuming,	difficult	 to	scale,	 requires	significant	training	of	 the	observer	who	
must	 normally	 belong	 to	 the	 same	professional	 group	 that	 are	 administering	
care	(Flynn	et	al.	2002;	Michel	2004)	and	is	liable	to	the	Hawthorne	effect	i.e.	
the	 observer	 modifies	 their	 behavior/actions	 as	 a	 consequence	 of	 being	
observed	(McCarney	et	al.	2007).	Chart	review	on	the	other	hand	is	a	commonly	
used	method	 to	 retrospectively	 analyse	 data	 sources	 such	 as	medical	 charts,	
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prescription	 data	 and	 laboratory	 data	 against	 standardised	 criteria.	 The	
challenges	in	using	this	data	is	that	it	can	be	difficult	to	train	assessors,	it	is	time-
consuming	and	laborious	to	analyse	such	records	at	scale	and	the	results	depend	
on	the	quality	of	documentation	and	record	keeping.	Despite	such	limitations,	
chart	review	is	a	commonly	used	methodology	for	detecting	medicines	errors	
(Morimoto	et	al.	2004;	de	Vries	et	al.	2008;	Hogan	et	al.	2008;	Tam	et	al.	2008).		
However,	the	identification	of	medicines	errors	using	any	methodology	must	be	
treated	with	caution	as	there	is	evidence	in	the	literature	that	indicates	that	the	
different	methodologies	often	pick	up	different	types	of	errors	with	sometimes	
limited	overlap.	For	example,	Hogan	and	colleagues	reviewed	seven	sources	of	
hospital	data	to	identify	harm:	(i)	Clinical	Incident	database;	(ii)	Health	and	Safety	
Incident	 database	 (iii)	 Complaints	 database	 (iv)	 Claims	 database;	 (v)	 Inquest	
database;	(vi)	the	Patient	Administration	System	and	(vii)	case	notes.	Case	notes	
(which	 share	 some	 similarities	 with	MAR	 charts)	 were	 found	 to	 identify	 the	
largest	number	of	incidents	but	there	was	little	overlap	with	errors	identified	in	
the	other	sources	investigated.	Along	with	other	factors	such	as	differences	in	
sample	size,		period	of	study,	local	systems	and	policies,	this	can	make	it	difficult	
to	 compare	 studies	 (Keers	 et	 al.	 2013b).	 To	 summarise,	 whilst	 any	 one	
methodology	will	capture	a	particular	range	of	errors	it	will	not	capture	all	errors	
in	 the	 setting	 and	 wherever	 possible	 a	 range	 of	 methodologies	 should	 be	
employed.		
In	 this	 study,	 MAR	 charts	 represented	 an	 accessible	 data	 source	 for	 the	
identification	of	medicines	related	errors	in	care	homes.	The	researcher	could	
find	 only	 one	 other	 study	 in	 the	 literature	 that	 used	MAR	 charts	 to	 identify	
medication	errors	in	nursing	home.	The	study,	published	in	the	US	in	1979	aimed	
to	 identify	 documentary	 issues	with	MAR	 charts.	 	 The	 process	 involved	 four	
members	of	staff	reviewing	15	MAR	charts	over	a	four-month	period	to	identify	
any	errors	in	the	documentation	using	a	protocol	that	was	developed	in	house.	
The	 study	 revealed	15	 types	of	errors	 related	 to	 the	documentation	 some	of	
which	were	similar	to	this	current	study	(Krikorian	1979).		
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In	this	current	study,	a	total	of	16,262	unique	errors	were	identified	in	the	MAR	
charts	across	the	five	main	error	categories.	This	corresponded	to	an	average	of	
17	(±3)	errors	per	resident	per	week.	This	however	does	not	reflect	the	errors	
that	patients	are	exposed	to	because	errors	such	as	stock	errors	are	not	usually	
immediately	resident	facing.	In	contrast,	administration	errors	(omitted	doses,	
missed	medication	cycles,	deviations	from	the	stated	does,	extra	doses,	doses	
administered	 at	 the	 wrong	 time	 and	 deviations	 from	 the	 prn	 protocol)	 are	
directly	patient	facing	and	have	the	greatest	potential	to	cause	patient	harm.	As	
such,	administration	errors	were	examined	in	some	detail	and	were	found	to	be	
the	 most	 common	 error	 type	 identified	 in	 seven	 of	 the	 ten	 care	 homes	
investigated.	 This	 finding	 is	 consistent	with	 other	 studies	 that	 have	 reported	
medication	administration	errors	 as	 the	main	 source	of	 errors	 in	 care	homes	
(Alldred	et	al.	2009;	Crespin	et	al.	2010;	Greene	et	al.	2010;	Lane	et	al.	2014;	
Pierson	et	al.	2007)	and	indeed	other	health	care	settings	(Ghaleb	et	al.	2010;	
Haw	 et	 al.	 2007;	 Kelly	 et	 al.	 2011;	 Keers	 et	 al.	 2013a;	 McLeod	 et	 al.	 2015;	
Härkänen	 et	 al.	 2017;	 Härkänen	 et	 al.	 2015).	 Indeed,	 a	 recent	 report	 on	 the	
‘Prevalence	and	economic	burden	of	medication	errors	 in	the	NHS	 in	England’	
found	that,	more	than	half	of	the	237.4	million	medication	errors	reported	in	the	
NHS	over	a	one	year	period	were	related	to	administration	errors,	although	the	
majority	of	these	errors	were	said	to	have	minor	or	no	potential	for	clinical	harm	
(Elliott	et	al.	2018).	
In	order	to	explore	the	patient	exposure	to	administration	errors,	the	number	of	
administration	 errors	 per	 resident	 per	 week	 was	 calculated.	 On	 average,	
residents	 were	 exposed	 to	 6	 (±3)	 administration	 errors	 per	 week	 and	 the	
prevalence	of	administration	errors	by	opportunity	was	8.6%	(±0.03).	 	 	 In	 the	
seminal	 CHUMs	 study	 (Alldred	 et	 al.	 2009),	 256	 residents	 had	 two	 of	 their	
medicines	rounds	observed	to	identify	administration	errors.	The	prevalence	of	
administration	 errors	 by	 total	 opportunities	 was	 8.4%	 which	 is	 remarkably	
similar	to	the	findings	in	this	current	study.		Whilst	the	approach	of	reviewing	
MAR	 charts	 to	 identify	 administration	 errors	 in	 this	 study	 showed	 good	
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alignment	 with	 the	 CHUMs	 study,	 Richard	 and	 colleagues	 reported	 an	
administration	error	rate	of	0.2%	using	chart	review	compared	to	10%	with	an	
observational	approach	 in	30	 long	 term	care	 facilities.	The	authors	 suggested	
that	this	underestimation	of	medication	errors	may	be	attributed	to	the	fact	that	
many	medication	errors	were	unreported	or	could	not	be	identified	using	MAR	
chart	review	as	this	process	didn’t	actually	reflect	the	administration	process.	
Also,	only	10%	of	the	MAR	charts	were	reviewed	in	detailed	leaving	90%	with	a	
cursory	 review	which	might	 lead	 to	 underestimation	 of	 errors	 that	 could	 be	
identified	through	MAR	charts.	(Shannon	and	De	Muth	1987).			
In	 common	 with	 the	 CHUMS	 study	 (and	 that	 of	 others	 (Pierson	 et	 al	 2007;	
Greene	 et	 al.	 2010),	 omitted	 doses	 were	 the	 most	 frequently	 encountered	
administration	error	 in	 this	current	study	accounting	 for	an	average	of	73.4%	
(data	not	shown)	of	the	administration	errors	across	the	ten	homes	compared	
for	 example	 to	 49.1%	 in	 the	CHUMS	 study.	 The	 reason	 for	 dose	omissions	 is	
multifactorial.	 There	 are	 human	 factors	 for	 example	 interruptions	 during	 the	
administration	 rounds	 and	 medicines	 related	 factors	 for	 example	 the	
unavailability	of	medications	at	the	time	of	administration.		
In	a	number	of	homes,	and	particularly	in	care	home	6,	there	was	evidence	of	
doses	 that	 were	 administered	 at	 the	 wrong	 time.	 This	 was	 shown	 to	 be	 a	
significant	issue	in	a	US	study	in	nursing	homes	which	reported	that	nearly	half	
of	the	administration	errors	identified	were	administrations	made	at	the	wrong	
time	(Scott	and	Volgesmier	2006).	In	care	home	6	in	this	study,	this	was	largely	
attributable	to	the	administration	of	stimulant	laxatives	at	4pm	instead	of	8pm	
as	prescribed.		Whilst	this	makes	sense	from	a	clinical	perspective	and	is	unlikely	
to	 cause	 resident	 harm,	 ultimately	 it	 contravenes	 the	prescriber’s	 intentions.	
There	 is	 a	 paucity	 of	 literature	 exploring	 the	 reason	 for	 such	 changes	 to	 the	
scheduled	 administration	 time	 and	 it	 is	 likely	 to	 be	 multifactorial	 however	
possible	reasons	might	include:	(i)	the	prescriber	has	changed	the	administration	
schedule	but	the	chart	has	not	been	updated,	 (ii)	somebody	 in	the	home	has	
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taken	the	decision	based	on	experience,	(iii)	it	is	a	genuine	error,	(iv)	a	dose	was	
missed	and	then	administered	at	the	next	medication	round,	(v)	limited	staffing	
levels	at	particular	times	(particularly	 for	the	night	time	and	morning	rounds)	
may	mean	that	it	is	more	expedient	to	change	the	administration	schedule.		
Whilst	this	close	alignment	of	results	in	a	similar	study	population	provided	some	
confidence	 that	 MAR	 chart	 review	 is	 accurate	 in	 estimating	 medication	
administration	errors,	not	all	studies	have	reported	similar	findings.	Indeed,	the	
prevalence	of	administration	errors	reported	across	a	number	of	studies	in	the	
US	in	care	homes	varies	between	10%-69%	of	all	administered	doses	(Barker	et	
al.	2002;	Zimmerman	et	al.	2011;	Desai	et	al.	2011;	Desai	et	al.	2013;	Lane	et	al.	
2014).		
The	 number	 of	 care	 homes	 within	 the	 study	 was	 too	 low	 to	make	 any	 firm	
conclusions	 on	 whether	 errors	 were	 higher	 in	 nursing	 homes	 compared	 to	
residential	homes.	In	terms	of	exposure	of	patients	to	administration	errors,	care	
home	 8	 (a	 residential	 home)	 was	 the	 best	 performing	 home	 with	 just	 one	
administration	error	per	 resident	per	week.	The	other	 residential	home,	 care	
home	1,	sat	at	the	average	with	six	administration	errors	per	week.	It	might	have	
been	 expected	 that	 nursing	 homes	 deliver	 better	 quality	 of	 medicines	
administration	because	of	the	higher	standard	of	professional	training	received	
by	 nurses	 (c.f.	 carers	 in	 residential	 homes)	 however	 there	 is	 evidence	 in	 the	
literature	to	suggest	that	this	is	not	the	case	(Scott-Cawiezell	et	al.	2007)	with	
residential	homes	having	a	lower	prevalence	of	medication	errors.	This	is	partly	
attributed	 to	 residential	 care	 home	 residents	 having	 less	 complex	 medical	
conditions	and	lower	rates	of	polypharmacy	(Szczepura	et	al.	2008).	Indeed,	in	
this	current	study	the	prevalence	of	polypharmacy	was	the	lowest	for	the	two	
residential	care	homes	(see	Chapter	2).	 	 	The	Care	Quality	Commission	(2014)	
has	identified	similar	differences	between	people	in	residential	care	homes	and	
those	in	nursing	homes	in	respect	to	the	quality	of	health	care.	They	highlighted	
an	 improved	 trend	 in	 the	 performance	 of	 residential	 homes	 against	 quality	
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standards	compared	to	nursing	homes	particularly	with	respect	to	suitability	of	
staff,	safeguarding	and	safety,	care	and	welfare	and	quality	of	monitoring	(CQC	
2014)						
From	 the	 total	 6770	 administration	 errors	 identified	 in	 this	 study,	 816	 (12%)	
were	 related	 to	 PIMs,	 while	 only	 39	 (5%)	 of	 the	 MAR	 chart	 errors	 were	
associated	 with	 PIMs	 from	 a	 total	 of	 730	 errors.	 The	 prevalence	 of	
administration	errors	associated	with	PIMs	was	particularly	high	for	drugs	that	
act	 in	the	CNS	system	(antipsychotics,	drugs	for	the	control	of	epilepsy,	other	
antidepressants)	 and	 antiplatelets.	 In	 the	 main,	 these	 administration	 errors	
were	associated	with	omitted	doses	which	can	lead	to	preventable	adverse	drug	
reactions	and	serious	patient	safety	issues	(Handler	et	al.	2006).		To	the	best	of	
the	 author’s	 knowledge,	 there	 is	 no	 literature	 related	 to	 errors	 in	 PIMs	
administration	in	care	homes.	However,	some	studies	have	examined	the	classes	
of	medications	that	are	most	commonly	involved	with	medication	errors	in	care	
homes.	A	study	by	Hughes	and	co-workers	in	North	Carolina	for	example	found	
that	antipsychotics	were	among	 the	 top	10	classes	of	medications	associated	
with	medication	errors	(Hughes	et	al.	2016).	Similarly,	an	earlier	study	by	Gurwitz	
and	colleagues	in	18	nursing	homes	found	that	546	adverse	drug	events	were	
associated	with	the	use	of	antipsychotics	and	anxiolytics	medications.	Of	note,	
85%	 of	 these	 preventable	 adverse	 events	 were	 related	 to	medication	 errors	
(Gurwitz	 et	 al.	 2000).	 The	 same	authors	 in	 another	 study	 in	 two	 care	homes	
found	just	less	than	half	of	the	adverse	drug	events	were	related	to	medication	
errors,	from	which,	antipsychotics	were	among	the	most	common	medications	
involved	in	the	occurrence	of	these	errors	(Gurwitz	et	al.	2005)	
The	 reasons	 that	administration	errors	occur	 is	 likely	 to	be	multifactorial	and	
may	be	as	a	consequence	of	‘follow	through	errors’	arising	from	errors	made	by	
the	 prescriber	 or	 at	 the	 pharmacy,	 they	 may	 be	 due	 to	 the	 individual	
administering	 the	 medicine	 or	 may	 be	 influenced	 by	 the	 patient	 /	 resident.		
Hughes	and	Ortiz	have	suggested	four	lines	of	defence	in	preventing	medication	
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errors;	the	prescriber,	the	dispenser,	the	administrator	(most	often	nurses),	and	
the	patient	 themselves	 (Hughes	and	Ortiz	2005).	 The	 responsibility	 to	deliver	
effective	care	to	residents	therefore	does	not	fall	solely	to	care	home	staff,	but	
all	 individuals	 involved	in	resident	care.	As	a	consequence,	the	administration	
process	is	exposed	to	both	human	errors	and	system	errors	(Reason	1991).		
A	number	of	 studies	have	explored	 the	 reasons	 for	medication	errors	 in	care	
home	and	have	highlighted	particular	issues	that	are	prevalent	in	the	care	home	
setting	(Dilles	et	al.	2011;		Vogelsmeier	et	al.	2007;	Crespin	et	al.	2010).	In	order	
of	prevalence	these	studies	have	shown	the	reasons	to	be	(i)	human	error;	(ii)	
transcription	errors;	(iii)	distractions;	(iv)	not	following	procedures	/	processes;	
(v)	a	lack	of	communication	between	relevant	parties;	(vi)	incorrect	medication	
received	 from	 the	 pharmacy	 or	 the	 medication	 is	 unavailable	 and	 (vii)	
documentation	 contains	 inadequate	 or	 inaccurate	 information.	 Dilles	 and	
colleagues	sought	to	codify	the	barriers	to	effective	medicines	management	in	
nursing	homes,	focusing	particularly	on	the	experience	of	nurses,	and	identified	
four	 domains	 (i)	 nurses;	 (ii)	 interdisciplinary	 co-operation;	 (iii)	 organisational	
structure	and	culture	and	(iv)	patient	and	family	(Dilles	et	al.	2011).		The	nurse	
related	 factors	 included	 a	 lack	 of	 knowledge	 of	 therapeutics,	 attitudinal	
problems	 and	 a	 sense	 of	 not	 understanding	 how	 far	 their	 responsibility	 for	
administrations	 reaches	 (this	 was	 particularly	 true	 for	 the	 monitoring	 phase	
following	 administration).	 	 In	 terms	 of	 interdisciplinary	 cooperation,	 lack	 of	
communication	between	staff	in	the	home,	poor	accessibility	to	prescribers	and	
pharmacists,	 problems	 in	 the	 legibility	 and	 completeness	 of	 documentary	
information	 and	 poor	 definition	 of	 the	 tasks	 to	 be	 completed	 were	 cited	 as	
barriers	 to	 effective	 medicines	 management.	 The	 organizational	 issues	 were	
similar	 to	 those	 seen	 in	 other	 industries,	 high	 workload,	 staff	 shortages	
(particularly	 nurses),	 interruption	 during	 the	 administration	 round,	 lack	 of	
standardisation	of	processes	across	and	within	care	homes	and	processes	that	
were	not	seen	to	be	effective.	Nurses	also	felt	that	administering	all	medicines	
at	the	same	time	was	a	barrier	to	effective	administration.	Finally,	the	patient	
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related	factors	were	related	to	capacity	and	consent,	the	intellect	of	the	patient	
and	their	family	and	the	emergence	of	new	and	more	complex	disease	states	in	
residents	that	demanded	higher	levels	of	care.			
Interruptions	and	distractions	during	 the	administration	 round	are	commonly	
cited	as	a	major	challenge	in	the	effective	administration	of	medicines	in	care	
homes	(Lee	et	al.	2015;	Alldred	et	al.	2009;	Dilles	et	al.	2011).	In	the	secondary	
care	setting,	they	have	been	shown	to	lead	to	a	loss	of	attention,	concentration	
and	focus	on	the	patient	and	in	observational	studies	in	both	the	secondary	care	
and	 nursing	 home	 setting	 they	 have	 been	 shown	 to	 increase	 the	 number	 of	
administration	errors	(Scott-Cawiezell	et	al.	2007;	Biron	2009;	Westbrook	et	al.	
2010)	.	There	are	essentially	two	sources	of	interruptions	which	might	lead	to	a	
medication	 errors,	 either	 individuals	 administering	 the	 medicines	 are	
interrupted	directly	(e.g.	by	other	staff,	other	residents,	phone	calls	etc.)	or	there	
is	a	technical	interruption	(e.g.	missing	equipment,	inability	to	find	medications)	
(O’Shea	1999;	Alldred	et	al.	2009).	NICE	have	recommended	that	interruptions	
and	 distractions	 should	 be	 kept	 to	 a	minimum	 during	 administration	 rounds	
(NICE	2014).	Whilst	to	date	there	have	been	no	observational	studies	that	have	
sought	 to	determine	 the	 impact	of	 interventions	 to	minimise	 interruptions,	a	
number	 of	 studies	 have	 suggested	 that	 training	 to	 enable	 nurses/carers	 to	
prioritise	 multiple	 requests	 and	 specifically	 targeting	 avoidable	 interruptions	
would	be	beneficial	(Colligan	and	Bass	2012;	Buchini	and	Quattrin	2012).		
The	risks	of	errors	arising	from	interruptions	is	compounded	when	staff	with	less	
training	or	lower	levels	of	competency	are	permitted	to	administer	medicines	in	
care	 homes	 (Hinchliffe	 A.	 2010;	 Dilles	 et	 al.	 2011).	 These	 staffs	 are	 usually	
inexperienced,	 have	 a	 lack	 of	 knowledge	 and	 thus	 are	 more	 likely	 to	 make	
mistakes	during	 the	administration	process.	NICE	Guidelines	 recommend	that	
skilled	and	trained	staffs	should	be	put	on	duty	and	planned	staff	breaks	should	
be	 avoided	during	medicines	 administration	 round	 (NICE	2015).	 Indeed,	 Care	
Inspectorate	Wales	 (Care	 Inspectorate	Wales	 2014),	 has	 a	 national	minimum	
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standard	that	requires	at	least	50%	of	the	staff	in	a	care	home	to	hold	an	NVQ	
level	2	(or	higher)	qualification.		
One	issue	here	 is	the	high	turnover	rate	and	shortage	of	staff	within	the	care	
home	sector	which	the	CQC	reported	on	 in	October	2014	(CQC	2014).	Similar	
issues	were	raised	by	Care	Inspectorate	Wales	(CIW)	in	their	annual	report	(Care	
Inspectorate	Wales	 2014).	 Adequate	 staffing	 is	 required	 to	 ensure	medicines	
administration	is	carried	out	properly	and	to	provide	good	care	to	the	resident.	
Studies	do	suggest	that	shortages	of	personnel	are	likely	to	increase	the	number	
of	 administration	 errors	 in	 care	 homes.	 For	 example	 in	 a	 report	 by	 the	 UK	
Department	of	Health		‘Building	a	safer	NHS	for	patients:	improving	medication	
safety’	and	in	a	study	by	Vaismoradi	and	colleagues	to	qualitatively	evaluate	the	
perceptions	of	nursing	students	on	medication	errors,	staff	shortages	and	poor	
training	were	 said	 to	 contribute	 to	 the	 high	 prevalence	 of	medication	 errors	
(Smith	2004;	Vaismoradi	et	al.	2014).		
In	 the	 care	 home	 setting,	 monitored	 dosage	 systems	 (MDS)	 are	 commonly	
employed	to	help	manage	the	administration	process	and	indeed,	in	this	study,	
all	 the	recruited	care	homes	used	MDS	trays.	However,	MDS	trays	have	their	
own	 limitations.	They	can	only	be	used	for	solid	oral	medicines	and	they	 lack	
flexibility	when	medicines	 or	 their	 doses	 are	 changed	mid-cycle	 (Alldred	 and	
Standage	 2011).	 Of	 note,	 there	 is	 little	 evidence	 to	 suggest	 MDS	 is	 a	 safer	
method	of	administration	compared	to	using	original	packs	(Alldred	et	al.	2009).	
It	does	however	increase	the	workload	demands	on	the	pharmacy	and	in	order	
to	 repackage	medicines	 at	 scale,	MDS	pharmacy	hubs	 are	 created	which	 can	
decrease	the	interdisciplinary	collaboration	with	the	home	as	the	hub	is	often	
more	 remote	 that	 the	 local	 pharmacy	 (Alldred	et	 al.	 2009).	 In	 addition,	 even	
where	 MDS	 systems	 are	 in	 place,	 medications	 such	 as	 oral	 liquid,	 inhalers,	
eye/ear	 drops	 and	 powders	 cannot	 be	 put	 in	 the	 MDS	 compartments	 and	
therefore	 arrive	 at	 the	 home	 in	 their	 original	 packing.	 This	 requires	 two	
              
	
	
Chapter	3	
	
	
152	
medication	administration	processes	to	be	 in	place	 increasing	complexity	and	
the	risk	of	making	an	error	(Morrison	2014).			
The	second	error	category	that	was	investigated	in	this	study	and	which	has	the	
potential	 to	cause	 resident	harm	was	MAR	charts	errors.	These	are	 instances	
where	the	MAR	chart	does	not	contain	all	the	necessary	information	to	make	a	
safe	administration.	For	example,	the	dose,	strength,	formulation	or	timing	of	
the	administration	may	be	missing	or	the	directions	for	use	are	simply	written	
up	as	“as	directed”.	It	is	a	regulatory	requirement	that	MAR	charts	contain	all	
the	 necessary	 information	 related	 to	 the	 medicine.	 Ultimately	 where	 this	
information	is	incomplete,	it	relies	on	an	individual	in	the	home	(nurse	or	carer)	
making	a	judgement.	If	the	medicines	are	assembled	in	the	MDS	tray,	then	the	
likelihood	of	error	is	reduced.	However,	for	medicines	that	cannot	be	put	in	an	
MDS	tray	then	the	potential	for	an	error	with	the	administration	increases.	There	
may	also	be	variation	in	administration	because	medicines	are	not	administered	
by	the	same	member	of	staff	all	the	time	and	different	staff	members	may	make	
a	different	judgement	call.	Therefore,	it	is	important	to	make	sure	that	all	the	
instructions	 are	 present	 on	 the	 MAR	 chart	 and	 that	 those	 individuals	
administering	 the	 medicines	 fully	 understand	 the	 instructions.	 There	 were	
occasions	where	a	resident	was	potentially	put	at	risk	due	to	insufficient	dosage	
information.	 The	 MAR	 charts	 where	 this	 occurred	 were	 therefore	 not	
compatible	with	recent	NICE	guidelines	that	are	definitive	about	the	importance	
of	clear	and	complete	information	concerning	drug	administration	(NICE	2014).		
In	this	current	study,	the	prevalence	of	MAR	chart	errors	was	relatively	small,	
accounting	for	3	–	12%	of	all	errors	identified	(range	of	absolute	errors	20	–	164).	
In	 the	 main,	 the	 errors	 were	 associated	 with	 either	 the	 absence	 of	 a	 dose,	
incomplete	 dosage	 information	 or	 there	 was	 no	 scheduled	 time	 for	 the	
administration;	missing	 formulation	details	and	absence	of	a	 strength	 for	 the	
medicine(s)	was	 less	common.	 It	 is	worth	reiterating	that	the	MAR	charts	are	
generated	in	the	pharmacy	based	on	the	resident’s	prescription	and	therefore	
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the	 source	 of	 the	 error	 is	 at	 the	 pharmacy.	 Nevertheless,	 from	 a	 regulatory	
perspective	 it	 is	 the	 responsibility	 of	 the	 home	 to	 ensure	 the	 MAR	 chart	 is	
accurate	and	complete.	Ultimately,	these	MAR	chart	errors	betray	a	failure	 in	
the	 systems	 and	 processes	 from	 the	 prescriber	 through	 to	 the	 home.	 The	
prescriber	 should	 ensure	 the	 prescription	 is	 complete,	 where	 it	 is	 not,	 the	
pharmacist	should	liaise	with	the	prescriber	to	rectify	any	missing	information	
and	 if	 that	slips	 through	on	the	MAR	chart	 the	home	should	engage	with	the	
pharmacist	 and/or	 prescriber	 to	 update	 the	MAR	 chart.	 Such	 errors	 are	 not	
unique	to	the	care	home	setting.	In	the	Institution	of	Medicine’s	(IOM)	report,	
‘Preventing	Medication	Errors’	 (Bates	2007),	 inappropriate	 labelling	has	been	
cited	as	a	cause	of	medication	errors	that	may	contribute	to	the	occurrence	of	
adverse	 events.	 In	 a	 study	 by	 	 Jeetu	 and	Girish,	 the	 authors	 highlighted	 that	
nearly	a	quarter	to	one	third	of	medication	errors	were	attributed	to	improper	
labeling	(Jeetu	and	Girish	2010).		
Another	type	of	MAR	chart	error	that	was	identified	in	this	study	was	where	a	
medicine	was	duplicated	on	the	MAR	chart.	Examples	of	duplicated	medicines	
were	found	in	seven	of	the	care	homes;	in	most	cases	the	duplicate	medicine	
was	on	a	second	chart	making	it	harder	to	spot.	To	the	best	of	the	researcher’s	
knowledge,	none	of	the	duplicated	medicines	were	administered	to	residents.	
However,	such	errors	have	the	potential,	if	left	unspotted,	to	cause	unwarranted	
duplication	of	therapy	which	may	lead	to	patient	harm.		
A	surprising	finding	was	that	the	number	of	MAR	chart	errors	strongly	correlated	
with	the	total	number	of	medicines	administered	(r	=	0.848;	P	=	0.0019).	In	fact,	
the	correlation	was	stronger	than	for	the	number	of	administration	errors.	With	
the	current	data	it	is	not	possible	to	determine	if	there	is	a	causal	relationship.			
There	 is	 an	 opportunity	 for	 pharmacists	 to	 play	 a	 greater	 role	 here.	 Beyond	
ensuring	that	MAR	charts	are	complete	and	accurate,	pharmacists	can	play	a	role	
in	 education	 and	 training	 and	medicines	 reviews	 at	 the	 care	 home.	 In	 2006,	
Zermansky	 and	 colleagues	 suggested	 that	 pharmacists	 can	play	 an	 important	
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role	in	minimising	the	occurrence	of	medication	errors	in	care	homes	but	they	
are	not	routinely	involved	in	medicines	management	in	care	homes	to	the	extent	
they	are	in	hospitals	(Zermansky	et	al.	2006).	Whilst	there	has	been	a	rise	in	the	
number	of	 care	home	based	pharmacists,	 research	 into	 their	 effectiveness	 is	
currently	lacking.		
In	this	study,	the	prevalence	of	regulatory	errors	was	also	explored.	Regulatory	
errors	comprised	six	subcategories:	(i)	as	directed	instructions;	(ii)	an	undefined	
code	was	used	on	the	MAR	chart;	(iii)	where	an	amendment	was	made	to	the	
MAR	 chart	 a	 confirmatory	 signature	 was	 not	made;	 (iv)	 the	 drug	 name	was	
misspelt;	(iv)	no	maximum	PRN	dose	was	indicated	when	one	was	required	and	
(vi)	there	was	missing	chart	information	such	as	DOB	or	allergy	status.		Similar	
to	MAR	chart	errors,	as	directed	instructions	and	maximum	PRN	doses	should	
be	 resolved	 at	 the	 pharmacy	 before	 the	 MAR	 chart	 arrives	 at	 the	 home.	
Nevertheless,	the	home	should	seek	to	rectify	such	errors	with	the	prescriber	or	
pharmacist	 as	 soon	 as	 it	 is	 identified.	 In	 contrast	 errors	 in	 the	 remaining	
subcategories	 should	be	 resolved	at	 the	 care	home.	 The	 absolute	number	of	
regulatory	errors	was	fairly	low	(at	least	in	comparison	to	other	categories)	and	
the	instances	of	a	drug	being	misspelt	were	almost	non-existent.	The	majority	of	
errors	in	this	category	were	associated	with	undefined	codes	being	used	to	make	
some	comment	about	an	administration	and	mid-cycle	changes	to	medicines	not	
being	signed.	From	a	governance	perspective,	the	latter	is	particularly	serious	as	
it	does	not	allow	for	an	audit	trail	to	fully	understand	the	nature	of	the	change.	
It	 was	 clear	 from	 the	 review	 of	 MAR	 charts	 that	 there	 were	 a	 lot	 of	 hand	
amendments	to	the	charts	and	these	did	not	always	have	signature	or	the	name	
of	prescriber	who	 instigated	or	authorised	the	changes.	The	use	of	undefined	
codes	 contravenes	 regulatory	 guidance	 (NICE	 2015)	 but	 is	 perhaps	 a	
consequence	of	local	practices	that	are	established	due	to	incomplete	and	non-
standardised	processes	within	the	sector	(Dilles	et	al.	2011).			
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Effective	stock	management	appeared	to	be	a	significant	issue	in	all	care	homes	
within	this	study.	The	absence	of	adequate	stock	has	been	shown	for	example	
to	 be	 a	 contributor	 to	medicines	 administration	 errors	 (omission	 and	wrong	
time)	in	the	secondary	care		setting	(Dean	et	al.	1995;	Ho	et	al.	1997;	Taxis	et	al.	
1999).	 Many	 of	 the	 medications	 received	 had	 no	 indication	 of	 ‘booked	 in’	
quantities,	 the	 date	 received	 or	 a	 signature	 to	 indicate	who	 receipted	 them.	
Together	 these	 can	 lead	 to	 errors	 in	 stock	management	 that	may	 result	 in	 a	
medication	 being	 unavailable	 for	 a	 resident	 at	 the	 point	 of	 administration.	
Where	 this	 is	associated	with	an	MDS	 tray	 it	may	be	 that	 the	entirety	of	 the	
resident’s	medicines	 is	missing.	 	 In	 addition,	 there	were	 discrepancies	 in	 the	
quantity	 received	 compared	 to	 the	 actual	 number	 of	 administration	 events	
indicated	on	 the	MAR	chart.	 	Again,	 this	may	 increase	 the	 risk	of	 a	medicine	
running	 out	 leading	 to	 an	 avoidable	 delay	 in	 administration	 to	 the	 resident.	
Another	 issue	 that	may	arise	out	of	poor	 stock	control	 is	waste	medicines.	A	
medicine	may	be	reordered	unnecessarily	due	to	discrepancies	between	actual	
stock	and	recorded	stock.			
In	the	study	presented	in	this	chapter,	errors	associated	with	stock,	regulatory	
requirements	and	information	on	the	MAR	chart	were	examined	in	addition	to	
administration	errors.	However,	a	search	of	the	literature	revealed	a	paucity	of	
literature	examining	for	similar	issues.	This	is	probably	as	a	consequence	of	most	
studies	 focusing	 on	 either	 detecting	 medication	 administration	 errors	 alone,	
(Flynn	et	al.	2002;	Dickens	2007;	van	den	Bemt	et	al.	2009;	Kim	and	Bates	2013)	
or	investigating	errors	in	other	elements	of	the	medication	management	process	
including	dispensing,	ordering	and	monitoring.	(Carayon	et	al.	2014;	Pierson	et	
al.	2007;	Barber	et	al.	2009a;	Latif	et	al.	2013).	These	areas	were	outside	the	
scope	 of	 this	 thesis	 and	 indeed	 could	 not	 be	 addressed	 through	MAR	 chart	
analysis.		
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In	 summary,	 this	 study	has	explored	 the	nature	and	prevalence	of	medicines	
management	 errors	 in	 care	 homes	 through	 a	 retrospective	 analysis	 of	 MAR	
charts.	The	number	of	errors	 identified	was	 significant	and	 in	 line	with	 those	
identified	 in	 the	 seminal	 CHUMS	 study	 (Alldred	 et	 al.	 2009).	 Medicines	
administration	errors	were	particularly	prevalent	and	this	was	primarily	related	
to	 dose	 omissions.	Whilst	 it	was	 beyond	 the	 scope	 of	 this	 study,	 the	 clinical	
consequences	 of	 such	 medication	 errors	 should	 be	 explored	 as	 a	 matter	 of	
urgency.			
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4.1.1 Medicines	use	in	the	UK	
Medicines	 play	 an	 important	 role	 in	 improving	 the	 health	 and	 wellbeing	 of	
patients	 and	 remain	 one	 of	 the	 most	 common	 health	 interventions.	 As	 a	
consequence,	the	volume	of	medicines	prescribed	in	the	UK	continues	to	grow	
year	on	year.	In	England,	NHS	spending	on	medicines	has	grown	from	£13	billion	
in	2010/11	to	17.4	billion	in	2016/17	representing	an	average	increase	of	5%	per	
annum.	The	majority	of	this	increase	in	spending	is	accounted	for	by	secondary	
care	where	medicines	 spend	has	 increased	 by	 approximately	 12%	per	 annum	
(Ewbank	et	al.	2018).	In	the	primary	care	setting,	spend	has	grown	more	steadily	
even	though	the	number	of	items	prescribed	has	almost	doubled	to	1.1	billion	in	
the	decade	leading	up	to	2016.		This	increase	in	the	prescribing	of	medicines	was	
partly	mitigated	 against	 by	 a	 reduction	 of	 approximately	 25%	 in	 the	 cost	 per	
prescribed	item	to	£8.34	over	the	same	period.	 In	Wales,	data	on	prescription	
spend	is	available	for	the	community	setting	(Welsh	Government	2017).	In	2017,	
80.4	million	items	were	dispensed	(up	0.2%	from	2016)	representing	a	spend	of	
approximately	£580	million.	Of	note,	 the	number	of	medicines	prescribed	per	
head	of	population	in	2017	was	higher	than	all	the	other	UK	territories	(25.8	items	
compared	 to	 22.3	 in	Northern	 Ireland,	 20.0	 in	 England	 and	 19.2	 in	 Scotland).	
Omeprazole	 was	 the	 most	 commonly	 prescribed	 item	 in	 Wales	 in	 2017	 (2.6	
million	items).	
Clearly,	the	extent	of	expenditure	on	medicines	in	the	UK	is	significant.	However,	
where	prescribing	is	appropriate	and	administration	is	effective,	the	therapeutic	
benefits	derived	from	medicines	are	likely	to	relieve	the	economic	pressure	on	
the	 NHS	 by	 preventing	 the	 use	 of	 alternative	 interventions	 (for	 example	 an	
unintended	 A&E	 visit	 or	 hospital	 admission)	 which	 are	 more	 costly	 than	
medicines	 (NICE	 2015).	 However,	 as	 has	 been	 described	 in	 Chapters	 2	 &	 3,	
medicines	 are	 not	 always	 prescribed	 appropriately	 nor	 are	 they	 always	
administered	or	taken	effectively	and	as	a	consequence	resources	are	wasted.	
These	wasted	resources	may	include	medicines	waste,	unwarranted	bed	days	in	
secondary	care	or	unnecessary	A&E	visits	and	GP	consultations	(Hyttinen	et	al.	
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2016;	Hyttinen	et	al.	2018;	Hudhra	et	al.	2016;	Heider	et	al.	2018).		The	World	
Health	Organisation	uses	an	umbrella	term	for	this:	“irrational	use	of	medicines”	
that	encompass	inappropriate	prescribing,	dispensing	or	patients	failing	to	take	
them	 properly	 which	 results	 in	 waste	 of	 healthcare	 resources	 (World	 Health	
Organisation	2016).	The	scale	of	the	problem	is	significant	with	WHO	estimating	
that	 greater	 than	 50%	 of	 all	 medicines	 are	 prescribed,	 dispensed	 or	 sold	
inappropriately,	and	50%	of	patients	do	not	take	their	medicines	correctly.		
4.1.2 Medicines	waste	
The	 issue	of	medicines	waste	has	been	well	established	nationally	 (Hazell	and	
Robson	2015).	Whilst	there	is	no	standardised	definition	of	waste	and	different	
authors	 use	 similar	 but	 subtly	 different	 definitions	 (White	 2010;	 	 Abou-Auda	
2003;	 York	 Health	 Economics	 Consort	 and	 The	 School	 of	 Pharmacy	 2010),	
medicines	 waste	 is	 categorised	 by	 the	 supply	 of	 prescription	 medicines	 to	
patients	 that	 are	 ultimately	 discarded.	 In	 the	 seminal	 ‘York	 Study’	 titled	
“Evaluation	of	the	scale,	causes	and	costs	of	waste	medicines”	by	the	York	Health	
Economics	Consortium	and	 the	 School	 of	 Pharmacy,	UCL	medicine	waste	was	
defined	as	“drugs	that	are	dispensed	but	are	ultimately	physically	discarded.	That	
is,	they	are	put	into	domestic	waste	or	the	drains,	or	returned	to	pharmacists	or	
dispensing	doctors	 for	 incineration.”	 This	definition	was	developed	out	of	 the	
European	 Waste	 Framework	 Directive	 (2008)	 that	 defines	 waste	 as	 ‘any	
substance	 or	 object	 the	 holder	 discards,	 intends	 to	 discard	 or	 is	 required	 to	
discard’.	Waste	medicines	therefore	are	medicines	that	have	been	supplied	to	
patients	but	not	consumed	or	are	partly	consumed	and	ultimately	are	disposed	
of.	This	can	be	because	there	is	no	longer	a	therapeutic	need	or	because	they	
have	exceeded	their	expiry	date.		At	some	stage,	the	medicines	are	then	disposed	
of	either	 in	household	waste	or	 returned	 to	a	pharmacy	or	other	appropriate	
medicines	disposal	service.		
In	the	UK,	there	have	been	a	small	number	of	robust	studies	evaluating	the	scale	
of	medicines	supplied	by	the	NHS	that	are	wasted.	 In	May	1995,	the	Office	of	
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Populations	and	Census	Surveys	(OPCS)	published	their	Omnibus	Survey	(Office	
of	 Population	 Censuses	 and	 Surveys	 1997)	 which	 included	 an	 evaluation	 of	
medicines	waste.	Officers	visited	2000	homes	 in	England	to	 identify	medicines	
that	were	not	currently	being	used.	Remaining	medicines	were	either	those	that	
were	intended	to	be	used	at	some	later	date	or	the	individual	had	no	intention	
of	using	them	at	any	point	in	the	future.	The	authors	classified	waste	as	those	
medicines	 that	were	not	 intended	 for	 future	use.	By	extrapolation,	 the	 report	
concluded	that	11	percent	of	homes	 in	the	UK	had	at	 least	one	medicine	that	
would	eventually	be	disposed	of.		
The	York	study	in	2010	expanded	the	definition	of	waste	medicines	to	medicines	
that	are	not	currently	in	use	i.e.	they	included	medicines	for	which	there	was	no	
intention	to	use	them	again	at	any	point	in	the	future	and	those	that	are	being	
retained	for	future	use	(or	just	in	case).	The	authors	justified	this	on	the	basis	that	
retaining	medicines	may	risk	patient	harm	on	two	counts.	Firstly,	the	individual	
has	to	make	a	judgement	on	self-medicating	and	there	is	a	risk	that	the	expiry	
date	 on	 the	 medicine	 has	 been	 achieved.	 The	 authors	 used	 a	 different	
methodological	 approach	 to	 that	 of	 the	 OPCS.	 They	 developed	 a	 telephone	
survey	 with	 a	 target	 (arbitrary)	 of	 1000	 responses	 (1185	 actual)	 and	 audited	
medicines	returned	to	114	community	pharmacies	across	five	primary	care	trusts	
in	England;	the	audit	also	included	medicines	returned	from	care	homes.		From	
the	 data	 collected,	 the	 authors	 estimated	 that	 some	 £300	 million	 worth	 of	
medicines	are	wasted	annually	in	England.	This	could	be	divided	into	£90	million	
of	medicines	retained	in	an	individuals	home,	£110	million	of	medicines	returned	
to	the	pharmacy	and	£50	million	returned	by	care	homes	(York	Health	Economics	
Consort	 and	 The	 School	 of	 Pharmacy	 2010).	 Put	 another	 way,	 these	 wasted	
medicines	account	for	£1	of	in	every	£25	spent	on	prescribed	medicines	or	0.3%	
of	overall	NHS	spend.	The	authors	concluded	that	the	scale	of	medicines	waste	is	
likely	 to	 be	 underestimated	 as	 a	 consequence	 of	 the	 survey	 methodology	
employed,	 disposal	 in	 household	 waste	 or	 via	 other	 disposal	 routes	 such	 as	
returning	medicines	to	dispensing	GPs.		
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It	is	worth	noting	that	the	issue	of	medicines	waste	is	not	unique	to	the	UK.	In	
Canada	in	a	study	to	quantify	the	value	of	returned	medicines	to	58	pharmacies	
over	a	two	month	period,	the	cost	of	discarded	medication	was	estimated	to	be	
$60,350	 (Cameron	 1996).	 Similarly,	 in	 Spain,	 the	 estimated	 cost	 of	 returned	
medicines	to	38	community	pharmacies	over	7	working	days	was	€8539.9	(Coma	
et	al.	2008),	while	in	the	USA,	wasted	medicines	are	said	to	accounted	for	US$1	
billion	annually	in	older	adults	aged	65	and	over	(Morgan	2001).	
There	 are	 several	 key	 consequences	 of	 medicines	 waste	 for	 patients,	
practitioners,	 healthcare	 organisations	 and	 society.	 Such	wastage	 imposes	 an	
economic	burdens	in	terms	of	direct	expenses	as	a	consequence	of	the	cost	of	
unused	medicines	 and	 their	 disposal	 and	 indirect	 costs	 for	 the	 time	 spent	 on	
prescribing	and	dispensing	process	(Langley	et	al.	2005b;	James	et	al.	2009).		
4.1.3 The	cause	of	medicines	waste	
Waste	can	happen	at	any	stage	in	the	medication	management	process	from	the	
time	of	 issuing	 the	 prescription	 until	 the	medications	 are	 in	 the	 hands	 of	 the	
patient.	The	causes	of	medicines	waste	are	outlined	in	Table	4.1	below.		As	can	
be	seen,	the	causes	of	waste	can	be	categorized	into	those	instances	where	the	
waste	is	unavoidable	(patient	death,	patient	recovery,	an	appropriate	change	of	
medication)	 and	 those	 that	 are	 avoidable	 (repeat	 dispensing,	 stock	 piling	 and	
over	ordering,	 the	duration	of	 the	prescription,	 inappropriate	disposal	 in	 care	
homes,	non-adherence).	It	is	also	clear	that	patients	and	healthcare	professionals	
(prescribers,	pharmacists,	care	home	personnel)	all	contribute	to	the	generation	
of	medicines	waste.		Indeed,	in	a	recent	report	in	Bristol	exploring	some	of	the	
main	causes	of	medicines	waste,	 lack	of	clinical	knowledge	of	care	home	staff	
was	said	to	be	a	contributory	factor.	In	their	report,	the	authors	stated	that	some	
staff	 were	 not	 confident	 with	 the	 administration	 of	 some	 medications	
(particularly	‘when	required’	medicines)	or	familiar	with	the	clinical	condition	of	
residents.	 As	 a	 consequence,	 they	 ordered	 all	 the	 prescribed	 medicines	
irrespective	of	whether	they	were	being	taken	regularly	by	the	resident.	Similarly,	
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suboptimal	working	processes	were	said	to	contribute	to	medicines	waste.	Such	
processes	included:	(i)	lack	of	space	to	store	medications	for	example	one	carer	
claimed	that	that	she	had	disposed	of	unused	sachets	of	laxatives	due	to	lack	of	
storage	space;	(ii)	inappropriate	storage	conditions	such	as	the	temperature	of	
the	refrigerator	was	not	regularly	monitored	and	went	out	of	range	leading	to	
the	 disposal	 of	 some	medicines;	 	 (iii)	 receiving	 the	 wrong	medication	 due	 to	
errors	 in	prescribing	or	dispensing	of	medicines	(Bristol	Clinical	Commissioning	
Group	2016).		
Whilst,	 patient	 non-adherence	 is	 commonly	 cited	 as	 the	 major	 contributory	
factor	leading	to	medicines	waste,	the	‘Evaluation	of	the	Scale,	Causes	and	Costs	
of	Medicine	Waste’	report	in	2010	concluded	that,	most	medicines	wastage	is	as	
a	consequence	of	issues	related	to	repeat	prescribing	and	dispensing	processes.		
For	example,	 in	a	study	that	sought	to	audit	the	appropriateness	of	medicines	
prescribed	by	GPs	in	Bristol,	of	the	3,693	medicines	dispensed	during	the	last	3	
months	 of	 the	 financial	 year	 2014-2015,	 	 approximately	 590	 (16%)	 were	
unnecessary	(Bristol	Clinical	Commissioning	Group	2016).	
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Table	4.1	The	causes	of	medicines	waste	(adapted	from	(Hazell	and	Robson	2015))	
Cause	of	waste	 Notes	 References	
Repeat	dispensing	 Medicines	that	have	been	prescribed	to	patients	are	dispensed	irrespective	of	whether	they	are	needed.		 (Petty	2017)	
Stock	piling	and	over	ordering	 Patients	or	care	homes	will	order	all	repeat	medication	irrespective	of	whether	it	is	required;	for	patients	this	
can	be	driven	by	a	fear	that	if	they	do	not	order	all	their	medicines	they	will	be	deprescribed.	
(Abahussain	et	al.	
2006)	
Change	of	medication	 In	 instances	 where	 a	 patient’s	 condition	 changes	 or	 where	 are	 adverse	 drug	 reactions	 to	 their	 existing	
therapies,	a	change	in	medication	may	be	necessitated.	The	remaining	stock	of	the	existing	medicine	is	then	
wasted.		
(Braund	 et	 al.	
2008)	
Patient	recovery	 A	 patient	 may	 recover	 from	 a	 condition	 before	 the	 stock	 of	 the	 medicine	 treating	 the	 condition	 is	 fully	
consumed.	Any	remaining	medicines	stock	is	waste.		
(Coma	et	al.	2008)	
Patient	death	 A	 patient	 death	may	 lead	 to	waste	medicines	where	 anticipatory	medications	 are	 prescribed	 or	where	 a	
patient’s	regular	medicines	are	not	used			
(Langley	 et	 al.	
2005a)	
The	duration	of	the	prescription	 Where	 the	 prescribing	 duration	 is	 extended	 (e.g.	 three	month’s	 worth	 of	 a	medicine	 are	 prescribed	 and	
dispensed)	there	is	an	increased	risk	that	the	patient	will	recover	or	change	medications	before	the	original	
prescribing	duration	is	exceeded.			
• (Hawksworth	
1996)		
	
Inappropriate	disposal	 Some	care	homes	dispose	of	all	remaining	medication	at	the	end	of	a	28-day	medicines	cycle	even	if	the	shelf-
life	of	the	product	has	not	been	reached.		
(Bristol	 Clinical	
Commissioning	
Group	2016)	
Non-adherence	 Patient	may	either	intentionally	or	non-intentionally	fail	to	adhere	to	their	prescribed	therapy.				 (Ryan	 and	
Wagner	2003)	
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In	2014,	West	and	colleagues	 conducted	a	 systematic	 review	of	 the	 literature	
related	 to	 medicine	 waste	 (West	 et	 al.	 2014).	 The	 authors	 retrieved	 14,157	
papers	related	to	waste	and	screened	this	down	to	42	papers.	The	authors	noted	
that	 there	 was	 a	 discrepancy	 in	 what	 constituted	 medicines	 waste	 between	
papers	which	made	 comparison	 difficult.	 However,	 the	most	 commonly	 cited	
reasons	 for	 medicines	 waste	 were:	 	 (i)	 medication	 changed	 (Morgan	
2001)(Mackridge	 and	 Marriott	 2007);	 (ii)	 patient’s	 death	 (Cook	 1996);	 (iii)	
resolution	of	the	patient’s	condition	(Coma	et	al.	2008);	(iv)	expired	medicines	
(Braund	et	al.	2009);	(v)	excessive	stock	at	home	(Abahussain	et	al.	2006)	and	(vii)	
discontinuation	by	the	patient	(Abahussain	et	al.	2006).	In	another	study,	West	
and	colleagues	used	the	Delphi	technique	to	define	medicines	waste	and	explore	
it’s	 contributory	 factors.	 Using	 an	 expert	 panel	 of	 academics,	 practitioners,	
government	 officials,	 representatives	 from	 professional	 organisations	 and	
patients	situated	in	Malta,	the	authors	identified	four	main	contributory	factors:	
(i)	 physical	 and	 environmental	 factors;	 (ii)	 social	 and	 psychological	 patient	
factors;	(iii)	cultural	factors	and	(iv)	practitioner	factors.	Each	of	these	factors	was	
associated	with	 one	 or	more	 conceptual	 themes	 that	 the	 panel	 perceived	 to	
contribute	to	medicines	waste	(see	Table	4.2).	
Table	4.2	Factors	contributing	to	medicines	waste	(adapted	from	(West	et	al.	2015)	
Contributory	factors	 Conceptual	themes	
Physical	and	environmental	factors	 Expiry	dates	reached	before	stock	used		
Providing	large	quantities	of	medicines	to	patient	
Social	and	psychological	patient	
factors	
Non-adherence	as	a	consequence	of	limited	patient	
education	
Medicines	ordered	by	relative	or	carer	when	they	
are	not	required		
Communication	issues	–	medicines	ordered	when	
not	needed	
Patient	death	
Cultural	factors	 Free	healthcare	system	
Practitioner	factors	 Inappropriate	or	unnecessary	medicines	prescribed		
Medication	reviews	not	undertaken	to	rationalise	
therapy		
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The	 York	 study	 (York	 Health	 Economics	 Consort	 and	 The	 School	 of	 Pharmacy	
2010)	attempted	to	link	medicines	wastage	with	loss	of	therapeutic	value	from	
medicines.	 	 The	use	of	medicines	was	 categorised	 then	as	 either	optimal	 (i.e.	
medicines	 are	 fully	 consumed,	 and	 therapeutic	 benefits	 maximised)	 or	
therapeutic	 loss	 (therapeutic	 benefits	 reduced	 or	 lost	 completely).	 They	 then	
developed	a	schematic	indicating	the	link	between	waste	and	loss	of	therapeutic	
outcomes	(see	Figure	4.1).	Clearly,	some	of	the	causes	of	waste	medicines	can	be	
prevented	(e.g.	preventing	over	supply,	encouraging	adherence	through	patient	
education	and	counselling)	whilst	some	are	non-preventable	(e.g.	patient	death)	
with	 estimates	 suggesting	 that	 the	 split	 between	 preventable	 and	 non-
preventable	 waste	 is	 roughly	 50:50	 (York	 Health	 Economics	 Consort	 and	 The	
School	of	Pharmacy	2010).			The	authors	suggested	that	reducing	the	avoidable	
waste	burden	would	 result	 in	 some	extra	 costs	 associated	with	 implementing	
better	waste	 control	measures.	 Even	 factoring	 this	 in,	 they	estimated	 that	on	
average	each	primary	 care	 trust	 in	England	 could	 realise	up	 to	£0.5	million	 in	
savings	per	annum	or	put	another	way	£1	-	£2	per	head	of	population.		Whilst	
such	savings	would	be	financially	and	politically	desirable,	the	authors	argue	that	
it	is	the	greater	returns	that	could	be	achieved	from	maximising	medicines	use	to	
improve	health	outcomes	is	more	effective	than	a	reduction	in	medicines	waste.	
For	example,	the	authors	suggest	that	the	therapeutic	loss	due	to	non-adherence	
in	five	therapeutic	domains	is	likely	to	be	more	than	£500	million	(York	Health	
Economics	Consort	and	The	School	of	Pharmacy	2010).	The	authors	 therefore	
suggest	that	tackling	inappropriate	medicines	use	by	patients	(which	may	lead	to	
reductions	in	medicine	waste	as	a	by-product)	should	be	a	priority.	
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Figure	4.1	Medicines	waste	and	therapeutic	loss	adapted	from	Hazell	and	Robson	2015)
Optimal Use
Medicines fully consumed
Medicines taken / 
administered in 
accordance with the 
prescriber’s intentions 
and therapeutic benefits 
maximized
Therapeutic Loss
Medicines fully consumed 
(but not in line with 
prescriber’s intentions 
e.g. incorrect doses, 
irregular dosing intervals)   
Medicines taken / 
administered in such a 
way that reduces or 
negates therapeutic 
benefits
Material Waste
Medicines partially 
consumed
Optimal therapeutic 
effects maintained
Material Waste & 
Therapeutic Loss (Partial)
Medicines partially 
consumed
Reduction in therapeutic 
benefits
Material Waste & 
Therapeutic Loss (Total)
Medicines completely
unconsumed
No therapeutic benefit
Intentional and Unintentional non-adherence
Other factors: over-supply, changes to medication, patient death
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4.1.4 Non-adherence	
Non-adherence	to	a	medication	is	defined	as	a	patient	failing	or	choosing	not	to	
take	medicines	in	a	way	agreed	with	the	prescriber.	Non-adherence	can	arise	as	
a	result	of	a	patient	deliberately	not	taking	their	medicine(s)	as	agreed	with	the	
prescriber	i.e.	intentional	non-adherence.	For	example,	they	may	hold	particular	
beliefs	or	concerns,	they	may	not	agree	with	their	diagnosis	or	they	may	adjust	
their	dose.	Non-adherence	can	also	be	unintentional	for	example	when	a	patient	
forgets	to	take	their	medicine.	It	is	worth	highlighting	that	patients	may	be	non-
adherent	to	a	number	of	medicines	at	the	same	time	but	for	different	reasons.	
The	World	Health	Organisation	has	highlighted	 five	 factors	 that	contribute	 to	
non-adherence	(World	Health	Organization	2003)(see	Table	4.3).	Allemann	and	
colleagues	 suggested	 that	 these	 factors	 could	be	divided	 into	modifiable	 and	
non-modifiable	 determinants	 of	 non-adherence	 (Allemann	 et	 al.	 2016).	 For	
example,	 a	 patient’s	 knowledge	 and	 beliefs	 about	 their	 medicines	 may	 be	
modifiable	 through	 an	 educational	 intervention	 whilst	 their	 educational	
attainment	may	 be	 non-modifiable	 (at	 least	 in	 the	 short	 term).	 The	 authors	
suggested	 that	 in	 the	 main	 interventions	 should	 be	 directly	 targeted	 at	 the	
modifiable	 determinants	 although	 there	 may	 be	 opportunities	 to	 tailor	 an	
intervention	towards	addressing	non-modifiable	determinants.			
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Table	4.3	Factors	that	contribute	to	non-adherence	to	medicines.		
Contributing	Factor	 Examples	
Socioeconomic	factors	 Poor	 educational	 attainment,	 unemployment,	 low	
socioeconomic	status	
Healthcare	systems	and	team	factors	 Ineffective	 medication	 distributions	 services,	
overworked	healthcare	professionals	
Therapy	related	factors	 The	 duration	 of	 treatment,	 how	 immediate	 the	
beneficial	 effects	 are	 seen,	past	 success	with	other	
treatments	
Conditions	related	factors	 Symptom	severity,	effective	 treatments	availability,	
the	individual’s	level	of	disability	as	a	consequence	of	
their	therapy	
Patient	related	factors	 Forgetfulness,	poor	motivation,	non-agreement	with	
the	diagnosis	
	
4.1.4.1 Non-adherence	in	care	homes		
	
There	 is	a	general	perception	that	because	residents	are	being	 ‘administered’	
medicines,	non-adherence	is	not	a	significant	issue.	Indeed,	Hughes	and	Goldie	
interviewed	eight	GPs,	17	residents	and	conducted	two	focus	groups	with	nurses	
(total	9	participants)	to	explore	adherence	and	shared	decision	making	 in	the	
nursing	 home	 environment.	 The	 authors	 concluded	 that	 the	major	 theme	 to	
emerge	was	‘control’.	GPs	and	nurses	respectively	felt	it	was	necessary	to	retain	
control	of	prescribing	and	administration	 to	ensure	 the	safety	and	efficacy	of	
medicines.	 Residents	 apparently	 accepted	 this	 control	 without	 question,	
reported	that	they	were	adherent	to	their	medicines	and	were	not	involved	in	
share	 decision	 making	 (Hughes	 and	 Goldie	 2009).	 Although	 adherence	 to	
medicines	 in	 the	care	home	setting	could	be	described	as	optimal	due	to	the	
regimented	administration	of	medicines,	 there	 is	evidence	 in	the	 literature	of	
enforced	adherence	(compliance)	whereby	a	resident	continues	to	receive	their	
medicines	 for	 extended	 durations	 without	 review.	 This	 may	 exacerbate	 any	
adverse	 reactions	 to	 such	medicines	 	 (Hughes	2008).	 	 	Barnes	and	colleagues	
used	 a	 qualitative	 approach	 to	 explore	medicines	 administration	 use	 in	 care	
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homes	and	found	that	the	priority	for	nursing	staff	was	to	ensure	all	medicines	
prescribed	for	a	patient	were	administered.	The	authors	suggested	that	there	
would	be	times	where	a	resident	was	not	able	to	exercise	any	form	of	“intelligent	
non-compliance”	 for	 example	where	 they	 had	 cognitive	 impairment	 or	were	
unable	 to	 communicate	 (Barnes	 et	 al.	 2006).	 	 This	 issue	 can	 be	 exacerbated	
where	covert	administration	occurs	i.e.	administrations	are	concealed	in	food	or	
drink.	Whilst	this	may	be	justified	on	medical	grounds,	there	are	instances	in	the	
literature	 where	 covert	 administration	 has	 occurred	 but	 is	 inappropriate	
(Kirkevold	 and	Engedal	 2005).	A	 second	 issue	 is	 one	of	 erratic	 adherence	 i.e.	
residents	may	be	administered	all	their	medicines	but	at	the	wrong	times	(for	
example	if	it	is	inconvenient	for	staff)	or	where	any	special	instructions	are	not	
followed	(for	example	taking	a	medicine	on	an	empty	stomach).	Ultimately,	the	
issues	 of	 adherence	 in	 care	 home	 residents	 is	 unexplored	 but	 may	 lead	 to	
therapeutic	loss	and	/	or	waste	medicines.			
4.1.5 Medicines	waste	in	care	homes	
Much	of	the	research	on	medicines	waste	in	care	homes	is	quite	historic	with	the	
first	reported	study	by	Mathieson	and	Rawlings	(1971)	who	estimated	that	15%	
of	 all	 medicines	 wasted	 were	 from	 nursing	 homes	 (Mathieson	 and	 Rawlings	
1971).	Then,	in	1978,	Howard	and	Strong	studied	medicines	return	books	for	a	
100-bed	nursing	home	over	a	4	year-period	in	the	US	and	estimated	$6,420.24	
worth	of	discarded	medicines	over	the	study	period.	The	authors	estimated	the	
cost	 for	 374	 items	 including	 solid	 dosage	 form	 (tablets,	 capsules),	 topical	
preparation,	 suppositories	 and	 parenteral	 preparation	 (Howard	 et	 al.	 1978).	
Much	of	the	research	then	focussed	on	exploring	reductions	in	medicines	waste	
that	could	be	achieved	through	monitored	dosage	systems.	For	example,	Parrot	
(1980)	 in	a	120-bed	nursing	home,	compared	 the	cost	of	discarded	medicines	
arising	from	a	30-day	card	dispensing	system	with	a	monitored	unit	dose	system.	
The	author	 showed	 that	nearly	$18	extra	medicines	waste	was	generated	per	
resident	 per	 month	 as	 a	 consequence	 of	 the	 traditional	 card	 system	 in	
comparison	with	that	of	a	monitored	unit	dose	system	(Parrott	1980).	Similarly,	
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Brown	and	Kirk	reported	that	the	annual	cost	of	discarded	medicines	using	unit	
dose	 systems	was	 17%	 less	 than	 generated	 by	 traditional	 systems	 in	 a	 study	
conducted	 in	17	 care	homes	 in	 Indiana,	USA	 (Brown	and	Kirk	1984).	 This	was	
followed	by	another	study	in	1985,	to	estimate	the	cost	of	discarded	medicines	
in	 12	 nursing	 homes	over	 a	 two-year	 period.	 This	 study	 found	 that	 $64.08	 of	
medicines	 was	 wasted	 per	 resident	 per	 year	 and	 this	 was	 largely	 as	 a	
consequence	of	either	a	change	in	the	resident’s	medicine	regimen	or	death	of	a	
resident	(Farmer	et	al.	1985).		
The	landmark	study	on	medicines	waste	in	care	homes	in	the	UK	was	conducted	
by	 the	 York	 Health	 Economics	 Consortium	 in	 partnership	 with	 The	 School	 of	
Pharmacy,	London	(York	Health	Economics	Consort	and	The	School	of	Pharmacy	
2010).	They	studied	the	medicines	returned	to	114	community	pharmacies	over	
a	one-month	period.	 The	medicines	 returned	 from	care	homes	 accounted	 for	
16%	of	the	total	wastage	at	a	value	of	£50	million.	In	Wales,	medicines	waste	in	
care	 homes	 is	 under-explored	 although	 from	 a	 total	 of	 £98	million	 spent	 on	
prescribed	 medications	 in	 2016,	 £650,000	 were	 associated	 with	 unused	
medicines	 in	 care	 homes	 in	 the	 Abertawe	 Bro	Morgannwg	 University	 Health	
Board	(ABMU)	area	(The	Welsh	NHS	Confederation	2017).	Ultimately,	medicines	
waste	from	care	homes	remains	underexplored.		
4.2 Aims	and	Objectives		
The	aim	of	this	study	was	to	explore	the	types	and	quantity	of	medicines	wasted	
in	a	sample	of	care	homes	in	the	South	Wales	area.	
The	objectives	were	to:	
1. Quantify	the	value	of	wasted	medicines	from	medicines	returns	books	
2. Quantify	the	value	of	medicines	stockpiled	or	overstocked		
3. Explore	the	types	of	medicines	wasted	in	this	sample	of	care	homes.	
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4.3 Methodology	
4.3.1 Study	design	overview	
This	study	sought	to	explore	medicines	waste	in	care	homes.	To	the	best	of	the	
researcher’s	knowledge,	there	is	no	established	protocol	for	the	measurement	of	
medicines	waste	 in	 care	 homes	 in	 the	 literature.	 As	 such	 a	methodology	was	
developed.	The	developed	methodology	was	in	two	parts:	(i)	medicines	returns	
books	were	requested	from	participating	care	homes	(it	 is	a	CQC	requirement	
that	returns	books	are	completed	each	month)	(CQC	2016);	(ii)	medicines	in	the	
home	were	physically	counted	and	then	reconciled	against	the	current	MAR	chart	
to	identify	the	stockpiling	or	overstock	of	medicines.	The	value	of	the	returned	
medicines	and	the	overstocked	medicines	was	then	calculated	using	the	British	
National	Formulary	(BNF	68)	to	estimate	the	scale	of	medicines	waste.	The	reader	
might	ask	whether	it	was	necessary	to	count	stock	in	the	home	and	instead	rely	
solely	on	the	returns	books.	However,	there	is	anecdotal	evidence	that	medicines	
are	stockpiled	and	the	returns	book	does	not	accurately	capture	the	totality	of	
medicines	that	have	been	or	need	to	be	returned.	Indeed,	during	visits	to	care	
homes,	 the	 researcher	 noted	 a	 number	 of	 practices	 that	 suggest	 direct	 stock	
counts	are	more	appropriate	and	valid.	For	example,	medicines	were	found	 in	
the	home	that	had	been	stopped	i.e.	they	were	not	on	the	resident’s	MAR	chart,	
storage	 areas	 that	 were	 labeled	 with	 one	 resident’s	 name	 contained	 the	
medicines	 of	 other	 residents	 and	 there	were	medicines	 for	 residents	who	 no	
longer	reside	in	the	home.	As	such,	it	was	necessary	to	account	for	unnecessary	
medicines	stock	that	is	held	at	the	home	but	that	has	not	been	or	will	never	be	
returned.	In	reconciling	the	stock	required	on	the	MAR	chart	against	the	stock	
held,	excess	stock	could	be	assessed.		
4.3.2 Recruitment	of	care	homes	
The	 recruitment	of	 care	homes	 to	 this	 phase	of	 the	 study	was	 similar	 to	 that	
described	in	section	2.3.2	but	with	some	modifications.	Briefly,	care	homes	were	
recruited	 by	 purposive	 sampling	 from	 the	 ABMU	 health	 board	 in	Wales	 with	
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recruitment	 lead	 by	 Invatech	 Health;	 inclusion/exclusion	 criteria	 and	 the	
recruitment	methodology	were	developed	in	partnership	with	the	researcher.	To	
be	eligible	for	the	study,	the	nursing	or	residential	home	had	to	be	located	in	the	
ABMU	health	board,	primarily	cater	for	older	adults,	be	fully	registered	with	the	
Social	 Inspectorate	 Wales	 (SIW)	 and	 currently	 use	 a	 paper-based	 MAR	 chart	
system.	 The	 mechanism	 by	 which	 care	 homes	 were	 identified	 is	 detailed	 in	
section	2.3.2.	Care	homes	that	participated	in	the	studies	detailed	in	Chapters	2	
and	3	were	asked	if	they	would	like	to	continue	their	participation	in	this	study;	
some	care	homes	chose	to	do	so	whilst	others	did	not.	As	a	consequence,	further	
care	homes	were	recruited	(care	homes	11	and	14),	 this	was	the	same	coding	
used	for	a	larger	study	(homes	12	and	13	did	not	take	part	in	this	phase	of	the	
study).	The	managers	of	participating	care	homes	were	asked	if	they	would	be	
willing	to	submit	returns	books	for	evaluation	(the	least	intrusive	option),	allow	
the	research	team	to	conduct	stock	counts	in	the	home	or	both	(preferred).		In	
total,	seven	care	homes	consented	to	stock	counts	of	which,	four	also	provided	
returns	books.		
	
4.3.3 Data	Collection	
4.3.3.1 Overstock	
	
Overstock	refers	to	any	stock	remaining	at	the	end	of	a	medicines	cycle	i.e.	if	a	
resident’s	medicines	are	not	administered	in	line	with	the	prescriber’s	intentions,	
there	will	be	stock	leftover.	These	should	be	returned	at	the	end	of	the	medicines	
cycle	but	where	it	is	not,	it	would	create	an	unnecessary	stockpile.	Medicines	may	
also	accumulate	for	‘when	required’	medicines	if	these	are	not	required	by	the	
resident	during	the	medicines	cycle	and	are	not	returned.	To	calculate	overstock,	
seven	care	homes	were	visited	during	2015	on	the	following	days:	(i)	17	March-
care	 home	 3;	 (ii)	 20	March-care	 home	 4;	 (iii)	 10	March-care	 home	 6;	 (iv)	 19	
February-care	home	8;	(v)	18	February-care	home	9;	(vi)	18	February-care	home	
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11;	 and	 (vii)	 18	 February-care	home	14.	 Ideally,	 each	home	would	have	been	
visited	with	the	same	number	of	days	remaining	in	the	medicines	cycle.	However,	
this	was	not	possible	as	the	research	team	had	to	work	around	the	care	home’s	
schedule.	 In	 addition,	 it	 became	 clear	 during	 stock	 counts	 that	 the	 remaining	
stock	in	some	cases	was	greater	than	the	total	monthly	supply	on	a	MAR	chart	
indicating	that	waste	had	been	accumulating	for	some	time	and	not	just	over	the	
period	of	the	medicines	cycle.				
A	 copy	 of	 the	MAR	 chart(s)	 for	 each	 of	 the	 residents	 was	 obtained	 and	 the	
quantity	of	medicine(s)	that	should	be	remaining	for	each	resident	to	the	end	of	
the	medicines	 cycle	was	 calculated	using	 the	dosage	 instructions	on	 the	MAR	
chart(s).	This	was	then	followed	by	a	physical	count	of	the	medicines	in	the	home.	
A	stepwise	process	of	counting	was	followed:	
1. Number	of	doses	in	the	resident’s	MDS	tray;	
2. Number	of	PRN	medications;	
3. Volume	of	liquid	formulations	(visual	estimation);	
4. Amount	of	creams	and	ointments	(visual	estimation);	
5. Any	medicines	in	the	refrigerator	(e.g.	insulins,	eye	drops);	
6. Number	of	dressings;	
7. Number	of	nutritional	supplements;	
	
These	 items	were	primarily	 located	on	the	medicines	administration	trolley	or	
stored	in	cabinets	or	on	shelves	in	a	dedicated	room.	Controlled	Drugs	(CDs)	and	
any	medicines	that	were	not	prescribed	on	a	named	patient	basis	were	excluded	
from	the	study.		
Discrepancies	in	stock	were	determined	by	comparing	the	quantity	required	by	
each	 patient	 until	 the	 next	medication	 cycle	 started	with	 the	 actual	 quantity	
determined	 from	 the	 stock	 count.	 Any	 discrepancy	 that	 amounted	 to	 an	
overstock	of	<	10	dosage	units	was	ignored.	This	was	a	pragmatic	approach	given	
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the	volume	of	medicines	to	be	counted	in	a	narrow	window	of	opportunity.	All	
counts	 were	 entered	 directly	 into	 Microsoft	 Excel	 for	 Mac	 version	 15.33	
(Microsoft	Corporation;	Seattle,	USA).		
The	 development	 of	 the	 protocol	 for	 counting	 medicines	 was	 led	 by	 the	
researcher.	Stock	counts	in	care	home	4	were	made	by	the	researcher	and	were	
used	to	train	two	Erasmus	students	who	completed	the	counts	in	the	remaining	
six	homes.	All	data	analysis	was	by	the	researcher.		
4.3.3.2 Returned	medicines	
Returned	medicines	data	was	obtained	from	the	returns	record	book.	This	is	a	
record	of	the	medicines	that	are	returned	to	the	supplying	pharmacy	(in	the	case	
of	residential	care	homes)	or	to	a	clinical	waste	supplier	(in	the	case	of	nursing	
homes)	following	completion	of	a	medicines	cycle.	Data	was	extracted	from	the	
returns	books	for	four	care	homes.	The	data	in	the	returns	books	corresponded	
to	the	end	of	a	monthly	medicines	cycle.	The	information	extracted	and	entered	
into	Microsoft	Excel	for	Mac	version	15.33	(Microsoft	Corporation;	Seattle,	USA)	
was:	(i)	the	date	of	the	return;	(ii)	id	of	the	resident;	(iii)	name	and	strength	of	the	
medication;	(iv)	quantity	returned;	(v)	pack	size;	(vi)	reason	for	disposal;	and	(vii)	
signature	 of	 the	 person	 responsible	 for	 entering	 the	 medicines	 returns	
information.	Where	data	 from	the	 returns	book	was	 incomplete,	a	number	of	
assumptions	were	made.	Where	the	pack	size	was	missing,	it	was	assumed	the	
smallest	pack	size	had	been	prescribed	to	be	consistent	and	where	the	strength	
of	the	formulation	was	missing	the	lowest	available	strength	of	the	medicine	was	
used.	 In	two	of	 the	homes,	 the	stock	 in	the	returns	bins	was	cross-referenced	
with	 the	 stock	 entered	 in	 the	 returns	 book	 and	 was	 found	 to	 be	 the	 same,	
validating	the	data	entry	in	the	returns	book.		
A	summary	of	the	data	collection	period	is	shown	in	Table	4.4	below.			
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Table	4.4	Summary	of	when	waste	data	was	collected.	
Care	Home	 Returns	book	analysed	 Stock	counts	made	 Number	of	days	remaining	in	
medicines	cycle	
3	 January	meds	cycle	 17/3/2015	 8	days	
4	 April	meds	cycle	 20/3/2015	 3	days	
6	 Not	available		 10/3/2015	 15	days	
8	 Not	available	 18/2/2015	 5	days	
9	 January	meds	cycle	 18/2/2015	 5	days	
11	 January	meds	cycle	 18/2/2015	 5	days	
14	 Not	available	 18/2/2015	 5	days	
	
4.3.4 Data	analysis	
The	 value	 of	 returned	 and	 overstock	 medicines	 was	 calculated	 from	 the	
generated	spreadsheets	based	on	the	cost	of	each	medicine	as	listed	in	the	British	
National	Formulary	(BNF	68).	To	do	this,	the	BNF	price	for	the	smallest	packet	
was	divided	by	the	pack	size	to	generate	the	cost	per	dosage	unit.	This	was	then	
multiplied	 by	 the	 number	 of	 dosage	 units	 that	 were	 either	 returned	 or	
overstocked	i.e.		
Cost	of	the	unused	medicines	=	Cost	per	unit	x	Quantity	unused	
(Ciullo	and	Shepherd.	1977).		
If	the	medicine	was	not	listed	in	the	BNF	or	there	was	no	price	associated	with	it	
(e.g.	Magnesium	Hydroxide,	Olive	Oil)	the	medicine	was	excluded.			
4.4 Results	
4.4.1 Quantifying	the	value	of	medicines	waste	from	overstock	
There	is	evidence	in	the	literature	that	medicines	are	stockpiled	‘just	in	case’	and	
therefore	returns	books	may	not	provide	a	full	picture	of	the	level	of	waste	 in	
care	homes.	 In	order	 to	better	 capture	 the	extent	of	medicines	waste	 in	 care	
homes,	the	value	of	medicines	stockpiled	(overstock)	was	estimated.	To	do	this,	
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a	copy	of	the	MAR	charts	for	all	residents	in	seven	care	homes	was	obtained.	At	
‘optimal	efficiency’,	there	would	be	no	overstock	and	the	stock	of	each	medicine	
would	be	exactly	 sufficient	 to	 last	 the	patient	until	 the	next	medication	cycle.	
Using	the	resident’	MAR	charts,	the	stock	needed	to	take	the	resident	to	the	next	
medicines	cycle	was	determined.	The	stock	of	each	of	the	resident’s	medicines	
was	then	counted	and	any	excess	was	deemed	to	be	overstock.	
Table	 4.5	 represents	 the	 value	 of	 overstock	 in	 the	 seven	 participating	 care	
homes.	As	can	be	seen,	the	total	value	of	overstock	was	£3119.95	which	equates	
to	£20.25	of	overstock	per	 resident	based	on	154	 residents.	 The	 range	 in	 the	
value	of	overstock	per	care	home	was	fairly	large	with	care	home	14	overstocking	
just	£4.74	of	medicines	and	care	home	11	overstocking	£774.05.	Of	course,	not	
all	the	care	homes	housed	the	same	number	of	residents	and	therefore	the	value	
of	 overstock	was	 normalised	 to	 resident	 number.	 Care	 home	 14	 still	 had	 the	
lowest	value	of	overstock	(£0.68	per	resident)	but	care	home	9	had	the	most	with	
£44.29	0f	overstock	per	resident.			
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Table	4.5	The	value	of	overstocked	medicines	in	each	of	the	seven	care	homes	studied.		The	
total	value	of	the	medicines	stockpiled	was	£3119.95.	This	equates	to	£20.25	of	overstocked	
medicines	per	resident	per	month	(based	on	154	residents).		
Care	home	
number	
Type	of	home	 Number	of	
residents	
Value	of	waste	from	
overstock	
Average	value	of	
overstock	per	resident	
3	 Nursing	 25	 £451.25	 £18.05	
4	 Nursing	 29	 £130.68	 £4.50	
6	 Nursing	 27	 £746.41	 £27.64	
8	 Residential	 24	 £304.25	 £12.65	
9	 Nursing	 16	 £708.57	 £44.29	
11	 Nursing	 26	 £774.05	 £29.77	
14	 Residential	 7	 £4.74	 £0.68	
	 Total	 154	 £3119.95	
(£20.25/resident)	
	
	
4.4.2 Value	of	medicines	wasted	by	BNF	category	
In	 order	 to	 understand	 the	 nature	 of	 the	 medicines	 waste	 generated,	 the	
medicines	 were	 categorised	 according	 to	 BNF	 chapter	 which	 essentially	
represents	the	body	system	in	which	the	medicine	acts.	As	can	be	seen	in	Table	
4.6,	medicines	acting	in	the	nervous	system	was	the	category	that	generated	the	
most	waste	(£832.34)	representing	~	27%	of	the	waste	generated.	Four	of	the	
13	categories	examined	each	contributed	more	 than	10%	of	 the	value	of	 the	
waste	generated	and	combined	they	accounted	for	more	than	70%	of	the	value	
of	the	waste	generated.	These	represented	medicines	that	act	on	the	GI	system	
(£605.19;	 19.40%),	 the	 cardiovascular	 system	 (£411.11;	 13.18%),	 the	nervous	
system	(£832.34;	26.68%)	and	medicines	used	in	infections	(£365.61;	11.72%).	
Very	little	waste	in	terms	of	value	(less	than	5%	of	the	total)	was	generated	by	
medicines	 acting	 on	 the	 genito-urinary	 system,	 medicines	 used	 for	 blood	
disorders	or	nutritional	issues,	medicines	used	for	musculo-skeletal	problems	or	
used	to	treat	eye	conditions.	No	waste	was	identified	for	medicines	used	to	treat	
immune	 and	 malignant	 disease,	 skin	 conditions	 or	 ear,	 nose	 and	 throat	
problems.		
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Table	4.6	Medicines	waste	identified	in	seven	care	homes	through	stock	counts,	categorised	by	
BNF	chapter.		Drugs	acting	on	the	nervous	system	represented	the	therapeutic	area	in	which	
the	most	waste	was	generated	(£832.34)	representing	27%	of	all	the	waste	generated.	
Medicines	acting	on	the	GI	system,	cardiovascular	system	nervous	system	and	medicines	used	
in	infection	represented	almost	71%	of	the	waste	generated.		
BNF	chapter	 Value	of	medicines	
overstocked	
Percentage	of	total	
waste	
1	Gastro-intestinal	system	 £605.19	 19.40	
2	Cardiovascular	system	 £411.11	 13.18	
3	Respiratory	system	 £264.22	 8.47	
4	Nervous	system	 £832.34	 26.68	
5	Infections	 £365.61	 11.72	
6	Endocrine	system	 £172.84	 5.54	
7	Genito-urinary	system	 £3.25	 0.10	
8	Immune	system	and	malignant	disease	 ---	 ---	
9	Blood	and	nutrition	 £119.60	 3.83	
10	Musculoskeletal	system	 £40.50	 1.30	
11	Eye	 £58.71	 1.88	
12	Ear,	nose	and	oropharynx	 ---	 ---	
13	Skin	 ---	 ---	
Other	(e.g.	nutritional	supplements,	
nebules	etc)	
246.58	 7.90	
Total	 £3,119.95	 	
A	 breakdown	 of	 the	 individual	 medicines	 that	 were	 wasted	 in	 the	 four	
therapeutic	 areas	 where	 waste	 was	 highest	 (i.e.	 GI	 system,	 cardiovascular	
system,	nervous	system	and	medicines	used	to	treat	infections)	is	shown	in	Table	
4.7.	 As	 can	 be	 seen	 laxatives	 (£572.70)	 and	 paracetamol	 containing	 products	
(£253.67)	are	the	largest	contributors	to	the	total	value	of	waste	accumulated	
followed	closely	by	memantine	and	furosemide.	Unlike	memantine	which	has	a	
relatively	 high	 price	 (unit	 pack	 cost	 of	 £12.71),	 paracetamol,	 laxatives	 and		
furosemide	are	all	inexpensive	(unit	pack	costs	less	than	£10)	indicating	that	the	
volume	of	waste	associated	with	these	drugs	is	high.	Rifaximin	has	a	particularly	
high	unit	pack	cost	 (£259.23)	which	explains	why	 it	contributes	significantly	 in	
terms	of	waste	even	though	the	quantity	wasted	was	small	(39	tablets)	
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Table	4.7	A	breakdown	of	the	value	of	waste	medicines	in	the	four	therapeutic	areas	identified	
to	have	the	highest	value	of	waste	medicines.	Medicines	that	contributed	 less	than	1%	of	the	
total	 value	of	 the	waste	are	not	 included.	 It	 can	be	 seen	 that	a	number	of	 these	medicines	 /	
medicines	classes	are	PIPs.			
BNF	therapeutic	
category	
Individual	medications	 Value	of	medicine	 Percentage	of	total	
waste	
Nervous	System	–	total	waste	=	£832.34	
Non-opioid	
analgesics	
Paracetamol	 £219.67	 26	
Opioid	analgesics	 Co-codamol	 £34	 4	
Anxiolytics	 Diazepam	 £15.98	 2	
Lorazepam	 £26.81	 3	
Antipsychotics	 Amisulpride	 £21.18	 3	
Zuclopenthixol	 £9.96	 1	
Promazine	 £62.62	 8	
Pericyazine	 £111.66	 13	
Trifluperazine	 £10.85	 1	
Control	of	
epilepsies	
Sodium	valproate	 £27.46	 3	
Dementia	 Memantine	 £226.97	 27	
Anti-Parkinsonian	 Madopar	 £13.68	 2	
	
Gastrointestinal	System	–	total	waste	=	£609.19	
Laxatives	 Lactulose	 £201.83	 33	
	 Macrogol	 £99.55	 16	
	 Senna	 £237.43	 39	
	 Movicol	 £33.89	 6	
PPIs	 Omeprazole	 £16.23	 3	
	
Cardiovascular	system	–	total	waste	=	£411.11	
Beta-blocker	 Bisoprolol	 £33.79	 8	
ACIs	 Lisinopril	 £10.69	 3	
	 Ramipril	 £8.79	 2	
AIIRA	 Losartan	 £75	 18	
Cardiac	glycoside	 Digoxin	 £15.81	 4	
Diuretics	 Furosemide	 £204.23	 50	
	 Budesonide	 £25.45	 6	
Lipid	lowering	
agent	
Simvastatin	 £21.75	 5	
Calcium	channel	
blocker	
Tildiem	 £5.15	 1	
Antiplatelet	 Dipyridamole	 £8.05	 2	
	
Medicines	used	in	infection	–	total	waste	=	£365.61	
Bacterial	
infections	
Rifaximin	 £180.53	 49	
	 Nitrofurantoin	 £183.28	 50	
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4.4.3 Stratification	of	medicines	waste	by	the	cost	of	a	pack.			
One	argument	that	is	often	made	about	waste	medicines	is	that	it	is	largely	as	a	
consequence	of	a	small	volume	of	waste	associated	with	high	cost	medicines	i.e.	
the	 unit	 cost	 per	 pack	 is	 high.	 To	 address	 this,	 the	 value	 of	 the	 overstocked	
medicines	was	stratified	according	to	the	unit	cost	of	a	medicines	pack	(see	Table	
4.8).	The	price	bands	used	were	the	same	as	those	used	in	the	York	medicines	
study	(York	Health	Economics	Consort	and	The	School	of	Pharmacy	2010).	As	can	
be	seen	in	Table	4.8,	the	majority	of	the	medicines	wasted	(82.5%)	had	unit	pack	
costs	that	were	less	than	£10	per	pack.	This	 indicates	that	most	of	the	wasted	
medicines	 were	 relatively	 inexpensive	 and	 there	 were	 few	 instances	 of	
medications	with	a	relatively	high	unit	pack	cost	of	over	£50	being	wasted	(5.5%	
of	all	waste).	Of	course,	even	with	a	low	incidence	of	medicines	with	a	high	unit	
pack	 cost	 being	 wasted,	 if	 sufficient	 volume	 is	 wasted,	 this	 may	
disproportionately	 impact	 on	 the	 total	 value	 of	 the	waste.	 As	 can	 be	 seen	 in	
Tables	4.8	medicines	with	unit	pack	costs	of	less	than	£10	contributed	most	to	
the	overall	value	of	the	medicines	wasted	(£1,424.96;	~	46%)	and	medicines	with	
a	unit	pack	cost	of	 less	than	£50,	accounted	for	almost	80%	of	the	total	value	
(£2,472.22).	 	Medicines	with	high	unit	pack	costs	 (£50	or	greater),	meanwhile	
accounted	for	approximately	20%	of	the	value	of	the	waste	generated	(£647.73).		
Table	 4.8	Medicines	waste	 as	 overstock	 from	 seven	 care	 homes	 stratified	 by	 the	 cost	 of	 the	
medicines	pack.	The	majority	of	the	medicines	wasted	(82.5%)	had	pack	costs	of	less	than	£10.	
Very	few	(1.5%)	of	the	medicines	wasted	were	expensive	medicines	(£100+)		
Cost	of	
pack	
Frequency	of	medicines	
overstocked	
Percentage	
(1.dp)	
Value	 Percentage	of	total	
value	
£0	<10	 165	 82.5%	 £1,424.96	 45.67%	
£10-25	 17	 8.5%	 £658.61	 21.11%	
£25-50	 7	 3.5%	 £388.65	 12.46%	
£50-100	 8	 4%	 £304.00	 9.74%	
£100+	 3	 1.5%	 £343.73	 11.02%	
Total	 200	 	 £3,119.95	 	
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4.4.4 The	highest	quantities	of	medicines	wasted	in	care	homes		
In	order	to	further	characterise	the	waste	medicines	generated	in	care	homes,	
the	 highest	 quantities	 of	 wasted	 medicines	 (in	 terms	 of	 dosage	 units)	 was	
examined	in	each	of	the	seven	care	homes;	the	data	is	presented	in	Table	4.9.	
As	 can	 be	 seen,	 in	 some	 care	 homes	 (4,	 8,	 9,	 11)	 there	 were	 examples	 of	
medicines	 where	 there	 were	 more	 than	 1,000	 dosage	 units	 overstocked	
although	in	terms	of	value	these	did	not	exceed	£100	of	waste.	Paracetamol	was	
particularly	 over	 represented	 in	 the	 data	 featuring	 in	 the	 top	 five	medicines	
wasted	in	all	seven	care	homes	and	indeed	was	in	first	place	in	six	of	the	seven	
homes,	narrowly	beaten	into	third	place	by	ADCAL-D3	and	Pericyazine	in	care	
home	3.	In	total,	across	the	seven	homes	there	were	6,363	paracetamol	tablets	
overstocked,	all	prescribed	on	a	named	patient	basis.	Analgesics	on	the	whole	
were	over	represented	in	the	sample	with	compound	preparations	of	codeine	
and	paracetamol	also	featuring	in	the	top	five	wasted	medicines	in	three	of	the	
homes.	 Perhaps	 as	 a	 consequence,	 the	 quantity	 of	 waste	 associated	 with	
laxatives	(senna,	macrogol,	laxido	and	movicol)	was	also	high	and	featured	in	the	
top	five	wasted	medicines	in	five	of	the	seven	homes.	Similarly,	benzodiazepines	
(diazepam	and	lorazepam)	appeared	with	a	reasonably	high	frequency	in	three	
of	 the	 seven	 homes.	 It	 is	 worth	 highlighting	 that	 analgesics,	 laxatives	 and	
benzodiazepines	are	normally	prescribed	on	a	when	required	basis.	A	surprising	
finding	was	 that	 in	 two	of	 the	care	homes,	medicines	 for	Alzheimer’s	disease	
featured	in	the	top	five	wasted	medicines.		
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Table	4.9	The	top	five	medicines	with	the	highest	quantities	wasted	and	their	total	cost	in	seven	
care	homes.	Waste	paracetamol	 featured	 in	 the	 top	 five	 in	all	 care	homes	and	was	 the	most	
wasted	medicine	in	six	of	the	homes.		
Medication	 Total	quantity	wasted	 Value	(£)		
Care	home	3	
ADCAL-D3	1500mg/400-unit	eff.	tab.	 122	 £13.05	
Pericyazine	2.5mg	tab.	 110	 £20.39	
Paracetamol	500mg	tab	 84	 £2.68	
ADCAL-D3	1.5g/Colecalciferol	10mcg	tab.	 83	 £5.41	
Lorazepam	1mg	tab.	 43	 £4.05	
Care	home	4	
Paracetamol	500mg	tab	 1,057	 £47.03	
Co-Codamol	8/500mg	effervescent	tab.	 179	 £7.11	
Macrogol	compound	oral	powder	 87	 £25.72	
Senna	7.5mg	tab.	 74	 £8.78	
Folic	acid	400mcg	tab.	 53	 £1.60	
Care	home	6	
Paracetamol	500mg	tab	 882	 £28.14	
ADCAL-D3	chewable	tab.	 265	 £28.35	
Zapain	30mg/500mg	tab.	 200	 £9.34	
Co-Codamol	8mg/500mg	tab.	 148	 £5.88	
Movicol	oral	powder	sachets	 117	 £26.04	
Care	home	8	
Paracetamol	500mg	tab	 1,084	 £34.58	
Madopar	125mg	cap.	 198	 £13.68	
Movicol	oral	powder	sachets	 123	 £27.39	
Laxido	orange	oral	powder	sachets	 89	 £26.31	
Donepezil	5mg	tab.	 87	 £7.78	
Care	home	9	
Paracetamol	500mg	tab	 1,116	 £35.60	
Memantine	20mg	tab.	 486	 £220.61	
Sodium	valproate	200mg	tab.	 283	 £12.51	
ADCAL-D3	chewable	tab	 246	 £26.31	
Senna	7.5mg	tab.	 236	 £28.01	
Care	home	11	
Paracetamol	500mg	tab	 2,043	 £65.17	
Co-Codamol	30/500mg	tab.	 388	 £18.12	
Laxido	orange	oral	powder	sachets	 223	 £65.93	
Diazepam	2mg	tab	 188	 £6.45	
Lorazepam	1mg	tab.	 148	 £13.75	
Care	home	14*	
Paracetamol	500mg	tab	 97	 £3.09	
Diazepam	2mg	tab	 48	 £1.65	
*	care	home	14	was	a	small	home	(7	residents)	and	the	level	of	waste	was	small	hence	there	
are	only	two	medicines	listed	here.		
4.4.5 Wasted	medicines	with	the	highest	cost	
In	 addition	 to	 examining	 the	 medicines	 that	 were	 wasted	 in	 the	 highest	
quantities,	 the	 medicines	 contributing	 the	 highest	 costs	 were	 also	 explored.	
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Table	4.10	shows	the	top	five	waste	medicines	with	the	highest	costs	in	each	of	
the	seven	care	homes	examined.	Much	like	the	medicines	wasted	in	the	highest	
quantity	 (Table	 4.9),	 paracetamol	 and	 laxatives	 are	 over	 represented	 with	
paracetamol	featuring	in	the	top	five	in	six	care	homes	and	laxatives	featuring	in	
four.	 Beyond	 this,	 there	 is	 little	 commonality	 between	 care	 homes.	 In	 some	
homes,	the	most	costly	wasted	medicine	was	from	a	single	resident	(care	homes	
3,	6,	8)	whilst	for	other	homes,	the	most	costly	wasted	medicine	was	due	to	an	
accumulation	of	waste	from	a	number	of	residents.	Of	note,	with	the	exception	
of	care	home	11,	these	top	five	medicines	accounted	for	more	than	two	thirds	of	
the	 total	 value	 of	medicines	wasted;	 for	 care	 home	 11	 it	 was	 57%	 (data	 not	
shown).		
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Table	4.10	The	top	five	wasted	medicines	with	the	highest	cost	in	seven	care	homes.		
Medication	 Cost	of	waste	 Percentage	of	
total	waste	
No	of	
residents		
Quantity	wasted		
Care	home	3	–	total	waste	=	£451.25	
Levothyroxine	 £139.00		 30.80	 1	 180ml	
Furosemide	 £100.02	 22.17	 2	 480ml	
Losartan	 £51.00	 11.30	 1	 190ml	
Terbutaline	 £47.89	 10.61	 1	 692	doses	
Pericyazine	 £20.39	 4.52	 2	 (93	tab.+	17.5ml)	
Care	home	4	–	total	waste	=	£130.68	
Paracetamol		 £47.03	 35.99	 13	 1,057	tab.	
Macrogol	powder	 £25.73	 19.69	 3	 87	sachets	
Laxido	sachets	 £12.42	 9.50	 2	 42	sachets	
Senna	 £8.78	 6.72	 2	 74	tab.	
Co-codamol	 £7.11	 5.44	 3	 179	tab.	
Care	home	6	–	total	waste	=	£746.41	
Rifaximin	 £180.53	 24.19	 1	 39	tab.	
Nitrofurantoin	 £163.19	 21.86	 1	 250ml	
Pericyazine	 £91.27	 12.23	 2	 (95tab.+173.75ml)	
Paracetamol	 £33.65	 4.51	 14	 (898	tab.+670ml)	
Symbicort	 £31.66	 4.24	 1	 50	doses	
Care	home	8	–	total	waste	=	£304.25	
Symbicort	Inhaler	 £90.75	 29.83	 1	 330	doses	
Promazine	 £59.75	 19.64	 1	 755ml	
Paracetamol	 £46.03	 15.13	 20	 (1143tab.+1160ml)	
Laxido	sachets		 £43.29	 14.23	 3	 89	sachets	
Movicol		 £27.38	 9.00	 4	 123	sachets	
Care	home	9	–	total	waste	=	£708.57	
Memantine	tab.	 £220.65	 31.14	 4	 486	tab.	
Senna	 £170.41	 24.05	 5	 (236	tab.+1200ml)	
Fostair	Inhaler	 £85.52	 12.07	 1	 350	doses	
Paracetamol	 £37.65	 5.31	 7	 1178	tab.	
Stronium	sachets	 £30.95	 4.37	 1	 32	sachets	
Care	home	11	–	total	waste	=	£774.05	
Complan	shake		 £179.27	 23.16	 2	 122	sachets	
Seretide	Inhaler	 £114.00	 14.73	 1	 230	doses	
Paracetamol	 £72.44	 9.36	 15	 (2,043tab.+580ml)	
Laxido	sachets	 £65.94	 8.52	 4	 223	sachets	
Saline	2.5ml	 £58.71	 1.91	 1	 57	doses	
Care	home	14	–	total	waste	=	£4.74	
Paracetamol		 £3.09	 65.19	 2	 	 97	tab.	
Diazepam	2mg	tab	 £1.65	 34.81	 1	 48 tab.	
	
4.4.6 Medicines	 wasted	 characterised	 by	 whether	 the	 medicine	 was	
prescribed	with	regular	or	when	required	dosing	
The	findings	highlighted	in	Tables	4.9	and	4.10	suggested	that	wasted	medicines	
with	 ‘when	 required’	 dosage	 instructions	were	 over	 represented	 in	 the	 data	
(paracetamol,	laxatives	etc.).	Therefore,	the	cost	of	waste	medicines	in	each	of	
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the	homes	was	categorised	according	to	whether	the	dosage	instructions	were	
when	required	or	regular.	Table	4.11	details	this	categorisation.	The	table	shows	
that	the		waste	is	actually	reasonably	skewed	towards	regular	medicines	with	
the	cost	of	wasted	‘when	required’	medicines	greater	than	regular	medicines	in	
one	 care	 homes	 (care	 home	 11),	 in	 five	 care	 homes	 regular	 medicines	
contributed	more	to	the	total	waste	(care	homes	3,	6,	9	and	14)	whilst	in	one	
care	home	it	was	evenly	split	(care	home	8).	This	tendency	in	the	data	towards	
regular	 medicines	 contributing	 more	 towards	 the	 total	 value	 of	 wasted	
medicines	may	simply	be	as	a	consequence	of	prescribing	which	tends	towards	
medicines	with	regular	dosing	regimens	(see	Chapter	2).	It	may	also	reflect	that	
some	medicines	that	are	used	on	a	when	required	basis	(e.g.	paracetamol	and	
laxatives)	are	prescribed	on	a	regular	basis.		
Table	 4.11	 Value	 of	 waste	 associated	 with	 regular	 medications	 versus	 PRN	medications	 per	
month.	The	cost	of	wasted	‘when	required’	medicines	was	greater	than	regular	medicines	(care	
homes	11),	in	four	care	homes	regular	medicines	contributed	more	to	the	total	waste	(care	homes	
3,	4,	6,	9	and	14)	whilst	in	one	care	home	it	was	evenly	split	(care	home	8)	
Care	home		 Value	of	waste	
regular	medicines	
Value	of	waste	PRN	
medicines	
Contribution	of	
PRN	meds	to	total		
Total	waste	
3	 £427.01	 £24.24	 5.37%	 £451.25	
4	 £100.32	 £30.36	 23.23%	 £130.68	
6	 £434.36	 £312.04	 41.81%	 £746.40	
8	 £152.53	 £151.72	 49.87%	 £304.25	
9	 £533.83	 £174.74																																																		24.66%	 £708.57	
11	 £247.00	 £527.05	 68.09%	 £774.05	
14	 £3.88	 £0.86	 18.14%	 £4.74	
	
4.4.7 Quantifying	the	value	of	medicines	waste	from	return	books		
The	medicines	returns	record	book	from	four	care	homes	was	reviewed	following	
the	end	of	the	preceding	month’s	28-day	medicines	cycle	(January	or	April	2015).	
The	value	of	each	of	the	medicines	in	the	returns	book	was	then	calculated	and	
summed	in	order	to	determine	the	total	value	of	medicines	returned	(see	Table	
4.12).	 The	 total	 value	 of	 the	 medicines	 returned	 from	 the	 four	 homes	 was	
£1780.64	 which	 equates	 to	 £18.54	 returned	 per	 month	 for	 each	 of	 the	 96	
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residents	 in	 the	 homes.	 This	 is	 remarkably	 similar	 to	 the	 estimated	 cost	 of	
medicines	 wasted	 using	 an	 audit	 of	 the	 overstock	 in	 the	 homes	 (£20.05	 per	
resident).	The	range	in	the	value	of	returned	medicines	was	from	£41.26	(care	
home	 4)	 to	 £792.53	 (care	 home	 11)	 with	 an	 average	 of	 £445.16	 (±	 £327.95)	
returned	 per	 home.	 In	 order	 to	 account	 for	 the	 difference	 in	 the	 number	 of	
residents	in	each	home,	the	average	value	of	returned	medicines	per	resident	in	
each	of	the	homes	was	calculated.	The	average	value	ranged	from	£1.42	(care	
home	4)	to	£42.63	(care	home	9)	demonstrating	significant	variability	across	the	
homes.		
Table	4.12	The	value	of	medicines	returned	over	a	1-month	period	from	four	care	homes.	The	
total	value	of	medicines	returned	was	£1780.64.	This	equates	to	£18.54	of	returned	medicines	
per	resident	per	month	(based	on	96	residents).		
Care	home		 Type	of	home	 Number	of	
residents	
Value	of	waste	from	
returns	book	
Average	value	of	
return	per	resident	
3	 Nursing	 25	 £336.96	 £13.49	
4	 Nursing	 29	 £41.26	 £1.42	
9	 Nursing	 16	 £609.89	 £42.63	
11	 Nursing	 26	 £792.53	 £27.25	
	 Total	 96	 £1,780.64	
(£18.54/resident)	
	
	
4.4 Discussion	
There	 have	 been	 numerous	 debates	 in	 the	 literature	 on	 the	 definitions	 of	
medicines	waste	and	at	what	point	 it	occurs.	Does	 it	occur	for	example	at	the	
point	 it	 is	 returned	to	a	pharmacy	or	when	 it	 is	destroyed	by	a	medical	waste	
contractor	 or	 does	 that	 fail	 to	 capture	 medicines	 that	 are	 destroyed	
inappropriately	 by	 individuals	 in	 their	 own	 homes	 or	 by	 staff	 in	 a	 healthcare	
setting.		Similarly,	the	literature	suggests	that	patients	and	staff	have	a	tendency	
to	stockpile	medicines	unnecessarily,	presumably	for	‘just	in	case’	scenarios	or	to	
be	 returned	 or	 destroyed	 at	 some	 point	 in	 the	 future.	 Together,	 these	
considerations	make	the	accurate	measurement	of	waste	challenging	and	most	
studies	 recognise	 any	 approach	 to	be	 an	estimate	of	 the	waste	 rather	 than	 a	
definitive	value.	Given	the	pathways	for	waste	(returned	to	an	organisation	that	
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will	dispose	of	 the	medicine(s),	destruction	at	home,	stockpiled	etc)	 it	 is	 likely	
that	methods	to	establish	waste	will	underestimate	the	total	level.		In	the	care	
home	setting,	there	is	an	expectation	that	any	medicines	prescribed	on	a	named	
patient	basis	(i.e.	not	ward	stock)	that	are	unused	at	the	end	of	a	medicines	cycle	
are	returned	to	the	supplying	pharmacy	(in	the	case	of	a	residential	home)	or	to	
a	specialist	waste	disposal	contractor	(in	the	case	of	a	nursing	home).	However,	
where	processes	are	not	robust	or	there	is	a	culture	of	stockpiling,	then	returns	
records	may	not	be	reliable.	As	a	consequence,	 it	 is	useful	 to	undertake	stock	
audits	to	understand	if	medicines	are	being	kept	in	the	home	inappropriately	in	
addition	 to	 those	medicines	 that	 are	 being	 returned.	 In	 this	 study	 then,	 two	
methods	were	used	to	determine	the	scale	of	waste.	In	one	part	of	the	study,	the	
stock	of	medicines	that	the	care	home	was	holding	for	it’s	residents	was	counted	
towards	the	end	of	a	medicines	cycle.	The	expected	quantity	of	each	medicine	
remaining	 (based	 on	 the	MAR	 chart)	was	 subtracted	 from	 the	 count	 and	 any	
remaining	 medicines	 for	 the	 resident	 was	 termed	 overstock.	 The	 medicines	
returns	 books	 from	 four	 homes	 were	 also	 analysed	 to	 calculate	 the	 value	 of	
medicines	returned	at	the	end	of	a	medicines	cycle.	Ideally,	it	would	have	been	
possible	 to	 gather	 returns	 books	 and	 stock	 counts	 in	 the	 same	 month	 to	
understand	if	all	the	medicines	that	were	unused	during	the	month	were	indeed	
returned	but	this	was	not	possible.	
It	is	worth	reflecting	on	some	observations	that	were	made	during	visits	to	the	
homes	to	count	their	stock.	In	most	homes	visited,	the	organisation	of	stock	was	
reasonably	poor.	As	was	seen	in	Chapter	3,	many	care	homes	had	a	significant	
volume	 of	 stock	 errors	 related	 to	 their	 MAR	 charts	 including	 no	 records	 of	
quantity	received,	no	signature	to	 indicate	receipt	of	stock	etc.	These	types	of	
issues	were	borne	out	on	visits	to	the	home.	Typically,	the	resident’s	medicines	
should	be	kept	in	a	medicines	trolley	in	a	secure	location	arranged	according	to	
the	 resident’s	 name.	 However,	 in	 some	 homes,	 there	 was	 evidence	 of	
medications	 that	were	no	 longer	being	taken	by	the	resident,	shelves	 labelled	
with	one	patient’s	name	contained	medicines	for	another	individual,	there	were	
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medicines	for	residents	that	no	longer	resided	in	the	home,	medicines	stored	in	
communal	areas	such	as	the	kitchen	and	in	some	homes	non-medicinal	products	
(food	and	hair	dye)	were	stored	alongside	medicines.	In	some	care	homes,	it	was	
apparent	 that	 there	 was	 a	 significant	 volume	 of	 excess	 stock	 and	 that	 some	
homes	did	not	operate	a	robust	returns	process	as	the	returns	books	were	not	
available	or	accessible.		
However,	four	returns	books	(from	the	seven	care	homes	that	participated)	were	
available.	A	calculation	of	the	medicines	returned	at	the	end	of	a	medicines	cycle	
revealed	an	estimated	waste	medicines	bill	 of	 £18.54	per	 resident	per	month	
(£1780.64	 total	 waste	 for	 96	 patients).	 	 In	Wales,	 there	 are	 estimated	 to	 be	
approximately	26,000	care	home	beds	(Statistics	for	Wales	2017).	With	a	monthly	
waste	medicines	bill	estimated	to	be	£18.54	per	resident	in	this	small	sample	of	
care	homes,	this	extrapolates	to	an	annual	medicines	waste	bill	of	around	£5.8	
million	in	Wales.	Across	the	UK	there	are	estimated	to	be	approximately	410,000	
beds	(Iliffe	et	al.	2016)	which	similarly	extrapolates	to	approximately	£90	million	
of	medicines	waste.	According	to	research	undertaken	in	2009,	it	was	estimated	
that	the	annual	cost	of	waste	medicines	was	£300	million	in	England	only	(York	
Health	Economics	Consort	and	The	School	of	Pharmacy	2010).	Of	this,	16%	or	~	
£50	million	was	related	to	medicines	returned	to	pharmacies	by	care	homes	(York	
Health	Economics	Consort	and	The	School	of	Pharmacy	2010).	This	 is	 likely	 to	
underestimate	the	total	value	of	waste	medicines	from	care	homes	because	the	
study	 methodology	 only	 captured	 medicines	 returned	 to	 a	 pharmacy	 from	
residential	 homes	 and	 did	 not	 account	 for	 the	 fact	 that	 nursing	 homes	 use	
specialist	waste	contractors	for	the	return	of	their	medicines.	Similarly,	year	on	
year	inflation	costs	and	increases	in	the	number	of	items	prescribed	per	annum	
(grown	on	average	by	5%	per	annum)	along	with	a	growing	older	adult	population	
may	 also	 be	 expected	 to	 increase	 the	 volume	 of	medicines	waste	 generated.		
Nevertheless,	the	findings	in	this	current	study	of	returned	medicines	are	broadly	
in	line	with	the	literature	caveated	by	the	fact	that	the	analysis	represents	a	small	
sample.		
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In	addition	to	analysing	returns	books,	seven	care	homes	were	visited	and	the	
medicines	stock	was	counted.	Only	medicines	that	were	prescribed	on	a	named	
patient	basis	were	 included	 in	 the	 count	 i.e.	no	 ‘ward	 stock’	was	 counted.	 To	
assess	the	‘over	stock’	of	medicines,	the	current	MAR	charts	were	collected	and	
the	number	of	dosage	units	needed	to	meet	the	prescriber’s	intentions	until	the	
end	of	the	current	medicines	cycle	was	calculated.	Whilst	the	time	to	the	end	of	
the	medicines	cycle	was	not	identical,	all	stock	counts	were	in	the	second	half	of	
the	medicines	cycle.	The	number	of	dosage	units	 required	was	then	deducted	
from	the	total	medicines	count	to	determine	the	over	stock.	Whilst	this	approach	
also	has	its	limitations	(more	waste	could	be	generated	between	the	count	and	
the	 end	 of	 the	medicines	 cycle),	 it	 better	 captures	 the	 totality	 of	 the	wasted	
medicines	because	it	accounts	for	any	stock	piling.	The	actual	value	of	the	waste	
counted	was	in	good	agreement	with	the	returns	book	with	£20.25	of	medicines	
waste	per	 resident	 (£3119.95	of	waste	 for	154	 residents).	 In	each	of	 the	 care	
homes	studied,	the	researcher	confirmed	that	medicines	had	been	returned	at	
the	 end	 of	 the	 previous	medicines	 cycle	 and	 therefore	 the	 accumulated	 over	
stock	 is	 likely	 to	 be	 close	 to	 the	 monthly	 waste	 generated	 including	 some	
stockpiling	from	previous	medicines	cycle.		Extrapolating	to	the	number	of	beds	
in	Wales	this	would	generate	an	annual	medicines	waste	bill	of	approximately	
£6.3M	and	across	the	UK	a	bill	of	£100M.		
In	 line	with	 other	 studies,	 the	majority	 of	medicines	wasted	were	 reasonably	
inexpensive	with	82.5%	of	the	waste	having	a	unit	cost	that	was	less	than	£10.		
For	example,	in	the	seminal	York	study	(York	Health	Economics	Consort	and	The	
School	 of	 Pharmacy	 2010),	 72.96%	 of	 all	 waste	 medicines	 were	 in	 this	 cost	
banding	and	in	a	study	in	425	nursing	homes	in	the	US	approximately	83%	of	all	
unused	medicines	had	a	unit	cost	of	$1	or	more	(Bazalo	and	Weiss	2011).	Whilst	
the	volume	of	waste	generated	tends	towards	the	less	expensive	medicines,	it	is	
also	important	to	determine	if	these	medicines	contribute	extensively	to	the	total	
value	of	medicines	wasted	or	whether	a	small	volume	of	expensive	medicines	
overshadows	those	that	are	less	expensive.	The	data	showed	that	approximately	
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80%	of	the	value	of	medicines	wasted	(£2472.22	of	£3119.95)	was	accounted	for	
by	medicines	that	cost	less	than	£50	per	pack.	In	contrast,	medicines	with	unit	
cost	of	greater	than	£100	accounted	for	just	11%	of	the	value	of	waste	medicines.	
Nevertheless,	there	are	thought	to	be	a	number	of	prescribing	practices	that	can	
lead	 to	 high	 value	 waste.	 The	 first	 is	 the	 supply	 of	 three	 months	 worth	 of	
medicines	which	would	 result	 in	 significant	waste	 if	 there	 is	 any	 change	 to	 a	
resident’s	medicines	regimen	during	the	period	and	the	prescribing	of	‘specials’	
where	a	specialist	formulation	manufacturer	are	individually	made	for	a	resident.	
Of	course,	there	are	instances	where	such	specials	are	appropriate	but	in	other	
cases	it	is	not	(e.g.	500ml	of	500mg/5ml	paracetamol	special	=	£250	vs	1000ml	of	
250mg/5ml	paracetamol	standard	=	£7.32)	(York	Health	Economics	Consort	and	
The	School	of	Pharmacy	2010)	.		
The	 most	 commonly	 wasted	 medicines	 in	 this	 study	 were	 paracetamol	 (and	
associated	 compound	 preparations)	 and	 laxatives	 (particularly	 senna	 and	
lactulose)	accounting	for	£826.37	(~	27%)	of	the	value	of	wasted	medicines.	In	
terms	of	paracetamol,	this	finding	is	consistent	with	a	number	of	other	studies	
that	have	sought	to	evaluate	medicines	waste	in	an	individual’s	home	(Wingard	
et	al.	2005),	returned	to	a	community	pharmacy	(Ekedahl	et	al.	2003;	Mackridge	
and	Marriott	2007;	James	et	al.	2009;		Health	and	Social	Care	Information	Centre	
2013;	York	Health	Economics	Consort	and	The	School	of	Pharmacy	2010)	and	in	
care	homes	(Ciullo	and	Shepherd	1977;		York	Health	Economics	Consort	and	The	
School	 of	 Pharmacy	 2010;	Herefordshire	 Clinical	 Commissioning	Group	 2015).		
The	same	is	true	of	 laxatives	 in	the	care	home	setting	(York	Health	Economics	
Consort	 and	 The	 School	 of	 Pharmacy	 2010).	 For	 example,	 paracetamol	 and	
paracetamol	containing	preparations	accounted	for	14.4%	of	all	medicines	waste	
in	the	York	study	and	laxatives	accounted	for	15.5%.	In	total,	these	two	groups	
accounted	 for	 ~	 30%	 of	 the	 medicines	 waste	 identified	 which	 is	 remarkably	
similar	 to	 the	 findings	 in	 this	 study	 (27%).	Of	 note,	many	 of	 the	 paracetamol	
containing	compound	preparations	also	include	an	opiate	which	in	turn	causes	
constipation	which	may	be	driving	the	prescribing	of	laxatives	in	some	instances.	
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Ultimately,	there	is	a	culture	of	prescribing	analgesics	and	laxatives	for	extended	
durations	when	 they	 are	 only	 required	 to	manage	 acute	 issues	 	 (York	 Health	
Economics	Consort	and	The	School	of	Pharmacy	2010).		
One	 common	 feature	 of	 laxatives	 and	paracetamol	 containing	 preparations	 is	
that	they	are	both	commonly	prescribed	on	an	‘as	required’	(PRN)	basis.	They	are	
then	sporadically	 required	by	 the	 residents	during	a	medicines	cycle,	but	care	
home	 staff	 continue	 to	 automatically	 order	 them	 even	 when	 there	 is	 excess	
(Aaen	2017;	Birchall	2016;	Darracott	and	Johnstone	2012).	Indeed,	in	an	earlier	
study	by	Howard	and	Strong	nearly	20%	of	the	cost	of	waste	medicines	analysed	
over	a	four-year	period	in	a	100-bed	nursing	was	related	to	PRN	medications.	In	
this	 current	 study,	 in	 all	 but	 one	 home,	 regular	medicines	 accounted	 for	 the	
majority	of	the	value	of	the	waste	generated.	Nevertheless,	their	contribution	to	
the	value	of	waste	medicines	exceeds	their	prescribing	prevalence	(see	Chapter	
2).				
The	 reasons	 that	medicines	 are	wasted	 should	be	documented	as	part	 of	 the	
returns	procedure.	However,	in	the	four	returns	books	that	were	analysed,	the	
documentation	was	sketchy	at	best	and	the	reasons	for	returns	were	either	listed	
as	a	patient	refusal	or	were	left	blank.	The	researcher	could	not	be	certain	of	the	
veracity	of	the	data	and	therefore	it	is	not	included	here.	Perhaps	what	is	worth	
highlighting	however	is	how	medicines	waste	may	be	generated	in	the	care	home	
setting.		Medicines	are	ordered	by	the	care	home	towards	the	latter	part	of	the	
medicines	cycle	and	the	medicines	are	then	delivered	to	the	care	home	by	the	
supplying	pharmacy	prior	to	the	start	of	the	next	medicines	cycle.	Waste	occurs	
when	the	rate	at	which	medicines	are	supplied	exceeds	the	rate	at	which	they	
are	 taken	by	 residents.	This	generally	has	 two	causes:	 (i)	 there	 is	 a	 significant	
patient	 event	during	 the	medicines	 cycle	 such	as	 a	death,	 hospital	 admission,	
change	in	a	medicine(s)	or	the	patient’s	condition	changes	to	the	extent	that	they	
cannot	 or	 refuse	 to	 take	 their	 medicine(s);	 (ii)	 repeat	 medicines	 are	 ordered	
irrespective	of	patient	need	i.e.	there	is	a	breakdown	in	the	relationship	between	
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patient	 consumption	 and	 repeat	 ordering.	 The	 first	 cause	 is	 reasonably	
intractable	 and	 probably	 represents	 a	 source	 of	 waste	 that	 is	 not	modifiable	
(unless	the	particular	issue	is	caused	by	inappropriate	prescribing,	polypharmacy	
or	the	patient	refuses	their	medicine(s)	due	to	lack	of	knowledge	or	the	exhibition	
of	adverse	drug	effects).	However,	the	second	cause	can	be	targeted	to	reduce	
medicines	waste.		It	might	be	difficult	to	identify	the	underlying	issues	that	result	
in	 the	 over	 ordering	 of	 medicines	 because	 responsibility	 should	 be	 shared	
between	care	home	staff	and	other	stakeholders	who	involved	in	the	supply	of	
medicines	(Bristol	Clinical	Commissioning	Group	2016).	Whilst	care	home	staff	
should	manually	review	the	medicines	on	the	MAR	charts	for	each	resident	and	
examine	 the	 stock	before	 requesting	 the	new	monthly	 cycle,	 it	would	also	be	
appropriate	that	members	of	the	pharmacy	team	challenge	the	order	where	it	is	
evident	that	medicines	are	reordered	ad	infinitum.		
In	 the	 literature,	 a	 number	 of	 interventions	 have	 been	 suggested	 to	 reduce	
medicines	waste	 in	 care	homes	 (Roberts	 et	 al.	 2001;	Crotty	 2007;	 Koria	 et	 al.	
2018).	One	of	the	primary	mechanisms	is	through	the	use	of	regular	medicines	
reviews.	NICE	defines	medication	review	as:	“a	structured,	critical	examination	of	
a	 person’s	 medicines	 with	 the	 objective	 of	 reaching	 an	 agreement	 with	 the	
person	 about	 treatment,	 optimising	 the	 impact	 of	 medicines,	 minimising	 the	
number	of	medicationrelated	problems	and	reducing	waste”	(NICE	2015).	Such	
reviews	(undertaken	by	a	GP	or	pharmacist)	would	account	for	any	changes	in	
the	 resident’s	 management	 plan	 and	 would	 serve	 to	 optimise	 a	 resident’s	
pharmaceutical	 care	 (Duerden	M	2013;	 Royal	 Pharmaceutical	 Society	 England	
2016).	 Not	 only	 does	 this	 medicines	 optimisation	 improve	 health	 outcomes	
(Royal	Pharmaceutical	Society	Wales	2016)	and	resident	safety	(Welsh	Medicines	
Resource	 Centre	 2016),	 as	 a	 by-product	 there	 is	 evidence	 that	 it	 leads	 to	
reduction	in	medicines	waste	(Crotty	2007).			
Another	area	where	interventions	can	be	targeted	is	through	the	continuous	and	
systematic	 analysis	 of	 why	 residents	 refuse	 their	 medications.	 As	 such,	 it	 is	
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beneficial	to	record	not	only	that	a	resident	has	refused	their	medicine(s)	but	also	
the	frequency	with	which	they	refuse	and	also	the	reasons	for	refusing.	 In	the	
analysis	of	administration	data	presented	in	Chapter	3,	although	it	was	evident	
that	residents	refused	medicines	on	occasion	(denoted	by	an	R	on	the	MAR	chart)	
there	were	no	examples	where	the	reasons	for	this	refusal	were	documented,	at	
least	not	on	the	MAR	chart.	This	represents	a	missed	opportunity	to	explore	a	
resident’s	 beliefs	 about	 their	medicines	 and	 to	 subsequently	 develop	 tailored	
education	 to	 support	 better	 adherence	 and	 maximise	 therapeutic	 outcomes	
(Goodyer	et	al.	1995;	Horne	and	Weinman	1999;	Khurana	2003;	Hugtenburg	et	
al.	2006).		
The	findings	in	this	chapter	have	a	number	of	implications	for	practice.	Much	like	
the	data	presented	in	Chapter	3,	it	was	evident	that	practice	varied	across	homes	
in	terms	of	the	extent	of	waste	(some	homes	had	only	very	small	quantities	of	
medicines	waste	whilst	in	other	homes	it	was	significant)	and	in	the	robustness	
of	 the	 processes	 in	 place	 for	 managing	 waste.	 The	 CQC	 and	 analogous	
organisation	 have	 set	 out	 clear	 requirements	 for	 the	medicines	management	
process	that	includes	standards	related	to	the	documentary	trail	of	medicines	in	
the	 home,	 from	 receipt	 on	 arrival,	 administration	 and	 return	 or	 disposal.	
However,	there	was	evidence	that	such	practices	are	not	universally	adopted	or	
embedded.	 Developing	 care	 home	 staff	 to	 better	 manage	 waste	 would	 be	 a	
priority	 area	 for	 attention.	 Similarly,	 better	 interprofessional	 co-operation	
(between	the	prescriber,	pharmacist	and	care	home)	on	prescribing	and	repeat	
dispensing	 would	 help	 to	 bring	 medicines	 waste	 down.	 For	 example,	 if	 the	
pharmacist	 (or	member	 of	 the	 pharmacy	 team)	 checked	with	 the	 care	 home	
whether	each	medicine	was	required,	any	unnecessary	supply	could	be	avoided.	
Certainly,	prescribing	durations	of	greater	than	28	days	should	be	avoided	and	
indeed	it	may	be	prudent	(although	resource	intensive)	to	consider	prescribing	
durations	that	are	less	than	28	days.		
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In	 summary,	 the	 studies	 conducted	 in	 this	 chapter	 have	 demonstrated	 that	
medicines	waste	in	care	homes	remains	a	significant	issue.	Some	of	this	waste	in	
unavoidable	for	example	when	a	resident’s	medicines	change	due	to	a	change	in	
their	condition	or	when	there	is	a	resident	death.	However,	a	significant	volume	
of	waste,	 particularly	 associated	with	 paracetamol,	 laxatives	 and	 other	 ‘when	
required’	medicines	could	be	at	least	partly	avoidable	and	should	be	prioritised	
in	any	interventions	seeking	to	reduce	medicines	waste.			
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There	is	a	global	challenge	in	meeting	the	health	needs	of	a	growing	older	adult	
population.	Estimates	suggest	that	the	population	of	older	adults	(aged	65	and	
over)	 in	 developed	 countries	 will	 rise	 from	 17.8%	 of	 the	 total	 population	 to	
24.5%	between	now	and	the	year	2050.	In	real	terms,	this	represents	an	increase	
of	1	billion	people	up	from	2.4	billion	to	3.4	billion	(Stegemann	et	al.	2010).	In	
the	UK,	by	2040	the	population	of	adults	over	65	years	of	age	is	expected	to	have	
risen	 from	 11.8M	 to	 16M.	 Consistent	 with	 this	 shift	 in	 the	 population	 is	 an	
expected	rise	in	the	number	of	older	adults	with	multiple-chronic	comorbidities	
that	impact	on	both	physical	and	cognitive	function.	Of	note,	at	75	years	of	age	
the	number	of	people	who	are	classed	as	disabled	outnumber	those	that	are	in	
good	health	 (Brown	2015).	 	 The	NHS	continues	 to	 face	considerable	 financial	
pressure	and	this	pressure	is	not	predicted	to	ease	anytime	in	the	near	future	
(Robertson	et	al.	2017).	Indeed,	the	spend	on	the	NHS	is	greater	than	it	has	ever	
been.	In	2017	the	Institute	for	Fiscal	Studies	reported	that	£140Bn	was	spent	on	
health	in	the	UK	(30p	of	every	pound	spent)	which	is	more	than	10	times	the	
investment	 made	 60	 years	 ago	 (Institute	 for	 Fiscal	 Studies	 2018).	 Even	
accounting	for	inflation	rises,	this	represents	an	incredible	increase	in	spending.	
Nevertheless,	 the	 UK	 spends	 proportionately	 less	 on	 health	 than	 other	 EU	
countries	(Appleby	and	Gershlick	2017).	Despite	record	investment,	key	metrics	
continue	to	underperform.	For	example,	the	target	of	every	patient	receiving	a	
consultation	in	A&E	within	four-hours	continues	to	fall	year	on	year	(Dorning	and	
Blunt	 2015).	 	 An	 ageing	 population	 contributes	 to	 these	 problems.	 Life	
expectancy	 has	 grown	 significantly,	 for	 example	 the	 life	 expectancy	 of	 an	
individual	born	today	is	13	years	longer	than	when	the	NHS	was	founded	(Office	
for	National	Statistics	2015).	For	the	individual,	this	rise	is	fantastic	however	this	
rise	in	life	expectancy	has	consequences.	As	individuals	live	longer	they	are	more	
likely	 to	 have	 chronic	 conditions	 such	 as	 cardiovascular	 disease,	 respiratory	
disease,	cognitive	impairments	(particularly	dementia)	and	cancer	(Nihtilä	et	al.	
2008;	 Goodwin	 et	 al.	 2010).	Many	 of	 these	 diseases	 and	 conditions	 are	 not	
amenable	to	curative	interventions	and	they	require	continued	health	and	social	
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support	which	requires	ongoing	resource	allocation.	 	Diseases	that	were	once	
guaranteed	killers	can	now	be	ameliorated	 if	not	cured.	For	example,	50%	of	
people	who	have	a	 cancer	diagnosis	will	 live	 for	at	 least	a	decade	 (Office	 for	
National	Statistics	2016).		Moreover,	managing	the	health	needs	of	older	adults	
is	significantly	more	expensive	than	younger	adults.	A	65-year	old	is	estimated	
to	cost	the	NHS	2.5	times	more	than	the	average	30-year	old	and	an	85-year	old	
five	times	more	(Institute	for	Fiscal	Studies	2018).	Of	note,	despite	representing	
just	one-third	of	the	population,	individuals	with	long-term	chronic	conditions	
occupy	two-thirds	of	the	~	150,000	hospital	beds	in	the	UK		(Institute	for	Fiscal	
Studies	2018).		
One	of	the	major	contributors	to	the	rising	number	of	patients	being	looked	after	
in	 secondary	 care	 is	 the	 shrinking	 spend	 on	 council-lead	 social	 care	 that	 has	
squeezed	domiciliary	care.	In	the	face	of	a	rising	population	of	older	adults,	the	
number	 receiving	 state	 social	 care	 has	 fallen	 by	 25%	 in	 the	 last	 four	 years	
(Cromarty	2018).	Of	note	the	healthcare	budget	for	2017/18	was	over	five	times	
that	 of	 the	 social	 care	 budget	 (£110bn	 vs	 20.8bn)(THE	 UK’S	 INDEPENDENT	
FACTCHECKING	CHARITY	2018).	This	shifts	people	towards	the	secondary	care	
environment	when	policy	is	to	keep	people	in	primary	care	for	as	long	as	possible	
(Association	of	Directors	 of	Adult	 Social	 Services	 2018).	As	 long	 ago	 as	 2010,	
unnecessary	overnight	hospital	stays	were	said	to	cost	the	NHS	£330M	per	year	
(Nuffieldtrust	2010).	This	is	a	particularly	curious	position	to	be	in	because	many	
of	these	individual	do	not	require	a	health	intervention	but	rather	they	require	
social	support	with	their	daily	living	needs.			
Care	homes,	either	private	or	state	 funded,	are	 in	a	prime	position	to	relieve	
some	of	the	burden	from	the	NHS	as	they	can	support	both	the	social	and	health	
needs	of	the	older	adult	population	who	have	a	requirement	for	such	care.	Many	
people	are	surprised	to	learn	that	there	are	estimated	to	be	three	times	as	many	
care	home	beds	in	the	UK	as	there	are	hospital	beds.	Indeed,	many	people	think	
the	care	home	population	is	rather	small	however	there	are	approximately	420K	
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individuals	residing	in	care	homes	in	the	UK	which	represents	about	0.64%	of	the	
UK	population	as	a	whole.	Care	homes	are	divided	into	nursing	and	residential	
homes.	Historically,	this	division	has	demarcated	by	the	level	of	care	residents	
required.	 Nursing	 homes	 which	 provide	 round	 the	 clock	 nursing	 care	 would	
typically	 have	 supported	 residents	 with	 challenging	 health	 and	 social	 needs	
whilst	residential	homes	would	support	those	 individuals	who	needed	help	 in	
their	daily	activities	rather	than	medical	or	nursing	interventions.	However,	 in	
recent	years	the	growth	in	the	older	adult	population	and	particularly	the	rise	in	
the	number	of	individuals	with	chronic	conditions	has	exceeded	the	availability	
of	 nursing	 home	 beds	 and	 the	 boundaries	 between	 residential	 and	 nursing	
homes	have	blurred.	It	is	not	uncommon	to	see	residents	of	residential	homes	
with	conditions	and	health	needs	that	would	be	better	served	by	a	nursing	home	
(Dudman	et	al.	2018).		Indeed,	during	visits	to	residential	homes,	the	researcher	
observed	residents	with	significant	health	needs.		
On	average,	a	residential	home	costs	£600	per	week	and	a	nursing	home	£800	
per	week	(Age	UK	2017).	Following	a	care	needs	assessment,	individuals	may	be	
entitled	to	some	council	support	to	meet	these	costs	but	social	care	funding	as	
has	already	been	pointed	out	is	significantly	constrained.	In	order	to	account	for	
those	with	significant	medical	needs,	the	NHS	may	make	some	contribution	to	
the	cost	of	care	(NICE	2018).	Despite	these	costs,	in	common	with	the	NHS,	the	
care	home	sector	faces	significant	financial	challenges.	Indeed,	between	October	
2010	and	December	2015	some	2,444	care	homes	closed	in	the	UK	(Care	Quality	
Commission	2017).	This	included	the	collapse	of		Southern	Cross,	a	major	care	
home	 group	 that	 had	 750	 homes.	 Accountancy	 firm	 Moore	 Stephens	 have	
estimated	that	12%	of	all	care	homes	have	a	30%	or	greater	risk	of	bankruptcy	
within	 the	 next	 three	 years	 (Stephens	 2016).	 This	 is	 as	 a	 consequence	 of	 a	
number	of	factors	including	a	31%	(£4.1bn)	reduction	in	local	authority	/	council	
funding,	a	cap	on	an	individual’s	contribution	to	their	care,	the	introduction	of	
the	 national	 living	 wage	 and	 the	 introduction	 of	 automatic	 state	 pension	
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enrolment	 which	 has	 pushed	 employment	 costs	 up	 (Roberts	 and	 Barnard	
2017a).		
Not	only	have	the	financial	pressures	increased,	but	recruitment	of	staff	to	the	
care	home	sector	remains	challenging.	There	is	a	shortage	of	UK	nurses	with	for	
example	42,000	vacant	nurse	posts	in	the	NHS	alone	(NHS	2017).	Studies	have	
suggested	that	nurses	prefer	to	work	in	primary	or	secondary	care	rather	than	
the	care	home	sector	(Royal	College	of	Nursing	2012;	Spilsbury	et	al.	2015).	This	
is	 partly	 as	 a	 consequence	 of	 improved	 access	 to	 resources	 and	 the	 multi-
disciplinary	environment	in	such	settings	that	is	deficient	in	the	care	home	sector	
(Dilles	et	al.	2011).	 In	addition,	 there	 is	a	shortage	of	experienced	care	home	
managers	with	estimates	suggesting	 that	 some	care	homes	operate	 for	years	
without	 a	 registered	 manager	 (Roberts	 and	 Barnard	 2017b).	 This	 trend	 is	
expected	to	continue	given	the	fact	that	more	than	50%	of	care	home	managers	
are	over	50	years	of	age	and	 likely	to	retire	 in	the	next	15	or	so	years.	These	
issues	are	compounded	by	the	high	turnover	of	staff	(Agboji	2012).		
A	 further	 pressure	 on	 the	 sector	 is	 increased	 regulatory	 scrutiny	 as	 a	
consequence	 of	 a	 number	 of	 significant	 incidents	 in	 the	 care	 home	 setting	
(Phelan	2015;	Manthorpe	and	Martineau	2016).	This	scrutiny	is	understandable	
as	 care	 home	 residents	 often	 represent	 the	 most	 vulnerable	 individuals	 in	
society.	However,	it	comes	at	a	cost.	Regulators	such	as	the	Care	Inspectorate	
Wales,	benchmark	care	homes	against	standards	and	provide	a	rating	 for	 the	
care	home.	Where	this	rating	is	below	the	threshold	standard	the	inspectorate	
has	 a	 range	 of	 powers	 up	 to	 and	 including	 the	 ability	 to	 revoke	 the	 home’s	
registration.	Even	where	it	chooses	not	to	do	so,	a	sub-standard	rating	is	likely	
to	 deter	 potential	 residents.	 In	 addition,	 the	 cost	 of	 monitoring	 compliance	
within	the	home	has	increased	as	a	consequence	of	increased	scrutiny.		
Together,	these	pressures	can	present	the	perfect	storm	for	sub-optimal	care.	
One	of	the	major	health	interventions	employed	in	care	homes	is	the	prescribing	
and	administration	of	medicines.	 Commonly,	 in	 residential	 homes	and	nearly	
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exclusively	in	nursing	homes,	residents	do	not	have	the	capability	of	managing	
their	 own	 medicines	 and	 therefore	 care	 home	 staff	 are	 involved	 in	 the	
management	and	administration	of	their	medicines.	Evidence	suggests	that	care	
home	residents	are	particularly	susceptible	to	medicines	related	harm	(Barber	
et	al.	2009a).	This	can	be	exacerbated	by	poor	prescribing	decisions	(Ruggiero	et	
al.	2010)	and	by	inappropriate	administration	practices	in	the	home	(Alldred	et	
al.	 2009;	 Dilles	 et	 al.	 2011)	 although	 the	 field	 remains	 underexplored.	 As	 a	
consequence,	this	thesis	explored	medicines	management	in	a	sample	of	care	
homes	in	the	South	Wales	region	focussing	on	prescribing,	administration	and	
medicines	waste.		
In	Chapter	2,	the	prescribing	landscape	for	260	residents	in	ten	care	homes	was	
explored	using	a	retrospective	analysis	of	anonymised	MAR	charts	that	covered	
a	28	day	medicines	cycle.	This	involved	extracting	a	range	of	data	associated	with	
the	medicines	prescribed	including	name,	strength,	formulation,	dose,	quantity	
etc.	 for	 each	 resident.	 This	 data	was	 then	used	 to	 identify	 the	prevalence	of	
polypharmacy	 (more	 than	 five	 medicines	 prescribed)	 and	 excessive	
polypharmacy	 (more	 than	 10	 medicines	 prescribed),	 the	 prevalence	 of	
prescribing	of	potentially	inappropriate	medicines	(using	Beers	Criteria)	and	the	
anticholinergic	burden	faced	by	residents.		
The	residents	included	in	the	study	had	an	average	age	of	83,	firmly	placing	them	
in	the	older	adult	population.	The	levels	of	polypharmacy	were	significant	within	
the	study	population	with	84%	of	all	residents	receiving	five	or	more	medicines	
and	33%	receiving	10	or	more	medicines.	Polypharmacy	has	been	shown	 in	a	
number	of	 studies	 to	be	a	positive	contributor	 to	adverse	drug	reactions	and	
negative	health	outcomes	(Nguyen	et	al.	2006;	Jyrkkä	et	al.	2011;	Kojima	et	al.	
2012).	The	reasons	for	polypharmacy	are	multifactorial,	however	the	concept	of	
prescribing	cascades	plays	a	significant	role	where	an	adverse	reaction	to	drug	A	
is	misdiagnosed	as	a	new	symptom	such	that	drug	B	is	prescribed	rather	than	
rationalising	drug	A	(Lavan	and	Gallagher	2016;	Cahir	et	al.	2010).	This	is	made	
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more	complicated	in	the	care	home	setting	where	there	are	multiple	sources	of	
health	interventions	involving	a	variety	of	prescribers	who	often	do	not	consult	
the	 resident	 directly	 but	 rather	 receive	 information	 related	 to	 the	 resident	
second-hand	via	the	nurse	or	carer	(Bergman	et	al.	2007).		
In	common	with	other	studies,	a	significant	number	of	residents	were	prescribed	
proton	 pump	 inhibitors	 (McDonald	 et	 al.	 2015;	 Rane	 et	 al.	 2017)	 and	
psychotropic	medicines	(Ruggiero	et	al.	2010;	Shah	et	al.	2012;	Beers	et	al.	1988;	
B.	 Hagen	 et	 al.	 2005;	 Vieira	 De	 Lima	 et	 al.	 2013).	 The	 use	 of	 proton	 pump	
inhibitors	and	psychotropic	agents	has	come	under	increased	scrutiny	in	recent	
years	and	feature	as	National	Prescribing	Indicators	where	the	aim	is	to	reduce	
their	prescribing	prevalence.	Long	term	use	of	proton	pump	inhibitors	in	older	
adults	is	associated	with	fractures	and	clostridium	difficile	infection	(McDonald	
et	al.	2015).	 	 In	a	population	that	 is	susceptible	to	falls	(Ding	et	al.	2014),	the	
increased	 risk	of	 fractures	 is	particularly	problematic.	Psychotropic	medicines	
use	in	older	adults	is	similarly	problematic.	Many	care	home	residents	have	some	
degree	 of	 cognitive	 impairment	 and	 the	 inappropriate	 use	 of	 antipsychotics,	
hypnotics	 and	 anxiolytics	 can	 exacerbate	 such	 impairment	 (Foy	 et	 al.	 1995;	
Nazareth,	Burkhardt	2008).	Concerns	have	been	raised	over	the	inappropriate	
use	of	psychotropics	in	care	homes	and	particularly	the	use	of	antipsychotics	in	
residents	with	dementia	where	they	are	used	off	label	to	sedate	residents	where	
there	are	behavioural	issues	(Harding	and	Peel	2013).	There	have	been	calls	for	
regulatory	interventions	in	order	to	safeguard	such	individuals.		
Similarly,	the	prevalence	of	paracetamol	and	laxative	prescribing	was	significant.	
These	 medicines	 were	 generally	 prescribed	 on	 a	 use	 ‘when	 required’	 basis.	
Whilst	 the	 risk	 of	 harm	 from	 such	 agents	 is	 much	 lower	 than	 for	 PPIs	 and	
psychotropic	agents,	there	is	a	tendency	to	prescribe	such	medicines	chronically	
rather	 than	 to	 treat	 acute	 conditions.	 	 Of	 note,	 in	 line	 with	 other	 studies	
(Darracott	and	Johnstone	2012;	York	Health	Economics	Consort	and	The	School	
of	 Pharmacy	 2010;	 Herefordshire	 Clinical	 Commissioning	 Group	 2015)	 in	
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Chapter	 4,	 paracetamol	 and	 laxatives	 represented	 the	 highest	 quantity	 and	
value	of	medicines	wasted.			
There	is	evidence	in	the	literature	that	not	only	are	older	adults	susceptible	to	
polypharmacy	but	that	there	is	a	high	prevalence	of	inappropriate	prescribing	
(King	and	Roberts	2007;	Niwata	et	al.	2006;	Varallo	et	al.	2012;	Hosia-Randell	et	
al.	2008;	Barnett	et	al.	2011;	Hwang	et	al.	2015;	O’Sullivan	et	al.	2013;	Vieira	de	
Lima	et	al.	2013;	Verrue	et	al.	2012;	Ryan	et	al.	2013).	A	number	of	criteria	have	
been	 developed	 that	 seek	 to	 categorise	 such	 inappropriate	 prescribing.	 Such	
criteria	are	either	explicit	(a	list	of	medicines	to	be	avoided	or	used	with	caution)	
or	 implicit	 (relying	 on	 the	 judgement	 of	 clinicians).	 Beers	 criteria,	 an	 explicit	
criteria,	were	used	in	this	study.	Published	by	the	American	Geriatrics	Society	in	
2015,	the	criteria	provides	a	list	of	drug	to	be	avoided	and	those	that	should	be	
used	with	caution	independent	of	disease	or	condition.	Overall,	87%	of	residents	
were	prescribed	a	medicine	 that	 should	be	 avoided	or	used	with	 caution.	Of	
note,	60%	of	residents	received	at	least	one	medicine	that	should	be	avoided.	
Much	like	polypharmacy	this	 is	 likely	a	consequence	of	 infrequent	review	and	
optimisation	of	medicines	in	the	care	home	setting	(Spinewine	et	al.	2007;	De	
Smet	et	al.	2007).		
More	 recently,	 there	 has	 been	 a	 growing	 concern	 on	 the	 use	 of	 drugs	 with	
anticholinergic	properties	in	older	adults	(Chatterjee	et	al.	2017;	Pfistermeister	
et	 al.	 2017).	 Increased	 anticholinergic	 burden	 is	 associated	 with	 dementia,	
cognitive	 impairment,	 falls	 and	 increased	 risk	 of	 mortality	 	 (Fox	 et	 al.	 2011)	
(Marcum	 et	 al.	 2015;	 Naja	 et	 al.	 2016;	 Chatterjee	 et	 al.	 2017).	 	 Using	 the	
Anticholinergic	Effect	on	Cognition	scoring	system,	the	anticholinergic	burden	
was	 calculated	 for	 each	 resident	 in	 the	 study	 population.	 	 Some	 11.9%	 (31	
residents)	of	all	residents	accrued	an	anticholinergic	score	of	three	or	four	which	
is	thought	to	be	clinically	relevant	and	4.2%	(11	residents)	a	score	of	five	or	more	
which	 is	 likely	 to	 place	 the	 resident	 at	 a	 risk	 of	 severe	 cognitive	 impairment	
(Pfistermeister	et	al.	2017).			
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Taken	together,	it	is	clear	that	prescribing	for	older	adults	in	care	homes	could	
be	significantly	improved.	The	use	of	regular	medication	reviews	(Furniss	et	al.	
2000;	 Koria	 et	 al.	 2018)	 and	 deprescribing	 algorithms	 (Liu	 2014)	 would	 be	
beneficial	in	mitigating	any	medicines	harm	that	may	result	from	inappropriate	
prescribing	in	care	home	residents.			
In	Chapter	3,	the	medicines	management	practices	in	the	care	home	itself	were	
explored	again	using	a	 retrospective	analysis	of	anonymised	MAR	charts.	The	
aim	 was	 to	 identify	 errors	 associated	 with	 medicines	 management	 in	 care	
homes.	This	can	be	achieved	through	a	number	of	mechanisms	including	direct	
observation,	incident	reporting	systems		or	documentary	analysis	(charts,	clinical	
notes	etc).	The	analysis	of	documentary	sources	has	the	advantage	that	analysis	
can	be	done	at	scale	(at	least	in	comparison	to	observational	approaches)	but	is	
reliant	on	the	accuracy	of	the	documentation.	The	researcher	was	unable	to	find	
any	 protocols	within	 the	 literature	 to	 characterise	 errors	 on	MAR	 charts	 and	
therefore	 an	 in-house	 protocol	 was	 developed.	 The	 starting	 place	 for	 this	
protocol	was	NICE	guidelines	(NICE	2014).	Using	a	‘test’	care	home	and	historic	
MAR	charts,	a	protocol	was	developed	and	refined	that	captured	errors	in	five	
major	categories:	 regulatory	errors,	administration	errors,	MAR	charts	errors,	
stock	errors	and	miscellaneous	errors.	An	analysis	of	ten	care	homes	was	then	
undertaken	and	the	error	rate	was	calculated.	In	terms	of	administration	errors	
(i.e.	those	that	are	directly	resident	facing)	each	resident	was	on	average	likely	
to	be	exposed	to	six	errors	per	week.	 	There	is	evidence	in	the	literature	that	
administration	 errors	 arise	 as	 a	 consequence	 of	 a	 range	 of	 factors	 including	
distractions	 (Barber	 et	 al.	 2009b)	 and	 interruptions	 (Thomson	 et	 al.	 2009),	
workload	(Biron	2009),	lack	of	knowledge	of	medications	(Dilles	et	al.	2011),	lack	
of	training	(Zimmerman	et	al.	2011),	and	incomplete	medication	charts	(Fry	and	
Dacey	2007).	
The	majority	of	the	administration	errors	were	dose	omissions.	This	finding	is	in	
common	with	other	studies	(Redley	and	Botti	2013;	Pierson	et	al.	2007;	Greene	
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et	al.	2010)	 including	those	that	use	an	observational	approach	(Alldred	et	al.	
2009;	Verrue	et	al.	2010).		
Of	concern,	was	that	a	number	of	MAR	charts	across	the	care	homes	contained	
insufficient	information	to	make	an	administration.	There	were	examples	of	the	
dose,	formulation	and	strength	being	absent	which	requires	a	clinical	judgement	
by	staff	members	in	the	home	who	may	not	have	the	knowledge	or	experience	
to	manage	such	situations	and	indeed	from	a	regulatory	perspective	it	may	not	
be	 appropriate	 for	 the	 individual	 to	make	 such	 a	 judgement.	 Similarly,	 there	
were	examples	of	medicines	being	duplicated	on	the	MAR	chart	which	risks	a	
patient	 receiving	 an	 overdose	 of	 their	 medicine(s).	 One	 of	 the	 contributory	
factors	 leading	 to	 this	 is	 a	 lack	of	 interprofessional	 co-operation	 (Dilles	 et	 al.	
2011;	 Baylis	 and	 Perks-Baker	 2017).	 These	 types	 of	 issues	 are	 everybody’s	
responsibility	 i.e.	 the	 prescriber’s,	 the	 pharmacist’s	 and	 the	 staff	 in	 the	 care	
home.	However,	the	literature	suggests	that	the	co-operation	is	poor	(Alldred	et	
al.	2009;		Welsh	Medicines	Resource	Centre	2016).		
In	this	Chapter,	the	number	of	administration	and	MAR	chart	errors	associated	
with	potentially	inappropriate	medicines	was	also	examined.	The	prevalence	of	
administration	 errors	 with	 psychotropic	 agents	 was	 particularly	 high	 and	 is	
worthy	of	further	investigation.		
Whilst	it	was	beyond	the	scope	of	this	thesis,	it	would	be	useful	to	analyse	the	
likely	clinical	consequences	of	such	administration	and	MAR	chart	errors.	There	
are	 a	 number	 of	 methodologies	 that	 can	 be	 employed	 to	 predict	 clinical	
consequences	including	independent	physicians’	review	or	expert	panel	made	
up	of	a	range	of	healthcare	practitioners	including	physicians	and	pharmacists	
(Dornan	et	al.	2009).	All	of	these	methods	generally	classify	the	consequences	in	
terms	of	a	 level	of	harm	(Gurwitz	et	al.	2000;	Lisby	et	al.	2005;	Bohand	et	al.	
2009;	Young	et	al.	2009)	and	the	predicted	outcomes	(e.g.	unintended	hospital	
admission.	A&E	visit,	death	etc)	(Davies	et	al.	2009;	Meier	et	al.	2015;	da	Silva	
and	Krishnamurthy	2016).		
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Finally,	errors	associated	with	stock	were	examined.	Whilst	such	errors	may	not	
be	immediately	resident	facing,	where	stock	control	is	poor	this	can	result	in	the	
home	either	running	out	of	medicines	(potentially	delaying	an	administration	to	
a	resident)	or	medicines	waste.	In	all	care	homes	studied,	the	management	of	
stock	appeared	to	be	challenging.	There	were	examples	where	stock	was	not	
receipted,	quantities	were	not	recorded	and	there	were	discrepancies	between	
the	 quantity	 recorded	 and	 that	 administered.	 Given	 the	 prevalence	 of	 stock	
errors	identified	on	MAR	charts,	an	exploration	of	the	scale	of	waste	medicines	
in	care	homes	was	explored	in	Chapter	4.		
It	is	widely	recognised	that	medicines	waste	represents	a	significant	cost	to	the	
NHS	with	estimates	suggesting	the	total	value	of	medicines	wasted	in	the	UK	is	
in	 the	 order	 of	 £300M	 per	 annum	 of	 which	 £50	 million	 is	 estimated	 to	 be	
associated	with	medicines	returned	from	care	homes	(York	Health	Economics	
Consort	and	The	School	of	Pharmacy	2010).	In	this	current	study,	returns	books	
were	analysed	and	physical	counts	were	made	of	the	stocks	in	the	care	home	to	
identify	the	scale	of	the	waste.	The	waste	recorded	in	the		returns	books	resulted	
in	an	average	monthly	waste	of	£18.54	per	resident	whilst	overstock	was	£20.25.	
Extrapolated	to	the	number	of	care	home	beds	in	the	UK	this	results	in	a	waste	
bill	of	approximately	£90M	per	annum.	This	is	broadly	in	line	with	other	studies	
that	 have	 sought	 to	 estimate	 the	 scale	 of	waste	 in	 care	 homes	 (Caswell	 and	
Cleverley	 1983;	 Brown	 and	 Kirk	 1984;	 Farmer,	 R	 G.	 et	 al.	 1985).	 	 Given	 a	
residential	 care	 home	 stay	 costs	 ~£600	 per	 week,	 this	 equates	 to	 150,000	
resident	weeks	 lost	 to	waste	medicines.	Whilst	 a	 proportion	 of	 this	waste	 is	
unavoidable,	for	example	when	a	patient	dies	or	when	there	is	an	appropriate	
change	 in	 a	 patient’s	 medication	 regimen	 as	 a	 result	 of	 a	 change	 in	 their	
condition	or	due	to	an	adverse	drug	reaction,	there	is	evidence	that	a	significant	
volume	of	waste	could	be	avoided	(West	2015).	In	care	homes,	this	is	normally	
associated	with	 poor	 prescribing,	 ordering	 and	 dispensing	 processes	 that	 are	
insensitive	 to	 the	 actual	 use	 of	 medicines	 by	 patients	 or	 residents.	 In	 other	
words,	repeat	dispensing	processes	are	setup	for	continuous	28-day	supply	even	
Chapter	5	
	 221	
when	 this	 is	 unnecessary	 because	 a	 patient	 or	 resident	 has	 accumulated	
medicines	due	to	a	break	in	their	last	medicines	cycle	(Birchall	2016).		
Of	note,	 a	 significant	 volume	of	 the	waste	both	 in	 terms	of	 the	dosage	units	
wasted	 and	 the	 value	 of	 the	 waste	 was	 associated	 with	 laxatives	 and	
paracetamol	 containing	 products	 (accounting	 for	 27%	 of	 all	 the	 waste	
generated).	 Again,	 extrapolating	 to	 the	 UK	 care	 home	 population,	 this	
represents	a	potential	waste	of	approximately	£4M	per	annum.	As	was	seen	in	
Chapter	2,	the	prescribing	of	such	products	which	should	be	on	an	acute	basis	is	
generally	prescribed	continuously	 to	 residents	even	when	 they	don’t	need	 it.	
There	is	a	strong	argument	to	only	provide	paracetamol	and	laxatives	as	‘ward	
stock’	rather	than	on	a	named	patient	basis	to	reduce	the	waste	associated	with	
such	medicines.			
One	 theory	 that	 continues	 to	 be	 promoted	 in	 some	 circles	 is	 that	medicines	
waste	 is	as	a	 consequence	of	a	 low	volume	of	high	cost	waste.	 In	 this	 study,	
waste	was	stratified	by	the	unit	pack	cost.	This	revealed,	in	common	with	other	
studies,	that	medicines	waste	in	care	home	is	associated	with	high	volumes	of	
low	unit	cost	waste.	For	example,	over	45%	of	the	total	value	of	waste	identified	
in	this	study	cost	less	than	£10	per	pack	with	just	11%	associated	with	drugs	that	
cost	more	than	£100	per	pack.	It	was	clear	however	that	expensive	medicines	
can	skew	the	results,	for	example	the	waste	associated	with	Rifamixin	which	has	
a	pack	 cost	of	 (£259.23)	 contributed	5.7%	of	 the	 total	waste	and	24%	of	 the	
waste	in	the	home	in	which	its	as	generated.		
Whilst	 the	 process	 of	 incremental	 gains	 (every	 little	 helps)	 is	 a	 valuable	
approach,	 if	 the	 sector	 is	 to	 tackle	 the	 problem	 of	 waste	 medicines	 in	 care	
homes,	a	rethink	of	the	system	is	needed.	The	system	for	reordering,	prescribing	
and	 then	dispensing	 remain	 largely	paper-based	and	unlike	others	 industries,	
where	stock	ordering	and	monitoring	would	be	automated	and	based	on	existing	
stock,	in	care	homes	significant	human	intervention	is	needed.	Medicines	would	
need	to	be	counted	in	the	second-half	of	the	medicines	cycle	by	an	individual	in	
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the	home	prior	to	the	cut-off	for	ordering	the	next	monthly	cycle.	This	is	resource	
intensive	and	given	 the	 staff	 and	workload	pressures	 (Kavanagh	2017)in	 care	
homes	this	approach	is	unrealistic.	The	digital	enablement	of	care	homes,	and	
more	broadly	the	healthcare	sector	(Maguire	et	al.	2018),	is	on	the	horizon	and	
a	 number	 eMAR	 	 systems	 (Redley	 and	 Botti	 2013)	 are	 in	 development	 that	
include	 automated	 stock	 ordering	 	 based	 on	 current	 holdings	 of	 medicines.	
However,	GP	prescribing	systems	are	generally	not	connected	to	such	systems	
and	are	designed	to	generate	prescriptions	in	multiples	of	28	days.	Any	deviation	
from	 such	 an	 approach	 generally	 needs	 manual	 intervention.	 Ultimately,	
addressing	avoidable	medicines	waste	in	care	homes	is	a	priority	and	would	free	
up	resources	both	financial	and	human	to	better	support	resident	care.		
One	 of	 the	 primary	 issues	 related	 to	medicines	 in	 care	 homes	 is	 the	 lack	 of	
recognition	that	it	is	a	problem.	Indeed,	in	a	recent	study	to	identify	the	research	
priorities	in	care	home,	not	one	of	the	15	research	priorities	identified	featured	
medicines	 (Shepherd	 et	 al.	 2017).	 However,	 the	 priorities	 did	 include	 for	
example	 “What	 is	 the	public	 and	media	perception	of	 care	homes	 compared	
with	other	care	settings,	and	what	is	the	impact	on	care	home	staff	attitudes?”.	
This	is	by	no	means	a	criticism,	these	priorities	were	generated	within	the	sector	
itself	 and	 these	 are	 clearly	 important	 to	 the	 participant	 of	 the	 study	 but	 it	
perhaps	demonstrates	how	medicines	management	is	not	seen	as	an	issue	in	a	
care	home.	This	is	probably	a	consequence	of	the	system	in	that	negative	health	
outcomes	arising	from	medicines	errors	are	rarely	recorded	as	such	and	even	
when	they	are,	for	example	when	an	unintended	hospital	admission	occurs	due	
to	a	medicines	error,	reporting	lines	back	to	the	home	from	secondary	care	are	
poor	(Smith	2004;		Desai	et	al.	2011)	making	it	difficult	to	learn	from	such	events.	
A	confounding	 factor	 is	 that	 it	 is	difficult	 for	 regulators	 to	monitor	medicines	
management	 performance	 in	 homes.	 Despite	 regulatory	 standards	 for	
medicines	 management	 (Welsh	 Assembly	 Government	 2004;	 Royal	
Pharmaceutical	Soceity	of	Great	Britain	2007),	the	MAR	chart	remains	one	of	the	
few	 sources	 of	 evidence	 in	 the	 home	 that	 provides	 some	 indication	 of	 the	
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standard	 of	medicines	management.	 The	 researcher	 can	 personally	 evidence	
how	 challenging	 and	 resource	 intensive	 it	 is	 to	 analyse	 MAR	 charts	 and	
realistically	 it	 needs	 to	 be	 carried	 out	 by	 a	 healthcare	 professional	 with	 a	
background	 in	medicines	 use	 (pharmacist,	 physician	 etc).	 If	 regulators	 are	 to	
better	 understand	 the	 issues	 of	 medicines	 management	 in	 care	 homes	 it	 is	
necessary	 to	 work	 with	 care	 homes	 to	 develop	 a	 series	 of	 key	 performance	
indicators	and	associated	metrics	to	better	monitor	compliance	with	standards.	
This	is	in	the	interest	of	the	residents,	the	care	homes	and	the	regulators.		
Limitations:	
The	studies	presented	in	this	thesis	had	some	limitations.	Most	notably,	the	care	
home	setting	does	not	allow	 for	 ready	access	 to	patient	data	particularly	 the	
resident’s	 diagnoses.	 This	 data	 would	 have	 been	 particularly	 useful	 when	
assessing	potentially	inappropriate	prescribing	as	it	would	have	allowed	for	the	
use	 of	 a	 wider	 range	 of	 tools	 that	 require	 diagnostic	 information.	 As	 a	
consequence	the	study	employed	an	explicit	criteria	(Beers)	to	mitigate	against	
this.	Even	in	using	Beers	it	would	have	helpful	to	have	diagnostic	information	as	
an	 assessment	 could	 have	 been	 made	 as	 to	 whether	 the	 medicine(s)	 was	
appropriate	 given	 the	 condition.	 Lack	 of	 diagnostic	 data	 also	 made	 the	
measurement	 of	 potentially	 appropriate	 omissions	 impractical.	 For	 example,	
where	a	resident’s	vital	signs,	clinical	condition	or	biochemical	markers	indicate	
that	 an	 administration	 or	 a	 medicine	 should	 not	 be	made	 and	 therefore	 an	
omission	is	entirely	appropriate,	in	this	study	we	could	not	assess	this.		
As	discussed	in	chapter	3,	this	study	employed	a	retrospective	review	of	MAR	
charts.	The	researcher	made	the	assumption	that	the	records	of	administrations	
were	accurate	and	reflective	of	resident	administrations.	However,	there	may	
be	a	degree	of	error	in	the	records	such	that	they	are	not	entirely	reflective	of	
the	 administrations	 that	 took	 place.	 Nevertheless,	 the	 scale	 of	 the	 errors	
identified	were	in	line	with	observational	studies.	In	addition,	BNF	coding	was	
used	in	this	study	which	did	not	allow	for	sub-coding	of	medicines	as	it	groups	
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medications	into	a	single	human	system	however,	it	was	appropriate	to	use	in	
this	 study	 as	 it	 is	 UK	 based.	 However,	 the	 use	 of	 the	 global	 coding	 system		
‘anatomical-technical-chemical’	coding	(ATC)	which	was	developed	by	the	WHO	
would	 have	 allowed	 for	 further	 sub-categorisation	 of	 medicines	 within	 each	
system.	
				
Future	work	
Based	on	the	findings	in	this	thesis	a	number	of	next	steps	were	identified.	These	
focus	on	an	estimation	of		the	clinical	consequences	of	potentially	inappropriate	
prescribing	and	medication	errors.	This	could	be	undertaken	using	a	framework	
for	error	rating	such	as	the	Equip	framework	(Dornan	et	al.	2009)	or	Fleet	model	
(a	model	for	pharmaceutical	care	and	error	reduction	in	US).	This	 is	crucial	to	
understand	 the	 impact	 of	 medication	 errors	 on	 clinical	 health	 outcomes	 in	
residents.	An	important	consideration	here	would	be	assessing	residents	against	
a	 	 frailty	 index	 to	 provide	 a	more	 holistic	 understanding	 of	 their	 health	 and	
wellbeing	and	how	medicines	harm	might	impact	on	this.	
	
Conclusion	
In	 conclusion,	 the	 results	 described	 in	 this	 thesis	 have	 explored	 issues	
surrounding	medicines	prescribing,	administration	and	waste	in	the	care	home	
setting.	Although	not	explicitly	tested,	the	issues	identified	have	the	potential	to	
result	 in	resident	harm	and	will	 likely	 further	constrain	health	and	social	care	
resources.	 	 Residents	 of	 care	 homes	 represent	 a	 particularly	 vulnerable	
population	 and	 efforts	 should	 be	 renewed	 to	 enhance	 or	 embed	 a	
multidisciplinary	 approach	 to	 the	 health	 and	 social	 care	 of	 such	 residents.	
Currently,	the	system	does	not	enable	practitioners	to	effectively	collaborate	on	
the	 care	 of	 residents	 and	 as	 a	 consequence,	 the	 pharmaceutical	 care	 of	 the	
residents	of	care	homes	is	not	optimal.		
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Appendix	2	–	Guidance	used	in	developing	MAR	chart	analysis	rulebook	
Sub-categories	of	the	guidance	used	to	develop	the	rule	book	(adapted	from	‘Full	guideline	Managing	medicines	in	care	homes’	(NICE	2014)	
Sub-categories	of	the	guidance	 Recommendations	
1.4	 Ensuring	 that	 records	 are	 accurate	
and	up	to	date	
Health	and	social	care	practitioners	should	ensure	that	records	about	medicines	are	accurate	and	up-to-date	by	following	
the	process	set	out	in	the	care	home	medicines	policy	
1.7	 Accurately	 listing	 a	 resident’s	
medicines	(medicines	reconciliation)	
The	care	home	manager	or	the	person	responsible	for	a	resident’s	transfer	into	a	care	home	should	coordinate	the	accurate	
listing	of	all	the	resident’s	medicines	(medicines	reconciliation)	as	part	of	a	full	needs	assessment	and	care	plan.	The	care	
home	manager	should	consider	the	resources	needed	to	ensure	that	medicines	reconciliation	occurs	in	a	timely	manner	
1.10	Ordering	medicines	 Care	home	providers	should	ensure	that	care	home	staff	 (registered	nurses	and	social	care	practitioners	working	 in	care	
homes)	have	protected	time	to	order	medicines	and	check	medicines	delivered	to	the	home.	
1.12	 Receiving,	 storing	 and	 disposing	 of	
medicines	
Care	home	providers	should	assess	each	resident’s	needs	for	storing	their	medicines	and	should	provide	storage	that	meets	
the	resident’s	needs,	choices,	risk	assessment	and	type	of	medicines	system	they	are	using.	
1.14	 Care	 home	 staff	 administering	
medicines	to	residents	Recommendation	
1.14.1	Care	home	providers	should	consider:	(i)	the	6	R’s	of	administration:	–	right	resident	–	right	medicine	–	right	route	–	
right	dose	–	right	time	–	resident’s	right	to	refuse;	(ii)	making	a	record	of	the	administration	as	soon	as	possible;	(iii)	how	to	
record	and	report	a	resident’s	refusal	to	take	a	medicine(s).	
	
	 1.14.7	Paper-based	or	electronic	medicines	administration	records	should:	
(i)	be	legible	(ii)	be	signed	by	the	care	home	staff	(iii)	be	clear	and	accurate	(iv)	be	factual	(v)	have	the	correct	date	and	time	
(vi)	be	completed	as	soon	as	possible	after	administration	(vii)	avoid	jargon	and	abbreviations	(viii)	be	easily	understood	by	
the	resident,	their	family	member	or	carer.	
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	 1.14.8	Care	home	providers	should	ensure	that	medicines	administration	records	(paper-based	or	electronic)	include:	
(i)	the	full	name,	date	of	birth	and	weight	(for	example,	frail	older	residents)	of	the	resident	
(ii)	details	of	any	medicines	the	resident	is	taking,	including	the	name	of	the	medicine	and	its	strength,	form,	dose,	how	often	
it	is	given	and	where	it	is	given	(route	of	administration);	(iii)	known	allergies	and	reactions	to	medicines	or	their	ingredients,	
and	the	type	of	reaction	experienced;	and	(iv)	any	special	 instructions	about	how	the	medicine	should	be	taken	(such	as	
before,	with	or	after	food).	
	
	 1.14.9	Care	home	providers	should	ensure	that	a	new,	hand-written	medicines	administration	record	should	be	checked	for	
accuracy	and	signed	by	a	second	trained	and	skilled	member	of	staff	before	it	is	first	used.	
	 1.14.11	 Care	 home	 staff	must	 record	medicines	 administration,	 including	 the	date	 and	 time,	 on	 the	 relevant	medicines	
administration	record,	as	soon	as	possible	and	ensure	that	they:	(i)	make	the	record	only	when	the	resident	has	taken	their	
prescribed	medicine	 (ii)	 complete	 the	 administration	 before	moving	 on	 to	 the	 next	 resident	 (iii)	 record	when	 and	why	
medicines	have	not	been	given	(iv)	correct	written	mistakes	with	a	single	line	through	the	mistake	followed	by	the	correction	
and	a	signature,	date	and	time	(correction	fluid	should	not	be	used).	
	
	 1.14.14	Care	home	staff	responsible	for	administering	medicines	should	add	a	cross-	reference	(for	example,	‘see	warfarin	
administration	record’)	to	the	resident’s	medicines	administration	record	when	a	medicine	has	a	separate	administration	
record.	
	
	 1.14.16	Care	home	staff	should	make	appropriate	records	of	controlled	drugs	that	have	been	administered	to	residents.	The	
care	home	staff	responsible	for	administering	the	controlled	drug	and	a	trained	witness	should	sign	the	controlled	drugs	
register.	The	staff	member	administering	the	controlled	drug	should	also	sign	the	medicines	administration	record.	
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Appendix	4	–	MAR	chart	error	collection	form	
Care	
Home	
Patient	
Number	
Total	
Number	of	
Medications	
Chart	
Number	of	
Medications	
On	Chart	
Medication	 CD	 BNF	Section	
BNF	
Category	
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Present	 Day	 Round	
PRN	
Protocol	
Error	
Type	
Error	
Defined	
Error	
Description	
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Appendix	5–	Protocol	for	counting	total	number	of	administrations		
The	developed	protocol	for	counting	total	number	of	administrations.	
First,	 the	 counting	 includes	 regular	medication,	where	a	distinct	 instruction	 for	each	
medicine	was	written.	This	was	considered	as	a	theoretical	administration	from	which,	
any	missing	boxes	were	reported	as	an	omission	and	it	didn’t	count.	Note	(theoretical	
administration	means	if	the	medicine	should	be	given	once	daily	as	a	regular	treatment,	
the	 total	 number	 of	 administration	 should	 be	 28	 administration	 for	 28	 days’	 cycle	
regardless	the	fact	that	there	were	empty	boxes	since	each	empty	box	was	considered	
omission	and	counted	as	an	error)	
Secondly,	all	the	medicines	with	“as	directed”	note,	the	counting	was	done	as	follows:	
1-	Medicines	with	full	instruction	were	treated	as	the	regular	ones.	
2-	Other	medications	without	any	instruction	especially;	emollient,	dressing,	nutritional	
supplement,	 they	 were	 counted	 according	 to	 the	 actual	 administration	 with	 the	
exception	of	any	box	with	codes	i.e.	(offered	not	required,	refused	etc.),	because	this	
indicates	that	these	medications	were	not	given.	The	codes	may	be	different	according	
to	the	care	homes.		
There	was	an	exemption	to	some	medications	according	to	specific	drug	or	issue:	
1. For	 analgesics,	 this	 class	 of	 drugs	 represents	 the	 majority	 of	 medicines	
administered	 in	 care	 homes	 particularly,	 Paracetamol	
and	Paracetamol	 containing	product.	 If	 the	product	was	written	as	a	 regular	
treatment,	the	counting	was	according	to	the	actual	administration	since	the	
staff	didn’t	follow	the	instruction	and	offered	it	according	to	the	resident	need	
and	most	 boxes	were	 filled	with	 codes	 referred	 to	 (offered	 not	 required	 or	
refusal)	therefore	all	these	boxes	were	excluded.		
2. Antibiotics,	 with	 this	 class	 of	 drugs,	 the	 administration	 was	 for	 short	 term	
course	and	in	some	cases,	they	didn’t	specify	the	time	to	complete	the	course,	
therefore	 the	 actual	 administration	 were	 counted	 while	 the	 ones	 with	 full	
instruction,	it	was	counted	as	theoretical	administration.	
3. For	Warfarin,	 it	was	counted	according	to	the	actual	administration	because;	
there	was	a	need	to	measure	the	INR	before	the	administration.	
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4. For	double	entry	of	the	same	medicine,	it	counted	just	one	entry.	
5. For	 medication	 with	 no	 entry,	 the	 counting	 was	 similar	 to	 the	 theoretical	
administration	depending	on	the	instructions.	
6. For	 medicines	 with	 unclear	 instructions	 about	 the	 frequency	 of	
administration	like:	“take	up	to	three	times	a	day”,	it	was	counted	according	to	
the	actual	administration.	
7. For	 hand	 amendment	 to	 the	 times	 of	 administration,	 the	 counting	 was	
according	to	the	frequency	of	administration	presented	in	the	boxes	to	know	if	
they	followed	the	amendment	or	not.	
	Meanwhile,	there	were	some	exceptions:		
1-	For	cases	where	written	(maximum	twice	a	day)	and	there	was	no	administration	for	
example;	(Movelat	gel),	it	counted	for	the	minimum	(once).	
2-	 Any	 treatment	 discontinued	 during	 the	 cycle,	 the	 counting	 was	 for	 the	
actual	administration	not	theoretical.	
3-	 Any	 regular	 treatment	 with	 codes	 of	 refusal,	 it	 was	 excluded	 from	 the	 whole	
administration).	
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Appendix	6	-	Conference	abstracts	
A	Retrospective	Analysis	of	Medicines	Administration	Records	to	Quantify	Medicines	Related	
Issues.	
Al-Hamadani	F,	Mantzourani	E,	Smith	M,	James	D		
Int.	J.	Pharm.	Practice	24	(S3),	pp.22-104	DOI:	10.1111/ijpp.12289	
Focal	Points:	
• The	majority	of	care	homes	use	paper-based	‘Medicines	Administration	Record’	charts	
to	document	administrations.	
• In	this	study	we	collected	MAR	charts	from	11	care	homes	and	retrospectively	
analysed	the	charts	for	errors	in	medicines	administration	to	care	home	residents	
against	the	prescriber’s	intentions.	
• On	average,	8%	(S.D±	3.6)	of	all	administrations	were	associated	with	an	
administration	error.	
Introduction:	In	the	seminal	‘CHUMS’	study[1]	researchers	directly	observed	medicines	
administration	rounds	in	care	homes	and	highlighted	the	significant	potential	for	patient	harm	
in	the	medicines	administration	process.	In	the	main,	care	homes	use	paper-based	‘Medicines	
Administration	Record’	(MAR)	charts	to	document	medicines	administrations	against	the	
prescriber’s	intentions.	The	aim	of	this	study	was	to	analyse	MAR	charts	to	determine	the	types	
and	frequencies	of	errors	that	occur	in	the	administration	and	management	of	medicines	in	a	
cohort	of	care	homes.	
Methods:	MAR	charts	for	each	resident	in	11	care	homes	in	South	Wales	were	retrieved	from	
each	home	for	a	28-day	medicines	cycle	in	September	2014.	The	research	team	(11	members)	
analysed	all	MAR	charts	using	an	‘in	house’	protocol	for	errors	that	were	categorised	using	
NICE	guidance	[2]	for	medicines	management.	The	error	categories	were:	(i)	CQC	regulatory	
compliance;	(ii)	incorrect	medicines	administration	against	the	prescriber’s	intentions;	(iii)	
issues	associated	with	risk	to	the	patient	such	as	medicines	prescribed	as	‘when	required’	or	‘as	
directed’;	(iv)	incorrect	stock	recording	and	(v)	miscellaneous	issues	that	could	not	be	
categorised	through	MAR	charts	alone.	Data	were	analysed	using	descriptive	statistics.	Ethical	
approval	was	obtained	from	the	School’s	ethics	committee.	
Results:	The	analysis	period	accounted	for	medicines	administration	to	a	total	of	297	patients	
and	the	frequency	of	errors	identified	and	the	error	rate	per	resident	is	shown	in	Table	1.	A	
total	of	7739	errors	were	identified	directly	relating	to	the	administration	of	medicines	to	
patients	i.e.	no	record	of	administration,	a	deviation	from	the	prescribed	dose,	a	cancelling	of	
the	administration	without	explanation.	Care	home	8	had	the	lowest	number	of	administration	
errors	per	resident	per	week	1	error	and	the	highest	number	of	errors	was	13	administration-
related	errors	per	resident	per	week	in	care	home	10.	
Discussion:	This	study	has	demonstrated	that	medicines	administration	in	care	homes	remains	
a	significant	challenge	and	the	recording	of	administrations	on	the	MAR	chart	can	best	be	
described	as	inconsistent.	Such	inconsistency	has	the	potential	to	lead	to	significant	patient	
harm.	Whilst	MAR	charts	are	the	de	facto	record	of	medicines	administration,	a	limitation	of	
this	study	is	that	the	MAR	charts	may	not	accurately	reflect	the	administration	process	in	the	
home.	Nevertheless,	pharmacists	as	experts	in	medicines,	are	ideally	placed	to	play	a	
significant	role	in	the	education	and	training	of	care	homes	staff	to	ensure	that	medicines	are	
administered	safely	and	effectively.	
References:	
1.	Barber	ND,	Alldred	DP,	Raynor	DK,	Dickinson	R	et	al.	Care	homes’	use	of	medicines	study:	
prevalence,	causes	and	potential	harm	of	medication	errors	in	care	homes	for	older	people.	Qual	
Saf	Health	Care	2009;	18:	341–56.	
2.	National	Institute	for	Health	and	Care	Excellence	(2014)	Managing	medicines	in	care	homes.	
NICE	guideline	(SC1).	Available	at	[https://www.nice.org.	uk/guidance/sc1]	
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Data	in	Care	Home	Settings	–	Can	We	Get	it	Right?	
Mantzourani	E,	Smith	M,	Al-Hamadani	F,	Safaei	H,	James	D	2016	Capturing	Medicines	Waste	
Int.	J.	Pharm.	Practice	24	(S3),	pp.22-104	DOI:	10.1111/ijpp.12289	
Focal	Points:	
• This	study	addresses	the	challenges	of	quantifying	medicines	waste	 in	care	homes	in	
South	Wales.	
• Analysis	of	paper-based	returns	log	and/or	visits	to	count	all	overstocked	medicines	was	
completed	across	ten	different	care	homes.	
• Results	 indicate	 that	 medicines	 returned	 to	 the	 pharmacy	 may	 under-estimate	 the	
amount	 of	 waste	 and	 that	 there	 is	 a	 tendency	 to	 overstock	 medicines	 which	 may	
contribute	to	patient	harm	and	avoidable	waste.		
Introduction:	It	is	estimated	that	£50	million	worth	of	medicines	are	wasted	in	Wales	each	year1.	
One	 study	 found	 that	 wasted	medicines	 in	 care	 homes	 (CHs)	 accounts	 for	 16%	 of	 the	 total	
medicines	wastage	and	that	50%	of	wasted	medicines	can	be	avoided2.	The	cause	of	medicines	
waste	 in	 CHs	 is	 multifactorial	 and	 accurately	 quantifying	 such	 waste	 is	 methodologically	
challenging.	 It	 is	 recognised	 that	 using	 data	 from	 returns	 logs	 alone	 provides	 an	 incomplete	
picture.	 The	 aim	 of	 this	 study	 was	 to	 quantify	 medicines	 waste	 utilising	 two	 different	
methodologies	 namely	 (i)	 analysis	 of	 waste	 medicines	 ‘return	 logs’	 and	 (ii)	 direct	 counts	 of	
overstocked	medicines	in	the	CH.	
Methods:Twelve	CHs	in	one	Health	Board	were	invited	to	provide	baseline	waste	data	from	their	
‘returns	log’	and	were	offered	a	visit	from	a	researcher	to	calculate	the	amount	of	overstocked	
medication	over	a	one	month	period.	 The	patients’	paper	Medication	Administration	Record	
(MAR)	chart	were	used	to	calculate	the	stock	requirements	for	each	medicine	up	to	the	start	of	
the	 next	 medication	 cycle.	 A	 physical	 count	 of	 stock	 was	 conducted	 by	 the	 researcher	 to	
determine	 the	 quantity	 of	 overstock.	 A	 standardised	 protocol	was	 developed	 for	 calculating	
overstock	for	all	formulations	including		solid	dosage	froms,	those	in	liquid	form,	dermatological	
preparations	 and	 nebulizers.	 	 An	 average	 value	 of	 returned	 and	 overstocked	medicines	 per	
resident	was	then	calculated;	unit	costs	of	medicines	were	determined	using	the	British	National	
Formulary	683.	Items	not	specifically	named	for	an	individual	resident	and	medicines	where	the	
returns	 log	was	not	complete	were	excluded.	Approval	was	granted	by	a	University	Research	
Ethics	Committee.	
Results:Ten	CHs	participated	in	the	study.	Data	for	both	returns	log	and	overstock	were	
obtained	for	four;	return	logs	only	for	three	and	overstock	only	for	another	three	CHs.	Values	
of	medicines	waste	from	returns	log	in	the	seven	CHs	ranged	from	£41.26	to	£1299.32.	The	
average	value	of	return	per	resident	in	each	care	home	ranged	from	£1.42	to	£36.09	with	an	
overall	average	of	medicines	returned	estimated	at	£19.01	per	resident	per	month.	The	value	
of	total	overstock	calculated	was	over	£3000	(range	from	£4.74-£774.05	across	seven	CHs),	
equating	to	an	average	overstock	of	£20.25	per	resident	per	month.			
Discussion:	This	study	quantified	medicines	waste	across	10	different	care	homes	utilising	two	
different	methodologies	and	is	the	first	time	that	real-time	data	on	medicines	overstock	in	care	
homes	has	been	reported.	A	number	of	limitations	may	be	associated	with	the	interpretation	of	
these	 data.	 For	 example,	 the	 two	 methods	 were	 conducted	 at	 different	 time	 points,	 and	
therefore	determining	an	average	value	per	 resident	per	month	enabled	us	 to	normalise	 the	
data	and	compare	the	two	different	measures	of	waste.	This	study	confirms	that	a	significant	
number	of	medicines	are	overstocked	and	this	surplus	is	not	always	returned	to	the	pharmacy	
at	the	end	of	the	subsequent	month.	This	may	contribute	towards	avoidable	medicines	waste	
and	risks	developing	a	culture	of	keeping	medicines	which	may	then	exceed	their	expiry	date	or	
inadvertently	be	administered	to	other	residents.	Further	studies	are	required	to	explore	how	
CH	staff	manage	the	supply	and	returns	of	medicines.	
References:	
1. Welsh	Government.	Reducing	Medicines	Waste:	A	team	approach	across	health	and	social	
care.	2010.	Available	at:	
http://wales.gov.uk/docs/phhs/publications/100921pharmwsttoolfinalen.pdf	 (accessed	 11th	
March	2016)	
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2. Evaluation	of	the	Scale,	Causes	and	Costs	of	Waste	Medicines,	Final	Report,	York	Health	
Economics	Consortium	and	the	School	of	Pharmacy,	University	of	London,	2009	
3. British	National	Formulary	edition	68	
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FIP	conference	Glasgow	2018	
High	risk	medications	in	care	homes:	a	retrospective	analysis	of	administration	errors	
	
Fadya	Al-Hamadani*	1,	Efthymia	Mantzourani1,	Mark	Gumbleton1,	Delyth	James2,	Mathew	Smith	
1School	of	Pharmacy	and	Pharmaceutical	Sciences,	Cardiff	University,	2School	of	Sport	&	Health	
Sciences,	Cardiff	Metropolitan	University,	Cardiff.	
	
Background:	Residents	of	care	homes	are	particularly	at	risk	of	medicines	related	harm	due	to	
complex	pathologies	and	polypharmacy.	The	American	Geriatric	Society	produces	Beers	Criteria,	
a	list	of	medications	that	are	potentially	inappropriate	in	older	adults	as	they	pose	an	unwanted	
risk	of	medicines	related	harm.			
Purpose:	 The	purpose	of	 this	 study	was	 to	 identify	 the	administration	errors	associated	with	
Beers	Criteria	medications	in	Care	Homes	
Methods:	 A	 retrospective	 analysis	 of	 Medicines	 Administration	 Records	 (MAR	 charts)	 was	
carried	out	 in	ten	care	homes	over	a	28-day	medicines	cycle	to	 identify	administration	errors	
associated	with	Beers	Criteria	medications.	Administration	errors	were	defined	as	 (i)	omitted	
does;	(ii)	deviations	from	the	prescribed	dose;	(iii)	extra	doses;	(iv)	medicines	omitted	for	the	
medicines	cycle;	(v)	medicines	administered	at	the	wrong	time	and	(vi)	medicines	administration	
struck	through.		
Results:	 Some	 82,817	 medicines	 administrations	 were	 analysed	 and	 a	 total	 of	 6770	
administration	errors	were	identified	for	all	medications	representing	an	error	rate	of	8.2%.	Of	
these	 administration	 errors,	 858	 were	 related	 to	 medications	 found	 in	 Beers	 Criteria.	 This	
equates	to	12.6%	of	all	 the	administration	errors.	The	majority	 (58%)	of	these	administration	
errors	were	associated	with	antipsychotic	and	anxiolytic	drugs.		
Conclusion:	This	study	has	revealed	a	high	prevalence	of	administration	errors	associated	with	
high	risk	drugs	in	care	homes.	Whilst	the	clinical	impact	of	such	errors	remains	to	be	elucidated,	
pharmacists	 as	 experts	 in	 medicines	 can	 play	 an	 active	 role	 in	 addressing	 medicines	
administration	issues	in	care	homes	to	reduce	the	risk	of	medicines	related	harm.	
References:	 Wiley	 Online	 Library.	 (2016).	 American	 Geriatric	 Society	 2015	 Updated	 Beers	
Criteria	 for	 Potentially	 Inappropriate	 Medication	 Use	 in	 Older	 Adults.	 [online]	 Available	 at:	
http://onlinelibrary.wiley.com/doi/10.1111/jgs.13702/pdf	[Accessed	2	Apr.	2018].	
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Appendix	3	–	MAR	chart	analysis	rulebook		
PRN rules in Blue 
AS DIRECTED rules in pink 
PRN 
Structured PRN (e.g. Take ONE four times a day when required) should show record of given or 
offered/refused.  Blank box = yes (error) ­ cannot assess ­ cannot assess PER blank box 
Unstructured PRN (e.g. take ONE when required) Blank Boxes = Cannot be judged ­ cannot 
assess­ cannot assess PER med.   
REGULATORY ERRORS 
. Any dose/form/strength hand amendments require TWO signatures  
. Changes mid­month need to be stopped (TWO signatures) and a new entry written (2 
signatures) 
. Pulse left blank = error if nursing home. Hand written signature required 
. Everything handwritten entry requires TWO signatures. 
. Discontinued requires TWO signatures. 
. Abx course completed requires ONE signatures. 
. Abx stopped required TWO signatures.   
. Clarification of instructions requires ONE signature. 
. Defined code required. Error PER DRUG undefined code. (NOT per entry) 
. If “C” is recorded for a dose, a carer administered the dose and this is not an error.   
. Variable doses, if dose on label is 1­2 tablets or 10­15ml, doses given on specific 
administrations should be clear, if not its an ERROR = missing chart information.   
. CD witness signature missing ­ error per dose given. 
. Apply as directed ­ 2 errors (As directed written AND incomplete dosage instructions 
RISK) 
. As directed (on its own) ­ 2 errors (As directed written AND dose missing.) 
. If its as directed, NOT an error if the time isn’t written but dose is required. 
.  As directed is an error by default. 
. Food “as directed” still an error. 
. Unstructured PRN requires MAX PRN, regardless of whether it is GTN spray, inhaler 
. Topical (creams/ointments etc.) PRN do not need max PRN 
. Structured PRN does not require max PRN as daily dose given.   
. Handwritten times for prn fine – alterations to regulars require a signature. 
 
ADMINISTRATION ERRORS 
. Crossed out signature no explanation – error (scribble) 
. If a scribble has been corrected underneath with the correct code, this is NOT an error.   
. One error PER omission and per PER deviation from dose 
. Omission = Doses missing 
. Deviation from stated dose = Extra doses given 
. “AS DIRECTED” meds are not assessed for omissions ­ can’t tell if they’ve been 
directed not to give 
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RISK ERRORS 
. Apply as directed ­ 2 errors (As directed written AND incomplete dosage instructions 
RISK) 
. As directed (on its own) ­ 2 errors (As directed written AND dose missing RISK) 
. Absent dose / form / strength are 3 separate errors. 
. Time missing in prn is a risk ERROR (missing time).  
. Time not required for as directed because you assume that they know how often to 
take it. 
. “Read leaflet” – error (incomplete dosage information) 
. Anything with “Space doses evenly” on label where doses have not been administered 
evenly = error (Deviation from stated dose) 
. Creams and ointments require site of application and frequency. 
. “Apply to affected area/eye” is error­Incomplete dosage information. 
 
STOCK ERRORS 
. Stock not received but given / stock quantity mismatch = error 
. Existing medication can be “carried forward” 
. Quantity of meds must be booked in but is not required on label. 
. N/A in signature box error (No sig) 
. 0g in quantity = 1 error each no sig and no date. 
. If quantity is “0” and it has been signed, if the chart is empty there is no error. 
 
CANNOT BE ASSESSED 
. ½ hour before/after food cannot be judged and cannot be assessed ­ unsure of exact 
meal/drug round completion. 
.  “At night” dose given at 5pm cannot be judged due to patient individual bedtimes. 
. Drainage bags treat like other meds 
 
OTHER POINTS OF NOTE 
.  Care homes will be numbered 
.  2 individual entries of same drug are counted as 1 drug 
.  2 formulations are 2 separate medications. 
. Chart errors vs medication errors. 
. Patients given their own medication is handled the same as the others. 
.   “Space doses evenly” absent NOT an error.  
. BD/TDS/QDS individual judgement as to time intervals. 
. Schedule 2 & 3 drugs counted as CDs. 
. Creams and QOL? 
. Dressings are treated as medications – ANALYSIS POINT 
 
 
 
